,molecule_chembl_id,molecule_pref_name,canonical_smiles,pchembl_value,standard_type,standard_relation,standard_value,standard_units,potential_duplicate,target_pref_name,target_organism,assay_type,assay_description,chembl_id_duplicate,mean_pchembl_value,max_pchembl_value,min_pchembl_value,core_smiles,Mol,Scaffold
0,CHEMBL10,SB-203580,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,5.70,Kd,=,2000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,5.70,5.70,5.70,c1ccc(-c2nc(-c3ccccc3)c(-c3ccncc3)[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a496d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977890>
1,CHEMBL1076700,,Cc1cc(Nc2nc3cccc(-c4cc(F)c(CN5CCOCC5)c(F)c4)c3o2)ccc1C(=O)NCCCN(C)C,7.01,IC50,=,97.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged TYK2 assessed as inhibition of biotinylated IRS1 substrate phosphorylation after 60 mins by caliper mobility shift assay,False,7.01,7.01,7.01,c1ccc(Nc2nc3cccc(-c4ccc(CN5CCOCC5)cc4)c3o2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09777b0>
2,CHEMBL1078178,MOMELOTINIB,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,6.40,Kd,=,401.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",False,6.40,6.40,6.40,c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977900>
3,CHEMBL1080159,,Cc1cc(Nc2nc3cccc(-c4cc(F)c(CN5CCOCC5)c(F)c4)c3o2)ccc1C(=O)N(C)C,6.70,IC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged TYK2 assessed as inhibition of biotinylated IRS1 substrate phosphorylation after 60 mins by caliper mobility shift assay,False,6.70,6.70,6.70,c1ccc(Nc2nc3cccc(-c4ccc(CN5CCOCC5)cc4)c3o2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977970>
4,CHEMBL1081290,,COc1cc(Nc2nc3cccc(-c4ccccc4)c3o2)cc(OC)c1OC,5.47,IC50,=,3400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged TYK2 assessed as inhibition of biotinylated IRS1 substrate phosphorylation after 60 mins by caliper mobility shift assay,False,5.47,5.47,5.47,c1ccc(Nc2nc3cccc(-c4ccccc4)c3o2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09779e0>
5,CHEMBL1081443,,COc1cc(Nc2nc3cccc(-c4ccccn4)c3o2)cc(OC)c1OC,6.19,IC50,=,640.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged TYK2 assessed as inhibition of biotinylated IRS1 substrate phosphorylation after 60 mins by caliper mobility shift assay,False,6.19,6.19,6.19,c1ccc(Nc2nc3cccc(-c4ccccn4)c3o2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977a50>
6,CHEMBL1081484,,COc1cc(Nc2nc3cccc(-c4ccc(C(=O)N5CCOCC5)c(F)c4)c3o2)cc(OC)c1OC,7.20,IC50,=,63.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged TYK2 assessed as inhibition of biotinylated IRS1 substrate phosphorylation after 60 mins by caliper mobility shift assay,False,7.20,7.20,7.20,O=C(c1ccc(-c2cccc3nc(Nc4ccccc4)oc23)cc1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a499e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977ac0>
7,CHEMBL1081485,,COc1cc(Nc2nc3cccc(-c4ccc(CN5CCOCC5)cc4)c3o2)cc(OC)c1OC,6.51,IC50,=,310.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged TYK2 assessed as inhibition of biotinylated IRS1 substrate phosphorylation after 60 mins by caliper mobility shift assay,False,6.51,6.51,6.51,c1ccc(Nc2nc3cccc(-c4ccc(CN5CCOCC5)cc4)c3o2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977b30>
8,CHEMBL1081663,,CN(C)C(=O)c1ccc(Nc2nc3cccc(-c4ccc(C(=O)N5CCOCC5)cc4)c3o2)cc1,6.14,IC50,=,730.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged TYK2 assessed as inhibition of biotinylated IRS1 substrate phosphorylation after 60 mins by caliper mobility shift assay,False,6.14,6.14,6.14,O=C(c1ccc(-c2cccc3nc(Nc4ccccc4)oc23)cc1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977ba0>
9,CHEMBL1081975,,COc1cc(Nc2nc3cccc(-c4ccc5ncccc5c4)c3o2)cc(OC)c1OC,5.85,IC50,=,1400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged TYK2 assessed as inhibition of biotinylated IRS1 substrate phosphorylation after 60 mins by caliper mobility shift assay,False,5.85,5.85,5.85,c1ccc(Nc2nc3cccc(-c4ccc5ncccc5c4)c3o2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977c10>
10,CHEMBL1081976,,COc1cc(Nc2nc3cccc(-c4cccc(NS(C)(=O)=O)c4)c3o2)cc(OC)c1OC,5.44,IC50,=,3600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged TYK2 assessed as inhibition of biotinylated IRS1 substrate phosphorylation after 60 mins by caliper mobility shift assay,False,5.44,5.44,5.44,c1ccc(Nc2nc3cccc(-c4ccccc4)c3o2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977c80>
11,CHEMBL1081977,,COc1cc(Nc2nc3cccc(-c4ccc(NS(C)(=O)=O)cc4)c3o2)cc(OC)c1OC,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged TYK2 assessed as inhibition of biotinylated IRS1 substrate phosphorylation after 60 mins by caliper mobility shift assay,False,6.82,6.82,6.82,c1ccc(Nc2nc3cccc(-c4ccccc4)c3o2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977cf0>
12,CHEMBL1081978,,COc1cc(Nc2nc3cccc(-c4ccc(C(=O)N5CCOCC5)cc4)c3o2)cc(OC)c1OC,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged TYK2 assessed as inhibition of biotinylated IRS1 substrate phosphorylation after 60 mins by caliper mobility shift assay,False,6.96,6.96,6.96,O=C(c1ccc(-c2cccc3nc(Nc4ccccc4)oc23)cc1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977d60>
13,CHEMBL1082022,,CNC(=O)c1ccc(Nc2nc3cccc(-c4cc(F)c(CN5CCOCC5)c(F)c4)c3o2)cc1C,6.92,IC50,=,120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged TYK2 assessed as inhibition of biotinylated IRS1 substrate phosphorylation after 60 mins by caliper mobility shift assay,False,6.92,6.92,6.92,c1ccc(Nc2nc3cccc(-c4ccc(CN5CCOCC5)cc4)c3o2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977dd0>
14,CHEMBL1082023,,Cc1cc(-c2cccc3nc(Nc4ccc(N5CCN(C)CC5)cc4)oc23)ccc1C(=O)N1CCOCC1,6.52,IC50,=,300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged TYK2 assessed as inhibition of biotinylated IRS1 substrate phosphorylation after 60 mins by caliper mobility shift assay,False,6.52,6.52,6.52,O=C(c1ccc(-c2cccc3nc(Nc4ccc(N5CCNCC5)cc4)oc23)cc1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977e40>
15,CHEMBL1084546,PF-00562271,CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O,6.50,Ki,=,316.23,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.50,6.50,6.50,O=C1Cc2cc(Nc3nccc(NCc4cccnc4)n3)ccc2N1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977eb0>
16,CHEMBL1088856,,COc1cc(-c2cnc3cccc(-c4ccc(C(=O)N5CCOCC5)c(C)c4)c3n2)cc(OC)c1OC,5.85,IC50,=,1400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,5.85,5.85,5.85,O=C(c1ccc(-c2cccc3ncc(-c4ccccc4)nc23)cc1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977f20>
17,CHEMBL1088857,,COc1cc(-c2cnc3cccc(-c4ccc(CN5CCOCC5)c(F)c4)c3n2)cc(OC)c1OC,5.66,IC50,=,2200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,5.66,5.66,5.66,c1ccc(-c2cnc3cccc(-c4ccc(CN5CCOCC5)cc4)c3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977f90>
18,CHEMBL1089773,,CN1CCN(c2ccc(-c3cnc4cccc(-c5cc(F)c(CN6CCOCC6)c(F)c5)c4n3)cc2)CC1,7.03,IC50,=,94.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,7.03,7.03,7.03,c1cc(-c2ccc(CN3CCOCC3)cc2)c2nc(-c3ccc(N4CCNCC4)cc3)cnc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8040>
19,CHEMBL1089813,,COc1cc(-c2cnc3cccc(-c4ccc(CN5CCOCC5)cc4C)c3n2)cc(OC)c1OC,5.38,IC50,=,4200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,5.38,5.38,5.38,c1ccc(-c2cnc3cccc(-c4ccc(CN5CCOCC5)cc4)c3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0a49f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f80b0>
20,CHEMBL1089814,,COc1cc(-c2cnc3cccc(-c4ccc(CN5CCOCC5)cc4F)c3n2)cc(OC)c1OC,5.03,IC50,=,9300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,5.03,5.03,5.03,c1ccc(-c2cnc3cccc(-c4ccc(CN5CCOCC5)cc4)c3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8120>
21,CHEMBL1089815,,Cc1cc(-c2cccc3ncc(-c4ccc(C(=O)N5CCOCC5)c(C)c4)nc23)ccc1CN1CCOCC1,6.36,IC50,=,439.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,6.36,6.36,6.36,O=C(c1ccc(-c2cnc3cccc(-c4ccc(CN5CCOCC5)cc4)c3n2)cc1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8190>
22,CHEMBL1089833,,COc1cc(-c2cnc3cccc(-c4ccc(CN5CCS(=O)(=O)CC5)cc4)c3n2)cc(OC)c1OC,6.28,IC50,=,520.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,6.28,6.28,6.28,O=S1(=O)CCN(Cc2ccc(-c3cccc4ncc(-c5ccccc5)nc34)cc2)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8200>
23,CHEMBL1090360,,O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1,6.00,Ki,=,1000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.00,6.00,6.00,O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8270>
24,CHEMBL1091565,,COc1cc(-c2cnc3cccc(-c4ccc(C(=O)N5CCOCC5)cc4)c3n2)cc(OC)c1OC,5.54,IC50,=,2900.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,5.54,5.54,5.54,O=C(c1ccc(-c2cccc3ncc(-c4ccccc4)nc23)cc1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f82e0>
25,CHEMBL1092063,,Cc1cc(-c2cnc3cccc(-c4ccc(CN5CCS(=O)(=O)CC5)cc4)c3n2)ccc1C(=O)N1CCN(C)CC1,6.48,IC50,=,330.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,6.48,6.48,6.48,O=C(c1ccc(-c2cnc3cccc(-c4ccc(CN5CCS(=O)(=O)CC5)cc4)c3n2)cc1)N1CCNCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8350>
26,CHEMBL1092840,,Cc1cc(-c2cnc3cccc(-c4ccc(CN5CCOCC5)c(F)c4)c3n2)ccc1C(=O)N1CCOCC1,6.28,IC50,=,520.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,6.28,6.28,6.28,O=C(c1ccc(-c2cnc3cccc(-c4ccc(CN5CCOCC5)cc4)c3n2)cc1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f83c0>
27,CHEMBL1092925,,CN1CCN(c2ccc(-c3cnc4cccc(-c5cc(F)c(CN6CCS(=O)(=O)CC6)c(F)c5)c4n3)cn2)CC1,7.07,IC50,=,86.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,7.07,7.07,7.07,O=S1(=O)CCN(Cc2ccc(-c3cccc4ncc(-c5ccc(N6CCNCC6)nc5)nc34)cc2)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8430>
28,CHEMBL1092926,,Fc1cc(-c2cccc3ncc(-c4cnn(C5CCNCC5)c4)nc23)cc(F)c1CN1CCOCC1,6.42,IC50,=,384.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,6.42,6.42,6.42,c1cc(-c2ccc(CN3CCOCC3)cc2)c2nc(-c3cnn(C4CCNCC4)c3)cnc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f84a0>
29,CHEMBL1093119,,Cc1cc(-c2cnc3cccc(-c4cc(F)c(CN5CCOCC5)c(F)c4)c3n2)ccc1C(=O)N1CCOCC1,6.92,IC50,=,120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,6.92,6.92,6.92,O=C(c1ccc(-c2cnc3cccc(-c4ccc(CN5CCOCC5)cc4)c3n2)cc1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8510>
30,CHEMBL1093191,,COc1cc(-c2cnc3cccc(-c4ccc(CC(=O)N5CCOCC5)cc4)c3n2)cc(OC)c1OC,6.19,IC50,=,640.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,6.19,6.19,6.19,O=C(Cc1ccc(-c2cccc3ncc(-c4ccccc4)nc23)cc1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8580>
31,CHEMBL1093454,,COc1cc(-c2cnc3cccc(-c4ccc(CN5CCOCC5)c(C)c4)c3n2)cc(OC)c1OC,5.15,IC50,=,7130.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,5.15,5.15,5.15,c1ccc(-c2cnc3cccc(-c4ccc(CN5CCOCC5)cc4)c3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f85f0>
32,CHEMBL1093468,,COc1cc(-c2cnc3cccc(-c4ccc(CC(=O)N5CCS(=O)(=O)CC5)cc4)c3n2)cc(OC)c1OC,6.47,IC50,=,340.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,6.47,6.47,6.47,O=C(Cc1ccc(-c2cccc3ncc(-c4ccccc4)nc23)cc1)N1CCS(=O)(=O)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8660>
33,CHEMBL1093749,,CNS(=O)(=O)c1ccc(-c2cccc3ncc(-c4cc(OC)c(OC)c(OC)c4)nc23)cc1,6.19,IC50,=,640.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant GST tagged TYK2 protein after 60 mins using FITC-Ahx-KKSRGDYMTMQIG-NH2 substrate,False,6.19,6.19,6.19,c1ccc(-c2cnc3cccc(-c4ccccc4)c3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f86d0>
34,CHEMBL1230165,SILMITASERTIB,O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12,5.62,Kd,=,2382.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",False,5.62,5.62,5.62,c1ccc(Nc2nc3ccccc3c3cnccc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8740>
35,CHEMBL1230609,FORETINIB,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,5.30,Kd,=,5000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH1domain-catalytic) kinase domain,False,5.30,5.30,5.30,O=C(Nc1ccccc1)C1(C(=O)Nc2ccc(Oc3ccnc4cc(OCCCN5CCOCC5)ccc34)cc2)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f87b0>
36,CHEMBL1235315,,O=C1CCN(c2ncc(C(F)(F)F)c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)n2)CC1,5.36,IC50,=,4333.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged Tyk2 expressed in insect cells using 35 uM ATP,False,5.36,5.36,5.36,O=C1CCN(c2nccc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)n2)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8820>
37,CHEMBL1241473,,COc1cc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(N)=O)n2)cc(OC)c1OC,6.80,Ki,=,158.49,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.80,6.80,6.80,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8890>
38,CHEMBL1241674,,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21,5.47,Kd,=,3400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,6.01,6.55,5.47,c1ccc2[nH]c(-c3n[nH]c4ncncc34)cc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8900>
39,CHEMBL1287812,,CCOC(=O)c1cccc(Nc2nc(N)n(C(=O)c3c(F)cccc3F)n2)c1,5.76,IC50,=,1720.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 by TR-FRET assay,False,5.76,5.76,5.76,O=C(c1ccccc1)n1cnc(Nc2ccccc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8970>
40,CHEMBL1287853,FEDRATINIB,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,6.35,Kd,=,450.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,6.81,7.68,6.35,c1ccc(Nc2ccnc(Nc3ccc(OCCN4CCCC4)cc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f89e0>
41,CHEMBL1287883,,Nc1nc(Nc2cccc(S(N)(=O)=O)c2)nn1C(=O)c1c(F)cccc1F,7.16,IC50,=,70.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 by TR-FRET assay,False,7.16,7.16,7.16,O=C(c1ccccc1)n1cnc(Nc2ccccc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8a50>
42,CHEMBL1287910,,Nc1nc(Nc2cccc(C(=O)O)c2)nn1C(=O)c1c(F)cccc1F,6.16,IC50,=,690.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 by TR-FRET assay,False,6.16,6.16,6.16,O=C(c1ccccc1)n1cnc(Nc2ccccc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094a9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8ac0>
43,CHEMBL1287940,,COC(=O)c1ccc(Nc2nc(N)n(C(=O)c3c(F)cccc3F)n2)cc1,6.12,IC50,=,760.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 by TR-FRET assay,False,6.12,6.12,6.12,O=C(c1ccccc1)n1cnc(Nc2ccccc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094aa50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8b30>
44,CHEMBL1287941,,Nc1nc(Nc2ccc(C(=O)O)cc2)nn1C(=O)c1c(F)cccc1F,7.38,IC50,=,42.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 by TR-FRET assay,False,7.38,7.38,7.38,O=C(c1ccccc1)n1cnc(Nc2ccccc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094aac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8ba0>
45,CHEMBL1287971,,Nc1nc(Nc2ccccc2)nn1C(=O)c1c(F)cccc1F,6.44,IC50,=,360.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 by TR-FRET assay,False,6.44,6.44,6.44,O=C(c1ccccc1)n1cnc(Nc2ccccc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ab30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8c10>
46,CHEMBL1288001,,CN(C)c1cccc(Nc2nc(N)n(C(=O)c3c(F)cccc3F)n2)c1,7.16,IC50,=,70.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 by TR-FRET assay,False,7.16,7.16,7.16,O=C(c1ccccc1)n1cnc(Nc2ccccc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094aba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8c80>
47,CHEMBL1288002,,CN(C)c1ccc(Nc2nc(N)n(C(=O)c3c(F)cccc3F)n2)cc1,7.16,IC50,=,70.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 by TR-FRET assay,False,7.16,7.16,7.16,O=C(c1ccccc1)n1cnc(Nc2ccccc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ac10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8cf0>
48,CHEMBL1288032,,Nc1nc(Nc2cccnc2)nn1C(=O)c1c(F)cccc1F,6.52,IC50,=,300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 by TR-FRET assay,False,6.52,6.52,6.52,O=C(c1ccccc1)n1cnc(Nc2cccnc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ac80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8d60>
49,CHEMBL1288062,,CCOC(=O)c1cccc(Nc2nc(N)n(C(=O)c3ccccc3F)n2)c1,5.22,IC50,=,6040.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 by TR-FRET assay,False,5.22,5.22,5.22,O=C(c1ccccc1)n1cnc(Nc2ccccc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094acf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8dd0>
50,CHEMBL1289926,AXITINIB,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,5.44,Kd,=,3600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH1domain-catalytic) kinase domain,False,5.44,5.44,5.44,C(=C/c1n[nH]c2cc(Sc3ccccc3)ccc12)\c1ccccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ad60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8e40>
51,CHEMBL1327969,,O=C(Nc1ccncc1)c1c(Cl)cccc1Cl,6.64,Ki,=,230.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,6.64,6.64,6.64,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094add0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8eb0>
52,CHEMBL1370276,,O=C(Nc1ccncc1)c1c(F)cccc1F,6.27,Ki,=,540.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,6.27,6.27,6.27,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ae40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8f20>
53,CHEMBL1421,DASATINIB,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,5.75,Kd,=,1800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH1domain-catalytic) kinase domain,False,6.19,6.96,5.75,O=C(Nc1ccccc1)c1cnc(Nc2cc(N3CCNCC3)ncn2)s1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094aeb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f8f90>
54,CHEMBL1472492,,CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C,5.80,Ki,=,1584.89,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.80,5.80,5.80,c1ccc(Cn2cc[nH+]c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094af20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9040>
55,CHEMBL1650951,,CC(C)(O)C(=O)N1CCN(c2ccc(C(F)(F)F)c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c2)CC1,5.09,IC50,=,8055.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged Tyk2 expressed in insect cells using 35 uM ATP,False,5.51,5.77,5.09,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1cccc(N2CCNCC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094af90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f90b0>
56,CHEMBL1650955,,O=CN1CCN(c2ccc(C(F)(F)F)c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c2)CC1,5.30,IC50,=,5040.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of GST-tagged Tyk2 expressed in insect cells using 35 uM ATP,False,5.30,5.30,5.30,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1cccc(N2CCNCC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9120>
57,CHEMBL1651521,,COc1cc(O)c2c(c1)CCC[C@H](O)CC(=O)/C=C\C[C@H](C)OC2=O,5.36,IC50,=,4400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 by TR-FRET based LanthaScreen assay,False,5.36,5.36,5.36,O=C1/C=C\CCOC(=O)c2ccccc2CCCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09500b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9190>
58,CHEMBL1702157,,O=C(Nc1ccncc1)c1ccccc1Cl,5.96,Ki,=,1100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,5.96,5.96,5.96,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9200>
59,CHEMBL1721885,SU-014813,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,5.29,Kd,=,5100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH1domain-catalytic) kinase domain,False,5.7,6.12,5.29,O=C1Nc2ccccc2/C1=C/c1cc(C(=O)NCCCN2CCOCC2)c[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9270>
60,CHEMBL1725279,SP-600125,Oc1c2ccccc2c2c3c(cccc13)N=N2,5.90,Ki,=,1258.93,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.90,5.90,5.90,c1ccc2c3c4c(cccc4cc2c1)N=N3,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f92e0>
61,CHEMBL1789941,RUXOLITINIB,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,5.85,Kd,=,1400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,8.34,9.4,5.85,c1nc(-c2cnn(CC3CCCC3)c2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9350>
62,CHEMBL1795071,RUXOLITINIB PHOSPHATE,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O,6.94,IC50,=,116.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.94,6.94,6.94,c1nc(-c2cnn(CC3CCCC3)c2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09502e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f93c0>
63,CHEMBL1834657,INFIGRATINIB PHOSPHATE,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O,5.48,IC50,=,3303.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2-mediated proliferation of mouse BAF3 cells transformed with TEL-Kinase construct,False,5.48,5.48,5.48,O=C(Nc1ccccc1)Nc1cc(Nc2ccc(N3CCNCC3)cc2)ncn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9430>
64,CHEMBL1908395,,CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl,6.33,Kd,=,470.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,7.28,8.24,6.33,O=C(Nc1ccc(C2CCNCC2)cc1C1=CCCCC1)c1ncc[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09503c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f94a0>
65,CHEMBL1908397,KW-2449,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,6.28,Kd,=,520.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,6.54,6.8,6.28,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9510>
66,CHEMBL191003,JNJ-7706621,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F,7.50,Kd,=,32.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding affinity to TYK2,False,7.50,7.50,7.50,O=C(c1ccccc1)n1cnc(Nc2ccccc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09504a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9580>
67,CHEMBL1938642,,NC(=O)c1cnc(N)c2cc(-c3ccc(N4CCOCC4)cc3)sc12,7.18,IC50,=,66.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,7.18,7.18,7.18,c1cc2sc(-c3ccc(N4CCOCC4)cc3)cc2cn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f95f0>
68,CHEMBL1938643,,CNC(=O)c1cnc(N)c2cc(-c3ccc(N4CCOCC4)cc3)sc12,5.88,IC50,=,1330.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,5.88,5.88,5.88,c1cc2sc(-c3ccc(N4CCOCC4)cc3)cc2cn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9660>
69,CHEMBL1938644,,CCNC(=O)c1cnc(N)c2cc(-c3ccc(N4CCOCC4)cc3)sc12,5.97,IC50,=,1070.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,5.97,5.97,5.97,c1cc2sc(-c3ccc(N4CCOCC4)cc3)cc2cn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09505f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f96d0>
70,CHEMBL1938645,,Nc1ncc(C(=O)Nc2ccccc2)c2sc(-c3ccc(N4CCOCC4)cc3)cc12,5.70,IC50,=,1990.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,5.70,5.70,5.70,O=C(Nc1ccccc1)c1cncc2cc(-c3ccc(N4CCOCC4)cc3)sc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9740>
71,CHEMBL1938646,,Nc1ncc(C(=O)NCc2ccccc2)c2sc(-c3ccc(N4CCOCC4)cc3)cc12,5.58,IC50,=,2600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,5.58,5.58,5.58,O=C(NCc1ccccc1)c1cncc2cc(-c3ccc(N4CCOCC4)cc3)sc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c09506d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f97b0>
72,CHEMBL1938647,,CC(C)(C)NC(=O)c1cnc(N)c2cc(-c3ccc(N4CCOCC4)cc3)sc12,5.16,IC50,=,6980.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,5.16,5.16,5.16,c1cc2sc(-c3ccc(N4CCOCC4)cc3)cc2cn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9820>
73,CHEMBL1938648,,CN(C)C(=O)c1cnc(N)c2cc(-c3ccc(N4CCOCC4)cc3)sc12,5.29,IC50,=,5150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,5.29,5.29,5.29,c1cc2sc(-c3ccc(N4CCOCC4)cc3)cc2cn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09507b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9890>
74,CHEMBL1938649,,CNC(=O)c1cnc(N)c2cc(-c3ccccc3)sc12,6.03,IC50,=,937.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,6.03,6.03,6.03,c1ccc(-c2cc3cnccc3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9900>
75,CHEMBL1938650,,CNC(=O)c1cnc(N)c2cc(-c3ccc(C)cc3)sc12,6.05,IC50,=,888.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,6.05,6.05,6.05,c1ccc(-c2cc3cnccc3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9970>
76,CHEMBL1938651,,CNC(=O)c1cnc(N)c2cc(-c3ccc(C(C)(C)C)cc3)sc12,6.70,IC50,=,202.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,6.70,6.70,6.70,c1ccc(-c2cc3cnccc3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f99e0>
77,CHEMBL1938652,,CNC(=O)c1cnc(N)c2cc(-c3ccc(OC(F)(F)F)cc3)sc12,6.68,IC50,=,208.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,6.68,6.68,6.68,c1ccc(-c2cc3cnccc3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9a50>
78,CHEMBL1938653,,CNC(=O)c1cnc(N)c2cc(-c3ccc(C(C)(C)C#N)cc3)sc12,6.84,IC50,=,146.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,6.84,6.84,6.84,c1ccc(-c2cc3cnccc3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09509e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9ac0>
79,CHEMBL1938654,,CNC(=O)c1cnc(N)c2cc(-c3ccc(S(=O)(=O)NC(C)(C)C)cc3)sc12,6.58,IC50,=,266.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,6.58,6.58,6.58,c1ccc(-c2cc3cnccc3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9b30>
80,CHEMBL1938655,,CC(C)(C)NS(=O)(=O)c1ccc(-c2cc3c(N)ncc(C(=O)NCCO)c3s2)cc1,6.03,IC50,=,932.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,6.03,6.03,6.03,c1ccc(-c2cc3cnccc3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9ba0>
81,CHEMBL1938656,,COCCNC(=O)c1cnc(N)c2cc(-c3ccc(S(=O)(=O)NC(C)(C)C)cc3)sc12,5.83,IC50,=,1480.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,5.83,5.83,5.83,c1ccc(-c2cc3cnccc3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9c10>
82,CHEMBL1938657,,CN(C)CCNC(=O)c1cnc(N)c2cc(-c3ccc(S(=O)(=O)NC(C)(C)C)cc3)sc12,5.39,IC50,=,4100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,5.39,5.39,5.39,c1ccc(-c2cc3cnccc3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9c80>
83,CHEMBL1938658,,CC(C)(C)NS(=O)(=O)c1ccc(-c2cc3c(N)ncc(C(=O)NCCN4CCCCC4)c3s2)cc1,5.57,IC50,=,2670.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,5.57,5.57,5.57,O=C(NCCN1CCCCC1)c1cncc2cc(-c3ccccc3)sc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9cf0>
84,CHEMBL1938659,,CC(C)(C)NS(=O)(=O)c1ccc(-c2cc3c(N)ncc(C(=O)NCCN4CCOCC4)c3s2)cc1,6.12,IC50,=,757.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,6.12,6.12,6.12,O=C(NCCN1CCOCC1)c1cncc2cc(-c3ccccc3)sc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9d60>
85,CHEMBL1938660,,CC(C)(C)NS(=O)(=O)c1ccc(-c2cc3c(N)ncc(C(=O)NCCCN4CCOCC4)c3s2)cc1,5.81,IC50,=,1550.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay,False,5.81,5.81,5.81,O=C(NCCCN1CCOCC1)c1cncc2cc(-c3ccccc3)sc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9dd0>
86,CHEMBL196363,,Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1,6.20,Ki,=,630.96,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.20,6.20,6.20,O=C(Nc1ccccc1)Nc1ccc(-c2csc3ncncc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9e40>
87,CHEMBL1965351,,Cc1cccc(C=NNc2cc(N3CCOCC3)nc(OCCc3ccccn3)n2)c1,5.90,Ki,=,1258.93,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.90,5.90,5.90,C(=NNc1cc(N2CCOCC2)nc(OCCc2ccccn2)n1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9eb0>
88,CHEMBL1965495,,Cc1n[nH]c2ncc(C#N)c(-c3ccccc3)c12,5.90,Ki,=,1258.93,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.90,5.90,5.90,c1ccc(-c2ccnc3[nH]ncc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9f20>
89,CHEMBL1965660,,NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl,6.10,Ki,=,794.33,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.10,6.10,6.10,c1ccc(-c2ccc(-c3ccncn3)[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08f9f90>
90,CHEMBL1966343,,CC(C)Cc1cc(-c2ccc3[nH]nc(N)c3c2)on1,6.80,Ki,=,158.49,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.80,6.80,6.80,c1cc(-c2ccc3[nH]ncc3c2)on1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa040>
91,CHEMBL1966628,,NC1CCC(Nc2nccc(-c3c[nH]c4ncccc34)n2)CC1,6.10,Ki,=,794.33,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.10,6.10,6.10,c1cnc2[nH]cc(-c3ccnc(NC4CCCCC4)n3)c2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0950f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa0b0>
92,CHEMBL1967116,,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)c1,6.40,Ki,=,398.11,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.40,6.40,6.40,O=C(Nc1ccccc1)Nc1ccc(-c2csc3c(-c4cn[nH]c4)cncc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa120>
93,CHEMBL1967878,CENISERTIB,Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1,8.20,Ki,=,6.31,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,8.20,8.20,8.20,C1=CC2CC1CC2Nc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa190>
94,CHEMBL1969102,,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1,6.30,Ki,=,501.19,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.30,6.30,6.30,O=C(Nc1ccccc1)Nc1ccc(-c2csc3c(-c4cn[nH]c4)cncc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa200>
95,CHEMBL1969502,,O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23,6.50,Ki,=,316.23,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.50,6.50,6.50,O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa270>
96,CHEMBL1969588,,Clc1cc(-c2c[nH]c3ncccc23)cc(NCc2ccccc2)n1,6.50,Ki,=,316.23,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.50,6.50,6.50,c1ccc(CNc2cc(-c3c[nH]c4ncccc34)ccn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa2e0>
97,CHEMBL1969879,,CC1CCN(C(=O)CO)CC1N(C)c1ncnc2[nH]ccc12,5.70,Ki,=,1995.26,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.70,5.70,5.70,c1nc(NC2CCCNC2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa350>
98,CHEMBL1970104,,CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1,6.60,Ki,=,251.19,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.60,6.60,6.60,c1ccc2[nH]c(-c3n[nH]c4ccccc34)nc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa3c0>
99,CHEMBL1971029,,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Br,7.10,Ki,=,79.43,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.10,7.10,7.10,c1ccc(Nc2ccnc(Nc3cccc(N4CCNCC4)c3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa430>
100,CHEMBL1972221,,CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(=O)CC)c3c2)cc1,7.10,Ki,=,79.43,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.10,7.10,7.10,c1ccc(-c2ccc3[nH]ncc3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa4a0>
101,CHEMBL1972659,,Cc1c(O)ccc2c1CCCC2=NNC(=O)Cc1cccc2ccccc12,5.90,Ki,=,1258.93,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.90,5.90,5.90,O=C(Cc1cccc2ccccc12)NN=C1CCCc2ccccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa510>
102,CHEMBL1973540,,O=C1Nc2ccc3ncsc3c2C1=CNc1ccc(S(=O)(=O)Nc2ccccn2)cc1,6.60,Ki,=,251.19,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.60,6.60,6.60,O=C1Nc2ccc3ncsc3c2C1=CNc1ccc(S(=O)(=O)Nc2ccccn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa580>
103,CHEMBL1973893,,CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(C)=O)c3c2)cc1,7.60,Ki,=,25.12,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.60,7.60,7.60,c1ccc(-c2ccc3[nH]ncc3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa5f0>
104,CHEMBL1974328,,Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1,5.90,Ki,=,1258.93,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.90,5.90,5.90,c1ccc(Nc2cncc(NC3CCCCC3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa660>
105,CHEMBL1974664,,COc1ccc(C=NNc2ncnc3c2[nH]c2ccccc23)cc1OC,6.50,Ki,=,316.23,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.50,6.50,6.50,C(=NNc1ncnc2c1[nH]c1ccccc12)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa6d0>
106,CHEMBL1975128,,Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12,7.00,Ki,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.00,7.00,7.00,c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa740>
107,CHEMBL1976420,,CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12,5.90,Ki,=,1258.93,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.90,5.90,5.90,c1ccc(-c2cc3nccnc3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa7b0>
108,CHEMBL1978099,,CNC(=O)COc1ccc(Nc2nc(Nc3ccc(C)c(S(N)(=O)=O)c3)ncc2F)cc1,7.20,Ki,=,63.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.20,7.20,7.20,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa820>
109,CHEMBL1980297,ILORASERTIB,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12,6.10,Ki,=,794.33,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.10,6.10,6.10,O=C(Nc1ccccc1)Nc1ccc(-c2csc3c(-c4cn[nH]c4)cncc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa890>
110,CHEMBL1980391,RG-1530,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2,7.30,Ki,=,50.12,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.30,7.30,7.30,c1ccc(C2=Nc3c[nH]nc3Nc3ccccc32)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa900>
111,CHEMBL1981725,,CCN1CCN(c2ccc(Nc3nccc(-c4c(-c5cccc(C(=O)Nc6ccccc6F)c5)nc5ccccn45)n3)cc2)CC1,5.70,Ki,=,1995.26,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.70,5.70,5.70,O=C(Nc1ccccc1)c1cccc(-c2nc3ccccn3c2-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa970>
112,CHEMBL1982476,,CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)csc12,6.30,Ki,=,501.19,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.30,6.30,6.30,O=C(Nc1ccccc1)Nc1ccc(-c2csc3ccncc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fa9e0>
113,CHEMBL1983111,,CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12,5.73,Kd,=,1866.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",False,6.82,7.9,5.73,c1cc(NC2CCC2)nc(Nc2ccc3c(c2)C2CCC3N2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08faa50>
114,CHEMBL1983923,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1,6.70,Ki,=,199.53,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.70,6.70,6.70,C(=Cc1nc(Nc2cc[nH]n2)cc(N2CCNCC2)n1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094e9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08faac0>
115,CHEMBL1984162,,COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(C)c5o4)cc3)c3c(N)ncnc32)CC1,6.20,Ki,=,630.96,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.20,6.20,6.20,c1ccc2oc(Nc3ccc(-c4nn(C5CCCCC5)c5ncncc45)cc3)nc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ea50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fab30>
116,CHEMBL1986263,,CCn1c(C)c(-c2ccnc(Nc3cccc(OC)c3)n2)sc1=O,6.30,Ki,=,501.19,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.30,6.30,6.30,O=c1[nH]cc(-c2ccnc(Nc3ccccc3)n2)s1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094eac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08faba0>
117,CHEMBL1986943,,OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1,6.00,Ki,=,1000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.00,6.00,6.00,c1cnc2[nH]cc(-c3ccnc(NC4CCCCC4)n3)c2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094eb30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fac10>
118,CHEMBL1987034,,N#CCOc1ccc(Nc2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2Br)cc1,8.20,Ki,=,6.31,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,8.20,8.20,8.20,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094eba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fac80>
119,CHEMBL1987054,,COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(Cl)c5o4)cc3)c3c(N)ncnc32)CC1,6.00,Ki,=,1000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.00,6.00,6.00,c1ccc2oc(Nc3ccc(-c4nn(C5CCCCC5)c5ncncc45)cc3)nc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ec10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08facf0>
120,CHEMBL1988163,,NS(=O)(=O)c1cccc(Nc2ncc3ccn(-c4ccccc4)c3n2)c1,7.80,Ki,=,15.85,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.80,7.80,7.80,c1ccc(Nc2ncc3ccn(-c4ccccc4)c3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ec80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fad60>
121,CHEMBL1988437,,CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1,6.50,Ki,=,316.23,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.50,6.50,6.50,C(=Cc1n[nH]c2cc(Sc3ccccc3)ccc12)c1ccccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ecf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fadd0>
122,CHEMBL1988838,,Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1,7.60,Ki,=,25.12,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.60,7.60,7.60,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ed60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fae40>
123,CHEMBL1989646,,Cc1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1,6.20,Ki,=,630.96,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.20,6.20,6.20,c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094edd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08faeb0>
124,CHEMBL1989957,,OCCNc1cc2cc(-c3ccccc3)ccc2cn1,6.10,Ki,=,794.33,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.10,6.10,6.10,c1ccc(-c2ccc3cnccc3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ee40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08faf20>
125,CHEMBL1991078,,COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC,7.70,Ki,=,19.95,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.70,7.70,7.70,O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094eeb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08faf90>
126,CHEMBL1991180,,COCc1nnn(-c2nonc2N)c1C(=O)NN=C(C)c1ccc(O)cc1O,5.80,Ki,=,1584.89,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.80,5.80,5.80,O=C(NN=Cc1ccccc1)c1cnnn1-c1cnon1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ef20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb040>
127,CHEMBL1991728,,CC(=NNC(=N)N)c1cc(NC(=O)NCCCCCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1,5.70,Ki,=,1995.26,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.70,5.70,5.70,O=C(NCCCCCCNC(=O)Nc1ccccc1)Nc1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ef90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb0b0>
128,CHEMBL1992306,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccn1,5.80,Ki,=,1584.89,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.80,5.80,5.80,O=C(Nc1ccccc1)Nc1ccc(Oc2ccncc2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb120>
129,CHEMBL1992342,,CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1,7.50,Ki,=,31.62,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.50,7.50,7.50,c1ccc(-c2ccc3[nH]ncc3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb190>
130,CHEMBL1993243,,CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)OCO4)csc12,5.80,Ki,=,1584.89,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.80,5.80,5.80,c1cc2scc(-c3ccc4c(c3)OCO4)c2cn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb200>
131,CHEMBL1993424,,NS(=O)(=O)c1cccc(Nc2ncc3ccn(Cc4ccccc4)c3n2)c1,6.80,Ki,=,158.49,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.80,6.80,6.80,c1ccc(Cn2ccc3cnc(Nc4ccccc4)nc32)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb270>
132,CHEMBL1993661,,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl,8.20,Ki,=,6.31,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,8.20,8.20,8.20,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb2e0>
133,CHEMBL1994241,,COc1cc(C=C(C#N)c2nc3ccccc3[nH]2)c(Br)cc1O,6.40,Ki,=,398.11,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.40,6.40,6.40,C(=Cc1nc2ccccc2[nH]1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb350>
134,CHEMBL1996208,,NNc1cc(N2CCOCC2)nc(OCCc2ccccn2)n1,5.80,Ki,=,1584.89,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.80,5.80,5.80,c1ccc(CCOc2nccc(N3CCOCC3)n2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb3c0>
135,CHEMBL1997597,,CCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1,6.70,Ki,=,199.53,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.70,6.70,6.70,c1ccc(-c2ccc3[nH]ncc3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb430>
136,CHEMBL1997846,,Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1,5.80,Ki,=,1584.89,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.80,5.80,5.80,c1cnc2[nH]cc(-c3nccc(NC4CCCCC4)n3)c2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb4a0>
137,CHEMBL1998435,,OCCNc1cc2cc(-c3ccncc3)ccc2cn1,6.00,Ki,=,1000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.00,6.00,6.00,c1cc(-c2ccc3cnccc3c2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb510>
138,CHEMBL1999811,,O=C(NN=Cc1ccc(O)cc1O)Nc1cccc2nsnc12,5.90,Ki,=,1258.93,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.90,5.90,5.90,O=C(NN=Cc1ccccc1)Nc1cccc2nsnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb580>
139,CHEMBL1999931,,O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccccc1,6.30,Ki,=,501.19,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.30,6.30,6.30,O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb5f0>
140,CHEMBL2000345,,COc1cc(C=C(C#N)c2nc3cc(C)ccc3[nH]2)c(Br)cc1O,6.00,Ki,=,1000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.00,6.00,6.00,C(=Cc1nc2ccccc2[nH]1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb660>
141,CHEMBL2000393,,O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1C1CCOc2c(F)cccc21,7.20,Ki,=,63.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.20,7.20,7.20,O=c1[nH]c2cnc(-n3cnc4ccccc43)nc2n1C1CCOc2ccccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb6d0>
142,CHEMBL2002346,,c1ccc(CNc2cc(-c3c[nH]c4ncccc34)ncn2)cc1,7.00,Ki,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.00,7.00,7.00,c1ccc(CNc2cc(-c3c[nH]c4ncccc34)ncn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb740>
143,CHEMBL2002407,,COc1cc(C=C(C#N)c2n[nH]c(N)c2C#N)ccc1O,6.10,Ki,=,794.33,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.10,6.10,6.10,C(=Cc1cc[nH]n1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb7b0>
144,CHEMBL2002649,,COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2,5.70,Ki,=,1995.26,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.70,5.70,5.70,O=C1Nc2ccccc2C1=Cc1c[nH]cn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb820>
145,CHEMBL2002702,,Cc1cc(C)c(C=C2C(=O)Nc3ccccc32)[nH]1,6.00,Ki,=,1000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.00,6.00,6.00,O=C1Nc2ccccc2C1=Cc1ccc[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb890>
146,CHEMBL2003420,,O=C(NCCCCCCNC(=O)NCc1cccnc1)NCc1cccnc1,6.50,Ki,=,316.23,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.50,6.50,6.50,O=C(NCCCCCCNC(=O)NCc1cccnc1)NCc1cccnc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb900>
147,CHEMBL2003638,,O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(F)c1,5.90,Ki,=,1258.93,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,5.90,5.90,5.90,O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb970>
148,CHEMBL2004716,,CCN(CC)CCNC(=O)C=Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12,6.10,Ki,=,794.33,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.10,6.10,6.10,O=C(Nc1ccccc1)Nc1ccc(-c2csc3ccncc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fb9e0>
149,CHEMBL2004892,,CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1,6.70,Ki,=,199.53,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.70,6.70,6.70,c1ccc(-c2ccc3[nH]ncc3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fba50>
150,CHEMBL2005886,,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,7.30,Ki,=,50.12,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.30,7.30,7.30,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCOCC3)cc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094f9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fbac0>
151,CHEMBL2006778,,CNC(=O)C=Cc1cnc(N)c2c(-c3cc(F)c4[nH]c(C)cc4c3)csc12,6.70,Ki,=,199.53,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.70,6.70,6.70,c1cc2scc(-c3ccc4[nH]ccc4c3)c2cn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094fa50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fbb30>
152,CHEMBL2012519,,COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O,5.39,IC50,=,4100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 by TR-FRET based LanthaScreen assay,False,5.39,5.39,5.39,O=C1/C=C\CCOC(=O)c2ccccc2CCCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094fac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fbba0>
153,CHEMBL2035042,,CN1C/C=C/CCn2ccc3ccc(cc32)-c2ccnc(n2)Nc2cccc(c2)C1,5.82,IC50,=,1500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,5.82,5.82,5.82,C1=C/CNCc2cccc(c2)Nc2nccc(n2)-c2ccc3ccn(c3c2)CC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094fb30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fbc10>
154,CHEMBL2035043,,C1=C/Cn2ccc3ccc(cc32)-c2ccnc(n2)Nc2cccc(c2)COC/1,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.82,6.82,6.82,C1=C/Cn2ccc3ccc(cc32)-c2ccnc(n2)Nc2cccc(c2)COC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094fba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fbc80>
155,CHEMBL2035044,,CN1C/C=C/CCOc2cc(ccn2)-c2ccnc(n2)Nc2cccc(c2)C1,7.19,IC50,=,65.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,7.19,7.19,7.19,C1=C/CNCc2cccc(c2)Nc2nccc(n2)-c2ccnc(c2)OCC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094fc10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fbcf0>
156,CHEMBL2035045,,CN1C/C=C/COCc2cncc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,5.23,IC50,=,5900.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,5.23,5.23,5.23,C1=C/COCc2cncc(c2)-c2ccnc(n2)Nc2cccc(c2)CNC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094fc80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fbd60>
157,CHEMBL2035046,,C1=C/COCc2cncc(c2)-c2ccnc(n2)Nc2cccc(c2)COC/1,6.02,IC50,=,950.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.02,6.02,6.02,C1=C/COCc2cncc(c2)-c2ccnc(n2)Nc2cccc(c2)COC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094fcf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fbdd0>
158,CHEMBL2035047,,CN1C/C=C/COCc2ccc(o2)-c2ccnc(n2)Nc2cccc(c2)C1,5.82,IC50,=,1500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,5.82,5.82,5.82,C1=C/COCc2ccc(o2)-c2ccnc(n2)Nc2cccc(c2)CNC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094fd60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fbe40>
159,CHEMBL2035048,,C1=C/COCc2ccc(o2)-c2ccnc(n2)Nc2cccc(c2)COC/1,6.17,IC50,=,670.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.17,6.17,6.17,C1=C/COCc2ccc(o2)-c2ccnc(n2)Nc2cccc(c2)COC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094fdd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fbeb0>
160,CHEMBL2035050,,Cc1cnc2nc1-c1ccc3ccn(c3c1)C/C=C/COCc1cc(ccc1OCCN1CCCC1)N2,6.36,IC50,=,440.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.36,6.36,6.36,C1=C/Cn2ccc3ccc(cc32)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)COC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094fe40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fbf20>
161,CHEMBL2035051,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cncc(c2)COC/1,6.20,IC50,=,630.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.20,6.20,6.20,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cncc(c2)COC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094feb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fbf90>
162,CHEMBL2035052,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccnc(c2)OCC/1,7.52,IC50,=,30.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,7.52,7.52,7.52,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccnc(c2)OCC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ff20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc040>
163,CHEMBL2035053,,Cc1cnc2nc1-c1ccnc(c1)OCC/C=C/COCc1cc(ccc1OCCN1CCCC1)N2,7.14,IC50,=,72.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,7.14,7.14,7.14,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccnc(c2)OCC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c094ff90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc0b0>
164,CHEMBL2035054,,CN1C/C=C/COCc2ccc(o2)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)C1,6.15,IC50,=,710.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.15,6.15,6.15,C1=C/COCc2ccc(o2)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)CNC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc120>
165,CHEMBL2035055,,CN1C/C=C/COCc2ccc(s2)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)C1,7.39,IC50,=,41.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,7.39,7.39,7.39,C1=C/COCc2ccc(s2)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)CNC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09510b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc190>
166,CHEMBL2035056,,COCCOc1ccc2cc1CN(C)C/C=C/COCc1ccc(o1)-c1ccnc(n1)N2,6.23,IC50,=,590.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.23,6.23,6.23,C1=C/COCc2ccc(o2)-c2ccnc(n2)Nc2cccc(c2)CNC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc200>
167,CHEMBL2035181,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cc(co2)COC/1,6.51,IC50,=,310.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.51,6.51,6.51,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cc(co2)COC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc270>
168,CHEMBL2035182,,COCCOc1ccc2cc1CN(C)C/C=C/COCc1ccc(s1)-c1ccnc(n1)N2,7.48,IC50,=,33.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,7.48,7.48,7.48,C1=C/COCc2ccc(s2)-c2ccnc(n2)Nc2cccc(c2)CNC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc2e0>
169,CHEMBL2035183,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(s2)COC/1,7.50,IC50,=,32.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,7.50,7.50,7.50,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(s2)COC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc350>
170,CHEMBL2035184,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2csc(c2)COC/1,7.33,IC50,=,47.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,7.33,7.33,7.33,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2csc(c2)COC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09512e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc3c0>
171,CHEMBL2035185,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1,6.64,IC50,=,230.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.64,6.64,6.64,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc430>
172,CHEMBL2035186,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2coc(c2)COC/1,6.92,IC50,=,120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.92,6.92,6.92,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2coc(c2)COC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09513c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc4a0>
173,CHEMBL2035187,PACRITINIB,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,7.30,IC50,=,50.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,7.36,7.42,7.3,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc510>
174,CHEMBL2103874,OCLACITINIB,CNS(=O)(=O)C[C@H]1CC[C@H](N(C)c2ncnc3[nH]ccc23)CC1,7.12,IC50,=,75.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"JAK Enzymatic Assay: Methods: A peptide mobility shift assay was used to quantify the phosphorylation of the JAKtide (JAK-2 and JAK-3) or the IRS-1 peptide (JAK-1 and Tyk-2). Reactions were carried out in a 384-well plate (Matrical MP-101) in a 10 microliter total volume. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween-20, ATP (4 micromolar for JAK-2 and JAK-3, 40 micromolar for JAK-1 and 7 micromolar for Tyk-2)), 2% DMSO and 1 micromolar peptide substrate (JAKtide for JAK-2 and JAK-3 or IRS-1 peptide for JAK-1 and Tyk-2). Compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate (200 nl of compound/DMSO was added per 10 microliter reaction). The reactions were initiated by the addition of enzyme to the final concentration of 2 nM JAK-2, 1 nM JAK-3, 7 nM Tyk2 or 20 nM JAK-1. The assay was run for 240 minutes for JAK-1, 150 minutes for JAK-2, 90 minutes for JAK-3 and 60 minutes for Tyk-2.",False,7.12,7.12,7.12,c1nc(NC2CCCCC2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09514a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc580>
175,CHEMBL2105759,BARICITINIB,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,7.21,IC50,=,61.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human N-terminal GST-tagged TYK2 (871 to 1187 residues) expressed in baculovirus expression system,False,7.46,8.06,7.21,c1nc(-c2cnn(C3CNC3)c2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc5f0>
176,CHEMBL21156,,CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1,5.77,IC50,=,1700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 1 mM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,7.69,9.0,5.77,O=c1[nH]ccc2c3[nH]cnc3c3ccccc3c12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc660>
177,CHEMBL2152297,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1n1cnc2cnc3[nH]ccc3c21,8.38,Ki,=,4.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,8.38,8.38,8.38,c1cc2c(ncc3ncn([C@@H]4CCCNC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09515f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc6d0>
178,CHEMBL2152298,,C[C@@H]1CCN(Cc2ccccc2)C[C@@H]1N(C)c1ncnc2[nH]ccc12,5.46,Ki,=,3500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,5.46,5.46,5.46,c1ccc(CN2CCC[C@@H](Nc3ncnc4[nH]ccc34)C2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc740>
179,CHEMBL2152299,,C[C@@H]1CCN(Cc2ccccc2)C[C@@H]1n1cnc2cnc3[nH]ccc3c21,6.80,Ki,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.80,6.80,6.80,c1ccc(CN2CCC[C@@H](n3cnc4cnc5[nH]ccc5c43)C2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09516d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc7b0>
180,CHEMBL2152300,,N#CCC(=O)N1CCC[C@@H](n2cnc3cnc4[nH]ccc4c32)C1,8.33,Ki,=,4.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,8.33,8.33,8.33,c1cc2c(ncc3ncn([C@@H]4CCCNC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc820>
181,CHEMBL2152301,,c1ccc(CN2CCC[C@@H](n3cnc4cnc5[nH]ccc5c43)C2)cc1,6.60,Ki,=,250.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.60,6.60,6.60,c1ccc(CN2CCC[C@@H](n3cnc4cnc5[nH]ccc5c43)C2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09517b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc890>
182,CHEMBL2152302,,c1ccc(CN2CCC[C@H](n3cnc4cnc5[nH]ccc5c43)C2)cc1,7.15,Ki,=,71.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,7.15,7.15,7.15,c1ccc(CN2CCC[C@H](n3cnc4cnc5[nH]ccc5c43)C2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc900>
183,CHEMBL2152303,,c1ccc(CN2CC[C@@H](n3cnc4cnc5[nH]ccc5c43)C2)cc1,7.05,Ki,=,89.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,7.05,7.05,7.05,c1ccc(CN2CC[C@@H](n3cnc4cnc5[nH]ccc5c43)C2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc970>
184,CHEMBL2152304,,c1ccc(CN2CC(n3cnc4cnc5[nH]ccc5c43)C2)cc1,6.27,Ki,=,540.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.27,6.27,6.27,c1ccc(CN2CC(n3cnc4cnc5[nH]ccc5c43)C2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fc9e0>
185,CHEMBL2152305,,c1ccc(CN2CCC(n3cnc4cnc5[nH]ccc5c43)CC2)cc1,7.07,Ki,=,85.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,7.07,7.07,7.07,c1ccc(CN2CCC(n3cnc4cnc5[nH]ccc5c43)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fca50>
186,CHEMBL2153266,,Nc1nc2c(-c3cnc4ccccc4c3)nccc2[nH]1,6.54,Kd,=,290.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding affinity to JH domain of TYK2,False,6.54,6.54,6.54,c1ccc2ncc(-c3nccc4[nH]cnc34)cc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09519e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fcac0>
187,CHEMBL2159210,,Cc1nc2cnc3[nH]ccc3c2n1[C@@H]1CCC[C@@H](O)C1,8.21,Ki,=,6.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 kinase domain using N-terminal 5-carboxyfluorescein-tagged Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr as substrate after 30 mins,False,8.21,8.21,8.21,c1cc2c(ncc3ncn(C4CCCCC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fcb30>
188,CHEMBL215943,,Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2nc(NCCN3CCOCC3)ncc2c1,5.74,IC50,=,1830.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 by HTRF kinase assay,False,5.74,5.74,5.74,O=C(Nc1ccccc1)c1cccc(-c2ccc3nc(NCCN4CCOCC4)ncc3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fcba0>
189,CHEMBL2178257,,Nc1ccn2ncc(C(=O)Nc3conc3-c3cccc(Cl)c3)c2n1,7.44,Ki,=,36.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"JAK1 and TYK2 Inhibition Assay: To determine inhibition constants (Ki), compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. After termination of the kinase reaction, the proportion of phosphorylated product was determined as a fraction of total peptide substrate using the Caliper LabChip 3000 according to the manufacturer's specifications. Ki values were then determined using the Morrison tight binding model (Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969).",False,7.44,7.44,7.44,O=C(Nc1conc1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fcc10>
190,CHEMBL2178352,,CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccccc5)n(C5CCCC5)c4n3)cc2)CC1,5.17,IC50,=,6700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 by radiometric kinase assay,False,5.17,5.17,5.17,c1ccc(Nc2nc3cnc(Nc4ccc(N5CCNCC5)cc4)nc3n2C2CCCC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fcc80>
191,CHEMBL2178799,,Cn1cc(NC(=O)c2cnn3cccnc23)c(-c2cc(Cl)ccc2Cl)n1,6.34,Ki,=,459.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,6.34,6.34,6.34,O=C(Nc1c[nH]nc1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fccf0>
192,CHEMBL2178803,,Cc1ccc(C)c(-c2nn(C)cc2NC(=O)c2cnn3ccc(N)nc23)c1,8.14,Ki,=,7.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"JAK1 and TYK2 Inhibition Assay: To determine inhibition constants (Ki), compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. After termination of the kinase reaction, the proportion of phosphorylated product was determined as a fraction of total peptide substrate using the Caliper LabChip 3000 according to the manufacturer's specifications. Ki values were then determined using the Morrison tight binding model (Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969).",False,8.14,8.14,8.14,O=C(Nc1c[nH]nc1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fcd60>
193,CHEMBL2181082,,O=C1CCN(CCOc2ccc3cc2COCC=CCOCc2cccc(c2)-c2ccnc(n2)N3)C1,6.85,IC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.85,6.85,6.85,O=C1CCN(CCOc2ccc3cc2COCC=CCOCc2cccc(c2)-c2ccnc(n2)N3)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fcdd0>
194,CHEMBL2181083,,C1=CCOCc2cccc(c2)-c2ccnc(n2)Nc2cc(cc(OCCN3CCCC3)c2)COC1,7.10,IC50,=,80.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,7.10,7.10,7.10,C1=CCOCc2cccc(c2)-c2ccnc(n2)Nc2cc(cc(OCCN3CCCC3)c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fce40>
195,CHEMBL2181084,,C1=CCOCc2cccc(c2)-c2ccnc(n2)Nc2cc(cc(OCCN3CCOCC3)c2)COC1,7.09,IC50,=,81.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,7.09,7.09,7.09,C1=CCOCc2cccc(c2)-c2ccnc(n2)Nc2cc(cc(OCCN3CCOCC3)c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fceb0>
196,CHEMBL2181086,,CCN(CC)CCC(=O)Nc1cc2cc(c1)Nc1nccc(n1)-c1cccc(c1)COCC=CCOC2,7.75,IC50,=,18.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,7.75,7.75,7.75,C1=CCOCc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fcf20>
197,CHEMBL2181087,,COc1cc2cc(c1OCCN1CCCC1)COCC=CCOCc1cccc(c1)-c1ccnc(n1)N2,6.77,IC50,=,170.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.77,6.77,6.77,C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fcf90>
198,CHEMBL2181088,,Cc1cnc2nc1-c1cccc(c1)COCC=CCOCc1cc(ccc1OCCN1CCCC1)N2,7.24,IC50,=,57.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,7.24,7.24,7.24,C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd040>
199,CHEMBL2181310,,Fc1cnc2nc1-c1cccc(c1)COCC=CCOCc1cc(ccc1OCCN1CCCC1)N2,6.85,IC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.85,6.85,6.85,C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0951f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd0b0>
200,CHEMBL2181311,,COc1ccc2cc1-c1ccnc(n1)Nc1ccc(OCCN3CCCC3)c(c1)COCC=CCOC2,6.21,IC50,=,620.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.21,6.21,6.21,C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd120>
201,CHEMBL2181312,,Fc1cc2cc(c1)-c1ccnc(n1)Nc1ccc(OCCN3CCCC3)c(c1)COCC=CCOC2,7.44,IC50,=,36.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,7.44,7.44,7.44,C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09520b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd190>
202,CHEMBL2181313,,COc1ccc2cc1COCC=CCOCc1cc(ccc1OCCN1CCCC1)Nc1nccc-2n1,6.75,IC50,=,180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.75,6.75,6.75,C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd200>
203,CHEMBL2181315,,C1=CCCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)OCC1,5.28,IC50,=,5200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,5.28,5.28,5.28,C1=CCCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)OCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd270>
204,CHEMBL2181316,,C1=CCOc2cccc(c2)Nc2nccc(n2)-c2cccc(c2)OCC1,7.16,IC50,=,70.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,7.16,7.16,7.16,C1=CCOc2cccc(c2)Nc2nccc(n2)-c2cccc(c2)OCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd2e0>
205,CHEMBL2181317,,COc1ccc2cc1COCC=CCCOc1cccc(c1)-c1ccnc(n1)N2,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.82,6.82,6.82,C1=CCOCc2cccc(c2)Nc2nccc(n2)-c2cccc(c2)OCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd350>
206,CHEMBL2181318,,COc1ccc2cc1COCC=CCOc1cccc(c1)-c1ccnc(n1)N2,6.92,IC50,=,120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.92,6.92,6.92,C1=CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09522e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd3c0>
207,CHEMBL2181319,,COc1ccc2cc1COCC=CCOCc1cccc(c1)-c1ccnc(n1)N2,6.68,IC50,=,210.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.68,6.68,6.68,C1=CCOCc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd430>
208,CHEMBL2181320,,Oc1ccc2cc1COCC=CCOCc1cccc(c1)-c1ccnc(n1)N2,6.77,IC50,=,170.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.77,6.77,6.77,C1=CCOCc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09523c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd4a0>
209,CHEMBL2181321,,C1=CCOCc2cc(ccc2N2CCOCC2)Nc2nccc(n2)-c2cccc(c2)COC1,6.80,IC50,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.80,6.80,6.80,C1=CCOCc2cc(ccc2N2CCOCC2)Nc2nccc(n2)-c2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd510>
210,CHEMBL2181322,,C1=CCOCc2cc(ccc2N2CCNCC2)Nc2nccc(n2)-c2cccc(c2)COC1,6.85,IC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.85,6.85,6.85,C1=CCOCc2cc(ccc2N2CCNCC2)Nc2nccc(n2)-c2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09524a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd580>
211,CHEMBL2181323,,CN1CCN(c2ccc3cc2COCC=CCOCc2cccc(c2)-c2ccnc(n2)N3)CC1,6.72,IC50,=,190.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.72,6.72,6.72,C1=CCOCc2cc(ccc2N2CCNCC2)Nc2nccc(n2)-c2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd5f0>
212,CHEMBL2181324,,OCCN1CCN(c2ccc3cc2COCC=CCOCc2cccc(c2)-c2ccnc(n2)N3)CC1,6.80,IC50,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.80,6.80,6.80,C1=CCOCc2cc(ccc2N2CCNCC2)Nc2nccc(n2)-c2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd660>
213,CHEMBL2181325,,CC(=O)N1CCN(c2ccc3cc2COCC=CCOCc2cccc(c2)-c2ccnc(n2)N3)CC1,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.96,6.96,6.96,C1=CCOCc2cc(ccc2N2CCNCC2)Nc2nccc(n2)-c2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09525f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd6d0>
214,CHEMBL2181326,,CCS(=O)(=O)N1CCN(c2ccc3cc2COCC=CCOCc2cccc(c2)-c2ccnc(n2)N3)CC1,6.85,IC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.85,6.85,6.85,C1=CCOCc2cc(ccc2N2CCNCC2)Nc2nccc(n2)-c2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd740>
215,CHEMBL2181327,,CN(C)CCN(C)c1ccc2cc1COCC=CCOCc1cccc(c1)-c1ccnc(n1)N2,7.15,IC50,=,71.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,7.15,7.15,7.15,C1=CCOCc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09526d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd7b0>
216,CHEMBL2181328,,ClCCOc1ccc2cc1COCC=CCOCc1cccc(c1)-c1ccnc(n1)N2,6.33,IC50,=,470.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.33,6.33,6.33,C1=CCOCc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd820>
217,CHEMBL2181329,,CCN(CC)CCOc1ccc2cc1COCC=CCOCc1cccc(c1)-c1ccnc(n1)N2,7.10,IC50,=,79.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,7.10,7.10,7.10,C1=CCOCc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09527b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd890>
218,CHEMBL2181331,,C1=CCOCc2cc(ccc2OCCN2CCCCC2)Nc2nccc(n2)-c2cccc(c2)COC1,7.08,IC50,=,84.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,7.08,7.08,7.08,C1=CCOCc2cc(ccc2OCCN2CCCCC2)Nc2nccc(n2)-c2cccc(c2)COC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd900>
219,CHEMBL2181332,,O=C1CCCN1CCOc1ccc2cc1COCC=CCOCc1cccc(c1)-c1ccnc(n1)N2,6.75,IC50,=,180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2,False,6.75,6.75,6.75,O=C1CCCN1CCOc1ccc2cc1COCC=CCOCc1cccc(c1)-c1ccnc(n1)N2,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd970>
220,CHEMBL219722,,Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12,6.40,Ki,=,398.11,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.40,6.40,6.40,O=C(Nc1ccccc1)Nc1ccc(-c2cccc3[nH]ncc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fd9e0>
221,CHEMBL2208034,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)[C@H]1CCCN1,6.46,IC50,=,348.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,6.46,6.46,6.46,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)[C@H]1CCCN1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fda50>
222,CHEMBL221959,TOFACITINIB,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,5.92,IC50,=,1200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TEL-fused TYK2 expressed in Ba/F3 cells assessed as inhibition of STAT5 phosphorylation after 60 mins by AlphaScreen assay,False,7.3,8.44,5.92,c1nc(N[C@@H]2CCCNC2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09529e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fdac0>
223,CHEMBL230011,TG100-115,Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,6.11,Kd,=,770.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,6.11,6.11,6.11,c1ccc(-c2nc3cncnc3nc2-c2ccccc2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fdb30>
224,CHEMBL2322135,,c1cc2c(ncc3[nH]nc(C4CCCCC4)c32)[nH]1,7.30,IC50,=,50.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 1 uM ATP,False,7.30,7.30,7.30,c1cc2c(ncc3[nH]nc(C4CCCCC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fdba0>
225,CHEMBL2322136,,Cn1nc(C2CCCCC2)c2c3cc[nH]c3ncc21,6.52,IC50,=,300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 1 uM ATP,False,6.52,6.52,6.52,c1cc2c(ncc3[nH]nc(C4CCCCC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fdc10>
226,CHEMBL2322137,,c1cc2c(ncc3onc(C4CCCCC4)c32)[nH]1,7.22,IC50,=,60.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 1 uM ATP,False,7.22,7.22,7.22,c1cc2c(ncc3onc(C4CCCCC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fdc80>
227,CHEMBL2322140,,c1cc2c3c(cnc2[nH]1)CCCN3C1CCCCC1,6.28,IC50,=,530.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 1 uM ATP,False,6.28,6.28,6.28,c1cc2c3c(cnc2[nH]1)CCCN3C1CCCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fdcf0>
228,CHEMBL2322141,,c1cc2c(ncc3nnc(C4CCCCC4)n32)[nH]1,5.92,IC50,=,1200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 1 uM ATP,False,5.92,5.92,5.92,c1cc2c(ncc3nnc(C4CCCCC4)n32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fdd60>
229,CHEMBL2322143,,c1cc2c(ncc3ccc(C4CCCCC4)n32)[nH]1,5.32,IC50,=,4800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 1 uM ATP,False,5.32,5.32,5.32,c1cc2c(ncc3ccc(C4CCCCC4)n32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fddd0>
230,CHEMBL2325895,,CC(C)(C)[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1,7.80,Kd,=,16.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding affinity to TYK2 (unknown origin),False,7.80,7.80,7.80,O=C(NCC(=O)N1CCC1)c1c[nH]c2ncc(C3CC3)nc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fde40>
231,CHEMBL234085,,CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12,7.30,Ki,=,50.12,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.30,7.30,7.30,c1nc(NC2CCCNC2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fdeb0>
232,CHEMBL2376144,,C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1,6.46,Kd,=,350.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding affinity to TYK2 (unknown origin) by ligand displacement assay,False,6.46,6.46,6.46,O=C(NCC(=O)N1CCC1)c1c[nH]c2ncc(-c3n[nH]c4ccccc34)nc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fdf20>
233,CHEMBL2385096,,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@@H](NCC(F)(F)F)C1,5.66,EC50,=,2200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human NK92 cells assessed as inhibition of IL12-induced STAT4 phosphorylation incubated for 20 mins followed by IL12 challenge for 45 mins,False,6.68,7.7,5.66,c1cc2c(ncc3ncn(C4CCCC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fdf90>
234,CHEMBL2385101,,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cc(-c2nnc[nH]2)cc1Cl,7.96,Ki,=,10.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.96,7.96,7.96,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccc(-c2nnc[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe040>
235,CHEMBL2386629,,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](NCC(F)(F)F)CC1,6.51,EC50,=,310.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human NK92 cells assessed as inhibition of IL12-induced STAT4 phosphorylation incubated for 20 mins followed by IL12 challenge for 45 mins,False,7.49,8.47,6.51,c1cc2c(ncc3ncn(C4CCCCC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0952f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe0b0>
236,CHEMBL2386633,,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](C#N)CC1,5.25,EC50,=,5600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human NK92 cells assessed as inhibition of IL12-induced STAT4 phosphorylation incubated for 20 mins followed by IL12 challenge for 45 mins,False,6.58,7.92,5.25,c1cc2c(ncc3ncn(C4CCCCC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe120>
237,CHEMBL2386635,,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1,7.00,EC50,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human NK92 cells assessed as inhibition of IL12-induced STAT4 phosphorylation incubated for 20 mins followed by IL12 challenge for 45 mins,False,8.2,9.4,7.0,c1cc2c(ncc3ncn(C4CCCCC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09530b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe190>
238,CHEMBL2386636,,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CCC#N)CC1,6.01,EC50,=,980.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human NK92 cells assessed as inhibition of IL12-induced STAT4 phosphorylation incubated for 20 mins followed by IL12 challenge for 45 mins,False,7.39,8.77,6.01,c1cc2c(ncc3ncn(C4CCCCC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe200>
239,CHEMBL2386653,,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CCCOC1,7.51,Ki,=,31.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr as substrate after 30 mins in presence of ATP,False,7.51,7.51,7.51,c1cc2c(ncc3ncn([C@H]4CCCOC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe270>
240,CHEMBL2387110,,CC(=O)Nc1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)C3CC3)c2)c(Cl)c1,6.41,EC50,=,393.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as inhibition of STAT4 phosphorylation by cell-based assay,False,7.46,8.52,6.41,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe2e0>
241,CHEMBL2387111,,CS(=O)(=O)Nc1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)C3CC3)c2)c(Cl)c1,7.87,Ki,=,13.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.87,7.87,7.87,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe350>
242,CHEMBL2387112,,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cc(O)cc1Cl,6.36,EC50,=,436.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as inhibition of STAT4 phosphorylation by cell-based assay,False,7.44,8.51,6.36,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09532e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe3c0>
243,CHEMBL2387113,,COc1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)C3CC3)c2)c(Cl)c1,8.11,Ki,=,7.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.11,8.11,8.11,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe430>
244,CHEMBL2387114,,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cc(CO)cc1Cl,8.27,Ki,=,5.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.27,8.27,8.27,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09533c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe4a0>
245,CHEMBL2387115,,CC(O)c1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)C3CC3)c2)c(Cl)c1,8.12,Ki,=,7.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.12,8.12,8.12,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe510>
246,CHEMBL2387116,,CC(C)(O)c1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)C3CC3)c2)c(Cl)c1,7.66,Ki,=,21.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.66,7.66,7.66,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09534a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe580>
247,CHEMBL2387117,,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cc(C#CCO)cc1Cl,7.99,Ki,=,10.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.99,7.99,7.99,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe5f0>
248,CHEMBL2387118,,NCc1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)C3CC3)c2)c(Cl)c1,6.34,EC50,=,452.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as inhibition of STAT4 phosphorylation by cell-based assay,False,7.35,8.36,6.34,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe660>
249,CHEMBL2387119,,CNCc1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)C3CC3)c2)c(Cl)c1,6.56,EC50,=,273.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as inhibition of STAT4 phosphorylation by cell-based assay,False,7.52,8.48,6.56,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09535f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe6d0>
250,CHEMBL2387120,,CN(C)Cc1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)C3CC3)c2)c(Cl)c1,7.22,Ki,=,60.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.22,7.22,7.22,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe740>
251,CHEMBL2387121,,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cc(CN2CCOCC2)cc1Cl,7.46,Ki,=,35.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.46,7.46,7.46,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccc(CN2CCOCC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09536d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe7b0>
252,CHEMBL2387122,,CC(=O)c1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)C3CC3)c2)c(Cl)c1,8.11,Ki,=,7.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.11,8.11,8.11,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe820>
253,CHEMBL2387123,,CN(C)C(=O)c1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)C3CC3)c2)c(Cl)c1,7.52,Ki,=,30.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.52,7.52,7.52,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09537b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe890>
254,CHEMBL2387124,,N#Cc1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)C3CC3)c2)c(Cl)c1,6.80,EC50,=,157.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as inhibition of STAT4 phosphorylation by cell-based assay,False,7.77,8.74,6.8,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe900>
255,CHEMBL2387125,,C#Cc1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)C3CC3)c2)c(Cl)c1,8.02,Ki,=,9.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.02,8.02,8.02,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe970>
256,CHEMBL2387126,,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cc(-c2cn[nH]c2)cc1Cl,6.70,EC50,=,198.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as inhibition of STAT4 phosphorylation by cell-based assay,False,7.59,8.47,6.7,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccc(-c2cn[nH]c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fe9e0>
257,CHEMBL2387127,,O=C(Nc1ccnc(NC(=O)[C@H]2C[C@H]2F)c1)c1c(Cl)cccc1Cl,6.71,EC50,=,193.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as inhibition of STAT4 phosphorylation by cell-based assay,False,7.65,8.6,6.71,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fea50>
258,CHEMBL2387128,,O=C(Nc1ccnc(NC(=O)[C@@H]2C[C@@H]2F)c1)c1c(Cl)cccc1Cl,8.15,Ki,=,7.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.15,8.15,8.15,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09539e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08feac0>
259,CHEMBL2387129,,O=C(Nc1ccnc(NC(=O)[C@H]2C[C@@H]2F)c1)c1c(Cl)cccc1Cl,7.94,Ki,=,11.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.94,7.94,7.94,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08feb30>
260,CHEMBL2387130,,O=C(Nc1ccnc(NC(=O)[C@@H]2C[C@H]2F)c1)c1c(Cl)cccc1Cl,7.65,Ki,=,22.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.65,7.65,7.65,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08feba0>
261,CHEMBL2387131,,O=C(Nc1ccnc(NC(=O)[C@H]2C[C@H]2Cl)c1)c1c(Cl)cccc1Cl,8.29,Ki,=,5.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.29,8.29,8.29,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fec10>
262,CHEMBL2387132,,C[C@@H]1C[C@@H]1C(=O)Nc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1,8.07,Ki,=,8.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.07,8.07,8.07,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fec80>
263,CHEMBL2387133,,O=C(Nc1ccnc(NC(=O)[C@H]2C[C@H]2CO)c1)c1c(Cl)cccc1Cl,7.84,Ki,=,14.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.84,7.84,7.84,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fecf0>
264,CHEMBL2387134,,N#C[C@@H]1C[C@@H]1C(=O)Nc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1,8.04,Ki,=,9.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.04,8.04,8.04,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fed60>
265,CHEMBL2387217,,NC(=O)[C@@H]1C[C@@H]1C(=O)Nc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1,7.96,Ki,=,11.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.96,7.96,7.96,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fedd0>
266,CHEMBL2387218,,O=C(Nc1ccnc(NC(=O)[C@@H]2C[C@@H]2C(=O)O)c1)c1c(Cl)cccc1Cl,8.49,Ki,=,3.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.49,8.49,8.49,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fee40>
267,CHEMBL2387219,,O=C(Nc1ccnc(NC(=O)[C@H]2C[C@H]2c2nn[nH]n2)c1)c1c(Cl)cccc1Cl,8.89,Ki,=,1.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.89,8.89,8.89,O=C(Nc1ccnc(NC(=O)[C@H]2C[C@H]2c2nn[nH]n2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08feeb0>
268,CHEMBL2387220,,O=C(Nc1ccnc(NC(=O)[C@H]2C[C@H]2c2nnc[nH]2)c1)c1c(Cl)cccc1Cl,7.82,Ki,=,15.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.82,7.82,7.82,O=C(Nc1ccnc(NC(=O)[C@H]2C[C@H]2c2nnc[nH]2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fef20>
269,CHEMBL2387221,,N#Cc1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)[C@H]3C[C@H]3F)c2)c(Cl)c1,6.84,EC50,=,145.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as inhibition of STAT4 phosphorylation by cell-based assay,False,7.84,8.85,6.84,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fef90>
270,CHEMBL2387222,,O=C(Nc1ccnc(NC(=O)[C@H]2C[C@H]2F)c1)c1c(F)cccc1Cl,6.68,EC50,=,211.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as inhibition of STAT4 phosphorylation by cell-based assay,False,7.74,8.8,6.68,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff040>
271,CHEMBL2387223,,N#Cc1cc(F)c(C(=O)Nc2ccnc(NC(=O)[C@H]3C[C@H]3F)c2)c(Cl)c1,5.92,EC50,=,1200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,6.86,8.8,5.92,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0953f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff0b0>
272,CHEMBL2387224,,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cccc1Cl,6.42,EC50,=,380.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as inhibition of STAT4 phosphorylation by cell-based assay,False,7.37,8.32,6.42,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff120>
273,CHEMBL2387225,,Nc1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)C3CC3)c2)c(Cl)c1,6.61,EC50,=,248.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as inhibition of STAT4 phosphorylation by cell-based assay,False,7.8,9.0,6.61,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09540b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff190>
274,CHEMBL2392480,,N#CCCN[C@H]1CC[C@H](n2nnc3cnc4[nH]ccc4c32)CC1,7.10,Ki,=,80.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.10,7.10,7.10,c1cc2c(ncc3nnn(C4CCCCC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff200>
275,CHEMBL2392493,,CC1(n2nnc3cnc4[nH]ccc4c32)CCN(S(C)(=O)=O)CC1,6.63,Ki,=,234.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.63,6.63,6.63,c1cc2c(ncc3nnn(C4CCNCC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff270>
276,CHEMBL2392500,,N#CCC(=O)N1CCC[C@@H](n2nnc3cnc4[nH]ccc4c32)C1,7.70,Ki,=,20.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.70,7.70,7.70,c1cc2c(ncc3nnn([C@@H]4CCCNC4)c32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff2e0>
277,CHEMBL2420811,,O=C(Nc1ccnc(NC(=O)C2CCCO2)c1)c1c(Cl)cccc1Cl,5.82,Ki,=,1500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,5.82,5.82,5.82,O=C(Nc1ccnc(NC(=O)C2CCCO2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff350>
278,CHEMBL2420812,,CCNC(=O)Nc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1,7.75,Ki,=,18.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,7.75,7.75,7.75,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09542e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff3c0>
279,CHEMBL2420813,,COC(=O)Nc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1,6.77,Ki,=,170.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,6.77,6.77,6.77,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff430>
280,CHEMBL2420819,,Nc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1,6.03,Ki,=,930.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,6.03,6.03,6.03,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09543c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff4a0>
281,CHEMBL2420820,,CNc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1,5.82,Ki,=,1500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,5.82,5.82,5.82,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff510>
282,CHEMBL2420821,,CC(=O)Nc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1,7.02,Ki,=,96.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,7.02,7.02,7.02,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09544a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff580>
283,CHEMBL2420823,,O=C(Nc1ccnc(Nc2ccccc2)c1)c1c(Cl)cccc1Cl,6.85,Ki,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,6.85,6.85,6.85,O=C(Nc1ccnc(Nc2ccccc2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff5f0>
284,CHEMBL2420824,,O=C(Nc1ccnc(Nc2ccccn2)c1)c1c(Cl)cccc1Cl,7.54,Ki,=,29.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,7.54,7.54,7.54,O=C(Nc1ccnc(Nc2ccccn2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff660>
285,CHEMBL2420825,,O=C(Nc1ccnc(Nc2ncccn2)c1)c1c(Cl)cccc1Cl,5.92,Ki,=,1200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,5.92,5.92,5.92,O=C(Nc1ccnc(Nc2ncccn2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09545f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff6d0>
286,CHEMBL2420826,,O=C(Nc1ccnc(Nc2cnccn2)c1)c1c(Cl)cccc1Cl,7.85,Ki,=,14.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,7.85,7.85,7.85,O=C(Nc1ccnc(Nc2cnccn2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff740>
287,CHEMBL2420827,,O=C(Nc1ccnc(Nc2ccncn2)c1)c1c(Cl)cccc1Cl,8.31,Ki,=,4.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,8.31,8.31,8.31,O=C(Nc1ccnc(Nc2ccncn2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09546d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff7b0>
288,CHEMBL2420828,,O=C(Nc1ccnc(Nc2cccnn2)c1)c1c(Cl)cccc1Cl,8.00,Ki,=,10.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,8.00,8.00,8.00,O=C(Nc1ccnc(Nc2cccnn2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff820>
289,CHEMBL2420829,,CCn1cc(Nc2cc(NC(=O)c3c(Cl)cccc3Cl)ccn2)cn1,7.72,Ki,=,19.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,7.72,7.72,7.72,O=C(Nc1ccnc(Nc2cn[nH]c2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09547b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff890>
290,CHEMBL2420830,,O=C(Nc1ccnc2[nH]ccc12)c1c(Cl)cccc1Cl,7.00,Ki,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,7.00,7.00,7.00,O=C(Nc1ccnc2[nH]ccc12)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff900>
291,CHEMBL2420831,,O=C(Nc1ccnc(O)c1)c1c(Cl)cccc1Cl,6.62,Ki,=,240.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,6.62,6.62,6.62,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff970>
292,CHEMBL2420832,,CCC(=O)Nc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1,7.19,Ki,=,64.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,7.19,7.19,7.19,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ff9e0>
293,CHEMBL2420833,,CC(C)C(=O)Nc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1,6.08,Ki,=,840.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,6.08,6.08,6.08,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ffa50>
294,CHEMBL2420835,,O=C(CC1CC1)Nc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1,7.03,Ki,=,94.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,7.03,7.03,7.03,O=C(CC1CC1)Nc1cc(NC(=O)c2ccccc2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09549e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ffac0>
295,CHEMBL2420836,,O=C(Nc1ccnc(NC(=O)C2CCC2)c1)c1c(Cl)cccc1Cl,7.13,Ki,=,74.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,7.13,7.13,7.13,O=C(Nc1ccnc(NC(=O)C2CCC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ffb30>
296,CHEMBL2420837,,O=C(Nc1ccnc(NC(=O)C2CCCC2)c1)c1c(Cl)cccc1Cl,6.62,Ki,=,240.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,6.62,6.62,6.62,O=C(Nc1ccnc(NC(=O)C2CCCC2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ffba0>
297,CHEMBL2420838,,O=C(Nc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1)c1ccccc1,5.70,Ki,=,2000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,5.70,5.70,5.70,O=C(Nc1ccnc(NC(=O)c2ccccc2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ffc10>
298,CHEMBL2420839,,O=C(CO)Nc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1,6.60,Ki,=,250.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,6.60,6.60,6.60,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ffc80>
299,CHEMBL2420840,,NCC(=O)Nc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1,5.92,Ki,=,1200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,5.92,5.92,5.92,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ffcf0>
300,CHEMBL2420841,,O=C(Nc1ccncc1)c1ccccc1,5.51,Ki,=,3100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,5.51,5.51,5.51,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ffd60>
301,CHEMBL2420842,,Cc1ccccc1C(=O)Nc1ccncc1,5.62,Ki,=,2400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,5.62,5.62,5.62,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ffdd0>
302,CHEMBL2420844,,O=C(Nc1ccncc1)c1c(F)cccc1Cl,6.64,Ki,=,230.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,6.64,6.64,6.64,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ffe40>
303,CHEMBL2420845,,Cc1cccc(Cl)c1C(=O)Nc1ccncc1,5.55,Ki,=,2800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,5.55,5.55,5.55,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08ffeb0>
304,CHEMBL2420847,,O=C(Nc1ccncc1)c1c(Cl)cccc1C(F)(F)F,5.72,Ki,=,1900.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,5.72,5.72,5.72,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fff20>
305,CHEMBL2420851,,O=C(Nc1ccncc1)c1cc(Cl)ccc1Cl,6.10,Ki,=,790.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,6.10,6.10,6.10,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c08fff90>
306,CHEMBL2420852,,O=C(Nc1ccncc1)c1cc(C(F)(F)F)ccc1Cl,6.05,Ki,=,900.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,6.05,6.05,6.05,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900040>
307,CHEMBL2420853,,COc1ccc(Cl)c(C(=O)Nc2ccncc2)c1,5.55,Ki,=,2800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,5.55,5.55,5.55,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0954f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09000b0>
308,CHEMBL2420854,,O=C(Nc1ccncc1)c1ccc(Cl)cc1Cl,5.92,Ki,=,1200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,5.92,5.92,5.92,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900120>
309,CHEMBL2420856,,Nc1ccc(C(=O)Nc2ccncc2)c(Cl)c1,6.42,Ki,=,380.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,6.42,6.42,6.42,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09550b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900190>
310,CHEMBL2420857,,COc1ccc(C(=O)Nc2ccncc2)c(Cl)c1,5.50,Ki,=,3200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,5.50,5.50,5.50,O=C(Nc1ccncc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900200>
311,CHEMBL2420858,,O=C(Nc1c(Cl)cccc1Cl)c1ccncc1,5.96,Ki,=,1100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using 5-carboxyfluorescein-VALVDGYFRLTT-NH2 as substrate,False,5.96,5.96,5.96,O=C(Nc1ccccc1)c1ccncc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900270>
312,CHEMBL243088,,O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1,7.30,Ki,=,50.12,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.30,7.30,7.30,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09002e0>
313,CHEMBL2436945,,CCc1nc(N[C@@H]2CCC[C@@H]2C#N)c2cc[nH]c(=O)c2n1,7.96,Ki,=,11.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin),False,7.96,7.96,7.96,O=c1[nH]ccc2c(NC3CCCC3)ncnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900350>
314,CHEMBL244378,,O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1,7.50,Ki,=,31.62,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.50,7.50,7.50,c1ccc(Nc2ccnc(Nc3ccc4cn[nH]c4c3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09552e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09003c0>
315,CHEMBL249697,BMS-345541,Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1,5.70,Kd,=,2000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,5.70,5.70,5.70,c1ccc2c(c1)ncc1nccn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900430>
316,CHEMBL261386,,O=c1[nH]ccc2c3[nH]c(-c4ccccc4Cl)nc3c3ccc(F)cc3c12,8.15,IC50,=,7.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,8.15,8.15,8.15,O=c1[nH]ccc2c3[nH]c(-c4ccccc4)nc3c3ccccc3c12,<rdkit.Chem.rdchem.Mol object at 0x7f46c09553c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09004a0>
317,CHEMBL288441,BOSUTINIB,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,5.19,Kd,=,6500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH1domain-catalytic) kinase domain,False,5.27,5.35,5.19,c1ccc(Nc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900510>
318,CHEMBL302449,GO-6976,Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O,8.50,Ki,=,3.162,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,8.50,8.50,8.50,O=C1NCc2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21,<rdkit.Chem.rdchem.Mol object at 0x7f46c09554a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900580>
319,CHEMBL3039513,DECERNOTINIB,CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F,7.96,IC50,=,11.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin),False,7.96,7.96,7.96,c1cnc(-c2c[nH]c3ncccc23)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09005f0>
320,CHEMBL3114761,,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(O[C@H]2CCN(c3ccnc(F)c3)C2)c1,5.24,IC50,=,5827.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,5.24,5.24,5.24,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(O[C@H]2CCN(c3ccncc3)C2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900660>
321,CHEMBL3114768,,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1ccc(OCCn2ccnc2)cc1,5.13,IC50,=,7368.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,5.13,5.13,5.13,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1ccc(OCCn2ccnc2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09555f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09006d0>
322,CHEMBL3114772,,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1ccc(OCCNc2ccnc(F)c2)cc1,5.01,IC50,=,9844.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,5.01,5.01,5.01,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1ccc(OCCNc2ccncc2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900740>
323,CHEMBL3114775,,Cn1cc(C2=C(Nc3cccc(OCCNc4ccnc(F)c4)c3)C(=O)NC2=O)c2ccccc21,5.29,IC50,=,5104.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,5.29,5.29,5.29,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(OCCNc2ccncc2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09556d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09007b0>
324,CHEMBL3114776,,CN(CCOc1cccc(NC2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c1)c1ccnc(F)c1,6.00,IC50,=,995.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.00,6.00,6.00,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(OCCNc2ccncc2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900820>
325,CHEMBL3114786,,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(OC2CCN(c3ccnc(F)c3)C2)c1,4.92,IC50,=,11927.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,4.92,4.92,4.92,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(OC2CCN(c3ccncc3)C2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09557b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900890>
326,CHEMBL3137308,PEFICITINIB,NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2CC3C[C@@H]1C[C@](O)(C3)C2,8.32,IC50,=,4.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin),False,8.32,8.32,8.32,c1cc(N[C@H]2[C@H]3CC4CC(C3)C[C@H]2C4)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900900>
327,CHEMBL3137331,DEFACTINIB,CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1,6.89,IC50,=,129.01,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) measured after 40 mins by HTRF,False,6.89,6.89,6.89,c1ccc(Nc2nccc(NCc3cnccn3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900970>
328,CHEMBL3301607,FILGOTINIB,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,5.58,IC50,=,2600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human Tyk2 expressed in sf21 baculovirus expression system assessed as phosphorylation level in presence of 1 mM ATP,False,6.88,7.18,5.58,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09009e0>
329,CHEMBL3352835,,COC1CCN(c2nccc(Nc3cc(NC(=O)c4c(Cl)cccc4Cl)ccn3)n2)CC1,7.80,Ki,=,16.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin),False,7.80,7.80,7.80,O=C(Nc1ccnc(Nc2ccnc(N3CCCCC3)n2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900a50>
330,CHEMBL3352892,,C[C@@]1(C#N)CCC[C@H]1Nc1c(C(N)=O)cnn2cccc12,7.52,IC50,=,30.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,7.52,7.52,7.52,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09559e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900ac0>
331,CHEMBL3354185,,COC1CCN(c2nccc(Nc3cc4[nH]c(-c5cn[nH]c5)nc4cn3)n2)CC1,5.51,Ki,=,3100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin),False,5.51,5.51,5.51,c1cc(Nc2cc3[nH]c(-c4cn[nH]c4)nc3cn2)nc(N2CCCCC2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900b30>
332,CHEMBL3354186,,COC1CCN(c2nccc(Nc3cc4[nH]c(-c5cn[nH]c5)cc4cn3)n2)CC1,7.44,Ki,=,36.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin),False,7.44,7.44,7.44,c1cc(Nc2cc3[nH]c(-c4cn[nH]c4)cc3cn2)nc(N2CCCCC2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900ba0>
333,CHEMBL3359907,,C[C@@H](Nc1c(C(N)=O)cnn2cccc12)C(C)(C)C,7.80,IC50,=,16.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,7.80,7.80,7.80,c1cnn2cccc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900c10>
334,CHEMBL3359908,,CC1(C)CCC[C@H]1Nc1c(C(N)=O)cnn2cccc12,8.10,IC50,=,8.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,8.10,8.10,8.10,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900c80>
335,CHEMBL3359909,,C[C@H](Nc1c(C(N)=O)cnn2cccc12)C(C)(C)C,6.17,IC50,=,680.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,6.17,6.17,6.17,c1cnn2cccc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900cf0>
336,CHEMBL3359910,,CC1(C)CCC[C@@H]1Nc1c(C(N)=O)cnn2cccc12,6.89,IC50,=,130.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,6.89,6.89,6.89,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900d60>
337,CHEMBL3359911,,NC(=O)c1cnn2cccc2c1NC1CCCC1,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,6.82,6.82,6.82,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900dd0>
338,CHEMBL3359912,,CC1(C)[C@@H](O)CC[C@H]1Nc1c(C(N)=O)cnn2cccc12,7.10,IC50,=,79.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,7.10,7.10,7.10,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900e40>
339,CHEMBL3359913,,CC1(C)[C@H](O)CC[C@H]1Nc1c(C(N)=O)cnn2cccc12,7.66,IC50,=,22.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,7.66,7.66,7.66,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900eb0>
340,CHEMBL3359914,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cccc23)CC[C@]1(C)O,6.68,IC50,=,210.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,6.68,6.68,6.68,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900f20>
341,CHEMBL3359915,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cccc23)CC[C@@]1(C)O,8.15,IC50,=,7.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,8.15,8.15,8.15,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0900f90>
342,CHEMBL3359916,,CC1(C)C[C@@](C)(O)C[C@H]1Nc1c(C(N)=O)cnn2cccc12,6.55,IC50,=,280.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,6.55,6.55,6.55,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901040>
343,CHEMBL3359917,,CC1(C)C[C@](C)(O)C[C@H]1Nc1c(C(N)=O)cnn2cccc12,7.05,IC50,=,90.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,7.05,7.05,7.05,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0955f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09010b0>
344,CHEMBL3359918,,CC1(C)[C@H](N)CC[C@H]1Nc1c(C(N)=O)cnn2cccc12,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,6.96,6.96,6.96,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901120>
345,CHEMBL3359919,,CC1(C)[C@@H](N)CC[C@H]1Nc1c(C(N)=O)cnn2cccc12,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,6.96,6.96,6.96,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09560b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901190>
346,CHEMBL3359920,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cccc23)CC[C@@]1(C)N,7.28,IC50,=,52.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,7.28,7.28,7.28,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901200>
347,CHEMBL3359921,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cccc23)CC[C@]1(C)N,7.01,IC50,=,97.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,7.01,7.01,7.01,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901270>
348,CHEMBL3359922,,C[C@]1(O)CCC[C@H]1Nc1c(C(N)=O)cnn2cccc12,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,6.82,6.82,6.82,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09012e0>
349,CHEMBL3359923,,C[C@@]1(O)CCC[C@H]1Nc1c(C(N)=O)cnn2cccc12,6.72,IC50,=,190.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,6.72,6.72,6.72,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901350>
350,CHEMBL3359924,,C[C@]1(CO)CCC[C@H]1Nc1c(C(N)=O)cnn2cccc12,7.47,IC50,=,34.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,7.47,7.47,7.47,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09562e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09013c0>
351,CHEMBL3359925,,C[C@@]1(CO)CCC[C@H]1Nc1c(C(N)=O)cnn2cccc12,6.41,IC50,=,390.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,6.41,6.41,6.41,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901430>
352,CHEMBL3359926,,C[C@]1(C#N)CCC[C@H]1Nc1c(C(N)=O)cnn2cccc12,8.22,IC50,=,6.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,8.22,8.22,8.22,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09563c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09014a0>
353,CHEMBL3359927,,C[C@]1(F)CCC[C@H]1Nc1c(C(N)=O)cnn2cccc12,8.70,IC50,=,2.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,8.70,8.70,8.70,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901510>
354,CHEMBL3359928,,C[C@@]1(F)CCC[C@@H]1Nc1c(C(N)=O)cnn2cccc12,6.40,IC50,=,400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,6.40,6.40,6.40,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09564a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901580>
355,CHEMBL3359929,,C[C@@]1(F)CCC[C@H]1Nc1c(C(N)=O)cnn2cccc12,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by caliper assay,False,6.96,6.96,6.96,c1cc2c(NC3CCCC3)ccnn2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09015f0>
356,CHEMBL3360318,,COc1ccc(-c2cccc3nc(NC(=O)C4CC4)nn23)cc1,6.29,IC50,=,519.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2,False,6.29,6.29,6.29,O=C(Nc1nc2cccc(-c3ccccc3)n2n1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901660>
357,CHEMBL3360353,,O=C(Nc1nc2cccc(-c3ccc(CN4CCOCC4)cc3)n2n1)C1CC1,5.68,IC50,=,2096.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition Assay: In vitro inhibition assay using various enzyme.,False,5.68,5.68,5.68,O=C(Nc1nc2cccc(-c3ccc(CN4CCOCC4)cc3)n2n1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09565f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09016d0>
358,CHEMBL3360356,,O=C(Nc1nc2cccc(-c3ccc(CN4CCC(F)(F)CC4)cc3)n2n1)C1CC1,6.90,IC50,=,125.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition Assay: In vitro inhibition assay using various enzyme.,False,6.90,6.90,6.90,O=C(Nc1nc2cccc(-c3ccc(CN4CCCCC4)cc3)n2n1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901740>
359,CHEMBL3426891,,CN1CCN(c2ccc(Nc3ncc(Cl)c(NC[C@H]4CCCO4)n3)cc2)CC1,8.30,IC50,=,5.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using KKSRGDYMTMQIG peptide substrate by 33P Hotspot assay,False,8.30,8.30,8.30,c1cc(NC[C@H]2CCCO2)nc(Nc2ccc(N3CCNCC3)cc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09566d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09017b0>
360,CHEMBL3545215,BMS-911543,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21,7.18,IC50,=,66.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) by scintillation counting method,False,7.18,7.18,7.18,O=C(c1cc2c(nc(Nc3cc[nH]n3)c3nc[nH]c32)[nH]1)N(C1CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901820>
361,CHEMBL3545241,AC-430,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1,5.75,Kd,=,1800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Competition Binding Assay: For the binding assays, streptavidin-coated magnetic beads were treated with biotinylated affinity ligands for 30 min at room temperature to generate affinity resins. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific binding. Binding reactions were assembled by combining kinase, liganded affinity beads, and test compounds in 1x binding buffer (20% SeaBlock, 0.17xPBS, 0.05% Tween 20, 6 mM DTT). Test compounds were prepared as 100x stocks in DMSO and rapidly diluted into the aqueous environment. DMSO was added to control assays lacking a test compound. Primary screen interactions were performed in polypropylene 384-well plates in a final volume of 34 uL, while Kd determinations were performed in polystyrene 96-well plates in a final volume of 135 uL. The assay plates were incubated at room temperature with shaking for 1 hr, long enough for binding reactions to reach equilibrium, and the affinity beads were washed extensively with wash buffer (1xPBS, 0.05% Tween 20) to remove unbound protein. The beads were then resuspended in elution buffer (1xPBS, 0.05% Tween 20, 2 uM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 min. The kinase concentration in the eluates was measured by quantitative PCR. Each kinase was tested individually against each compound.",False,5.75,5.75,5.75,c1ccc(Cc2nc(Nc3cc[nH]n3)c3ccccc3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09567b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901890>
362,CHEMBL3589164,,NC(=O)c1cc(-c2ccc(Cl)c(Cl)c2)cc2c1[nH]c1ccc(C(=O)N3CCOCC3)cc12,7.51,IC50,=,31.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.51,7.51,7.51,O=C(c1ccc2[nH]c3ccc(-c4ccccc4)cc3c2c1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901900>
363,CHEMBL3589165,,NC(=O)c1cc(-c2ccccc2)cc2c1[nH]c1ccc(C(=O)N3CCOCC3)cc12,7.80,IC50,=,16.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.80,7.80,7.80,O=C(c1ccc2[nH]c3ccc(-c4ccccc4)cc3c2c1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901970>
364,CHEMBL3589166,,COc1cccc(-c2cc(C(N)=O)c3[nH]c4ccc(C(=O)N5CCOCC5)cc4c3c2)c1,7.50,IC50,=,32.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.50,7.50,7.50,O=C(c1ccc2[nH]c3ccc(-c4ccccc4)cc3c2c1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09019e0>
365,CHEMBL3589167,,NC(=O)c1cc(-c2ccc(Cl)cc2Cl)cc2c1[nH]c1ccc(C(=O)N3CCOCC3)cc12,7.40,IC50,=,40.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.40,7.40,7.40,O=C(c1ccc2[nH]c3ccc(-c4ccccc4)cc3c2c1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901a50>
366,CHEMBL3589168,,CCCOc1cccc(-c2cc(C(N)=O)c3[nH]c4ccc(C(=O)N5CCOCC5)cc4c3c2)c1,6.89,IC50,=,129.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.89,6.89,6.89,O=C(c1ccc2[nH]c3ccc(-c4ccccc4)cc3c2c1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09569e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901ac0>
367,CHEMBL3589169,,CN1CCN(C(=O)c2ccc3[nH]c4c(C(N)=O)cc(-c5ccc(Cl)cc5)cc4c3c2)CC1,8.55,IC50,=,2.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.55,8.55,8.55,O=C(c1ccc2[nH]c3ccc(-c4ccccc4)cc3c2c1)N1CCNCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901b30>
368,CHEMBL3589170,,CN(C)[C@H]1CCN(C(=O)c2ccc3[nH]c4c(C(N)=O)cc(-c5ccc(Cl)c(Cl)c5)cc4c3c2)C1,7.35,IC50,=,45.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.35,7.35,7.35,O=C(c1ccc2[nH]c3ccc(-c4ccccc4)cc3c2c1)N1CCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901ba0>
369,CHEMBL3589171,,COc1cccc(-c2cc(C(N)=O)c3[nH]c4ccc(C(=O)N5CCN(C)CC5)cc4c3c2)c1,7.41,IC50,=,39.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.41,7.41,7.41,O=C(c1ccc2[nH]c3ccc(-c4ccccc4)cc3c2c1)N1CCNCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901c10>
370,CHEMBL3589172,,NC(=O)c1cc(Cc2ccccc2)cc2c1[nH]c1ccc(C(=O)N3CCOCC3)cc12,6.75,IC50,=,179.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.75,6.75,6.75,O=C(c1ccc2[nH]c3ccc(Cc4ccccc4)cc3c2c1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901c80>
371,CHEMBL3589173,,NC(=O)c1cc(-c2ccc(Cl)c(Cl)c2)cc2c3c([nH]c12)CCC(C(=O)N1CCOCC1)C3,6.22,IC50,=,608.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.22,6.22,6.22,O=C(C1CCc2[nH]c3ccc(-c4ccccc4)cc3c2C1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901cf0>
372,CHEMBL3589174,,NC(=O)c1cc(-c2ccccc2)cc2c1[nH]c1cc(C(=O)N3CCOCC3)ccc12,7.16,IC50,=,70.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.16,7.16,7.16,O=C(c1ccc2c(c1)[nH]c1ccc(-c3ccccc3)cc12)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901d60>
373,CHEMBL3589175,,COc1cccc(-c2cc(C(N)=O)c3[nH]c4cc(C(=O)N5CCOCC5)ccc4c3c2)c1,6.77,IC50,=,171.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.77,6.77,6.77,O=C(c1ccc2c(c1)[nH]c1ccc(-c3ccccc3)cc12)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901dd0>
374,CHEMBL3589176,,COc1ccc(-c2cc(C(N)=O)c3[nH]c4cc(C(=O)N5CCOCC5)ccc4c3c2)cc1F,6.70,IC50,=,201.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.70,6.70,6.70,O=C(c1ccc2c(c1)[nH]c1ccc(-c3ccccc3)cc12)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901e40>
375,CHEMBL3589177,,COc1cccc(-c2cc(C(N)=O)c3[nH]c4cc(C(=O)N5CC[C@H](N(C)C)C5)ccc4c3c2)c1,6.61,IC50,=,243.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.61,6.61,6.61,O=C(c1ccc2c(c1)[nH]c1ccc(-c3ccccc3)cc12)N1CCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901eb0>
376,CHEMBL3589178,,COc1cccc(-c2cc(C(N)=O)c3[nH]c4cc(NC(=O)C5CCOCC5)ccc4c3c2)c1,7.06,IC50,=,87.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.06,7.06,7.06,O=C(Nc1ccc2c(c1)[nH]c1ccc(-c3ccccc3)cc12)C1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901f20>
377,CHEMBL3589179,,NC(=O)c1cc(-c2ccccc2)cc2c1[nH]c1cc(N3CCOCC3)ccc12,6.80,IC50,=,158.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.80,6.80,6.80,c1ccc(-c2ccc3[nH]c4cc(N5CCOCC5)ccc4c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0901f90>
378,CHEMBL3589325,,CN1CCN(c2ccc3c(c2)[nH]c2c(C(N)=O)cc(-c4ccccc4)cc23)CC1,7.15,IC50,=,71.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.15,7.15,7.15,c1ccc(-c2ccc3[nH]c4cc(N5CCNCC5)ccc4c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902040>
379,CHEMBL3589326,,CN1CCN(c2ccc3c(c2)[nH]c2c(C(N)=O)cc(-c4cccc(Cl)c4)cc23)CC1,6.80,IC50,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.80,6.80,6.80,c1ccc(-c2ccc3[nH]c4cc(N5CCNCC5)ccc4c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0956f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09020b0>
380,CHEMBL3589327,,CN1CCN(c2ccc3c(c2)[nH]c2c(C(N)=O)cc(-c4ccc(CN5CCOCC5)c(Cl)c4)cc23)CC1,6.71,IC50,=,197.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.71,6.71,6.71,c1cc(-c2ccc3[nH]c4cc(N5CCNCC5)ccc4c3c2)ccc1CN1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902120>
381,CHEMBL3589328,,Cc1ccc(-c2cc(C(N)=O)c3[nH]c4cc(N5CCOCC5)ccc4c3c2)cn1,6.93,IC50,=,117.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.93,6.93,6.93,c1cncc(-c2ccc3[nH]c4cc(N5CCOCC5)ccc4c3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09570b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902190>
382,CHEMBL3589329,,CN1CCN(c2ccc3c(c2)[nH]c2c(C(N)=O)cc(-c4ccc5c(cnn5C)c4)cc23)CC1,6.61,IC50,=,247.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.61,6.61,6.61,c1cc2[nH]ncc2cc1-c1ccc2[nH]c3cc(N4CCNCC4)ccc3c2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902200>
383,CHEMBL3593765,,NC(=O)c1cnc2[nH]ccc2c1NC1CCN(Cc2ccccc2)CC1,6.96,IC50,=,110.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.96,6.96,6.96,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902270>
384,CHEMBL3601115,,C=CC(=O)Nc1cccc(CNc2nc(Nc3cnn(CCOC)c3)ncc2Cl)c1,6.39,IC50,=,407.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by Z'-Lyte assay,False,6.39,6.39,6.39,c1ccc(CNc2ccnc(Nc3cn[nH]c3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09022e0>
385,CHEMBL3601120,,C=CC(=O)Nc1cccc(CNc2nc(Nc3cnn(CCO)c3)ncc2Cl)c1,6.85,IC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by Z'-Lyte assay,False,6.85,6.85,6.85,c1ccc(CNc2ccnc(Nc3cn[nH]c3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902350>
386,CHEMBL3601862,,C=CC(=O)Nc1cccc(CNc2nc(Nc3cnn(CCOCCOCCOCCNC(=O)CCCC[C@@H]4SC[C@@H]5NC(=O)N[C@H]45)c3)ncc2Cl)c1,5.51,IC50,=,3120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by Z'-Lyte assay,False,5.51,5.51,5.51,O=C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)NCCOCCOCCOCCn1cc(Nc2nccc(NCc3ccccc3)n2)cn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09572e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09023c0>
387,CHEMBL3613597,,CC(C)c1nn(C)cc1-c1nc2c(N3CCN(Cc4cccnc4)CC3)c(Br)cnc2[nH]1,8.00,IC50,=,10.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin),False,8.00,8.00,8.00,c1cncc(CN2CCN(c3ccnc4[nH]c(-c5cn[nH]c5)nc34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902430>
388,CHEMBL3621496,,CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4ccccc4F)c23)CC1,6.12,IC50,=,753.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.12,6.12,6.12,O=C(c1ccc2c(c1)[nH]c1cccc(-c3ccccc3)c12)N1CCNCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09573c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09024a0>
389,CHEMBL3622130,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(NC)nc21,7.16,IC50,=,70.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant Tyk2 (unknown origin) using fluoresceinated peptide as substrate after 60 mins by HTRF assay,False,7.16,7.16,7.16,O=C(c1cc2c(ncc3nc[nH]c32)[nH]1)N(C1CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902510>
390,CHEMBL3622131,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(NCCCOC)nc21,6.16,IC50,=,690.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant Tyk2 (unknown origin) using fluoresceinated peptide as substrate after 60 mins by HTRF assay,False,6.16,6.16,6.16,O=C(c1cc2c(ncc3nc[nH]c32)[nH]1)N(C1CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09574a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902580>
391,CHEMBL3622132,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(NC(=O)OCCOC)nc21,5.77,IC50,=,1700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant Tyk2 (unknown origin) using fluoresceinated peptide as substrate after 60 mins by HTRF assay,False,5.77,5.77,5.77,O=C(c1cc2c(ncc3nc[nH]c32)[nH]1)N(C1CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09025f0>
392,CHEMBL3622133,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(NC(=O)NCCOC)nc21,6.54,IC50,=,290.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant Tyk2 (unknown origin) using fluoresceinated peptide as substrate after 60 mins by HTRF assay,False,6.54,6.54,6.54,O=C(c1cc2c(ncc3nc[nH]c32)[nH]1)N(C1CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902660>
393,CHEMBL3622134,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3nccs3)nc21,7.55,IC50,=,28.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant Tyk2 (unknown origin) using fluoresceinated peptide as substrate after 60 mins by HTRF assay,False,7.55,7.55,7.55,O=C(c1cc2c(nc(Nc3nccs3)c3nc[nH]c32)[nH]1)N(C1CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09575f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09026d0>
394,CHEMBL3622135,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3nc(C)cs3)nc21,7.35,IC50,=,45.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant Tyk2 (unknown origin) using fluoresceinated peptide as substrate after 60 mins by HTRF assay,False,7.35,7.35,7.35,O=C(c1cc2c(nc(Nc3nccs3)c3nc[nH]c32)[nH]1)N(C1CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902740>
395,CHEMBL3622136,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3ncc(C)s3)nc21,7.34,IC50,=,46.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant Tyk2 (unknown origin) using fluoresceinated peptide as substrate after 60 mins by HTRF assay,False,7.34,7.34,7.34,O=C(c1cc2c(nc(Nc3nccs3)c3nc[nH]c32)[nH]1)N(C1CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09576d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09027b0>
396,CHEMBL3622137,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3nc(C)c(C)s3)nc21,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant Tyk2 (unknown origin) using fluoresceinated peptide as substrate after 60 mins by HTRF assay,False,6.96,6.96,6.96,O=C(c1cc2c(nc(Nc3nccs3)c3nc[nH]c32)[nH]1)N(C1CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902820>
397,CHEMBL3622148,,CCn1nc(Nc2nc3c(cc(C(=O)N(C4CC4)C4CC4)n3CC)c3c2ncn3C)cc1C,6.66,IC50,=,220.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) by scintillation counting method,False,6.66,6.66,6.66,O=C(c1cc2c(nc(Nc3cc[nH]n3)c3nc[nH]c32)[nH]1)N(C1CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09577b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902890>
398,CHEMBL3622149,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)nn3C)nc21,5.64,IC50,=,2300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) by scintillation counting method,False,5.64,5.64,5.64,O=C(c1cc2c(nc(Nc3ccn[nH]3)c3nc[nH]c32)[nH]1)N(C1CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902900>
399,CHEMBL3622150,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)[nH]n3)nc21,8.72,IC50,=,1.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) by scintillation counting method,False,8.72,8.72,8.72,O=C(c1cc2c(nc(Nc3cc[nH]n3)c3nc[nH]c32)[nH]1)N(C1CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902970>
400,CHEMBL3622193,,CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4cccc(NC(=O)c5ccc(N(C)C)cc5)c4F)c23)CC1,4.84,IC50,=,14300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,4.84,4.84,4.84,O=C(Nc1cccc(-c2cccc3[nH]c4cc(C(=O)N5CCNCC5)ccc4c23)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09029e0>
401,CHEMBL3622376,,c1nc(-c2cn(CC3CO3)nn2)c2cc[nH]c2n1,5.25,IC50,=,5624.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using KKSRGDYMTMQIG] substrate preincubated for 20 mis followed by addition of ATP and measured after 120 mins in presence of 33P-gamma ATP by hotspot kinase assay,False,5.25,5.25,5.25,c1nc(-c2cn(CC3CO3)nn2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902a50>
402,CHEMBL3622821,UPADACITINIB,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,5.33,IC50,=,4700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) by alpha-screen assay,False,5.33,5.33,5.33,c1cc2c(ncc3ncc([C@@H]4CCNC4)n32)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09579e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902ac0>
403,CHEMBL3622822,,NCCCn1c(CCN)nc2cc(C(N)=O)ccc21,5.19,IC50,=,6400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.19,5.19,5.19,c1ccc2[nH]cnc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902b30>
404,CHEMBL3622823,,NCCCn1c(-c2ccccc2)nc2cc(C(N)=O)ccc21,5.57,IC50,=,2700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.57,5.57,5.57,c1ccc(-c2nc3ccccc3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902ba0>
405,CHEMBL3622824,,NCCc1nc2cc(C(N)=O)ccc2n1CCN,5.51,IC50,=,3100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.51,5.51,5.51,c1ccc2[nH]cnc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902c10>
406,CHEMBL3622825,,NCCCc1nc2cc(C(N)=O)ccc2n1CCN,5.60,IC50,=,2500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.60,5.60,5.60,c1ccc2[nH]cnc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902c80>
407,CHEMBL3622826,,NCCn1c(C2CCNCC2)nc2cc(C(N)=O)ccc21,5.43,IC50,=,3700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of FLAG-tagged human TYK2 expressed in insect Sf9 cells using biotin-EQEDEPEGDYFEWLE-NH2 as substrate by HTRF assay,False,5.43,5.43,5.43,c1ccc2[nH]c(C3CCNCC3)nc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902cf0>
408,CHEMBL3622827,,NCCn1c(C2CCCCC2)nc2cc(C(N)=O)ccc21,5.48,IC50,=,3300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.48,5.48,5.48,c1ccc2[nH]c(C3CCCCC3)nc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902d60>
409,CHEMBL3622828,,NCCn1c(-c2ccccc2)nc2cc(C(N)=O)ccc21,5.38,IC50,=,4200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.38,5.38,5.38,c1ccc(-c2nc3ccccc3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902dd0>
410,CHEMBL3622829,,NCCn1c(Cc2ccccc2)nc2cc(C(N)=O)ccc21,5.12,IC50,=,7500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.12,5.12,5.12,c1ccc(Cc2nc3ccccc3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902e40>
411,CHEMBL3622830,,N#Cc1ccc(-c2nc3cc(C(N)=O)ccc3n2CCN)cc1,5.60,IC50,=,2500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.60,5.60,5.60,c1ccc(-c2nc3ccccc3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902eb0>
412,CHEMBL3622831,,Cc1ccc(-c2nc3cc(C(N)=O)ccc3n2CCN)cc1,5.46,IC50,=,3500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.46,5.46,5.46,c1ccc(-c2nc3ccccc3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902f20>
413,CHEMBL3622832,,CC(C)c1ccc(-c2nc3cc(C(N)=O)ccc3n2CCN)cc1,5.57,IC50,=,2700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.57,5.57,5.57,c1ccc(-c2nc3ccccc3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0902f90>
414,CHEMBL3622833,,NCCn1c(-c2ccc(C(F)(F)F)cc2)nc2cc(C(N)=O)ccc21,5.50,IC50,=,3200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.50,5.50,5.50,c1ccc(-c2nc3ccccc3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903040>
415,CHEMBL3622834,,NCCn1c(-c2ccc(O)cc2)nc2cc(C(N)=O)ccc21,5.50,IC50,=,3200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.50,5.50,5.50,c1ccc(-c2nc3ccccc3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0957f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09030b0>
416,CHEMBL3622835,,NCCn1c(-c2ccc(O)cc2O)nc2cc(C(N)=O)ccc21,5.43,IC50,=,3700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.43,5.43,5.43,c1ccc(-c2nc3ccccc3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903120>
417,CHEMBL3622836,,NCCn1c(-c2ccncc2)nc2cc(C(N)=O)ccc21,5.24,IC50,=,5800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.24,5.24,5.24,c1ccc2[nH]c(-c3ccncc3)nc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09580b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903190>
418,CHEMBL3622837,,NCCn1c(-c2cccnc2N)nc2cc(C(N)=O)ccc21,5.37,IC50,=,4300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.37,5.37,5.37,c1cncc(-c2nc3ccccc3[nH]2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903200>
419,CHEMBL3622838,,NCCn1c(-c2cncnc2)nc2cc(C(N)=O)ccc21,5.55,IC50,=,2800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using 25 uM of ATP and Tyr3 peptide by Z'-LYTE kinase assay,False,5.55,5.55,5.55,c1ccc2[nH]c(-c3cncnc3)nc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903270>
420,CHEMBL3639663,,COc1ccc(Cl)cc1-c1nn(CC(O)(C(F)(F)F)C(F)(F)F)cc1NC(=O)c1cnn2cccnc12,7.51,Ki,=,31.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,7.51,7.51,7.51,O=C(Nc1c[nH]nc1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09032e0>
421,CHEMBL3644618,,CCc1cc(O)c(F)cc1-c1ccc2c(-c3nc4c([nH]3)CCN(C(=O)c3ccc(F)cc3)C4)n[nH]c2c1,9.10,IC50,=,0.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,9.10,9.10,9.10,O=C(c1ccccc1)N1CCc2[nH]c(-c3n[nH]c4cc(-c5ccccc5)ccc34)nc2C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903350>
422,CHEMBL3644620,,CCc1cc(O)c(F)cc1-c1ccc2c(-c3nc4c([nH]3)CCN(C(=O)c3cnc(N5CCCCC5)cn3)C4)n[nH]c2c1,7.53,IC50,=,29.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,7.53,7.53,7.53,O=C(c1cnc(N2CCCCC2)cn1)N1CCc2[nH]c(-c3n[nH]c4cc(-c5ccccc5)ccc34)nc2C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09582e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09033c0>
423,CHEMBL3655080,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)CC(F)(F)F)C1,5.99,IC50,=,1020.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.99,5.99,5.99,c1nc(NC2CCC2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903430>
424,CHEMBL3655081,ABROCITINIB,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1,5.90,IC50,=,1250.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.35,6.8,5.9,c1nc(NC2CCC2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09583c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09034a0>
425,CHEMBL3655082,,CC(C)CS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1,6.32,IC50,=,479.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.32,6.32,6.32,c1nc(NC2CCC2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903510>
426,CHEMBL3655083,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)[C@H]2C[C@H](CC#N)C2)C1,6.01,IC50,=,965.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.01,6.01,6.01,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)C1CCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09584a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903580>
427,CHEMBL3655084,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)[C@H]2C[C@@H](CC#N)C2)C1,5.57,IC50,=,2710.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.57,5.57,5.57,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)C1CCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09035f0>
428,CHEMBL3655085,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)CC2(CC#N)COC2)C1,6.06,IC50,=,878.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.06,6.06,6.06,O=S(=O)(CC1COC1)N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903660>
429,CHEMBL3655086,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)CC2COC2)C1,5.62,IC50,=,2380.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.62,5.62,5.62,O=S(=O)(CC1COC1)N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09585f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09036d0>
430,CHEMBL3655087,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)[C@H]2C[C@@](C)(CC#N)C2)C1,5.28,IC50,=,5240.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.28,5.28,5.28,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)C1CCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903740>
431,CHEMBL3655088,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)[C@H]2C[C@](C)(CC#N)C2)C1,5.61,IC50,=,2440.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.61,5.61,5.61,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)C1CCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09586d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09037b0>
432,CHEMBL3655089,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)c2cc(C#N)ccn2)C1,6.58,IC50,=,260.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.58,6.58,6.58,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)c1ccccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903820>
433,CHEMBL3655090,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)c2cccc(C(C)(C)O)c2)C1,5.18,IC50,=,6670.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.18,5.18,5.18,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09587b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903890>
434,CHEMBL3655092,,CCCS(=O)(=O)N[C@H]1CC[C@@H](N(C)c2ncnc3[nH]ccc23)C1,5.69,IC50,=,2040.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.69,5.69,5.69,c1nc(NC2CCCC2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903900>
435,CHEMBL3655093,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)CC2CC(F)(F)C2)C1,6.11,IC50,=,770.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.11,6.11,6.11,O=S(=O)(CC1CCC1)N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903970>
436,CHEMBL3655094,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)C2CC(F)(F)C2)C1,6.49,IC50,=,323.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.49,6.49,6.49,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)C1CCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09039e0>
437,CHEMBL3655095,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)CC2CC2)C1,5.73,IC50,=,1870.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.73,5.73,5.73,O=S(=O)(CC1CC1)N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903a50>
438,CHEMBL3655096,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)C2CN(C3CC3)C2)C1,5.31,IC50,=,4910.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.31,5.31,5.31,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)C1CN(C2CC2)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09589e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903ac0>
439,CHEMBL3655097,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)NCC2CC2)C1,5.75,IC50,=,1780.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.75,5.75,5.75,O=S(=O)(NCC1CC1)N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903b30>
440,CHEMBL3655098,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)N2CC[C@@H](C#N)C2)C1,6.47,IC50,=,337.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.47,6.47,6.47,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)N1CCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903ba0>
441,CHEMBL3655099,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)N2CC[C@H](C#N)C2)C1,5.95,IC50,=,1120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.95,5.95,5.95,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)N1CCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903c10>
442,CHEMBL3655100,,Cn1cc2c(n1)CN(S(=O)(=O)N[C@H]1C[C@@H](N(C)c3ncnc4[nH]ccc34)C1)C2,5.13,IC50,=,7380.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.13,5.13,5.13,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)N1Cc2c[nH]nc2C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903c80>
443,CHEMBL3655101,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)N2C[C@@H]3C[C@H](C2)O3)C1,5.69,IC50,=,2030.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.69,5.69,5.69,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)N1C[C@H]2C[C@@H](C1)O2,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903cf0>
444,CHEMBL3655102,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)N2CC(C#N)C2)C1,6.48,IC50,=,332.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.48,6.48,6.48,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)N1CCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903d60>
445,CHEMBL3655103,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)N2CCC(c3cc[nH]n3)CC2)C1,6.44,IC50,=,365.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.44,6.44,6.44,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)N1CCC(c2cc[nH]n2)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903dd0>
446,CHEMBL3655104,,CN(CCC#N)S(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1,5.92,IC50,=,1190.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.92,5.92,5.92,c1nc(NC2CCC2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903e40>
447,CHEMBL3658853,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)N2C[C@H]3C[C@@]3(C#N)C2)C1,6.25,IC50,=,565.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.25,6.25,6.25,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)N1CC2C[C@@H]2C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903eb0>
448,CHEMBL3658855,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@H](NS(=O)(=O)N2CCC(C#N)C2)C1,5.10,IC50,=,7870.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.10,5.10,5.10,O=S(=O)(N[C@H]1C[C@H](Nc2ncnc3[nH]ccc23)C1)N1CCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903f20>
449,CHEMBL3658856,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](CS(=O)(=O)N2CCC(F)(F)CC2)C1,6.15,IC50,=,713.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.15,6.15,6.15,O=S(=O)(C[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)N1CCCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0903f90>
450,CHEMBL3658857,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](CS(=O)(=O)N2CCC(O)(C(F)(F)F)CC2)C1,6.45,IC50,=,358.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.45,6.45,6.45,O=S(=O)(C[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)N1CCCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904040>
451,CHEMBL3658858,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](CS(=O)(=O)N2CC[C@@H](C#N)C2)C1,6.35,IC50,=,444.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.35,6.35,6.35,O=S(=O)(C[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)N1CCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0958f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09040b0>
452,CHEMBL3658859,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](CS(=O)(=O)N2CC[C@H](C#N)C2)C1,5.96,IC50,=,1100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.96,5.96,5.96,O=S(=O)(C[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)N1CCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904120>
453,CHEMBL3658860,,CCCCS(=O)(=O)C[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1,6.26,IC50,=,553.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.26,6.26,6.26,c1nc(NC2CCC2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09590b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904190>
454,CHEMBL3658861,,CCCS(=O)(=O)C[C@H]1C[C@H](N(C)c2ncnc3[nH]ccc23)C1,5.44,IC50,=,3610.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.44,5.44,5.44,c1nc(NC2CCC2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904200>
455,CHEMBL3658862,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](CS(=O)(=O)CCC2CC2)C1,5.84,IC50,=,1460.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.84,5.84,5.84,O=S(=O)(CCC1CC1)C[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904270>
456,CHEMBL3658863,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](CS(=O)(=O)CC2CC(F)(F)C2)C1,6.24,IC50,=,582.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.24,6.24,6.24,O=S(=O)(CC1CCC1)C[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09042e0>
457,CHEMBL3658864,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](CS(=O)(=O)[C@H]2CC[C@H](C#N)C2)C1,6.08,IC50,=,840.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.08,6.08,6.08,O=S(=O)(C[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)C1CCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904350>
458,CHEMBL3658865,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](CS(=O)(=O)[C@@H]2CC[C@@H](C#N)C2)C1,5.48,IC50,=,3280.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.48,5.48,5.48,O=S(=O)(C[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)C1CCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09592e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09043c0>
459,CHEMBL3658867,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](CS(=O)(=O)c2ccc(F)c(Cl)c2)C1,6.62,IC50,=,242.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.62,6.62,6.62,O=S(=O)(C[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904430>
460,CHEMBL3658868,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](CS(=O)(=O)c2cc(C#N)ccn2)C1,6.38,IC50,=,418.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.38,6.38,6.38,O=S(=O)(C[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)c1ccccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09593c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09044a0>
461,CHEMBL3658869,,Cc1ncc(S(=O)(=O)N[C@H]2C[C@@H](N(C)c3ncnc4[nH]ccc34)C2)s1,6.26,IC50,=,546.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,6.26,6.26,6.26,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)c1cncs1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904510>
462,CHEMBL366266,,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1,5.64,IC50,=,2310.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,5.64,5.64,5.64,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09594a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904580>
463,CHEMBL3667508,,Cc1cc(NC(=O)c2cnn3cccnc23)n(-c2cc(Cl)ccc2C)n1,7.00,Ki,=,99.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,7.00,7.00,7.00,O=C(Nc1ccnn1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09045f0>
464,CHEMBL3667509,,Cc1cc(NC(=O)c2cnn3cccnc23)n(-c2cc(C#N)ccc2C)n1,6.88,Ki,=,131.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,6.88,6.88,6.88,O=C(Nc1ccnn1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904660>
465,CHEMBL3667510,,Cc1cc(NC(=O)c2cnn3cccnc23)n(-c2cc(Cl)ccc2Cl)n1,6.98,Ki,=,104.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,6.98,6.98,6.98,O=C(Nc1ccnn1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c09595f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09046d0>
466,CHEMBL3667511,,Cc1cc(NC(=O)c2cnn3cccnc23)n(-c2ccccc2Br)n1,6.32,Ki,=,480.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,6.32,6.32,6.32,O=C(Nc1ccnn1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904740>
467,CHEMBL3667512,,O=C(Nc1ccnn1-c1ccccc1Cl)c1cnn2cccnc12,7.01,Ki,=,98.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,7.01,7.01,7.01,O=C(Nc1ccnn1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c09596d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09047b0>
468,CHEMBL3667513,,O=C(Nc1ccnn1-c1ccc(Cl)cc1)c1cnn2cccnc12,6.07,Ki,=,850.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,6.07,6.07,6.07,O=C(Nc1ccnn1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904820>
469,CHEMBL3667514,,O=C(Nc1ccncc1-c1cccc(F)c1)c1cnn2cccnc12,6.85,Ki,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,6.85,6.85,6.85,O=C(Nc1ccncc1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c09597b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904890>
470,CHEMBL3667515,,COc1ccc(Cl)cc1-c1c(NC(=O)c2cnn3cccnc23)cnn1CCO,8.25,Ki,=,5.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,8.25,8.25,8.25,O=C(Nc1cn[nH]c1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904900>
471,CHEMBL3667516,,COc1cnc(C(F)(F)F)cc1-c1nn(CC(C)(C)O)cc1NC(=O)c1cnn2cccnc12,6.46,Ki,=,350.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,6.46,6.46,6.46,O=C(Nc1c[nH]nc1-c1ccncc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904970>
472,CHEMBL3667517,,COc1ccc(C#N)cc1-c1nn(Cc2nncn2C)cc1NC(=O)c1cnn2cccnc12,7.19,Ki,=,65.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,7.19,7.19,7.19,O=C(Nc1cn(Cc2nnc[nH]2)nc1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09049e0>
473,CHEMBL3667518,,COc1ncc(C#N)cc1-c1n[nH]cc1NC(=O)c1cnn2cccnc12,8.18,Ki,=,6.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,8.18,8.18,8.18,O=C(Nc1c[nH]nc1-c1cccnc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904a50>
474,CHEMBL3667519,,COc1ccc(Cl)cc1-c1nc(C)sc1NC(=O)c1cnn2cccnc12,8.68,Ki,=,2.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,8.68,8.68,8.68,O=C(Nc1scnc1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c09599e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904ac0>
475,CHEMBL3667520,,O=C(Nc1c[nH]nc1-n1cc(Cl)ccc1=O)c1cnn2cccnc12,6.01,Ki,=,980.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,6.01,6.01,6.01,O=C(Nc1c[nH]nc1-n1ccccc1=O)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904b30>
476,CHEMBL3667521,,COc1ccc(Cl)cc1-c1c(NC(=O)c2c(N)nn3cccnc23)cnn1CC(N)=O,8.64,Ki,=,2.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,8.64,8.64,8.64,O=C(Nc1cn[nH]c1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904ba0>
477,CHEMBL3667522,,COc1ccc(Cl)cc1-c1nn(CC(=O)N2CCCC2C)cc1NC(=O)c1cnn2cccnc12,8.04,Ki,=,9.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,8.04,8.04,8.04,O=C(Nc1cn(CC(=O)N2CCCC2)nc1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904c10>
478,CHEMBL3667523,,COc1ccc(Cl)cc1-c1nn(CC(=O)N2CC=CCC2)cc1NC(=O)c1cnn2cccnc12,8.00,Ki,=,10.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,8.00,8.00,8.00,O=C(Nc1cn(CC(=O)N2CC=CCC2)nc1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904c80>
479,CHEMBL3667524,,COc1ccc(C#N)cc1-c1nn(CC2(O)CCCC2)cc1NC(=O)c1cnn2cccnc12,7.34,Ki,=,46.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,7.34,7.34,7.34,O=C(Nc1cn(CC2CCCC2)nc1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904cf0>
480,CHEMBL3667525,,COc1ccc(F)cc1-c1nn(CC2(O)CCOCC2)cc1NC(=O)c1cnn2cccnc12,7.33,Ki,=,47.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,7.33,7.33,7.33,O=C(Nc1cn(CC2CCOCC2)nc1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904d60>
481,CHEMBL3667526,,CC1CCCCN1c1nn(CC(C)(C)O)cc1NC(=O)c1cnn2cccnc12,6.39,Ki,=,410.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,6.39,6.39,6.39,O=C(Nc1c[nH]nc1N1CCCCC1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904dd0>
482,CHEMBL3667527,,N#CC1CCN(c2n[nH]cc2NC(=O)c2cnn3cccnc23)CC1,6.64,Ki,=,230.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,6.64,6.64,6.64,O=C(Nc1c[nH]nc1N1CCCCC1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904e40>
483,CHEMBL3667528,,CCOc1ccc(Cl)cc1-c1nn([C@H]2CCCC[C@@H]2O)cc1NC(=O)c1cnn2cccnc12,7.12,Ki,=,76.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,7.12,7.12,7.12,O=C(Nc1cn(C2CCCCC2)nc1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904eb0>
484,CHEMBL3667529,,COc1ncc(Cl)cc1-c1nn(CC(=O)N(C)C)cc1NC(=O)c1cnn2cccnc12,7.85,Ki,=,14.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: The activity of the isolated JAK1, JAK2 or TYK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr) fluorescently labeled on the N-terminus with 5-carboxyfluorescein using the Caliper LabChip technology (Caliper Life Sciences, Hopkinton, Mass.). To determine the inhibition constants (Ki) of Examples 1-508, compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM.",False,7.85,7.85,7.85,O=C(Nc1c[nH]nc1-c1cccnc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904f20>
485,CHEMBL3670390,,Cc1cc(NC(=O)c2cnn3ccc(N)nc23)n(-c2cc(Cl)ccc2C)n1,7.48,Ki,=,32.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"JAK1 and TYK2 Inhibition Assay: To determine inhibition constants (Ki), compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. After termination of the kinase reaction, the proportion of phosphorylated product was determined as a fraction of total peptide substrate using the Caliper LabChip 3000 according to the manufacturer's specifications. Ki values were then determined using the Morrison tight binding model (Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969).",False,7.48,7.48,7.48,O=C(Nc1ccnn1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0904f90>
486,CHEMBL3670391,,Cc1nc(-c2ccccc2C)c(NC(=O)c2cnn3ccc(N)nc23)s1,7.36,Ki,=,43.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"JAK1 and TYK2 Inhibition Assay: To determine inhibition constants (Ki), compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. After termination of the kinase reaction, the proportion of phosphorylated product was determined as a fraction of total peptide substrate using the Caliper LabChip 3000 according to the manufacturer's specifications. Ki values were then determined using the Morrison tight binding model (Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969).",False,7.36,7.36,7.36,O=C(Nc1scnc1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905040>
487,CHEMBL3670392,,Cc1cc(NC(=O)c2cnn3ccc(Nc4cccc(C(F)(F)F)c4)nc23)on1,7.21,Ki,=,62.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"JAK1 and TYK2 Inhibition Assay: To determine inhibition constants (Ki), compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. After termination of the kinase reaction, the proportion of phosphorylated product was determined as a fraction of total peptide substrate using the Caliper LabChip 3000 according to the manufacturer's specifications. Ki values were then determined using the Morrison tight binding model (Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969).",False,7.21,7.21,7.21,O=C(Nc1ccno1)c1cnn2ccc(Nc3ccccc3)nc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0959f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09050b0>
488,CHEMBL3670393,,Nc1ccn2ncc(C(=O)Nc3c[nH]nc3-c3cc(Cl)ccc3Cl)c2n1,8.39,Ki,=,4.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"JAK1 and TYK2 Inhibition Assay: To determine inhibition constants (Ki), compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. After termination of the kinase reaction, the proportion of phosphorylated product was determined as a fraction of total peptide substrate using the Caliper LabChip 3000 according to the manufacturer's specifications. Ki values were then determined using the Morrison tight binding model (Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969).",False,8.39,8.39,8.39,O=C(Nc1c[nH]nc1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905120>
489,CHEMBL3670394,,Nc1ccn2ncc(C(=O)Nc3ccnn3-c3cc(Cl)ccc3Cl)c2n1,7.36,Ki,=,43.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"JAK1 and TYK2 Inhibition Assay: To determine inhibition constants (Ki), compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. After termination of the kinase reaction, the proportion of phosphorylated product was determined as a fraction of total peptide substrate using the Caliper LabChip 3000 according to the manufacturer's specifications. Ki values were then determined using the Morrison tight binding model (Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969).",False,7.36,7.36,7.36,O=C(Nc1ccnn1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905190>
490,CHEMBL3670395,,O=C(NC1CCOCC1)c1cnn2ccc(NC3Cc4ccccc4C3)nc12,6.82,Ki,=,152.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"JAK1 and TYK2 Inhibition Assay: To determine inhibition constants (Ki), compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. After termination of the kinase reaction, the proportion of phosphorylated product was determined as a fraction of total peptide substrate using the Caliper LabChip 3000 according to the manufacturer's specifications. Ki values were then determined using the Morrison tight binding model (Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969).",False,6.82,6.82,6.82,O=C(NC1CCOCC1)c1cnn2ccc(NC3Cc4ccccc4C3)nc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905200>
491,CHEMBL3670397,,Cc1cc(NC(=O)c2cnn3ccc(N)nc23)n(-c2ccccc2C)n1,7.01,Ki,=,97.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"JAK1 and TYK2 Inhibition Assay: To determine inhibition constants (Ki), compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. After termination of the kinase reaction, the proportion of phosphorylated product was determined as a fraction of total peptide substrate using the Caliper LabChip 3000 according to the manufacturer's specifications. Ki values were then determined using the Morrison tight binding model (Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969).",False,7.01,7.01,7.01,O=C(Nc1ccnn1-c1ccccc1)c1cnn2cccnc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905270>
492,CHEMBL3671804,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4cccnc4)cc23)CC[C@]1(C)N,7.47,IC50,=,34.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.47,7.47,7.47,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09052e0>
493,CHEMBL3671805,,Cc1ccncc1-c1cc2c(N[C@@H]3CC[C@](C)(N)C3(C)C)c(C(N)=O)cnn2c1,6.75,IC50,=,180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,6.75,6.75,6.75,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905350>
494,CHEMBL3675685,,O=C(Nc1nccc2nc(-c3c(Cl)cccc3Cl)sc12)C1CC1,9.30,Ki,=,0.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,9.30,9.30,9.30,O=C(Nc1nccc2nc(-c3ccccc3)sc12)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09053c0>
495,CHEMBL3675686,,COC(=O)Nc1nccc2nc(-c3c(Cl)cccc3Cl)sc12,8.85,Ki,=,1.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,8.85,8.85,8.85,c1ccc(-c2nc3ccncc3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905430>
496,CHEMBL3675687,,O=C(CO)Nc1nccc2nc(-c3c(Cl)cccc3Cl)sc12,7.64,Ki,=,23.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,7.64,7.64,7.64,c1ccc(-c2nc3ccncc3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09054a0>
497,CHEMBL3675688,,O=C(Nc1nccc2nc(-c3c(F)cccc3Cl)sc12)NC1CC1,8.85,Ki,=,1.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,8.85,8.85,8.85,O=C(Nc1nccc2nc(-c3ccccc3)sc12)NC1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905510>
498,CHEMBL3675689,,OCc1ccnc(Nc2nccc3nc(-c4c(Cl)cccc4Cl)sc23)c1,9.52,Ki,=,0.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,9.52,9.52,9.52,c1ccc(-c2nc3ccnc(Nc4ccccn4)c3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905580>
499,CHEMBL3675690,,Cc1cc(Nc2nccc3nc(-c4c(Cl)cc(CO)cc4Cl)sc23)ncn1,9.00,Ki,=,1.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,9.00,9.00,9.00,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09055f0>
500,CHEMBL3675691,,O=C(Nc1ncnc2nc(-c3c(Cl)cccc3Cl)sc12)C1CC1,8.21,Ki,=,6.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,8.21,8.21,8.21,O=C(Nc1ncnc2nc(-c3ccccc3)sc12)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905660>
501,CHEMBL3675692,,OC1CN(c2cc(Nc3ncnc4nc(-c5c(Cl)cccc5Cl)sc34)ncn2)C1,7.06,Ki,=,87.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,7.06,7.06,7.06,c1ccc(-c2nc3ncnc(Nc4cc(N5CCC5)ncn4)c3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09056d0>
502,CHEMBL3675693,,Cc1cc(Nc2nccc3nc(-c4ccccc4Cl)sc23)nc(C)n1,8.07,Ki,=,8.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,8.07,8.07,8.07,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905740>
503,CHEMBL3675694,,CCc1cc(Nc2nccc3nc(-c4c(Cl)cc(C(N)=O)cc4Cl)sc23)ncn1,8.80,Ki,=,1.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,8.80,8.80,8.80,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09057b0>
504,CHEMBL3675695,,Cc1cc(Nc2nccc3nc(-c4c(Cl)cc(C5CC5)cc4Cl)sc23)ncn1,8.39,Ki,=,4.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,8.39,8.39,8.39,c1cc(Nc2nccc3nc(-c4ccc(C5CC5)cc4)sc23)ncn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905820>
505,CHEMBL3675696,,N#Cc1cc(Cl)c(-c2nc3c(F)cnc(NC(=O)C4CC4)c3s2)c(Cl)c1,8.82,Ki,=,1.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,8.82,8.82,8.82,O=C(Nc1nccc2nc(-c3ccccc3)sc12)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905890>
506,CHEMBL3675697,,N#Cc1cnc(Nc2cc(N)ncn2)c2sc(-c3c(F)cccc3Cl)nc12,9.40,Ki,=,0.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,9.40,9.40,9.40,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905900>
507,CHEMBL3675698,,[C-]#[N+]c1cccc(F)c1-c1nc2c(C#N)cnc(Nc3cc(N)ncn3)c2s1,9.52,Ki,=,0.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,9.52,9.52,9.52,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905970>
508,CHEMBL3675699,,[C-]#[N+]c1cc(C#N)cc([N+]#[C-])c1-c1nc2ccnc(Nc3cc(C)nc(C)n3)c2s1,9.10,Ki,=,0.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,9.10,9.10,9.10,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09059e0>
509,CHEMBL3675700,,[C-]#[N+]c1cccc(Cl)c1-c1nc2ccnc(Nc3cc(CO)nc(C)n3)c2s1,9.30,Ki,=,0.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 M peptide substrate, 25 M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979).",False,9.30,9.30,9.30,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3s2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905a50>
510,CHEMBL3694577,,Clc1cnc2nc1NCc1cccc(c1)OCc1cccc(c1)N2,6.40,IC50,=,400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"TYK2 Assay: TYK2 assays described by James E. Thompson et. al, Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor, Bioorganic & Medicinal Chemistry Letters, Volume 12, Issue 8, 22 Apr. 2002, Pages 1219-1223].",False,6.40,6.40,6.40,c1cc2cc(c1)Nc1nccc(n1)NCc1cccc(c1)OC2,<rdkit.Chem.rdchem.Mol object at 0x7f46c095a9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905ac0>
511,CHEMBL3694578,,Clc1cnc2nc1NCc1cccc(c1)OCCc1cccc(c1)N2,7.46,IC50,=,35.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"TYK2 Assay: TYK2 assays described by James E. Thompson et. al, Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor, Bioorganic & Medicinal Chemistry Letters, Volume 12, Issue 8, 22 Apr. 2002, Pages 1219-1223].",False,7.46,7.46,7.46,c1cc2cc(c1)Nc1nccc(n1)NCc1cccc(c1)OCC2,<rdkit.Chem.rdchem.Mol object at 0x7f46c095aa50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905b30>
512,CHEMBL3694579,,O=S1(=O)Nc2cccc(c2)CNc2nc(ncc2Cl)Nc2cccc1c2,6.08,IC50,=,830.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"TYK2 Assay: TYK2 assays described by James E. Thompson et. al, Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor, Bioorganic & Medicinal Chemistry Letters, Volume 12, Issue 8, 22 Apr. 2002, Pages 1219-1223].",False,6.08,6.08,6.08,O=S1(=O)Nc2cccc(c2)CNc2ccnc(n2)Nc2cccc1c2,<rdkit.Chem.rdchem.Mol object at 0x7f46c095aac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905ba0>
513,CHEMBL3694581,,Clc1cnc2nc1NCc1cccc(c1)OCCCc1cccc(c1)N2,7.60,IC50,=,25.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"TYK2 Assay: TYK2 assays described by James E. Thompson et. al, Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor, Bioorganic & Medicinal Chemistry Letters, Volume 12, Issue 8, 22 Apr. 2002, Pages 1219-1223].",False,7.60,7.60,7.60,c1cc2cc(c1)Nc1nccc(n1)NCc1cccc(c1)OCCC2,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ab30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905c10>
514,CHEMBL3694583,,Clc1cnc2nc1NCc1cccc(c1)OCCOc1cccc(c1)N2,7.37,IC50,=,43.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"TYK2 Assay: TYK2 assays described by James E. Thompson et. al, Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor, Bioorganic & Medicinal Chemistry Letters, Volume 12, Issue 8, 22 Apr. 2002, Pages 1219-1223].",False,7.37,7.37,7.37,c1cc2cc(c1)OCCOc1cccc(c1)Nc1nccc(n1)NC2,<rdkit.Chem.rdchem.Mol object at 0x7f46c095aba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905c80>
515,CHEMBL3694584,,Clc1cnc2nc1NCCc1cccc(c1)OCc1cccc(c1)N2,6.36,IC50,=,438.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"TYK2 Assay: TYK2 assays described by James E. Thompson et. al, Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor, Bioorganic & Medicinal Chemistry Letters, Volume 12, Issue 8, 22 Apr. 2002, Pages 1219-1223].",False,6.36,6.36,6.36,c1cc2cc(c1)Nc1nccc(n1)NCCc1cccc(c1)OC2,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ac10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905cf0>
516,CHEMBL3694585,,Clc1cnc2nc1NCCc1cccc(c1)OCCc1cccc(c1)N2,7.28,IC50,=,53.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"TYK2 Assay: TYK2 assays described by James E. Thompson et. al, Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor, Bioorganic & Medicinal Chemistry Letters, Volume 12, Issue 8, 22 Apr. 2002, Pages 1219-1223].",False,7.28,7.28,7.28,c1cc2cc(c1)Nc1nccc(n1)NCCc1cccc(c1)OCC2,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ac80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905d60>
517,CHEMBL3694586,,Clc1cnc2nc1NCCCc1cccc(c1)OCc1cccc(c1)N2,6.62,IC50,=,237.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"TYK2 Assay: TYK2 assays described by James E. Thompson et. al, Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor, Bioorganic & Medicinal Chemistry Letters, Volume 12, Issue 8, 22 Apr. 2002, Pages 1219-1223].",False,6.62,6.62,6.62,c1cc2cc(c1)Nc1nccc(n1)NCCCc1cccc(c1)OC2,<rdkit.Chem.rdchem.Mol object at 0x7f46c095acf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905dd0>
518,CHEMBL3694588,,Clc1cnc2nc1NCCc1cccc(c1)OCCCc1cccc(c1)N2,6.40,IC50,=,400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"TYK2 Assay: TYK2 assays described by James E. Thompson et. al, Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor, Bioorganic & Medicinal Chemistry Letters, Volume 12, Issue 8, 22 Apr. 2002, Pages 1219-1223].",False,6.40,6.40,6.40,c1cc2cc(c1)Nc1nccc(n1)NCCc1cccc(c1)OCCC2,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ad60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905e40>
519,CHEMBL3694589,,Clc1cnc2nc1NCCCc1cccc(c1)OCCc1cccc(c1)N2,6.97,IC50,=,106.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"TYK2 Assay: TYK2 assays described by James E. Thompson et. al, Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor, Bioorganic & Medicinal Chemistry Letters, Volume 12, Issue 8, 22 Apr. 2002, Pages 1219-1223].",False,6.97,6.97,6.97,c1cc2cc(c1)Nc1nccc(n1)NCCCc1cccc(c1)OCC2,<rdkit.Chem.rdchem.Mol object at 0x7f46c095add0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905eb0>
520,CHEMBL3694590,,Clc1cnc2nc1NCc1cc(ccc1Br)OCCCc1cccc(c1)N2,6.52,IC50,=,300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"TYK2 Assay: TYK2 assays described by James E. Thompson et. al, Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor, Bioorganic & Medicinal Chemistry Letters, Volume 12, Issue 8, 22 Apr. 2002, Pages 1219-1223].",False,6.52,6.52,6.52,c1cc2cc(c1)Nc1nccc(n1)NCc1cccc(c1)OCCC2,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ae40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905f20>
521,CHEMBL3694591,,Clc1cnc2nc1NCc1cc(ccc1-c1ccccc1)OCCCc1cccc(c1)N2,6.40,IC50,=,400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"TYK2 Assay: TYK2 assays described by James E. Thompson et. al, Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor, Bioorganic & Medicinal Chemistry Letters, Volume 12, Issue 8, 22 Apr. 2002, Pages 1219-1223].",False,6.40,6.40,6.40,c1ccc(-c2ccc3cc2CNc2ccnc(n2)Nc2cccc(c2)CCCO3)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095aeb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0905f90>
522,CHEMBL3694592,,Clc1cnc2nc1NCc1cc(Br)cc(c1)OCCCc1cccc(c1)N2,6.83,IC50,=,149.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"TYK2 Assay: TYK2 assays described by James E. Thompson et. al, Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor, Bioorganic & Medicinal Chemistry Letters, Volume 12, Issue 8, 22 Apr. 2002, Pages 1219-1223].",False,6.83,6.83,6.83,c1cc2cc(c1)Nc1nccc(n1)NCc1cccc(c1)OCCC2,<rdkit.Chem.rdchem.Mol object at 0x7f46c095af20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906040>
523,CHEMBL3694593,,Nc1ccc2cc1CCc1cncc(c1)Nc1ncc(Cl)c(n1)NC2,6.41,IC50,=,386.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"TYK2 Assay: TYK2 assays described by James E. Thompson et. al, Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor, Bioorganic & Medicinal Chemistry Letters, Volume 12, Issue 8, 22 Apr. 2002, Pages 1219-1223].",False,6.41,6.41,6.41,c1cc2cc(c1)CNc1ccnc(n1)Nc1cncc(c1)CC2,<rdkit.Chem.rdchem.Mol object at 0x7f46c095af90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09060b0>
524,CHEMBL3703085,,CN(C)[C@H]1CC[C@H](n2cc(C(N)=O)c(Nc3ccc(Cl)cc3)n2)[C@@H](C#N)C1,7.89,IC50,=,13.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,7.89,7.89,7.89,c1ccc(Nc2ccn(C3CCCCC3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906120>
525,CHEMBL3745954,,COc1ccc(F)c(-c2nc3c(NCC4CCNCC4)c(Cl)cnc3[nH]2)c1,4.94,IC50,=,11400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal 6His-tagged human recombinant Tyk2,False,4.94,4.94,4.94,c1ccc(-c2nc3c(NCC4CCNCC4)ccnc3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906190>
526,CHEMBL3746463,,COc1cc(F)c(-c2nc3c(NCC4CCNCC4)c(Cl)cnc3[nH]2)cc1OC,4.55,IC50,=,28000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal 6His-tagged human recombinant Tyk2,False,4.55,4.55,4.55,c1ccc(-c2nc3c(NCC4CCNCC4)ccnc3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906200>
527,CHEMBL3747305,,COc1ccc(-c2nc3c(NCC4CCNCC4)c(Cl)cnc3[nH]2)cc1OC,5.89,IC50,=,1280.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal 6His-tagged human recombinant Tyk2,False,5.89,5.89,5.89,c1ccc(-c2nc3c(NCC4CCNCC4)ccnc3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906270>
528,CHEMBL375284,,Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]ncc34)cc2)c1,6.00,Ki,=,1000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.00,6.00,6.00,O=C(Nc1ccccc1)Nc1ccc(-c2cccc3[nH]ncc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09062e0>
529,CHEMBL3763184,,CCC(C(C)C)n1cc(-c2ccn(C)n2)c2[nH]nc(N)c2c1=O,5.16,IC50,=,6900.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells assessed as reduction in IL-23-induced luciferase gene expression after 24 hrs,False,6.1,7.04,5.16,O=c1[nH]cc(-c2cc[nH]n2)c2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906350>
530,CHEMBL3763213,,CC(C)[C@H](C)n1cc(-c2cc(N3CCOCC3)n(C)n2)c2[nH]nc(N)c2c1=O,6.70,IC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells assessed as reduction in IL-23-induced luciferase gene expression after 24 hrs,False,7.98,9.26,6.7,O=c1[nH]cc(-c2cc(N3CCOCC3)[nH]n2)c2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09063c0>
531,CHEMBL3763252,,CC(C)C(C)n1cc(-c2ccc(N3CCOCC3)cn2)c2[nH]nc(N)c2c1=O,7.27,IC50,=,54.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells assessed as reduction in IL-23-induced luciferase gene expression after 24 hrs,False,8.04,8.82,7.27,O=c1[nH]cc(-c2ccc(N3CCOCC3)cn2)c2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906430>
532,CHEMBL3763289,,Nc1n[nH]c2ccn(-c3ccccc3Cl)c(=O)c12,6.43,IC50,=,370.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 kinase domain (885-1176 residues) using Ulight-JAK1 substrate peptide assessed as reduction in ATP-dependent substrate phosphorylation after 45 mins by TR-FRET assay,False,6.43,6.43,6.43,O=c1c2cn[nH]c2ccn1-c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09064a0>
533,CHEMBL3763310,,O=C(O)Cc1cnc(Nc2n[nH]c3ccc(-c4ncccc4Cl)cc23)s1,6.19,IC50,=,650.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 kinase domain (885-1176 residues) using Ulight-JAK1 substrate peptide assessed as reduction in ATP-dependent substrate phosphorylation after 45 mins by TR-FRET assay,False,6.19,6.19,6.19,c1ccc(-c2ccc3[nH]nc(Nc4nccs4)c3c2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906510>
534,CHEMBL3763358,,COCCOc1cc2c(-n3nc(-c4ccccn4)nc3N)ncnc2cc1OC,7.39,Kd,=,41.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding affinity to human TYK2 JH2 domain pseudokinase,False,7.39,7.39,7.39,c1ccc(-c2ncn(-c3ncnc4ccccc34)n2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906580>
535,CHEMBL3763697,,CC(C)Cn1cc(-c2ccn(C)n2)c2[nH]nc(N)c2c1=O,5.96,IC50,=,1100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells assessed as reduction in IL-23-induced luciferase gene expression after 24 hrs,False,6.55,7.14,5.96,O=c1[nH]cc(-c2cc[nH]n2)c2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09065f0>
536,CHEMBL3763833,,Cc1ccccc1-n1cc(-c2ccccc2)c2[nH]nc(N)c2c1=O,6.11,IC50,=,770.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 kinase domain (885-1176 residues) using Ulight-JAK1 substrate peptide assessed as reduction in ATP-dependent substrate phosphorylation after 45 mins by TR-FRET assay,False,6.11,6.11,6.11,O=c1c2cn[nH]c2c(-c2ccccc2)cn1-c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906660>
537,CHEMBL3763864,,Cc1ccccc1-n1cc(-c2ccn(C)n2)c2[nH]nc(N)c2c1=O,7.52,IC50,=,30.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 kinase domain (885-1176 residues) using Ulight-JAK1 substrate peptide assessed as reduction in ATP-dependent substrate phosphorylation after 45 mins by TR-FRET assay,False,7.52,7.52,7.52,O=c1c2cn[nH]c2c(-c2cc[nH]n2)cn1-c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09066d0>
538,CHEMBL3763991,,CC(C)[C@H](C)n1cc(-c2ccc(N3CCOCC3)cn2)c2[nH]nc(N)c2c1=O,7.32,IC50,=,48.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells assessed as reduction in IL-23-induced luciferase gene expression after 24 hrs,False,8.18,9.04,7.32,O=c1[nH]cc(-c2ccc(N3CCOCC3)cn2)c2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906740>
539,CHEMBL3764030,,CC(C)[C@H](C)n1cc(-c2ccn(C)n2)c2[nH]nc(N)c2c1=O,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells assessed as reduction in IL-23-induced luciferase gene expression after 24 hrs,False,7.54,8.26,6.82,O=c1[nH]cc(-c2cc[nH]n2)c2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09067b0>
540,CHEMBL3764167,,CCC(C)n1cc(-c2ccn(C)n2)c2[nH]nc(N)c2c1=O,6.19,IC50,=,650.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells assessed as reduction in IL-23-induced luciferase gene expression after 24 hrs,False,6.84,7.48,6.19,O=c1[nH]cc(-c2cc[nH]n2)c2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906820>
541,CHEMBL3764277,,CC(C)[C@H](C)n1cc(-c2cc(C3CCOCC3)n(C)n2)c2[nH]nc(N)c2c1=O,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells assessed as reduction in IL-23-induced luciferase gene expression after 24 hrs,False,7.98,9.01,6.96,O=c1[nH]cc(-c2cc(C3CCOCC3)[nH]n2)c2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906890>
542,CHEMBL3764383,,CC(C)[C@@H](C)n1cc(-c2ccc(N3CCOCC3)cn2)c2[nH]nc(N)c2c1=O,6.36,IC50,=,440.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells assessed as reduction in IL-23-induced luciferase gene expression after 24 hrs,False,7.18,8.01,6.36,O=c1[nH]cc(-c2ccc(N3CCOCC3)cn2)c2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906900>
543,CHEMBL3764463,,Nc1n[nH]c2c(-c3ccccn3)cn(-c3ccccc3Cl)c(=O)c12,8.17,IC50,=,6.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 kinase domain (885-1176 residues) using Ulight-JAK1 substrate peptide assessed as reduction in ATP-dependent substrate phosphorylation after 45 mins by TR-FRET assay,False,8.17,8.17,8.17,O=c1c2cn[nH]c2c(-c2ccccn2)cn1-c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906970>
544,CHEMBL3764637,,CC(C)C(C)n1cc(-c2ccn(C)n2)c2[nH]nc(N)c2c1=O,6.51,IC50,=,310.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells assessed as reduction in IL-23-induced luciferase gene expression after 24 hrs,False,7.36,8.2,6.51,O=c1[nH]cc(-c2cc[nH]n2)c2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09069e0>
545,CHEMBL3765131,,Cn1ccc(-c2cn(-c3ccccc3Cl)c(=O)c3c(N)n[nH]c23)n1,8.00,IC50,=,9.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 kinase domain (885-1176 residues) using Ulight-JAK1 substrate peptide assessed as reduction in ATP-dependent substrate phosphorylation after 45 mins by TR-FRET assay,False,8.00,8.00,8.00,O=c1c2cn[nH]c2c(-c2cc[nH]n2)cn1-c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906a50>
546,CHEMBL3765517,,CC(C)[C@H](C)n1cc(-c2cc(N3CCS(=O)(=O)CC3)n(C)n2)c2[nH]nc(N)c2c1=O,6.64,IC50,=,230.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells assessed as reduction in IL-23-induced luciferase gene expression after 24 hrs,False,7.78,8.92,6.64,O=c1[nH]cc(-c2cc(N3CCS(=O)(=O)CC3)[nH]n2)c2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095b9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906ac0>
547,CHEMBL3765822,,CC(C)[C@@H](C)n1cc(-c2cc(C(C)(C)O)n(C)n2)c2[nH]nc(N)c2c1=O,6.72,IC50,=,190.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells assessed as reduction in IL-23-induced luciferase gene expression after 24 hrs,False,7.7,8.68,6.72,O=c1[nH]cc(-c2cc[nH]n2)c2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ba50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906b30>
548,CHEMBL3780091,,N[C@H]1CC[C@@H](Nc2cc[nH]c(=O)c2-c2nc3ccccc3[nH]2)CC1,8.82,IC50,=,1.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.82,8.82,8.82,O=c1[nH]ccc(NC2CCCCC2)c1-c1nc2ccccc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095bac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906ba0>
549,CHEMBL3780467,,COC(=O)C1CCc2[nH]c(-c3c(N[C@H]4CC[C@@H](N)CC4)cc[nH]c3=O)nc2C1,8.15,IC50,=,7.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.15,8.15,8.15,O=c1[nH]ccc(NC2CCCCC2)c1-c1nc2c([nH]1)CCCC2,<rdkit.Chem.rdchem.Mol object at 0x7f46c095bb30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906c10>
550,CHEMBL3781427,,O=c1[nH]ccc(NC2CCOCC2)c1-c1nc2ccccc2[nH]1,8.05,IC50,=,9.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.05,8.05,8.05,O=c1[nH]ccc(NC2CCOCC2)c1-c1nc2ccccc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095bba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906c80>
551,CHEMBL3782012,,CS(=O)(=O)c1ccc(Nc2nn(C3CCOCC3)cc2C(N)=O)cc1,7.22,IC50,=,60.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,7.22,7.22,7.22,c1ccc(Nc2ccn(C3CCOCC3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095bc10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906cf0>
552,CHEMBL3787112,,Nc1ncnc2c1c(-c1cccc(O)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,5.82,IC50,=,1500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) in presence of [gamma33P]ATP,False,5.82,5.82,5.82,c1ccc(-c2cn([C@H]3C[C@@H](CN4CCC4)C3)c3ncncc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095bc80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906d60>
553,CHEMBL3814099,,NCCCn1c2ccc(C(N)=O)cc2nc1[C@H]1CC[C@H](O)CC1,4.51,IC50,=,30700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using tyrosine 3 peptide as substrate by z'-lyte assay,False,4.51,4.51,4.51,c1ccc2[nH]c(C3CCCCC3)nc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095bcf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906dd0>
554,CHEMBL3814195,,NCCCn1c(C2CCNCC2)nc2cc(C(N)=O)ccc21,4.51,IC50,=,31000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using tyrosine 3 peptide as substrate by z'-lyte assay,False,4.51,4.51,4.51,c1ccc2[nH]c(C3CCNCC3)nc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095bd60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906e40>
555,CHEMBL3814293,,NC(=O)c1ccc2c(c1)nc([C@H]1CC[C@H](O)CC1)n2CCO,5.37,IC50,=,4300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using tyrosine 3 peptide as substrate by z'-lyte assay,False,5.37,5.37,5.37,c1ccc2[nH]c(C3CCCCC3)nc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095bdd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906eb0>
556,CHEMBL3814406,,C[C@@H](O)Cn1c2ccc(C(N)=O)cc2nc1[C@H]1CC[C@H](O)CC1,4.59,IC50,=,25700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using tyrosine 3 peptide as substrate by z'-lyte assay,False,4.59,4.59,4.59,c1ccc2[nH]c(C3CCCCC3)nc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095be40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906f20>
557,CHEMBL3814934,,CNCCn1c(C2CCNCC2)nc2cc(C(N)=O)ccc21,5.39,IC50,=,4100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using tyrosine 3 peptide as substrate by z'-lyte assay,False,5.39,5.39,5.39,c1ccc2[nH]c(C3CCNCC3)nc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095beb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0906f90>
558,CHEMBL3814951,,NC(=O)c1ccc2c(c1)nc([C@H]1CC[C@H](O)CC1)n2CCCO,4.38,IC50,=,42200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using tyrosine 3 peptide as substrate by z'-lyte assay,False,4.38,4.38,4.38,c1ccc2[nH]c(C3CCCCC3)nc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095bf20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907040>
559,CHEMBL3815154,,CNCCn1c2ccc(C(N)=O)cc2nc1[C@H]1CC[C@H](O)CC1,5.25,IC50,=,5600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using tyrosine 3 peptide as substrate by z'-lyte assay,False,5.25,5.25,5.25,c1ccc2[nH]c(C3CCCCC3)nc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095bf90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09070b0>
560,CHEMBL385478,,c1cnc2[nH]cc(-c3ccnc(NC4CCCCC4)n3)c2c1,6.50,Ki,=,316.23,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.50,6.50,6.50,c1cnc2[nH]cc(-c3ccnc(NC4CCCCC4)n3)c2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907120>
561,CHEMBL386051,,CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1,6.37,Kd,=,430.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH1domain-catalytic) kinase domain,False,6.37,6.37,6.37,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907190>
562,CHEMBL386661,,CNc1ncc2cc(-c3cc(C(=O)Nc4cc(C(F)(F)F)ccc4OC4CCN(C)CC4)ccc3C)ccc2n1,5.56,IC50,=,2730.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 by HTRF kinase assay,False,5.56,5.56,5.56,O=C(Nc1ccccc1OC1CCNCC1)c1cccc(-c2ccc3ncncc3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907200>
563,CHEMBL3884319,,CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21,5.00,IC50,=,10000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant N-terminal GST-tagged TYK2 cytoplasmic domain (833 to 1187 residues) expressed in baculovirus expression system,False,5.00,5.00,5.00,O=C1Cc2cnc(Nc3ccccc3)nc2N1[C@H]1CCc2ccccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907270>
564,CHEMBL3889588,,Fc1ccc(C2(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)CC2)cc1,6.11,IC50,=,780.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.11,6.11,6.11,c1ccc(C2(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09072e0>
565,CHEMBL388978,STAUROSPORINE,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,5.51,Kd,=,3100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,8.28,9.69,5.51,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907350>
566,CHEMBL3889789,,O[C@H]1Cc2ccccc2[C@H]1NC1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.70,IC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.70,6.70,6.70,c1ccc2c(c1)CC[C@@H]2NC1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09073c0>
567,CHEMBL3890993,,OC1CN(C[C@H]2CC[C@@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.09,IC50,=,810.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.09,6.09,6.09,c1cc2c(ncn3nnc([C@H]4CC[C@@H](CN5CCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907430>
568,CHEMBL3891030,,c1coc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,6.77,IC50,=,170.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.77,6.77,6.77,c1coc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09074a0>
569,CHEMBL3891204,,c1cc2c(ncn3nnc(C4CCC4)c23)[nH]1,6.39,IC50,=,410.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.39,6.39,6.39,c1cc2c(ncn3nnc(C4CCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907510>
570,CHEMBL3891913,,O=C1c2cnc3[nH]ccc3c2N([C@H]2CC[C@H](CNCC(F)(F)F)CC2)CN1CC(F)(F)F,6.64,IC50,=,230.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.64,6.64,6.64,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907580>
571,CHEMBL3891947,,Cc1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)s1,8.44,IC50,=,3.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.44,8.44,8.44,c1csc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09075f0>
572,CHEMBL3892138,,N#Cc1cccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,6.34,IC50,=,460.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.34,6.34,6.34,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907660>
573,CHEMBL3892159,,CC1CC1NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.85,IC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.85,6.85,6.85,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09076d0>
574,CHEMBL3892296,,CC(=O)OC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.50,IC50,=,32.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.50,7.50,7.50,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907740>
575,CHEMBL3892444,,CN(CC(F)(F)F)C[C@H]1CC[C@H](N2CN(C)C(=O)c3cnc4[nH]ccc4c32)CC1,7.28,IC50,=,52.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.28,7.28,7.28,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09077b0>
576,CHEMBL3892634,,N#CCN1CN(C2CCCCC2)c2c(cnc3[nH]ccc23)C1=O,7.32,IC50,=,48.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.32,7.32,7.32,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907820>
577,CHEMBL3892672,,CN1CN([C@H]2CC[C@H](CNCC(F)(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,7.21,IC50,=,62.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.21,7.21,7.21,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907890>
578,CHEMBL3892991,,CN(C[C@H]1CC[C@H](N2CN(CC(F)(F)F)C(=O)c3cnc4[nH]ccc4c32)CC1)S(C)(=O)=O,6.37,IC50,=,430.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.37,6.37,6.37,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907900>
579,CHEMBL3893247,,CCN1CN([C@H]2CC[C@H](CNS(=O)(=O)CC(F)(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,6.77,IC50,=,170.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.77,6.77,6.77,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907970>
580,CHEMBL3893600,,O=C1NCN([C@H]2CC[C@H](CN3CC[C@@H](F)C3)CC2)c2c1cnc1[nH]ccc21,6.48,IC50,=,330.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.48,6.48,6.48,O=C1NCN([C@H]2CC[C@H](CN3CCCC3)CC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09079e0>
581,CHEMBL3894161,,c1cc2c(ncn3nnc(C4CCN(Cc5csnn5)CC4)c23)[nH]1,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.96,6.96,6.96,c1cc2c(ncn3nnc(C4CCN(Cc5csnn5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907a50>
582,CHEMBL3894474,,N#CCCNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.36,IC50,=,44.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.36,7.36,7.36,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095c9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907ac0>
583,CHEMBL3894490,,COCN1CN([C@H]2CC[C@H](CNCC(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,6.64,IC50,=,230.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.64,6.64,6.64,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ca50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907b30>
584,CHEMBL3894516,,O=C(NCC(F)(F)F)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.80,IC50,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.80,6.80,6.80,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095cac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907ba0>
585,CHEMBL3894535,,CS(=O)(=O)c1ccc2c(c1)CCN2C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.42,IC50,=,380.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.42,6.42,6.42,c1ccc2c(c1)CCN2C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095cb30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907c10>
586,CHEMBL3895546,,F[C@H]1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.60,IC50,=,250.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.60,6.60,6.60,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095cba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907c80>
587,CHEMBL3896113,,CN1CN([C@H]2CC[C@H](COCCC#N)CC2)c2c(cnc3[nH]ccc23)C1=O,7.62,IC50,=,24.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.62,7.62,7.62,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095cc10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907cf0>
588,CHEMBL3896215,,O=C(Nc1nncs1)N1CCCC(c2nnn3cnc4[nH]ccc4c23)C1,6.38,IC50,=,420.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.38,6.38,6.38,O=C(Nc1nncs1)N1CCCC(c2nnn3cnc4[nH]ccc4c23)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095cc80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907d60>
589,CHEMBL3896236,,CCN1CN([C@H]2CC[C@H](CN(C)CC#N)CC2)c2c(cnc3[nH]ccc23)C1=O,6.16,IC50,=,700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.16,6.16,6.16,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ccf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907dd0>
590,CHEMBL3896324,,N#CCNS(=O)(=O)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.57,IC50,=,270.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.57,6.57,6.57,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095cd60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907e40>
591,CHEMBL3896461,,OC1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.37,IC50,=,430.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.37,6.37,6.37,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095cdd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907eb0>
592,CHEMBL3896712,,c1ccc(CN2CCCC(c3nnn4cnc5[nH]ccc5c34)C2)cc1,5.58,IC50,=,2600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,5.58,5.58,5.58,c1ccc(CN2CCCC(c3nnn4cnc5[nH]ccc5c34)C2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ce40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907f20>
593,CHEMBL3896725,,O[C@@H](CNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)c1ccccc1,7.50,IC50,=,32.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.50,7.50,7.50,c1ccc(CCNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ceb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0907f90>
594,CHEMBL3896766,,CC(C)(C)NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.31,IC50,=,490.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.31,6.31,6.31,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095cf20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908040>
595,CHEMBL3896777,,O=S1(=O)CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.82,6.82,6.82,O=S1(=O)CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095cf90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09080b0>
596,CHEMBL3896784,,OC(CNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)c1ccccc1,7.36,IC50,=,44.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.36,7.36,7.36,c1ccc(CCNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908120>
597,CHEMBL3897300,,c1ccc(CCCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.35,IC50,=,450.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.35,6.35,6.35,c1ccc(CCCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908190>
598,CHEMBL3897648,,CN(C)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.10,IC50,=,800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.10,6.10,6.10,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908200>
599,CHEMBL3897798,,FC(F)(F)c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cn1,6.44,IC50,=,360.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.44,6.44,6.44,c1cncc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908270>
600,CHEMBL3897849,,CN(C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)c1ccc(C#N)cc1,6.24,IC50,=,580.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.24,6.24,6.24,c1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09082e0>
601,CHEMBL3898196,,O[C@@H](CN[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)c1ccccc1,6.46,IC50,=,350.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.46,6.46,6.46,c1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908350>
602,CHEMBL3898786,,N#CCC(=O)N1CCCC(c2ncn3cnc4[nH]ccc4c23)C1,6.64,IC50,=,230.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.64,6.64,6.64,c1cc2c(ncn3cnc(C4CCCNC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09083c0>
603,CHEMBL3898818,,N#CC(C#N)=C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.62,IC50,=,240.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.62,6.62,6.62,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908430>
604,CHEMBL3898972,,CN(C[C@H]1CC[C@H](N2CN(C3CC3)C(=O)c3cnc4[nH]ccc4c32)CC1)S(C)(=O)=O,6.58,IC50,=,260.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.58,6.58,6.58,O=C1c2cnc3[nH]ccc3c2N(C2CCCCC2)CN1C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09084a0>
605,CHEMBL3899570,,Fc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1C(F)(F)F,6.16,IC50,=,700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.16,6.16,6.16,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908510>
606,CHEMBL3899634,,N#Cc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c(F)c1,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.82,6.82,6.82,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908580>
607,CHEMBL3899650,,Cc1cc(C#N)ccc1NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.33,IC50,=,470.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.33,6.33,6.33,c1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09085f0>
608,CHEMBL3900105,,N#CC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,8.54,IC50,=,2.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.54,8.54,8.54,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908660>
609,CHEMBL3900224,,FC(F)(F)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.39,IC50,=,41.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.39,7.39,7.39,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09086d0>
610,CHEMBL3900631,,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCC5)CC4)c23)[nH]1,6.48,IC50,=,330.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.48,6.48,6.48,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908740>
611,CHEMBL3900746,,FC(F)(F)c1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,8.59,IC50,=,2.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.59,8.59,8.59,c1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09087b0>
612,CHEMBL3901392,,N#CCN1CN([C@H]2CC[C@H](CNCC(F)(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,7.24,IC50,=,57.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.24,7.24,7.24,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908820>
613,CHEMBL3901870,,CN(C)C(=O)CN1CN([C@H]2CC[C@H](CNCC(F)(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,7.10,IC50,=,80.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.10,7.10,7.10,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908890>
614,CHEMBL3902123,,N#CCN1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.85,IC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.85,6.85,6.85,c1cc2c(ncn3nnc(C4CCNCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908900>
615,CHEMBL3902287,,C[C@H](O)CNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.06,IC50,=,87.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.06,7.06,7.06,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908970>
616,CHEMBL3902333,,N#C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.39,IC50,=,410.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.39,6.39,6.39,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09089e0>
617,CHEMBL3902428,,OCCN1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.28,IC50,=,530.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.28,6.28,6.28,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCNCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908a50>
618,CHEMBL3902431,,OC12CC3CC(C1)CC(c1nnn4cnc5[nH]ccc5c14)(C3)C2,7.28,IC50,=,52.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.28,7.28,7.28,c1cc2c(ncn3nnc(C45CC6CC(CC(C6)C4)C5)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095d9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908ac0>
619,CHEMBL3902447,,N#Cc1ccc(CN2CCCC(c3nnn4cnc5[nH]ccc5c34)C2)cc1,6.06,IC50,=,880.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.06,6.06,6.06,c1ccc(CN2CCCC(c3nnn4cnc5[nH]ccc5c34)C2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095da50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908b30>
620,CHEMBL3902570,,OC[C@H]1CC[C@@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.82,6.82,6.82,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095dac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908ba0>
621,CHEMBL3902992,,N#CC[C@H]1CC[C@@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.77,IC50,=,170.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.77,6.77,6.77,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095db30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908c10>
622,CHEMBL3903790,,N#Cc1ccc(CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,7.06,IC50,=,88.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.06,7.06,7.06,c1ccc(CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095dba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908c80>
623,CHEMBL3903817,,CN1CN([C@H]2CC[C@H](CNC3(C(F)(F)F)CC3)CC2)c2c(cnc3[nH]ccc23)C1=O,7.47,IC50,=,34.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.47,7.47,7.47,O=C1NCN([C@H]2CC[C@H](CNC3CC3)CC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095dc10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908cf0>
624,CHEMBL3904186,,CC1(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.48,IC50,=,330.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.48,6.48,6.48,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095dc80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908d60>
625,CHEMBL3904312,,OCCNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.03,IC50,=,94.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.03,7.03,7.03,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095dcf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908dd0>
626,CHEMBL3904453,,c1cc2c(ncn3nnc([C@H]4CC[C@H](NCC5CC5)CC4)c23)[nH]1,6.15,IC50,=,710.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.15,6.15,6.15,c1cc2c(ncn3nnc([C@H]4CC[C@H](NCC5CC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095dd60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908e40>
627,CHEMBL3904533,,CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)N2C[C@@H]3C[C@]3(C#N)C2)C1,5.71,IC50,=,1970.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 M peptide substrate. The JAK1 and TYK2 assays contained 1 M of the IRStide peptide (5FAMKKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 M of the JAKtide peptide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1, 1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room temperature for three hours for JAK1, 60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20%-30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1% Coating Reagent and 100 mM HEPES, pH=7.4.",False,5.71,5.71,5.71,O=S(=O)(N[C@H]1C[C@@H](Nc2ncnc3[nH]ccc23)C1)N1CC2C[C@H]2C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ddd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908eb0>
628,CHEMBL3904571,,N#CCC(=O)N(CC#N)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.51,IC50,=,310.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.51,6.51,6.51,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095de40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908f20>
629,CHEMBL3904756,,Clc1ccc(CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.96,6.96,6.96,c1ccc(CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095deb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0908f90>
630,CHEMBL3905498,,c1cc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)ccn1,6.19,IC50,=,650.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.19,6.19,6.19,c1cc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095df20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909040>
631,CHEMBL3905617,,CC(C)(C)OC(=O)N1CCC(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.15,IC50,=,710.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.15,6.15,6.15,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNCC5CCNCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095df90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09090b0>
632,CHEMBL3905627,,CC(=O)SC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.55,IC50,=,28.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.55,7.55,7.55,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909120>
633,CHEMBL3905686,,CC(=O)N1CCC2(CCC(Nc3nc(Nc4cnn(C)c4)ncc3Cl)CC2)CC1,8.40,IC50,=,4.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Kinase Assay: TYK2 (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 250 M GGMEDIYFEFMGGKKK, 10 mM MgAcetate and [-33P-ATP](specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 3% phosphoric acid solution. 10 L of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.",False,8.40,8.40,8.40,c1cc(NC2CCC3(CCNCC3)CC2)nc(Nc2cn[nH]c2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909190>
634,CHEMBL3906070,,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,7.58,IC50,=,26.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.58,7.58,7.58,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909200>
635,CHEMBL3906210,,CC(C)NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.38,IC50,=,420.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.38,6.38,6.38,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909270>
636,CHEMBL3906263,,c1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.75,IC50,=,180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.75,6.75,6.75,c1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09092e0>
637,CHEMBL3906776,,O[C@H]1CCCC[C@H]1CNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.43,IC50,=,370.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.43,6.43,6.43,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNCC5CCCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909350>
638,CHEMBL3906857,,N#Cc1ccc(N[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,7.25,IC50,=,56.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.25,7.25,7.25,c1ccc(N[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09093c0>
639,CHEMBL3906872,,O=C(OCc1ccccc1)N1CCCC(c2nnn3cnc4[nH]ccc4c23)C1,5.66,IC50,=,2200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,5.66,5.66,5.66,O=C(OCc1ccccc1)N1CCCC(c2nnn3cnc4[nH]ccc4c23)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909430>
640,CHEMBL3906967,,OC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.42,IC50,=,38.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.42,7.43,7.42,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09094a0>
641,CHEMBL3907076,,OC[C@@H]1CCCN1C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.46,IC50,=,350.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.46,6.46,6.46,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909510>
642,CHEMBL3907106,,CCN1CN([C@H]2CC[C@H](CNCC(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,6.48,IC50,=,330.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.48,6.48,6.48,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909580>
643,CHEMBL3907503,,C=C1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.92,IC50,=,120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.92,6.92,6.92,C=C1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09095f0>
644,CHEMBL3907565,,Fc1ccc(N[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.62,IC50,=,240.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.62,6.62,6.62,c1ccc(N[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909660>
645,CHEMBL3907648,,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5COC5)CC4)c23)[nH]1,6.47,IC50,=,340.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.47,6.47,6.47,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5COC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09096d0>
646,CHEMBL3907770,,Fc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c(F)c1,6.54,IC50,=,290.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.54,6.54,6.54,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909740>
647,CHEMBL3907774,,O=S(=O)(C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)C1CC1,6.58,IC50,=,260.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.58,6.58,6.58,O=S(=O)(C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09097b0>
648,CHEMBL3907944,,CN(c1ccc(F)cc1)C1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.75,IC50,=,180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.75,6.75,6.75,c1ccc(NC2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909820>
649,CHEMBL3908040,,N#Cc1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,8.23,IC50,=,5.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.23,8.23,8.23,c1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909890>
650,CHEMBL3908073,,Cc1ccc(CNC(=O)[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)o1,6.60,IC50,=,250.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.60,6.60,6.60,O=C(NCc1ccco1)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909900>
651,CHEMBL3908624,,CS(=O)(=O)c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.19,IC50,=,650.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.19,6.19,6.19,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909970>
652,CHEMBL3909024,,O=C1COc2cc(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)ccc2N1,6.62,IC50,=,240.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.62,6.62,6.62,O=C1COc2cc(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)ccc2N1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09099e0>
653,CHEMBL3909146,,FC(F)(F)c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)o1,6.92,IC50,=,120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.92,6.92,6.92,c1coc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909a50>
654,CHEMBL3909814,,Fc1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.33,IC50,=,470.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.33,6.33,6.33,c1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095e9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909ac0>
655,CHEMBL3910814,,CCN1CN([C@H]2CC[C@H](CN(C)S(C)(=O)=O)CC2)c2c(cnc3[nH]ccc23)C1=O,6.43,IC50,=,370.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.43,6.43,6.43,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ea50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909b30>
656,CHEMBL3911096,,FC(F)(F)C(F)(F)CN[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.77,IC50,=,170.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.77,6.77,6.77,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095eac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909ba0>
657,CHEMBL3911142,,FC(F)CNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.85,IC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.85,6.85,6.85,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095eb30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909c10>
658,CHEMBL3911186,,O=C1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.26,IC50,=,550.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.26,6.26,6.26,O=C1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095eba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909c80>
659,CHEMBL3911320,,Nc1n[nH]c2ccc(C(=O)N3CCC[C@H]3c3ccc(Cl)cc3)cc12,6.55,IC50,=,279.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.55,6.55,6.55,O=C(c1ccc2[nH]ncc2c1)N1CCC[C@H]1c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ec10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909cf0>
660,CHEMBL3911362,,N#Cc1ccc(CCNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,7.10,IC50,=,80.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.10,7.10,7.10,c1ccc(CCNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ec80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909d60>
661,CHEMBL3911589,,O=C1c2cnc3[nH]ccc3c2N([C@H]2CC[C@H](CN3CCCS3(=O)=O)CC2)CN1C1CC1,6.70,IC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.70,6.70,6.70,O=C1c2cnc3[nH]ccc3c2N([C@H]2CC[C@H](CN3CCCS3(=O)=O)CC2)CN1C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ecf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909dd0>
662,CHEMBL3911874,,Cc1ccccc1-c1nnn2cnc3[nH]ccc3c12,6.89,IC50,=,130.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.89,6.89,6.89,c1ccc(-c2nnn3cnc4[nH]ccc4c23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ed60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909e40>
663,CHEMBL3912419,,c1ccc(CCNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,7.00,IC50,=,99.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.00,7.00,7.00,c1ccc(CCNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095edd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909eb0>
664,CHEMBL3912503,,N#CCNC(=O)C[C@H]1CC[C@@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.27,IC50,=,540.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.27,6.27,6.27,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ee40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909f20>
665,CHEMBL3912553,,Clc1ncc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)s1,7.04,IC50,=,91.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.04,7.04,7.04,c1cc2c(ncn3nnc(C4CCN(Cc5cncs5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095eeb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0909f90>
666,CHEMBL3913143,,N#CCN1CN([C@H]2CC[C@H](CNC3CC3)CC2)c2c(cnc3[nH]ccc23)C1=O,6.89,IC50,=,130.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.89,6.89,6.89,O=C1NCN([C@H]2CC[C@H](CNC3CC3)CC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ef20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a040>
667,CHEMBL3913397,,Cc1cc(C#N)ccc1NC1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.96,6.96,6.96,c1ccc(NC2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ef90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a0b0>
668,CHEMBL3913565,,Cc1ccc(CN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C(=O)CC#N)o1,6.24,IC50,=,580.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.24,6.24,6.24,c1coc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a120>
669,CHEMBL3913622,,CCN1CN([C@H]2CC[C@H](CNS(=O)(=O)C3CC3)CC2)c2c(cnc3[nH]ccc23)C1=O,6.43,IC50,=,370.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.43,6.43,6.43,O=C1NCN([C@H]2CC[C@H](CNS(=O)(=O)C3CC3)CC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a190>
670,CHEMBL3914503,,COc1cc(O)ccc1-c1ccc2c(-c3nc4ccccc4[nH]3)n[nH]c2c1,6.99,IC50,=,102.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,6.99,6.99,6.99,c1ccc(-c2ccc3c(-c4nc5ccccc5[nH]4)n[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a200>
671,CHEMBL3914847,,OC1(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CCCCC1,6.29,IC50,=,510.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.29,6.29,6.29,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNCC5CCCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a270>
672,CHEMBL3915844,,CC1CCN(C(=O)CC#N)CC1c1nnn2cnc3[nH]ccc3c12,6.04,IC50,=,910.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.04,6.04,6.04,c1cc2c(ncn3nnc(C4CCCNC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a2e0>
673,CHEMBL3916308,,O=C1c2cnc3[nH]ccc3c2N([C@H]2CC[C@H](CNCC(F)(F)F)CC2)CN1CC1CCCO1,7.00,IC50,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.00,7.00,7.00,O=C1c2cnc3[nH]ccc3c2N(C2CCCCC2)CN1CC1CCCO1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a350>
674,CHEMBL3916457,,FC(F)(F)C(NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)C(F)(F)F,6.21,IC50,=,620.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.21,6.21,6.21,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a3c0>
675,CHEMBL3916636,,FC(F)(F)C1(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.57,IC50,=,270.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.57,6.57,6.57,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a430>
676,CHEMBL3916687,,O=C(CNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)NCC(F)(F)F,6.50,IC50,=,320.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.50,6.50,6.50,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a4a0>
677,CHEMBL3916915,,FC(F)(F)c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.20,IC50,=,630.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.20,6.20,6.20,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a510>
678,CHEMBL3917030,,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCOCC5)CC4)c23)[nH]1,6.50,IC50,=,320.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.50,6.50,6.50,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCOCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a580>
679,CHEMBL3917073,,Cn1cc(Nc2ncc(Cl)c(NC3CC4CN(S(C)(=O)=O)CC4C3)n2)cn1,7.75,IC50,=,18.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Kinase Assay: TYK2 (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 250 M GGMEDIYFEFMGGKKK, 10 mM MgAcetate and [-33P-ATP](specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 3% phosphoric acid solution. 10 L of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.",False,7.75,7.75,7.75,c1cc(NC2CC3CNCC3C2)nc(Nc2cn[nH]c2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a5f0>
680,CHEMBL3917405,,O=C(CCCCCCOc1ccc2cc1COC/C=C/COCc1cccc(c1)-c1ccnc(n1)N2)NO,8.00,IC50,=,10.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 (V877 to C1187 residues) expressed in mammalian expression system by KINOMEScan assay,False,8.00,8.00,8.00,C1=C/COCc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)COC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a660>
681,CHEMBL3917774,,c1cc2c(ncn3nnc(C4CCCCCC4)c23)[nH]1,7.57,IC50,=,27.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.57,7.57,7.57,c1cc2c(ncn3nnc(C4CCCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a6d0>
682,CHEMBL3917860,,OC(CNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)(c1ccccc1)C(F)(F)F,6.20,IC50,=,630.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.20,6.20,6.20,c1ccc(CCNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a740>
683,CHEMBL3917954,,FC1(F)Oc2ccc(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)cc2O1,6.28,IC50,=,520.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.28,6.28,6.28,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNc5ccc6c(c5)OCO6)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a7b0>
684,CHEMBL3918308,,BrC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,8.59,IC50,=,2.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.59,8.59,8.59,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a820>
685,CHEMBL3918943,,FC(F)(F)C(N[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)C(F)(F)F,6.08,IC50,=,840.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.08,6.08,6.08,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a890>
686,CHEMBL3919034,,CN(C)S(=O)(=O)c1ccc2c(c1)CCN2C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.21,IC50,=,610.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.21,6.21,6.21,c1ccc2c(c1)CCN2C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a900>
687,CHEMBL3919050,,COc1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,8.32,IC50,=,4.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.32,8.32,8.32,c1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a970>
688,CHEMBL3919463,,CN1CN([C@H]2CC[C@H](CNS(C)(=O)=O)CC2)c2c(cnc3[nH]ccc23)C1=O,7.50,IC50,=,32.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.50,7.50,7.50,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090a9e0>
689,CHEMBL3919766,,N#Cc1cc(F)ccc1NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.72,IC50,=,190.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.72,6.72,6.72,c1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090aa50>
690,CHEMBL3920091,,O=C1SCCC1NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.36,IC50,=,44.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.36,7.36,7.36,O=C1SCCC1NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095f9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090aac0>
691,CHEMBL3920329,,O=C(CC(F)(F)F)NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.28,IC50,=,530.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.28,6.28,6.28,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095fa50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ab30>
692,CHEMBL3921365,,CN(C)[C@H]1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.31,IC50,=,490.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.31,6.31,6.31,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095fac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090aba0>
693,CHEMBL3921442,,N#CCCNC(=O)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.80,IC50,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.80,6.80,6.80,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095fb30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ac10>
694,CHEMBL3922146,,CN(CC#N)C[C@H]1CC[C@H](N2CN(C3CC3)C(=O)c3cnc4[nH]ccc4c32)CC1,6.32,IC50,=,480.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.32,6.32,6.32,O=C1c2cnc3[nH]ccc3c2N(C2CCCCC2)CN1C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095fba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ac80>
695,CHEMBL3922240,,Fc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,7.00,IC50,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.00,7.00,7.00,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095fc10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090acf0>
696,CHEMBL3922303,,Fc1ccc([C@@H]2C[C@H]2CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.17,IC50,=,670.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.17,6.17,6.17,c1ccc([C@@H]2C[C@H]2CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095fc80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ad60>
697,CHEMBL3922392,,N#Cc1ccc(N[C@H]2CC[C@@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.43,IC50,=,370.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.43,6.43,6.43,c1ccc(N[C@H]2CC[C@@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095fcf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090add0>
698,CHEMBL3922488,,N#CC1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.21,IC50,=,610.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.21,6.21,6.21,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095fd60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ae40>
699,CHEMBL3923184,,NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.75,IC50,=,180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.75,6.75,6.75,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095fdd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090aeb0>
700,CHEMBL3923513,,Ic1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)o1,6.80,IC50,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.80,6.80,6.80,c1coc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095fe40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090af20>
701,CHEMBL3923711,,CCNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.85,IC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.85,6.85,6.85,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095feb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090af90>
702,CHEMBL3923802,,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CCCC5)CC4)c23)[nH]1,6.50,IC50,=,320.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.50,6.50,6.50,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ff20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b040>
703,CHEMBL3924572,,O=C(CC(F)(F)F)N(CC(F)(F)F)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.44,IC50,=,360.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.44,6.44,6.44,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c095ff90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b0b0>
704,CHEMBL3924902,,CN(C)C[C@H]1CC[C@H](N2CNC(=O)c3cnc4[nH]ccc4c32)CC1,6.70,IC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.70,6.70,6.70,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b120>
705,CHEMBL3925854,,Fc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c(Cl)c1,6.47,IC50,=,340.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.47,6.47,6.47,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09600b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b190>
706,CHEMBL3926516,,Fc1ccc(C2(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)COC2)cc1,6.37,IC50,=,430.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.37,6.37,6.37,c1ccc(C2(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)COC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b200>
707,CHEMBL3926748,,c1cc2c(ncn3nnc(C4CCC(N5CCOCC5)CC4)c23)[nH]1,6.26,IC50,=,550.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.26,6.26,6.26,c1cc2c(ncn3nnc(C4CCC(N5CCOCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b270>
708,CHEMBL3926766,,c1cc2c(ncn3nnc(C4CC5CCC4C5)c23)[nH]1,7.60,IC50,=,25.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.60,7.60,7.60,c1cc2c(ncn3nnc(C4CC5CCC4C5)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b2e0>
709,CHEMBL3926817,,Clc1ccc(CCNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,7.28,IC50,=,53.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.28,7.28,7.28,c1ccc(CCNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b350>
710,CHEMBL3926894,,OC(CN[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)(c1cccnc1)C(F)(F)F,6.68,IC50,=,210.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.68,6.68,6.68,c1cncc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09602e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b3c0>
711,CHEMBL3927252,,SC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,8.01,IC50,=,9.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.01,8.01,8.01,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b430>
712,CHEMBL3927649,,Brc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.82,6.82,6.82,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09603c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b4a0>
713,CHEMBL3927827,,O=C(N[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)OCc1ccccc1,5.38,IC50,=,4200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,5.38,5.38,5.38,O=C(N[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)OCc1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b510>
714,CHEMBL3927961,,c1cc2c(ncn3nnc([C@H]4CC[C@@H](CNC5CC5)CC4)c23)[nH]1,6.03,IC50,=,940.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.03,6.03,6.03,c1cc2c(ncn3nnc([C@H]4CC[C@@H](CNC5CC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09604a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b580>
715,CHEMBL3928091,,O=C1CN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CCN1,6.01,IC50,=,970.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.01,6.01,6.01,O=C1CN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CCN1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b5f0>
716,CHEMBL3928338,,O=C(NCS(=O)(=O)c1ccccc1)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.68,IC50,=,210.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.68,6.68,6.68,O=C(NCS(=O)(=O)c1ccccc1)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b660>
717,CHEMBL3928932,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4ccccc4[nH]3)n[nH]c2c1,8.04,IC50,=,9.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,8.04,8.04,8.04,c1ccc(-c2ccc3c(-c4nc5ccccc5[nH]4)n[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09605f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b6d0>
718,CHEMBL3929096,,FC(F)(F)CN1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.80,IC50,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.80,6.80,6.80,c1cc2c(ncn3nnc(C4CCNCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b740>
719,CHEMBL3929124,,FC(F)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.37,IC50,=,43.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.37,7.37,7.37,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09606d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b7b0>
720,CHEMBL3929865,,Oc1cccc(-c2ccc3c(-c4nc5ccccc5[nH]4)n[nH]c3c2)c1,6.54,IC50,=,291.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,6.54,6.54,6.54,c1ccc(-c2ccc3c(-c4nc5ccccc5[nH]4)n[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b820>
721,CHEMBL3930342,,CN(CC(F)(F)F)C[C@H]1CC[C@H](N2CNC(=O)c3cnc4[nH]ccc4c32)CC1,7.54,IC50,=,29.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.54,7.54,7.54,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c09607b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b890>
722,CHEMBL3930389,,N#CC(C#N)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.17,IC50,=,67.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.17,7.17,7.17,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b900>
723,CHEMBL3930431,,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCC5)CC4)c23)[nH]1,6.64,IC50,=,230.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.64,6.64,6.64,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b970>
724,CHEMBL3931093,,Brc1ncc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)s1,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.96,6.96,6.96,c1cc2c(ncn3nnc(C4CCN(Cc5cncs5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090b9e0>
725,CHEMBL3931226,,Fc1cc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)ccc1C(F)(F)F,6.01,IC50,=,980.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.01,6.01,6.01,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ba50>
726,CHEMBL3931368,,CN[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.12,IC50,=,750.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.12,6.12,6.12,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09609e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090bac0>
727,CHEMBL3931713,,FC1(F)CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.05,IC50,=,900.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.05,6.05,6.05,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090bb30>
728,CHEMBL3932070,,CN1CN([C@H]2CC[C@H](CNC3(C#N)CC3)CC2)c2c(cnc3[nH]ccc23)C1=O,7.19,IC50,=,65.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.19,7.19,7.19,O=C1NCN([C@H]2CC[C@H](CNC3CC3)CC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090bba0>
729,CHEMBL3932456,,FC(F)(F)CN[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.82,6.82,6.82,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090bc10>
730,CHEMBL3933397,,O=C1COc2ccc(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)cc2N1,6.70,IC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.70,6.70,6.70,O=C1COc2ccc(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)cc2N1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090bc80>
731,CHEMBL3933776,,O=C1c2cnc3[nH]ccc3c2N([C@H]2CC[C@H](CNCC(F)F)CC2)CN1C1CC1,6.54,IC50,=,290.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.54,6.54,6.54,O=C1c2cnc3[nH]ccc3c2N(C2CCCCC2)CN1C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090bcf0>
732,CHEMBL3934061,,O=C1NCN([C@H]2CC[C@H](CNCC(F)(F)Br)CC2)c2c1cnc1[nH]ccc21,7.43,IC50,=,37.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.43,7.43,7.43,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090bd60>
733,CHEMBL3934116,,IC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,8.14,IC50,=,7.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.14,8.14,8.14,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090bdd0>
734,CHEMBL3934192,,OCCN(C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)C1CCCCC1,6.21,IC50,=,620.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.21,6.21,6.21,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CCCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090be40>
735,CHEMBL3934426,,CN(CCC#N)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.44,IC50,=,360.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.44,6.44,6.44,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090beb0>
736,CHEMBL3934440,,Fc1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1F,6.07,IC50,=,860.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.07,6.07,6.07,c1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090bf20>
737,CHEMBL3934580,,CS(=O)(=O)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.36,IC50,=,44.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.36,7.36,7.36,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090bf90>
738,CHEMBL3934627,,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC[C@@H]5CCCO5)CC4)c23)[nH]1,6.92,IC50,=,120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.92,6.92,6.92,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC[C@@H]5CCCO5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c040>
739,CHEMBL3934831,,N#CCN1CN([C@H]2CC[C@H](CNCC(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,7.27,IC50,=,54.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.27,7.27,7.27,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0960f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c0b0>
740,CHEMBL3934891,,O=C[C@H]1CC[C@@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.00,IC50,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.00,7.00,7.00,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c120>
741,CHEMBL3935174,,Clc1ccc(NC2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.12,IC50,=,750.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.12,6.12,6.12,c1ccc(NC2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09610b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c190>
742,CHEMBL3935408,,CC(C#N)=C1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.35,IC50,=,450.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.35,6.35,6.35,C=C1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c200>
743,CHEMBL3935532,,FC(F)(F)CCNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.57,IC50,=,270.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.57,6.57,6.57,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c270>
744,CHEMBL3935688,,CN(C)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.72,IC50,=,190.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.72,6.72,6.72,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c2e0>
745,CHEMBL3935714,,S=c1[nH]c(C2CCCCC2)c2c3cc[nH]c3ncn12,7.44,IC50,=,36.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.44,7.44,7.44,S=c1[nH]c(C2CCCCC2)c2c3cc[nH]c3ncn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c350>
746,CHEMBL3936356,,CC1CCCCC1c1nnn2cnc3[nH]ccc3c12,7.25,IC50,=,56.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.25,7.25,7.25,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09612e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c3c0>
747,CHEMBL3936358,,CN1CN([C@H]2CC[C@H](CF)CC2)c2c(cnc3[nH]ccc23)C1=O,7.42,IC50,=,38.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.42,7.42,7.42,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c430>
748,CHEMBL3936693,,CCN1CN([C@H]2CC[C@H](CNCC(F)(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,6.58,IC50,=,260.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.58,6.58,6.58,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c09613c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c4a0>
749,CHEMBL3936877,,Clc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c(Cl)n1,6.21,IC50,=,610.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.21,6.21,6.21,c1cncc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c510>
750,CHEMBL3937067,,N#Cc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)s1,7.21,IC50,=,62.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.21,7.21,7.21,c1csc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09614a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c580>
751,CHEMBL3937827,,N#Cc1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1C(F)(F)F,6.43,IC50,=,370.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.43,6.43,6.43,c1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c5f0>
752,CHEMBL3938113,,O=C1NCN([C@H]2CC[C@H](CNC3(C(F)(F)F)CC3)CC2)c2c1cnc1[nH]ccc21,7.72,IC50,=,19.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.72,7.72,7.72,O=C1NCN([C@H]2CC[C@H](CNC3CC3)CC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c660>
753,CHEMBL3938593,,CCOC(=O)CC1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.24,IC50,=,580.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.24,6.24,6.24,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09615f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c6d0>
754,CHEMBL3939232,,OCC1(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.26,IC50,=,550.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.26,6.26,6.26,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c740>
755,CHEMBL3939325,,N#CC1CN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.32,IC50,=,480.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.32,6.32,6.32,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09616d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c7b0>
756,CHEMBL3939800,,Cc1cc(Nc2nc([C@@H](O)c3ccc(F)cc3)nc3ccccc23)n[nH]1,5.80,Kd,=,1600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Competition Binding Assay: For the binding assays, streptavidin-coated magnetic beads were treated with biotinylated affinity ligands for 30 min at room temperature to generate affinity resins. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific binding. Binding reactions were assembled by combining kinase, liganded affinity beads, and test compounds in 1x binding buffer (20% SeaBlock, 0.17xPBS, 0.05% Tween 20, 6 mM DTT). Test compounds were prepared as 100x stocks in DMSO and rapidly diluted into the aqueous environment. DMSO was added to control assays lacking a test compound. Primary screen interactions were performed in polypropylene 384-well plates in a final volume of 34 uL, while Kd determinations were performed in polystyrene 96-well plates in a final volume of 135 uL. The assay plates were incubated at room temperature with shaking for 1 hr, long enough for binding reactions to reach equilibrium, and the affinity beads were washed extensively with wash buffer (1xPBS, 0.05% Tween 20) to remove unbound protein. The beads were then resuspended in elution buffer (1xPBS, 0.05% Tween 20, 2 uM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 min. The kinase concentration in the eluates was measured by quantitative PCR. Each kinase was tested individually against each compound.",False,5.80,5.80,5.80,c1ccc(Cc2nc(Nc3cc[nH]n3)c3ccccc3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c820>
757,CHEMBL3940267,,Fc1cnccc1CN1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.85,IC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.85,6.85,6.85,c1cc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09617b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c890>
758,CHEMBL3940421,,O=S(=O)(c1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1)C(F)(F)F,6.34,IC50,=,460.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.34,6.34,6.34,c1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c900>
759,CHEMBL3940644,,FC(F)(F)C1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.13,IC50,=,740.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.13,6.13,6.13,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c970>
760,CHEMBL3940782,,Clc1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,7.19,IC50,=,65.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.19,7.19,7.19,c1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090c9e0>
761,CHEMBL3941241,,c1ccc(CN[C@H]2CC[C@@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.48,IC50,=,330.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.48,6.48,6.48,c1ccc(CN[C@H]2CC[C@@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ca50>
762,CHEMBL3941431,,N#CCN[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.42,IC50,=,380.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.42,6.42,6.42,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09619e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090cac0>
763,CHEMBL3941598,,c1cc2c(ncn3nnc([C@H]4CC[C@H](NC5CC5)CC4)c23)[nH]1,6.48,IC50,=,330.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.48,6.48,6.48,c1cc2c(ncn3nnc([C@H]4CC[C@H](NC5CC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090cb30>
764,CHEMBL3941925,,Clc1ccc(C2(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)COC2)cc1,6.10,IC50,=,790.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.10,6.10,6.10,c1ccc(C2(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)COC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090cba0>
765,CHEMBL3942120,,CN(CCO)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.50,IC50,=,320.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.50,6.50,6.50,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090cc10>
766,CHEMBL3942424,,Fc1ccc(CN[C@H]2CC[C@@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.51,IC50,=,310.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.51,6.51,6.51,c1ccc(CN[C@H]2CC[C@@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090cc80>
767,CHEMBL3942459,,N#CCN(CC1CC1)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.96,6.96,6.96,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNCC5CC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ccf0>
768,CHEMBL3942741,,FC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.96,IC50,=,11.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.96,7.96,7.96,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090cd60>
769,CHEMBL3942783,,CN(CC#N)C[C@H]1CC[C@H](N2CN(CC(F)(F)F)C(=O)c3cnc4[nH]ccc4c32)CC1,6.36,IC50,=,440.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.36,6.36,6.36,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090cdd0>
770,CHEMBL3943501,,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNc5ccc(N6CCOCC6)cc5)CC4)c23)[nH]1,6.89,IC50,=,130.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.89,6.89,6.89,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNc5ccc(N6CCOCC6)cc5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ce40>
771,CHEMBL3943509,,CN(CC#N)C[C@H]1CC[C@H](N2CN(C)C(=O)c3cnc4[nH]ccc4c32)CC1,6.62,IC50,=,240.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.62,6.62,6.62,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ceb0>
772,CHEMBL3943557,,O[C@H]1CC[C@@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.02,IC50,=,96.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.02,7.02,7.02,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090cf20>
773,CHEMBL3943928,,FC(F)(Br)CN[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.89,IC50,=,13.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.89,7.89,7.89,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090cf90>
774,CHEMBL3943994,,CS(=O)(=O)c1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,8.06,IC50,=,8.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.06,8.06,8.06,c1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d040>
775,CHEMBL3944182,,CCN1CN([C@H]2CC[C@H](CNCC#N)CC2)c2c(cnc3[nH]ccc23)C1=O,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.82,6.82,6.82,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0961f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d0b0>
776,CHEMBL3944237,,O=C1c2cnc3[nH]ccc3c2N([C@H]2CC[C@H](CNCC(F)(F)F)CC2)CN1CC1CC1,6.54,IC50,=,290.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.54,6.54,6.54,O=C1c2cnc3[nH]ccc3c2N(C2CCCCC2)CN1CC1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d120>
777,CHEMBL3944322,,Cn1cc(Nc2ncc(Cl)c(NC3CCC4(CC3)CCN(C(=O)CC#N)C4)n2)cn1,9.00,IC50,=,1.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Kinase Assay: TYK2 (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 250 M GGMEDIYFEFMGGKKK, 10 mM MgAcetate and [-33P-ATP](specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 3% phosphoric acid solution. 10 L of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.",False,9.00,9.00,9.00,c1cc(NC2CCC3(CCNC3)CC2)nc(Nc2cn[nH]c2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09620b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d190>
778,CHEMBL3944831,,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.00,IC50,=,990.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.00,6.00,6.00,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d200>
779,CHEMBL3944859,,N#CCC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.62,IC50,=,24.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.62,7.62,7.62,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d270>
780,CHEMBL3945378,,N#Cc1ccc(CNC(=O)[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.27,IC50,=,540.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.27,6.27,6.27,O=C(NCc1ccccc1)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d2e0>
781,CHEMBL3945399,,CC(C#N)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.60,IC50,=,25.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.60,7.60,7.60,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d350>
782,CHEMBL3945740,,OCc1ccc(-c2nnn3cnc4[nH]ccc4c23)cc1,6.89,IC50,=,130.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.89,6.89,6.89,c1ccc(-c2nnn3cnc4[nH]ccc4c23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09622e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d3c0>
783,CHEMBL3945787,,N[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.36,IC50,=,440.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.36,6.36,6.36,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d430>
784,CHEMBL3945964,,Fc1ccccc1CN1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.55,IC50,=,280.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.55,6.55,6.55,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09623c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d4a0>
785,CHEMBL3946125,,OC(CN[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)(c1ccc(F)cc1)C(F)(F)F,6.62,IC50,=,240.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.62,6.62,6.62,c1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d510>
786,CHEMBL3946758,,FC(F)CN[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.70,IC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.70,6.70,6.70,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09624a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d580>
787,CHEMBL3947242,,CN1CN([C@H]2CC[C@H](CNS(=O)(=O)CC(F)(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,7.58,IC50,=,26.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.58,7.58,7.58,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d5f0>
788,CHEMBL3947499,,CN1CN([C@H]2CC[C@H](CNC3CC3)CC2)c2c(cnc3[nH]ccc23)C1=O,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.82,6.82,6.82,O=C1NCN([C@H]2CC[C@H](CNC3CC3)CC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d660>
789,CHEMBL3947711,,OC(CN1CCC(c2nnn3cnc4[nH]ccc4c23)CC1)c1ccc(C(F)(F)F)cc1,6.35,IC50,=,450.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.35,6.35,6.35,c1ccc(CCN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09625f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d6d0>
790,CHEMBL3947782,,O=S(=O)(O)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.17,IC50,=,680.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.17,6.17,6.17,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d740>
791,CHEMBL3947889,,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCSC5)CC4)c23)[nH]1,6.80,IC50,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.80,6.80,6.80,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCSC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09626d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d7b0>
792,CHEMBL3948605,,c1cc2c(ncn3cnc(C4CCCCC4)c23)[nH]1,7.23,IC50,=,59.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.23,7.23,7.23,c1cc2c(ncn3cnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d820>
793,CHEMBL3948691,,Cc1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)o1,7.80,IC50,=,16.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.80,7.80,7.80,c1coc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09627b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d890>
794,CHEMBL3948921,,CNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.68,IC50,=,210.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.68,6.68,6.68,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d900>
795,CHEMBL3949040,,Fc1cc(Cl)ccc1CN1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,7.01,IC50,=,97.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.01,7.01,7.01,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d970>
796,CHEMBL3949226,,CN1CN([C@H]2CC[C@H](CN3CCN(CCC#N)CC3)CC2)c2c(cnc3[nH]ccc23)C1=O,6.04,IC50,=,910.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.04,6.04,6.04,O=C1NCN([C@H]2CC[C@H](CN3CCNCC3)CC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090d9e0>
797,CHEMBL3949242,,OC(CNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)C(F)(F)F,6.36,IC50,=,440.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.36,6.36,6.36,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090da50>
798,CHEMBL3949248,,COc1ccc(C(O)(CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C(F)(F)F)cc1OC,6.44,IC50,=,360.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.44,6.44,6.44,c1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09629e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090dac0>
799,CHEMBL3949257,,Fc1cc(C(F)(F)F)cc(F)c1CN1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.02,IC50,=,950.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.02,6.02,6.02,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090db30>
800,CHEMBL3949285,,Clc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)s1,7.24,IC50,=,57.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.24,7.24,7.24,c1csc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090dba0>
801,CHEMBL3949323,,Fc1ccc(CCNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,7.55,IC50,=,28.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.55,7.55,7.55,c1ccc(CCNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090dc10>
802,CHEMBL3949461,,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CCC5)CC4)c23)[nH]1,6.64,IC50,=,230.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.64,6.64,6.64,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090dc80>
803,CHEMBL3949572,,CCN1CN([C@H]2CC[C@H](CNS(C)(=O)=O)CC2)c2c(cnc3[nH]ccc23)C1=O,6.77,IC50,=,170.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.77,6.77,6.77,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090dcf0>
804,CHEMBL3950137,,O=C(C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)NCC(F)(F)F,6.06,IC50,=,880.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.06,6.06,6.06,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090dd60>
805,CHEMBL3950208,,CN1CN([C@H]2CC[C@H](CN3CC(O)C3)CC2)c2c(cnc3[nH]ccc23)C1=O,7.21,IC50,=,61.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.21,7.21,7.21,O=C1NCN([C@H]2CC[C@H](CN3CCC3)CC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ddd0>
806,CHEMBL3950399,,NC(=O)C1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.19,IC50,=,640.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.19,6.19,6.19,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090de40>
807,CHEMBL3950680,,Fc1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1C(F)(F)F,8.48,IC50,=,3.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.48,8.48,8.48,c1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090deb0>
808,CHEMBL3951060,,CO[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.70,IC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.70,6.70,6.70,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090df20>
809,CHEMBL3951107,,N#CCCN(CCC#N)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.66,IC50,=,22.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.66,7.66,7.66,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090df90>
810,CHEMBL3951230,,c1csc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,6.68,IC50,=,210.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.68,6.68,6.68,c1csc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e040>
811,CHEMBL3951710,,CC(C)(O)C1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.03,IC50,=,940.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.03,6.03,6.03,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0962f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e0b0>
812,CHEMBL3952221,,CN1CN([C@H]2CC[C@H](CN(C)S(C)(=O)=O)CC2)c2c(cnc3[nH]ccc23)C1=O,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.96,6.96,6.96,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e120>
813,CHEMBL3952261,,N#CCN(C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)C(=O)CC(F)(F)F,6.50,IC50,=,320.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.50,6.50,6.50,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09630b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e190>
814,CHEMBL3952936,,N#CCN1CN([C@H]2CC[C@H](CO)CC2)c2c(cnc3[nH]ccc23)C1=O,7.28,IC50,=,52.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.28,7.28,7.28,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e200>
815,CHEMBL3953229,,N#CCCN(CCC#N)C1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,7.55,IC50,=,28.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.55,7.55,7.55,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e270>
816,CHEMBL3953381,,COc1ccc(C(O)(CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C(F)(F)F)cc1,6.68,IC50,=,210.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.68,6.68,6.68,c1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e2e0>
817,CHEMBL3953486,,Fc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1F,6.31,IC50,=,490.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.31,6.31,6.31,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e350>
818,CHEMBL3953550,,N#Cc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.77,IC50,=,170.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.77,6.77,6.77,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09632e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e3c0>
819,CHEMBL3954454,,Clc1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,8.55,IC50,=,2.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.55,8.55,8.55,c1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e430>
820,CHEMBL3954540,,CN1CN(C2CCCCC2)c2c(cnc3[nH]ccc23)C1=O,7.34,IC50,=,46.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.34,7.34,7.34,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c09633c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e4a0>
821,CHEMBL3954792,,CC(C)(C)OC(=O)N1CC[C@H](NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.29,IC50,=,510.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.29,6.29,6.29,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN[C@H]5CCNC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e510>
822,CHEMBL3954819,,OC(CN[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)c1ccccc1,6.58,IC50,=,260.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.58,6.58,6.58,c1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09634a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e580>
823,CHEMBL3954894,,ClC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,8.92,IC50,=,1.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.92,8.92,8.92,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e5f0>
824,CHEMBL3955496,,O=c1[nH]c(C2CCCCC2)c2c3cc[nH]c3ncn12,7.11,IC50,=,78.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.11,7.11,7.11,O=c1[nH]c(C2CCCCC2)c2c3cc[nH]c3ncn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e660>
825,CHEMBL3955720,,N#CCNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.43,IC50,=,37.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.43,7.43,7.43,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09635f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e6d0>
826,CHEMBL3956418,,c1nc(CCNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)c[nH]1,7.00,IC50,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.00,7.00,7.00,c1nc(CCNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)c[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e740>
827,CHEMBL3956439,,O=C1c2cnc3[nH]ccc3c2N([C@H]2CC[C@H](CNCC(F)(F)F)CC2)CN1C1CC1,6.72,IC50,=,190.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.72,6.72,6.72,O=C1c2cnc3[nH]ccc3c2N(C2CCCCC2)CN1C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09636d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e7b0>
828,CHEMBL3956450,,CN(C)S(=O)(=O)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.77,IC50,=,170.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.77,6.77,6.77,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e820>
829,CHEMBL3956611,,N#Cc1ccc(NC2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.85,IC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.85,6.85,6.85,c1ccc(NC2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09637b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e890>
830,CHEMBL3956945,,OC1(C(F)(F)F)CN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.43,IC50,=,370.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.43,6.43,6.43,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e900>
831,CHEMBL3956966,,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.51,IC50,=,310.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.51,6.51,6.51,c1ccc(C2CCN(C[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e970>
832,CHEMBL3957421,,FC(F)(F)c1ccc(CN[C@H]2CC[C@@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.60,IC50,=,250.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.60,6.60,6.60,c1ccc(CN[C@H]2CC[C@@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090e9e0>
833,CHEMBL3957659,,Clc1cc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)ccn1,6.58,IC50,=,260.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.58,6.58,6.58,c1cc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ea50>
834,CHEMBL3957838,,O=C1c2cnc3[nH]ccc3c2N([C@H]2CC[C@H](CN3CCCS3(=O)=O)CC2)CN1CC(F)(F)F,6.46,IC50,=,350.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.46,6.46,6.46,O=C1NCN([C@H]2CC[C@H](CN3CCCS3(=O)=O)CC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c09639e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090eac0>
835,CHEMBL3957921,,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNCC5CC5)CC4)c23)[nH]1,7.17,IC50,=,68.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.17,7.17,7.17,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNCC5CC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090eb30>
836,CHEMBL3957937,,Fc1cccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,6.41,IC50,=,390.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.41,6.41,6.41,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090eba0>
837,CHEMBL3957990,,CC(NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)c1ccc(F)c(F)c1,7.14,IC50,=,72.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.14,7.14,7.14,c1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ec10>
838,CHEMBL3958508,,N#Cc1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.24,IC50,=,580.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.24,6.24,6.24,c1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ec80>
839,CHEMBL3958601,,O=C(OCc1ccccc1)N1CCC(c2[nH]c(=S)n3cnc4[nH]ccc4c23)CC1,6.30,IC50,=,500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.30,6.30,6.30,O=C(OCc1ccccc1)N1CCC(c2[nH]c(=S)n3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ecf0>
840,CHEMBL3958797,,c1cncc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,5.82,IC50,=,1500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,5.82,5.82,5.82,c1cncc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ed60>
841,CHEMBL3959556,,C#CCNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.57,IC50,=,270.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.57,6.57,6.57,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090edd0>
842,CHEMBL3959692,,Fc1ccc(C2(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)CCC2)cc1,6.12,IC50,=,750.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.12,6.12,6.12,c1ccc(C2(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)CCC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ee40>
843,CHEMBL3960109,,O=C1OCCC1NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.70,IC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.70,6.70,6.70,O=C1OCCC1NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090eeb0>
844,CHEMBL3960523,,O=C1c2cnc3[nH]ccc3c2N([C@H]2CC[C@H](CF)CC2)CN1C1CC1,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.96,6.96,6.96,O=C1c2cnc3[nH]ccc3c2N(C2CCCCC2)CN1C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ef20>
845,CHEMBL3960901,,O=C(NC1CCC(O)CC1)c1cnn2ccc(NC3CCc4ccccc43)nc12,7.29,Ki,=,50.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"JAK1 and TYK2 Inhibition Assay: To determine inhibition constants (Ki), compounds were diluted serially in DMSO and added to 50 uL kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 uM peptide substrate, 25 uM ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22 C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 uL of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. After termination of the kinase reaction, the proportion of phosphorylated product was determined as a fraction of total peptide substrate using the Caliper LabChip 3000 according to the manufacturer's specifications. Ki values were then determined using the Morrison tight binding model (Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969).",False,7.29,7.29,7.29,O=C(NC1CCCCC1)c1cnn2ccc(NC3CCc4ccccc43)nc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ef90>
846,CHEMBL3960910,,N#Cc1ccc(CN2CCC(c3ncn4cnc5[nH]ccc5c34)CC2)cc1,6.54,IC50,=,290.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.54,6.54,6.54,c1ccc(CN2CCC(c3ncn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f040>
847,CHEMBL3961357,,N#Cc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1F,6.11,IC50,=,770.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.11,6.11,6.11,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0963f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f0b0>
848,CHEMBL3961430,,COCN1CN([C@H]2CC[C@H](CN(C)CC(F)(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,7.14,IC50,=,72.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.14,7.14,7.14,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f120>
849,CHEMBL3962051,,N#CC1CC12CCC(c1nnn3cnc4[nH]ccc4c13)CC2,7.35,IC50,=,45.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.35,7.35,7.35,c1cc2c(ncn3nnc(C4CCC5(CC4)CC5)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09640b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f190>
850,CHEMBL3962117,,CC1(C)CC1NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.57,IC50,=,270.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.57,6.57,6.57,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f200>
851,CHEMBL3962138,,CSc1ccc(C(O)(CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C(F)(F)F)cc1,6.41,IC50,=,390.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.41,6.41,6.41,c1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f270>
852,CHEMBL3962269,,Cc1cc(Nc2nc([C@H](O)c3ccc(F)cc3)nc3ccccc23)n[nH]1,5.06,Kd,=,8800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Competition Binding Assay: For the binding assays, streptavidin-coated magnetic beads were treated with biotinylated affinity ligands for 30 min at room temperature to generate affinity resins. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific binding. Binding reactions were assembled by combining kinase, liganded affinity beads, and test compounds in 1x binding buffer (20% SeaBlock, 0.17xPBS, 0.05% Tween 20, 6 mM DTT). Test compounds were prepared as 100x stocks in DMSO and rapidly diluted into the aqueous environment. DMSO was added to control assays lacking a test compound. Primary screen interactions were performed in polypropylene 384-well plates in a final volume of 34 uL, while Kd determinations were performed in polystyrene 96-well plates in a final volume of 135 uL. The assay plates were incubated at room temperature with shaking for 1 hr, long enough for binding reactions to reach equilibrium, and the affinity beads were washed extensively with wash buffer (1xPBS, 0.05% Tween 20) to remove unbound protein. The beads were then resuspended in elution buffer (1xPBS, 0.05% Tween 20, 2 uM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 min. The kinase concentration in the eluates was measured by quantitative PCR. Each kinase was tested individually against each compound.",False,5.06,5.06,5.06,c1ccc(Cc2nc(Nc3cc[nH]n3)c3ccccc3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f2e0>
853,CHEMBL3962300,,O=C(NCCO)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.48,IC50,=,330.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.48,6.48,6.48,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f350>
854,CHEMBL3962451,,c1cc2c(ncn3nnc(C4CCN(Cc5cocn5)CC4)c23)[nH]1,6.01,IC50,=,970.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.01,6.01,6.01,c1cc2c(ncn3nnc(C4CCN(Cc5cocn5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09642e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f3c0>
855,CHEMBL3963319,,CC1CCN(C(=O)OC(C)(C)C)CC1c1nnn2cnc3[nH]ccc3c12,5.39,IC50,=,4100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,5.39,5.39,5.39,c1cc2c(ncn3nnc(C4CCCNC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f430>
856,CHEMBL3963387,,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CSC5)CC4)c23)[nH]1,6.41,IC50,=,390.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.41,6.41,6.41,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CSC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09643c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f4a0>
857,CHEMBL3963389,,COCN1CN([C@H]2CC[C@H](CNCC(F)(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,7.13,IC50,=,74.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.13,7.13,7.13,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f510>
858,CHEMBL3963428,,OC(CN[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)(c1ccccc1)C(F)(F)F,6.57,IC50,=,270.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.57,6.57,6.57,c1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09644a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f580>
859,CHEMBL3963443,,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CC5)CC4)c23)[nH]1,7.00,IC50,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.00,7.00,7.00,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f5f0>
860,CHEMBL3963532,,Cc1nc(C2CCCCC2)c2c3cc[nH]c3ncn12,6.23,IC50,=,590.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.23,6.23,6.23,c1cc2c(ncn3cnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f660>
861,CHEMBL3963555,,Cc1cc(NC(=O)N2CCCC(c3nnn4cnc5[nH]ccc5c34)C2)sn1,6.15,IC50,=,710.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.15,6.15,6.15,O=C(Nc1ccns1)N1CCCC(c2nnn3cnc4[nH]ccc4c23)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09645f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f6d0>
862,CHEMBL3964008,,FC1(F)Oc2ccc(CN3CCC(c4nnn5cnc6[nH]ccc6c45)CC3)cc2O1,6.24,IC50,=,570.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.24,6.24,6.24,c1cc2c(ncn3nnc(C4CCN(Cc5ccc6c(c5)OCO6)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f740>
863,CHEMBL3964946,,CN1CN([C@H]2CC[C@H](C(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,7.36,IC50,=,44.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.36,7.36,7.36,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c09646d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f7b0>
864,CHEMBL3965217,,N#Cc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1C(F)(F)F,6.10,IC50,=,790.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.10,6.10,6.10,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f820>
865,CHEMBL396523,,O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1,7.50,Ki,=,31.62,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,7.50,7.50,7.50,c1ccc(Nc2ccnc(Nc3ccc4[nH]ncc4c3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09647b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f890>
866,CHEMBL3965307,,OCCN(Cc1ccccc1)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.92,IC50,=,120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.92,6.92,6.92,c1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f900>
867,CHEMBL3965670,,FC(F)(F)c1nc2cc(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)ccc2[nH]1,7.35,IC50,=,45.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.35,7.35,7.35,c1nc2cc(NC[C@H]3CC[C@H](c4nnn5cnc6[nH]ccc6c45)CC3)ccc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f970>
868,CHEMBL3965965,,Fc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cn1,6.70,IC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.70,6.70,6.70,c1cncc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090f9e0>
869,CHEMBL3966425,,Clc1ccc(CN[C@H]2CC[C@@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.82,6.82,6.82,c1ccc(CN[C@H]2CC[C@@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090fa50>
870,CHEMBL3966746,,CSCN1CN([C@H]2CC[C@H](CNCC(F)(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,6.80,IC50,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.80,6.80,6.80,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c09649e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090fac0>
871,CHEMBL3966840,,OC1CN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,7.31,IC50,=,49.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.31,7.31,7.31,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090fb30>
872,CHEMBL3967370,,CS(=O)(=O)NC[C@H]1CC[C@H](N2CN(CC(F)(F)F)C(=O)c3cnc4[nH]ccc4c32)CC1,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.96,6.96,6.96,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090fba0>
873,CHEMBL3967397,,c1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,8.26,IC50,=,5.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.26,8.26,8.26,c1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090fc10>
874,CHEMBL3967682,,c1ccc(CCNC2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.64,IC50,=,230.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.64,6.64,6.64,c1ccc(CCNC2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090fc80>
875,CHEMBL3967688,,CN1CN([C@H]2CC[C@H](CNCC(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,7.08,IC50,=,84.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.08,7.08,7.08,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090fcf0>
876,CHEMBL3967735,,O=C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.26,IC50,=,55.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.26,7.26,7.26,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090fd60>
877,CHEMBL3967749,,Brc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)s1,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.96,6.96,6.96,c1csc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090fdd0>
878,CHEMBL3967880,,O=C(O)C1CN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.40,IC50,=,400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.40,6.40,6.40,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090fe40>
879,CHEMBL3968041,,O=S(=O)(C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)C(F)(F)F,7.52,IC50,=,30.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.52,7.52,7.52,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090feb0>
880,CHEMBL3968326,,N#CCNC[C@H]1CC[C@H](N2CN(CC(F)(F)F)C(=O)c3cnc4[nH]ccc4c32)CC1,6.80,IC50,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.80,6.80,6.80,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ff20>
881,CHEMBL3968423,,N#Cc1ccc(CN[C@H]2CC[C@@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.51,IC50,=,310.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.51,6.51,6.51,c1ccc(CN[C@H]2CC[C@@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c090ff90>
882,CHEMBL3968872,,CN(CC(F)(F)F)C[C@H]1CC[C@H](N2CN(CC#N)C(=O)c3cnc4[nH]ccc4c32)CC1,7.21,IC50,=,61.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.21,7.21,7.21,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910040>
883,CHEMBL3969473,,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,7.34,IC50,=,46.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.34,7.34,7.34,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0964f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09100b0>
884,CHEMBL3969516,,N#Cc1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1C#N,6.04,IC50,=,910.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.04,6.04,6.04,c1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910120>
885,CHEMBL3969865,,O=C(Nc1nncs1)N1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.70,IC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.70,6.70,6.70,O=C(Nc1nncs1)N1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09650b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910190>
886,CHEMBL3970109,,N#CC1CCN(C2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.38,IC50,=,420.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.38,6.38,6.38,c1cc2c(ncn3nnc(C4CCC(N5CCCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910200>
887,CHEMBL3971373,,N#C/C=C/[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.85,IC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.85,6.85,6.85,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910270>
888,CHEMBL3971389,,O=C(CC(F)(F)F)N1CCCC(c2nnn3cnc4[nH]ccc4c23)C1,6.24,IC50,=,570.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.24,6.24,6.24,c1cc2c(ncn3nnc(C4CCCNC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09102e0>
889,CHEMBL3971717,,OCCN(CCO)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.23,IC50,=,590.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.23,6.23,6.23,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910350>
890,CHEMBL3972033,,O=C(NCCc1ccc(F)cc1)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.43,IC50,=,370.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.43,6.43,6.43,O=C(NCCc1ccccc1)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09652e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09103c0>
891,CHEMBL3972067,,FC(F)(F)CN(CC1CC1)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.21,IC50,=,620.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.21,6.21,6.21,c1cc2c(ncn3nnc([C@H]4CC[C@H](NCC5CC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910430>
892,CHEMBL3972353,,FC(F)(F)C(F)(F)CNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.46,IC50,=,350.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.46,6.46,6.46,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09653c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09104a0>
893,CHEMBL3972475,,N#Cc1cc(F)c(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c(F)c1,7.33,IC50,=,47.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.33,7.33,7.33,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910510>
894,CHEMBL3972506,,FCCNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.44,IC50,=,36.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.44,7.44,7.44,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09654a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910580>
895,CHEMBL3973060,,O=C(OCc1ccccc1)N1CCC(c2ncn3cnc4[nH]ccc4c23)CC1,6.27,IC50,=,540.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.27,6.27,6.27,O=C(OCc1ccccc1)N1CCC(c2ncn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09105f0>
896,CHEMBL3973072,,N#CCCN1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.12,IC50,=,750.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.12,6.12,6.12,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCNCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910660>
897,CHEMBL3973102,,FC(F)(Br)CN[C@H]1CC[C@@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.12,IC50,=,760.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.12,6.12,6.12,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09655f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09106d0>
898,CHEMBL3973302,,Cc1cnc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cn1,7.39,IC50,=,41.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.39,7.39,7.39,c1cnc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910740>
899,CHEMBL3973343,,O/N=C/[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.28,IC50,=,520.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.28,6.28,6.28,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09656d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09107b0>
900,CHEMBL3973486,,FC(F)(F)Oc1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.06,IC50,=,870.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.06,6.06,6.06,c1ccc(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910820>
901,CHEMBL3974289,,O=C(C[C@H]1CC[C@@H](c2nnn3cnc4[nH]ccc4c23)CC1)NCC(F)(F)F,6.10,IC50,=,790.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.10,6.10,6.10,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09657b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910890>
902,CHEMBL3974989,,Fc1cc(C(F)(F)F)ccc1CN1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.51,IC50,=,310.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.51,6.51,6.51,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910900>
903,CHEMBL3975088,,O=S(=O)(C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)c1ccc(F)cc1,6.47,IC50,=,340.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.47,6.47,6.47,O=S(=O)(C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910970>
904,CHEMBL3975158,,COC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.85,IC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.85,6.85,6.85,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09109e0>
905,CHEMBL3975250,,N#Cc1ccc(NC2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c(F)c1,6.75,IC50,=,180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.75,6.75,6.75,c1ccc(NC2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910a50>
906,CHEMBL3975399,,N#CCC(=O)N(CC(F)(F)F)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.89,IC50,=,130.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.89,6.89,6.89,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09659e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910ac0>
907,CHEMBL3975439,,O=C1NCCN1CCNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.75,IC50,=,180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.75,6.75,6.75,O=C1NCCN1CCNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910b30>
908,CHEMBL3975691,,CS(=O)(=O)NC[C@H]1CC[C@H](N2CN(C3CC3)C(=O)c3cnc4[nH]ccc4c32)CC1,7.04,IC50,=,91.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.04,7.04,7.04,O=C1c2cnc3[nH]ccc3c2N(C2CCCCC2)CN1C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910ba0>
909,CHEMBL3976204,,CN1CN([C@H]2CC[C@H](CNCC#N)CC2)c2c(cnc3[nH]ccc23)C1=O,7.38,IC50,=,42.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.38,7.38,7.38,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910c10>
910,CHEMBL3976587,,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC56CC(C5)C6)CC4)c23)[nH]1,6.23,IC50,=,590.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.23,6.23,6.23,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC56CC(C5)C6)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910c80>
911,CHEMBL3976846,,N#CCNC[C@H]1CC[C@H](N2CN(C3CC3)C(=O)c3cnc4[nH]ccc4c32)CC1,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.96,6.96,6.96,O=C1c2cnc3[nH]ccc3c2N(C2CCCCC2)CN1C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910cf0>
912,CHEMBL3977017,,Clc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cn1,6.54,IC50,=,290.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.54,6.54,6.54,c1cncc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910d60>
913,CHEMBL3977129,,CC1(O)CN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.89,IC50,=,130.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.89,6.89,6.89,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910dd0>
914,CHEMBL3977718,,Cn1cc(Nc2ncc(Cl)c(NC3CC4CN(C(=O)CC#N)CC4C3)n2)cn1,8.15,IC50,=,7.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Kinase Assay: TYK2 (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 250 M GGMEDIYFEFMGGKKK, 10 mM MgAcetate and [-33P-ATP](specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 3% phosphoric acid solution. 10 L of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.",False,8.15,8.15,8.15,c1cc(NC2CC3CNCC3C2)nc(Nc2cn[nH]c2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910e40>
915,CHEMBL3978189,,COCC1(NC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)CC1,6.51,IC50,=,310.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.51,6.51,6.51,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910eb0>
916,CHEMBL3978202,,FC(F)(F)CNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.20,IC50,=,63.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.20,7.20,7.20,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910f20>
917,CHEMBL3978620,,OC(CN[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)(c1ccc(Cl)cc1)C(F)(F)F,6.36,IC50,=,440.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.36,6.36,6.36,c1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0910f90>
918,CHEMBL3978777,,c1cc(CCNC2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)ccn1,6.47,IC50,=,340.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.47,6.47,6.47,c1cc(CCNC2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911040>
919,CHEMBL3979340,,Brc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)o1,7.01,IC50,=,98.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.01,7.01,7.01,c1coc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0965f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09110b0>
920,CHEMBL3979623,,O=S(=O)(C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)NCC(F)(F)F,6.52,IC50,=,300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.52,6.52,6.52,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911120>
921,CHEMBL3979988,,Clc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)o1,7.00,IC50,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.00,7.00,7.00,c1coc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09660b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911190>
922,CHEMBL3980095,,Fc1ccc(CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.92,IC50,=,120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.92,6.92,6.92,c1ccc(CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911200>
923,CHEMBL3980241,,O[C@H]1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,7.00,IC50,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.00,7.00,7.00,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911270>
924,CHEMBL3980246,,N#CCC(=O)N(C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)C1CC1,6.08,IC50,=,840.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.08,6.08,6.08,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC5CC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09112e0>
925,CHEMBL3980979,,FC(F)(F)c1ccc(CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,7.34,IC50,=,46.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.34,7.34,7.34,c1ccc(CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911350>
926,CHEMBL3980992,,COCCN(C)C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.06,IC50,=,880.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.06,6.06,6.06,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09662e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09113c0>
927,CHEMBL3981038,,COCCN1CN([C@H]2CC[C@H](CNCC(F)(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,7.22,IC50,=,60.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.22,7.22,7.22,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911430>
928,CHEMBL3981130,,FC1(F)CN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.07,IC50,=,860.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.07,6.07,6.07,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09663c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09114a0>
929,CHEMBL3981338,,Clc1cnccc1CN1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.51,IC50,=,310.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.51,6.51,6.51,c1cc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911510>
930,CHEMBL3981393,,N#CCC(=O)NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.39,IC50,=,410.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.39,6.39,6.39,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09664a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911580>
931,CHEMBL3981443,,c1csc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)n1,6.34,IC50,=,460.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.34,6.34,6.34,c1csc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09115f0>
932,CHEMBL3981542,,N#CCNC(=O)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.82,6.82,6.82,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911660>
933,CHEMBL3981587,,N#CCNC[C@H]1CC[C@H](N2CNC(=O)c3cnc4[nH]ccc4c32)CC1,7.72,IC50,=,19.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.72,7.72,7.72,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c09665f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09116d0>
934,CHEMBL3981673,,O=C1c2cnc3[nH]ccc3c2N([C@H]2CC[C@H](CNS(=O)(=O)C3CC3)CC2)CN1CC(F)(F)F,6.38,IC50,=,420.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.38,6.38,6.38,O=C1NCN([C@H]2CC[C@H](CNS(=O)(=O)C3CC3)CC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911740>
935,CHEMBL3981841,,N#CCCCN1CN([C@H]2CC[C@H](CNCC(F)(F)F)CC2)c2c(cnc3[nH]ccc23)C1=O,6.70,IC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,6.70,6.70,6.70,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c09666d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09117b0>
936,CHEMBL3983078,,c1cc2c(ncn3nnc(C4CCN(Cc5cncs5)CC4)c23)[nH]1,6.92,IC50,=,120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.92,6.92,6.92,c1cc2c(ncn3nnc(C4CCN(Cc5cncs5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911820>
937,CHEMBL3983127,,FC1(F)CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.51,IC50,=,310.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.51,6.51,6.51,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09667b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911890>
938,CHEMBL3983231,,Fc1ccc(NC2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.89,IC50,=,130.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.89,6.89,6.89,c1ccc(NC2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911900>
939,CHEMBL3983344,,NC(=O)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.54,IC50,=,290.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.54,6.54,6.54,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911970>
940,CHEMBL3983447,,Fc1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,7.00,IC50,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.00,7.00,7.00,c1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09119e0>
941,CHEMBL3983594,,N#CCN1CN([C@H]2CC[C@H](CNC3(C(F)(F)F)CC3)CC2)c2c(cnc3[nH]ccc23)C1=O,7.35,IC50,=,45.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.35,7.35,7.35,O=C1NCN([C@H]2CC[C@H](CNC3CC3)CC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911a50>
942,CHEMBL3983856,,O=C(NC1CC1)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.25,IC50,=,560.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.25,6.25,6.25,O=C(NC1CC1)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09669e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911ac0>
943,CHEMBL3984424,,O[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.82,6.82,6.82,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911b30>
944,CHEMBL3984482,,c1cc2c(ncn3nnc([C@H]4CC[C@H](NN5CCOCC5)CC4)c23)[nH]1,6.30,IC50,=,500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.30,6.30,6.30,c1cc2c(ncn3nnc([C@H]4CC[C@H](NN5CCOCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911ba0>
945,CHEMBL3984562,,CS(=O)(=O)NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.80,IC50,=,16.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.80,7.80,7.80,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911c10>
946,CHEMBL3984749,,CN1CN([C@H]2CC[C@H](CN3CCCS3(=O)=O)CC2)c2c(cnc3[nH]ccc23)C1=O,7.03,IC50,=,94.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.03,7.03,7.03,O=C1NCN([C@H]2CC[C@H](CN3CCCS3(=O)=O)CC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911c80>
947,CHEMBL3984960,,Fc1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,8.64,IC50,=,2.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.64,8.64,8.64,c1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911cf0>
948,CHEMBL3985119,,O=S(=O)(C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)NC1CC1,6.38,IC50,=,420.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.38,6.38,6.38,O=S(=O)(C[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)NC1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911d60>
949,CHEMBL3985220,,N#CC=C1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,7.47,IC50,=,34.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.47,7.47,7.47,C=C1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911dd0>
950,CHEMBL3985243,,FC(F)(Br)CNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,7.00,IC50,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.00,7.00,7.00,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911e40>
951,CHEMBL3985363,,c1ccc(CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.96,6.96,6.96,c1ccc(CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911eb0>
952,CHEMBL3985390,,FC1CN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.23,IC50,=,590.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.23,6.23,6.23,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911f20>
953,CHEMBL3985391,,COc1ccc(C(O)(CN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C(F)(F)F)cn1,6.75,IC50,=,180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.75,6.75,6.75,c1cncc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0911f90>
954,CHEMBL3985528,,N#CCN1CN([C@H]2CC[C@H](CF)CC2)c2c(cnc3[nH]ccc23)C1=O,7.31,IC50,=,49.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.31,7.31,7.31,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912040>
955,CHEMBL3985597,,CC(C)(C)OC(=O)N1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,5.28,IC50,=,5300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,5.28,5.28,5.28,c1cc2c(ncn3nnc(C4CCNCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0966f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09120b0>
956,CHEMBL3985603,,O=C(NCC(F)(F)F)C1CN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.24,IC50,=,580.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.24,6.24,6.24,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912120>
957,CHEMBL3986377,,Fc1cc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)ccc1Cl,6.52,IC50,=,300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.52,6.52,6.52,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09670b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912190>
958,CHEMBL3986613,,O=C1NCN([C@H]2CC[C@H](CNCC(F)(F)F)CC2)c2c1cnc1[nH]ccc21,7.66,IC50,=,22.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: The inhibitory activity of the compounds of the present invention against JAK was measured.The respective enzymes (JAK1, JAK2, JAK3 and Tyk2) were purchased from Carna Biosciences, Inc.As a substrate of the enzymes (hereinafter referred to as substrate), LANCE Ultra ULight-JAK-1 (Tyr1023) Peptide (manufactured by PerkinElmer Inc.) was used.As an antibody for detecting phosphorylation of the substrate, LANCE Ultra Europium-anti-phospho tyrosine antibody (PT66) (manufactured by PerkinElmer Inc.) was used.The other reagents were purchased from the following.Adenosine triphosphate (ATP): Sigma-Aldrich4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): DOJINDO LABORATORIESGlycol ether diamine tetraacetic acid (EGTA): DOJINDO LABORATORIES Magnesium chloride (MgCl2): Wako Pure Chemical Industries, Ltd.Dithiothreitol (DTT): Wako Pure Chemical Industries, Ltd.Tween 20: Sigma-AldrichEthylenediaminetetraacetic acid (EDTA): DOJINDO LABORATORIESThe compounds of the present invention, the enzymes (JAK1, JAK2, JAK3 and Tyk2), the substrate and ATP were used for assay as diluted with assay buffer. As the assay buffer, one having the following composition was used. HEPES (pH7.5): 50 mM EGTA: 1 mM MgCl2: 10 mM DTT: 2 mM Tween 20: 0.01% (wt/wt). The dilute concentration and the addition amount on a well plate as described hereinafter were adjusted so that the following final concentrations were achieved on the well plate.",False,7.66,7.66,7.66,O=C1NCN(C2CCCCC2)c2c1cnc1[nH]ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912200>
959,CHEMBL3986618,,Clc1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,6.68,IC50,=,210.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.68,6.68,6.68,c1ccc(CN2CCC(c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912270>
960,CHEMBL3986660,,FC(F)(F)Oc1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,8.31,IC50,=,4.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.31,8.31,8.31,c1ccc(CNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09122e0>
961,CHEMBL3986686,,c1cc2c(ncn3nnc(C4CCCN(Cc5cncs5)C4)c23)[nH]1,6.00,IC50,=,1000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.00,6.00,6.00,c1cc2c(ncn3nnc(C4CCCN(Cc5cncs5)C4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912350>
962,CHEMBL3991929,Cerdulatinib Hydrochloride,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl,7.50,Kd,=,32.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",False,7.50,7.50,7.50,c1cc(NC2CC2)nc(Nc2ccc(N3CCNCC3)cc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09672e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09123c0>
963,CHEMBL400402,,Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,9.15,Kd,=,0.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",False,9.15,9.15,9.15,c1ccc(-c2ccc3nc(Nc4ccc(OCCN5CCCC5)cc4)nnc3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912430>
964,CHEMBL4060201,,O=C(CCCCCCn1cc(-c2ncnc3[nH]ccc23)cn1)NO,6.73,IC50,=,188.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using KKSRGDYMTMQIG as substrate in presence of [gamma-33P]-ATP,False,6.73,6.73,6.73,c1nc(-c2cn[nH]c2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09673c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09124a0>
965,CHEMBL4060444,,Cc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1,7.54,IC50,=,29.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.54,7.54,7.54,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912510>
966,CHEMBL4060536,,Cc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cc1,8.07,IC50,=,8.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,8.07,8.07,8.07,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09674a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912580>
967,CHEMBL4060984,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4cc[nH]n4)cc23)CC[C@]1(C)N,7.85,IC50,=,14.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.85,7.85,7.85,c1cc(NC2CCCC2)c2cc(-c3cc[nH]n3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09125f0>
968,CHEMBL4061128,,N#Cc1ccc(Nc2nn([C@H]3COCC[C@@H]3C#N)cc2C(N)=O)cc1,8.92,IC50,=,1.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,8.92,8.92,8.92,c1ccc(Nc2ccn([C@@H]3CCCOC3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912660>
969,CHEMBL4062062,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccc(Cl)cc4)cc23)CC[C@]1(C)N,8.00,IC50,=,10.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,8.00,8.00,8.00,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09675f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09126d0>
970,CHEMBL4062471,,NC(=O)c1cnn2cccc2c1NCc1cccc(NC(=O)Cn2sc3ccccc3c2=O)c1,6.62,IC50,=,240.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate after 3 hrs by caliper assay,False,6.62,6.62,6.62,O=C(Cn1sc2ccccc2c1=O)Nc1cccc(CNc2ccnn3cccc23)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912740>
971,CHEMBL4062680,,CNc1cc(Nc2nccc3nc(-c4c(Cl)cc(C#N)cc4Cl)[nH]c23)ncn1,7.14,EC50,=,72.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,8.18,9.22,7.14,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09676d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09127b0>
972,CHEMBL4062758,,Cc1cc(Nc2nccc3nc(-c4c(Cl)cccc4Cl)[nH]c23)ncn1,6.77,EC50,=,170.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,8.09,9.4,6.77,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912820>
973,CHEMBL4063870,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccncc4)cc23)CC[C@]1(C)N,7.36,IC50,=,44.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.36,7.36,7.36,c1cc(-c2cc3c(NC4CCCC4)ccnn3c2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09677b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912890>
974,CHEMBL4064171,,N#Cc1ccc(Nc2nn([C@H]3COCC[C@@H]3C#N)cc2C(N)=O)cc1C#N,7.96,IC50,=,11.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,7.96,7.96,7.96,c1ccc(Nc2ccn([C@@H]3CCCOC3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912900>
975,CHEMBL4064189,,O=C(Nc1nccc2nc(-c3c(Cl)cccc3Cl)[nH]c12)C1CC1,8.77,Ki,=,1.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,8.77,8.77,8.77,O=C(Nc1nccc2nc(-c3ccccc3)[nH]c12)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912970>
976,CHEMBL4065419,,Cc1nc(Nc2nccc3nc(-c4c(Cl)cccc4Cl)[nH]c23)cc(N(C)C)n1,8.49,Ki,=,3.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,8.49,8.49,8.49,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09129e0>
977,CHEMBL4066193,,COc1cc(Nc2nn([C@H]3COCC[C@@H]3C#N)cc2C(N)=O)cc(F)n1,7.89,IC50,=,13.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,7.89,7.89,7.89,c1cc(Nc2ccn([C@@H]3CCCOC3)n2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912a50>
978,CHEMBL4066236,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)CN(C)CC4)n[nH]c2c1,7.70,IC50,=,20.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,7.70,7.70,7.70,c1ccc(-c2ccc3c(-c4nc5c([nH]4)CNCC5)n[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09679e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912ac0>
979,CHEMBL4066730,,N#CCC(=O)Nc1cccc(CNc2c(C(N)=O)cnn3cccc23)c1,5.70,IC50,=,2000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate after 3 hrs by caliper assay,False,5.70,5.70,5.70,c1ccc(CNc2ccnn3cccc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912b30>
980,CHEMBL4066906,,C[C@@H]1NS(=O)(=O)c2ccc(Nc3nn([C@H]4COCC[C@@H]4C#N)cc3C(N)=O)cc21,8.77,IC50,=,1.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,8.77,8.77,8.77,O=S1(=O)NCc2cc(Nc3ccn([C@@H]4CCCOC4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912ba0>
981,CHEMBL4067915,,N#C[C@H]1CCOC[C@@H]1n1cc(C(N)=O)c(Nc2ccnc(F)c2)n1,8.52,IC50,=,3.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,8.52,8.52,8.52,c1cc(Nc2ccn([C@@H]3CCCOC3)n2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912c10>
982,CHEMBL4068357,,C[C@@H]1CCN(C(=O)N2CCCC2)C[C@@H]1N(C)c1ncnc2[nH]ccc12,5.79,IC50,=,1632.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,6.34,6.89,5.79,O=C(N1CCCC1)N1CCC[C@@H](Nc2ncnc3[nH]ccc23)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912c80>
983,CHEMBL4068427,,O=C(Nc1nccc2nc(-c3c(Cl)cccc3Cl)oc12)C1CC1,8.06,Ki,=,8.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,8.06,8.06,8.06,O=C(Nc1nccc2nc(-c3ccccc3)oc12)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912cf0>
984,CHEMBL4068856,,Cc1ccccc1-c1cc2c(N[C@@H]3CC[C@](C)(N)C3(C)C)c(C(N)=O)cnn2c1,7.29,IC50,=,51.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.29,7.29,7.29,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912d60>
985,CHEMBL4069127,,COc1cc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)ccn1,7.44,IC50,=,36.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.44,7.44,7.44,c1cc(-c2cc3c(NC4CCCC4)ccnn3c2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912dd0>
986,CHEMBL4069942,,CN(C)c1cc(Nc2nccc3nc(-c4c(Cl)cccc4Cl)[nH]c23)ncn1,6.85,EC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,8.04,9.22,6.85,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912e40>
987,CHEMBL4069951,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)CN(S(C)(=O)=O)CC4)n[nH]c2c1,7.60,IC50,=,25.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,7.60,7.60,7.60,c1ccc(-c2ccc3c(-c4nc5c([nH]4)CNCC5)n[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912eb0>
988,CHEMBL4070136,,CC(C)Oc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1,7.52,IC50,=,30.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.52,7.52,7.52,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912f20>
989,CHEMBL4070262,,OC1CCN(c2cc(Nc3nccc4nc(-c5c(Cl)cccc5Cl)[nH]c34)ncn2)CC1,6.44,EC50,=,360.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,7.72,9.0,6.44,c1ccc(-c2nc3ccnc(Nc4cc(N5CCCCC5)ncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0912f90>
990,CHEMBL4070687,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4cccc(C#N)c4)cc23)CC[C@]1(C)N,7.26,IC50,=,55.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.26,7.26,7.26,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913040>
991,CHEMBL4071005,,COc1cc(Nc2nn([C@H]3COCC[C@@H]3C#N)cc2C(N)=O)ccc1Cl,7.92,IC50,=,12.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,7.92,7.92,7.92,c1ccc(Nc2ccn([C@@H]3CCCOC3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0967f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09130b0>
992,CHEMBL4071255,,COc1ccccc1-c1cc2c(N[C@@H]3CC[C@](C)(N)C3(C)C)c(C(N)=O)cnn2c1,7.68,IC50,=,21.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.68,7.68,7.68,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913120>
993,CHEMBL4071399,,CNc1cc(Nc2nccc3nc(-c4c(Cl)cccc4Cl)[nH]c23)ncn1,7.36,EC50,=,44.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,8.33,9.3,7.36,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09680b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913190>
994,CHEMBL4071806,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4cccc(F)c4)cc23)CC[C@]1(C)N,7.66,IC50,=,22.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.66,7.66,7.66,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913200>
995,CHEMBL4072239,,NC(=O)c1cnc(Nc2ccccc2)cc1NCc1ccccc1,6.11,IC50,=,774.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate after 3 hrs by caliper assay,False,6.11,6.11,6.11,c1ccc(CNc2ccnc(Nc3ccccc3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913270>
996,CHEMBL4072848,,COc1cc(Nc2nn([C@H]3COCC[C@@H]3C#N)cc2C(N)=O)ccc1C#N,8.05,IC50,=,9.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,8.05,8.05,8.05,c1ccc(Nc2ccn([C@@H]3CCCOC3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09132e0>
997,CHEMBL4073562,,Cc1cc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)ccn1,8.24,IC50,=,5.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,8.24,8.24,8.24,c1cc(-c2cc3c(NC4CCCC4)ccnn3c2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913350>
998,CHEMBL4074130,,Clc1cccc(Cl)c1-c1nc2ccnc(Nc3ccncn3)c2[nH]1,9.22,Ki,=,0.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,9.22,9.22,9.22,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09682e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09133c0>
999,CHEMBL4075131,,Cn1c(-c2c(Cl)cccc2Cl)nc2c(NC(=O)C3CC3)nccc21,7.89,Ki,=,13.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,7.89,7.89,7.89,O=C(Nc1nccc2[nH]c(-c3ccccc3)nc12)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913430>
1000,CHEMBL4075453,,Clc1cccc(Cl)c1-c1nc2ccnc(Nc3cc(N4CCCC4)ncn3)c2[nH]1,6.28,EC50,=,520.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,7.79,9.3,6.28,c1ccc(-c2nc3ccnc(Nc4cc(N5CCCC5)ncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09683c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09134a0>
1001,CHEMBL4076191,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4F)cc23)CC[C@]1(C)N,7.82,IC50,=,15.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.82,7.82,7.82,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913510>
1002,CHEMBL4076473,,N#C[C@H]1CCOC[C@@H]1n1cc(C(N)=O)c(Nc2cc(F)c3nccc(Cl)c3c2)n1,7.92,IC50,=,12.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,7.92,7.92,7.92,c1cnc2ccc(Nc3ccn([C@@H]4CCCOC4)n3)cc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09684a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913580>
1003,CHEMBL4076794,,COc1cccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)c1,7.92,IC50,=,12.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.92,7.92,7.92,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09135f0>
1004,CHEMBL4076823,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4cccc(Cl)c4)cc23)CC[C@]1(C)N,7.70,IC50,=,20.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.70,7.70,7.70,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913660>
1005,CHEMBL4076947,,Cc1cc(Nc2nccc3nc(-c4c(Cl)cc(C#N)cc4Cl)[nH]c23)ncn1,7.18,EC50,=,66.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,8.16,9.15,7.18,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09685f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09136d0>
1006,CHEMBL4077508,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccc(F)cc4)cc23)CC[C@]1(C)N,7.85,IC50,=,14.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.85,7.85,7.85,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913740>
1007,CHEMBL4077886,,N#C[C@H]1CCOC[C@@H]1n1cc(C(N)=O)c(Nc2ccc(C3CC3)cc2)n1,8.41,IC50,=,3.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,8.41,8.41,8.41,c1cc(C2CC2)ccc1Nc1ccn([C@@H]2CCCOC2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09686d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09137b0>
1008,CHEMBL4078165,,CCc1cc(O)ccc1-c1ccc2c(C(=O)NC)n[nH]c2c1,6.10,IC50,=,796.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,6.10,6.10,6.10,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913820>
1009,CHEMBL4078773,,COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cc1,8.04,IC50,=,9.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,8.04,8.04,8.04,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09687b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913890>
1010,CHEMBL4078799,,Cn1cc(-c2ccc(Nc3nn([C@H]4COCC[C@@H]4C#N)cc3C(N)=O)cc2)cn1,9.70,IC50,=,0.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,9.70,9.70,9.70,c1cc(-c2cn[nH]c2)ccc1Nc1ccn([C@@H]2CCCOC2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913900>
1011,CHEMBL4079092,,Cc1ncnc2ccc(Nc3nn([C@H]4COCC[C@@H]4C#N)cc3C(N)=O)cc12,7.85,IC50,=,14.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,7.85,7.85,7.85,c1ncc2cc(Nc3ccn([C@@H]4CCCOC4)n3)ccc2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913970>
1012,CHEMBL4079880,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccncc4F)cc23)CC[C@]1(C)N,7.34,IC50,=,46.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.34,7.34,7.34,c1cc(-c2cc3c(NC4CCCC4)ccnn3c2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09139e0>
1013,CHEMBL4080797,,COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1,7.60,IC50,=,25.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.60,7.60,7.60,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913a50>
1014,CHEMBL4080904,,OCCN1CCN(c2cc(Nc3nccc4nc(-c5c(Cl)cccc5Cl)[nH]c34)ncn2)CC1,6.85,EC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,7.88,8.92,6.85,c1ccc(-c2nc3ccnc(Nc4cc(N5CCNCC5)ncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09689e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913ac0>
1015,CHEMBL4082575,,O=C(Nc1cc2cc(-c3c(Cl)cccc3Cl)ccc2cn1)C1CC1,7.38,Ki,=,42.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,7.38,7.38,7.38,O=C(Nc1cc2cc(-c3ccccc3)ccc2cn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913b30>
1016,CHEMBL4083798,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4C#N)cc23)CC[C@]1(C)N,7.47,IC50,=,34.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.47,7.47,7.47,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913ba0>
1017,CHEMBL4084341,,Cc1cnccc1-c1cc2c(N[C@@H]3CC[C@](C)(N)C3(C)C)c(C(N)=O)cnn2c1,7.54,IC50,=,29.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.54,7.54,7.54,c1cc(-c2cc3c(NC4CCCC4)ccnn3c2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913c10>
1018,CHEMBL4084436,,Nc1cc(Nc2nccc3nc(-c4c(Cl)cccc4Cl)[nH]c23)ncn1,6.58,EC50,=,260.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,8.05,9.52,6.58,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913c80>
1019,CHEMBL4085414,,O=C(Nc1nccc2oc(-c3c(Cl)cccc3Cl)nc12)C1CC1,7.70,Ki,=,20.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,7.70,7.70,7.70,O=C(Nc1nccc2oc(-c3ccccc3)nc12)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913cf0>
1020,CHEMBL4085737,,N#Cc1ccc(Nc2nn([C@H]3COCC[C@@H]3C#N)cc2C(N)=O)cc1Cl,8.40,IC50,=,4.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,8.40,8.40,8.40,c1ccc(Nc2ccn([C@@H]3CCCOC3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913d60>
1021,CHEMBL4086057,,CCc1cc(O)ccc1-c1ccc2c(-c3ncc[nH]3)n[nH]c2c1,8.34,IC50,=,4.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,8.34,8.34,8.34,c1ccc(-c2ccc3c(-c4ncc[nH]4)n[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913dd0>
1022,CHEMBL4086518,,O=C(Nc1cc2nc(-c3c(Cl)cccc3Cl)[nH]c2cn1)C1CC1,5.46,Ki,=,3500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,5.46,5.46,5.46,O=C(Nc1cc2nc(-c3ccccc3)[nH]c2cn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913e40>
1023,CHEMBL4087076,,CC(C)c1cc(O)ccc1-c1ccc2c(-c3nc4ccccc4[nH]3)n[nH]c2c1,6.41,IC50,=,392.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,6.41,6.41,6.41,c1ccc(-c2ccc3c(-c4nc5ccccc5[nH]4)n[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913eb0>
1024,CHEMBL4087655,,Cc1cccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)c1,8.10,IC50,=,7.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,8.10,8.10,8.10,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913f20>
1025,CHEMBL4088262,,COc1ccnc2c(F)cc(Nc3nn([C@H]4COCC[C@@H]4C#N)cc3C(N)=O)cc12,8.10,IC50,=,8.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,8.10,8.10,8.10,c1cnc2ccc(Nc3ccn([C@@H]4CCCOC4)n3)cc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0913f90>
1026,CHEMBL4088673,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4cncc(F)c4)cc23)CC[C@]1(C)N,7.22,IC50,=,60.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.22,7.22,7.22,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914040>
1027,CHEMBL4089118,,N#C[C@H]1CCOC[C@@H]1n1cc(C(N)=O)c(Nc2ccc([C@H](O)C(F)(F)F)cc2)n1,9.40,IC50,=,0.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,9.40,9.40,9.40,c1ccc(Nc2ccn([C@@H]3CCCOC3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0968f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09140b0>
1028,CHEMBL4089164,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4cncnc4)cc23)CC[C@]1(C)N,6.72,IC50,=,190.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,6.72,6.72,6.72,c1ncc(-c2cc3c(NC4CCCC4)ccnn3c2)cn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914120>
1029,CHEMBL4089234,,N#C[C@H]1CCOC[C@@H]1n1cc(C(N)=O)c(Nc2ccc(Cl)cc2)n1,8.70,IC50,=,2.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,8.70,8.70,8.70,c1ccc(Nc2ccn([C@@H]3CCCOC3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09690b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914190>
1030,CHEMBL4089515,,C[C@@H]1CCN(C(=O)N2CC[C@@H](S(=O)(=O)c3cccc(O)c3)C2)C[C@@H]1N(C)c1ncnc2[nH]ccc12,6.02,IC50,=,958.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,6.02,6.02,6.02,O=C(N1CCC[C@@H](Nc2ncnc3[nH]ccc23)C1)N1CC[C@@H](S(=O)(=O)c2ccccc2)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914200>
1031,CHEMBL4089568,,Cn1c(-c2c(Cl)cccc2Cl)nc2ccnc(NC(=O)C3CC3)c21,7.72,Ki,=,19.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,7.72,7.72,7.72,O=C(Nc1nccc2nc(-c3ccccc3)[nH]c12)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914270>
1032,CHEMBL4091096,,CCOc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1,7.42,IC50,=,38.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.42,7.42,7.42,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09142e0>
1033,CHEMBL4091582,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccc(C#N)cc4)cc23)CC[C@]1(C)N,8.07,IC50,=,8.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,8.07,8.07,8.07,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914350>
1034,CHEMBL4092116,,N#Cc1cc(Cl)c(-c2nc3ccnc(Nc4cc(N)ncn4)c3[nH]2)c(Cl)c1,6.35,EC50,=,450.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,7.78,9.22,6.35,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09692e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09143c0>
1035,CHEMBL4092191,,N#Cc1ccnc(Nc2nccc3nc(-c4c(Cl)cccc4Cl)[nH]c23)c1,7.46,EC50,=,35.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,8.3,9.15,7.46,c1ccc(-c2nc3ccnc(Nc4ccccn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914430>
1036,CHEMBL4092626,,CN(C)c1cc(Nc2nn([C@H]3COCC[C@@H]3C#N)cc2C(N)=O)cc(F)n1,7.89,IC50,=,13.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,7.89,7.89,7.89,c1cc(Nc2ccn([C@@H]3CCCOC3)n2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09693c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09144a0>
1037,CHEMBL4093092,,Cc1cc(Nc2nccc3nc(-c4c(Cl)cccc4Cl)[nH]c23)nc(N(C)C)n1,8.00,Ki,=,9.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,8.00,8.00,8.00,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914510>
1038,CHEMBL4093172,,O=C(Nc1nccc2cc(-c3c(Cl)cccc3Cl)sc12)C1CC1,9.10,Ki,=,0.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,9.10,9.10,9.10,O=C(Nc1nccc2cc(-c3ccccc3)sc12)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09694a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914580>
1039,CHEMBL4093318,,NC(=O)c1cnn2cc(-c3ccccc3)cc2c1NCc1ccccc1,6.93,IC50,=,118.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate after 3 hrs by caliper assay,False,6.93,6.93,6.93,c1ccc(CNc2ccnn3cc(-c4ccccc4)cc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09145f0>
1040,CHEMBL4093813,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)CN(C(C)=O)CC4)n[nH]c2c1,7.64,IC50,=,22.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,7.64,7.64,7.64,c1ccc(-c2ccc3c(-c4nc5c([nH]4)CNCC5)n[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914660>
1041,CHEMBL4093872,,Clc1cccc(Cl)c1-c1nc2ccnc(Nc3cc(N4CCOCC4)ncn3)c2[nH]1,6.70,EC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,7.96,9.22,6.7,c1ccc(-c2nc3ccnc(Nc4cc(N5CCOCC5)ncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09695f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09146d0>
1042,CHEMBL4095596,,CC(CCCCCC(=O)NO)n1cc(-c2ncnc3[nH]ccc23)cn1,6.84,IC50,=,144.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using KKSRGDYMTMQIG as substrate in presence of [gamma-33P]-ATP,False,6.84,6.84,6.84,c1nc(-c2cn[nH]c2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914740>
1043,CHEMBL4096145,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N,8.12,IC50,=,7.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,8.12,8.12,8.12,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09696d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09147b0>
1044,CHEMBL4096219,,CCc1cc(O)ccc1-c1ccc2c(C(N)=O)n[nH]c2c1,7.26,IC50,=,54.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,7.26,7.26,7.26,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914820>
1045,CHEMBL4096795,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccc(C#N)nc4)cc23)CC[C@]1(C)N,7.33,IC50,=,47.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.33,7.33,7.33,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09697b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914890>
1046,CHEMBL4096821,,N#C[C@H]1CCOC[C@@H]1n1cc(C(N)=O)c(Nc2ccc(-n3ccnn3)cc2)n1,9.30,IC50,=,0.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,9.30,9.30,9.30,c1cn(-c2ccc(Nc3ccn([C@@H]4CCCOC4)n3)cc2)nn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914900>
1047,CHEMBL4097152,,CCc1cc(O)c(F)cc1-c1ccc2c(-c3nc4c([nH]3)CN(Cc3ccccc3)CC4)n[nH]c2c1,7.24,IC50,=,57.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,7.24,7.24,7.24,c1ccc(CN2CCc3nc(-c4n[nH]c5cc(-c6ccccc6)ccc45)[nH]c3C2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914970>
1048,CHEMBL4097446,,Clc1cccc(Cl)c1-c1nc2ccnc(Nc3cc(N4CCN(C5COC5)CC4)ncn3)c2[nH]1,7.23,EC50,=,59.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,8.07,8.92,7.23,c1ccc(-c2nc3ccnc(Nc4cc(N5CCN(C6COC6)CC5)ncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09149e0>
1049,CHEMBL4098840,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccc(F)nc4)cc23)CC[C@]1(C)N,7.57,IC50,=,27.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.57,7.57,7.57,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914a50>
1050,CHEMBL4098999,,N#Cc1ccc(Nc2nn([C@H]3COCC[C@@H]3C#N)cc2C(N)=O)cc1C1CC1,7.40,IC50,=,40.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,7.40,7.40,7.40,c1cc(Nc2ccn([C@@H]3CCCOC3)n2)cc(C2CC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09699e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914ac0>
1051,CHEMBL4099854,,COc1cc(Nc2nccc3nc(-c4c(Cl)cccc4Cl)[nH]c23)ncn1,5.44,EC50,=,3600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,7.3,9.15,5.44,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914b30>
1052,CHEMBL4100288,,N#C[C@H]1CCOC[C@@H]1n1cc(C(N)=O)c(Nc2ccccc2)n1,8.54,IC50,=,2.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,8.54,8.54,8.54,c1ccc(Nc2ccn([C@@H]3CCCOC3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914ba0>
1053,CHEMBL4100889,,O=C(Nc1nccc2nn(-c3c(Cl)cccc3Cl)cc12)C1CC1,8.89,Ki,=,1.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,8.89,8.89,8.89,O=C(Nc1nccc2nn(-c3ccccc3)cc12)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914c10>
1054,CHEMBL4101534,,CCc1cc(O)ccc1-c1ccc2c(C(=O)Nc3ccc(C)nc3)n[nH]c2c1,6.09,IC50,=,815.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,6.09,6.09,6.09,O=C(Nc1cccnc1)c1n[nH]c2cc(-c3ccccc3)ccc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914c80>
1055,CHEMBL4101734,,O=C(Nc1nccc2cc(-c3c(Cl)cccc3Cl)ccc12)C1CC1,7.77,Ki,=,17.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,7.77,7.77,7.77,O=C(Nc1nccc2cc(-c3ccccc3)ccc12)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914cf0>
1056,CHEMBL4102140,,N#C[C@H]1CCOC[C@@H]1n1cc(C(N)=O)c(Nc2ccc(OC(F)F)cc2)n1,9.15,IC50,=,0.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,9.15,9.15,9.15,c1ccc(Nc2ccn([C@@H]3CCCOC3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914d60>
1057,CHEMBL410295,,Cc1cccc(C)c1-n1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n2c3ccccc3nc12,5.92,IC50,=,1200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 by HTRF assay,False,5.92,5.92,5.92,O=c1c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n2c3ccccc3nc2n1-c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914dd0>
1058,CHEMBL4103341,,O=C(Nc1nccc2cc(-c3c(Cl)cccc3Cl)oc12)C1CC1,7.51,Ki,=,31.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) by biochemical assay,False,7.51,7.51,7.51,O=C(Nc1nccc2cc(-c3ccccc3)oc12)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914e40>
1059,CHEMBL4103980,,CCc1cc(O)c(F)cc1-c1ccc2c(-c3nc4ccccc4[nH]3)n[nH]c2c1,7.82,IC50,=,15.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,7.82,7.82,7.82,c1ccc(-c2ccc3c(-c4nc5ccccc5[nH]4)n[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914eb0>
1060,CHEMBL4104127,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccnc(F)c4)cc23)CC[C@]1(C)N,7.23,IC50,=,59.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.23,7.23,7.23,c1cc(-c2cc3c(NC4CCCC4)ccnn3c2)ccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914f20>
1061,CHEMBL4104623,,N#C[C@H]1CCOC[C@@H]1n1cc(C(N)=O)c(Nc2ccc(F)cc2)n1,8.74,IC50,=,1.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged recombinant human TYK2 catalytic domain expressed in baculovirus expression system using LCB-EQEDEPEGDYFEWLW-NH2 as substrate preincubated for 30 mins followed by ATP addition measured after 120 mins by HTRF assay,False,8.74,8.74,8.74,c1ccc(Nc2ccn([C@@H]3CCCOC3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0914f90>
1062,CHEMBL4104931,,CCCc1cc(O)ccc1-c1ccc2c(-c3nc4ccccc4[nH]3)n[nH]c2c1,6.36,IC50,=,437.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin) using peptide substrate preincubated for 60 mins followed by substrate addition and measured after 60 mins by microfluidic assay,False,6.36,6.36,6.36,c1ccc(-c2ccc3c(-c4nc5ccccc5[nH]4)n[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915040>
1063,CHEMBL4105015,,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4Cl)cc23)CC[C@]1(C)N,7.33,IC50,=,47.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of His-tagged TYK2 (unknown origin) after 3 hrs by Caliper assay,False,7.33,7.33,7.33,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0969f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09150b0>
1064,CHEMBL4105148,,Cc1nccc(Nc2nccc3nc(-c4c(Cl)cccc4Cl)[nH]c23)n1,5.03,EC50,=,9400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) assessed as reduction in IL-23 induced STAT3 phosphorylation by cell based ELISA,False,6.66,8.29,5.03,c1ccc(-c2nc3ccnc(Nc4ccncn4)c3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915120>
1065,CHEMBL4106456,,O=C1NOC[C@H]1NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.43,IC50,=,370.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.43,6.43,6.43,O=C1NOC[C@H]1NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915190>
1066,CHEMBL4107757,,N#C[C@H]1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.44,IC50,=,360.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.44,6.44,6.44,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915200>
1067,CHEMBL4107883,,N#C[C@H]1CCN(C(=O)[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.06,IC50,=,870.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.06,6.06,6.06,O=C([C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)N1CCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915270>
1068,CHEMBL4109199,,C[C@@H](O)CNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.89,IC50,=,130.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.89,6.89,6.89,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09152e0>
1069,CHEMBL4109603,,O[C@H](CN[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)c1ccccc1,6.48,IC50,=,330.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.48,6.48,6.48,c1ccc(CCN[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915350>
1070,CHEMBL4110648,,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC[C@H]5CCCO5)CC4)c23)[nH]1,6.80,IC50,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.80,6.80,6.80,c1cc2c(ncn3nnc([C@H]4CC[C@H](CNC[C@H]5CCCO5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09153c0>
1071,CHEMBL4111044,,[N-]=[N+]=NC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,8.04,IC50,=,9.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,8.04,8.04,8.04,c1cc2c(ncn3nnc(C4CCCCC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915430>
1072,CHEMBL4111878,,O[C@@H]1Cc2ccccc2[C@@H]1NC1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,6.54,IC50,=,290.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.54,6.54,6.54,c1ccc2c(c1)CC[C@H]2NC1CCC(c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09154a0>
1073,CHEMBL4112119,,F[C@@H]1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.37,IC50,=,430.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.37,6.37,6.37,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915510>
1074,CHEMBL4112721,,O=C(N[C@@H]1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1)C(F)(F)F,6.07,IC50,=,860.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.07,6.07,6.07,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915580>
1075,CHEMBL4112919,,O[C@H](CNC[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1)c1ccccc1,7.30,IC50,=,50.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.30,7.30,7.30,c1ccc(CCNC[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09155f0>
1076,CHEMBL4112922,,CC(=O)N[C@@H]1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.21,IC50,=,610.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.21,6.21,6.21,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915660>
1077,CHEMBL4113620,,O[C@@H]1CCN(C[C@H]2CC[C@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,7.72,IC50,=,19.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,7.72,7.72,7.72,c1cc2c(ncn3nnc([C@H]4CC[C@H](CN5CCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09156d0>
1078,CHEMBL4114359,,O[C@@H]1CCN(C[C@H]2CC[C@@H](c3nnn4cnc5[nH]ccc5c34)CC2)C1,6.11,IC50,=,770.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.11,6.11,6.11,c1cc2c(ncn3nnc([C@H]4CC[C@@H](CN5CCCC5)CC4)c23)[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915740>
1079,CHEMBL4115208,,O=C(NC[C@@H](O)c1ccccc1)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,6.34,IC50,=,460.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.34,6.34,6.34,O=C(NCCc1ccccc1)[C@H]1CC[C@H](c2nnn3cnc4[nH]ccc4c23)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09157b0>
1080,CHEMBL4115251,,c1cc[n+]2cc(CN3CCC(c4nnn5cnc6[nH]ccc6c45)CC3)sc2c1,6.13,IC50,=,740.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Enzyme Assay: JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer Co., Ltd. (PE)) was used. Dilute solutions of compounds and enzymes in assay buffer (50 mM HEPES pH7.5, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.01% Tween20) were dispensed into wells of a 384-well black plate. After 5 minutes of preincubation, dilute solutions of the substrate and ATP (adenosine triphosphate) were added at a final concentration of 100 M, and the plate was incubated at room temperature for 2 hours. After addition of a termination reagent containing EDTA (ethylenediamine tetraacetic acid) at a final concentration of 10 mM, LANCE Eu-W1024 Anti-phosphotyrosine (PT66) (manufactured by PE) was added, and after 1 hour of incubation, the fluorescences were measured with ARVO-HTS.",False,6.13,6.13,6.13,c1cc[n+]2cc(CN3CCC(c4nnn5cnc6[nH]ccc6c45)CC3)sc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915820>
1081,CHEMBL4125719,,N#CC(C#N)=Cc1ccc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)o1,7.85,IC50,=,14.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using KKSRGDYMTMQIG as substrate in presence of 10 uM [gamma33P]ATP by radiometric method,False,7.85,7.85,7.85,c1coc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915890>
1082,CHEMBL4125861,,CN1CCN(C(=O)C(C#N)=Cc2ccc(-c3nc4cnc5[nH]ccc5c4n3C3CCCCC3)o2)CC1,6.10,IC50,=,791.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using KKSRGDYMTMQIG as substrate in presence of 10 uM [gamma33P]ATP by radiometric method,False,6.10,6.10,6.10,O=C(C=Cc1ccc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)o1)N1CCNCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915900>
1083,CHEMBL4126514,,CN(C)C(=O)CCc1ccc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)o1,6.86,IC50,=,139.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using KKSRGDYMTMQIG as substrate in presence of 10 uM [gamma33P]ATP by radiometric method,False,6.86,6.86,6.86,c1coc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915970>
1084,CHEMBL4127590,,N#CCCc1ccc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)o1,7.60,IC50,=,25.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using KKSRGDYMTMQIG as substrate in presence of 10 uM [gamma33P]ATP by radiometric method,False,7.60,7.60,7.60,c1coc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09159e0>
1085,CHEMBL4128181,,CN(C)C(=O)C(C#N)=Cc1ccc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)o1,4.93,IC50,=,11800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using KKSRGDYMTMQIG as substrate in presence of 200 uM [gamma33P]ATP by radiometric method,False,5.64,6.34,4.93,c1coc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915a50>
1086,CHEMBL4128266,,N#C/C=C/c1ccc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)o1,7.36,IC50,=,44.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using KKSRGDYMTMQIG as substrate in presence of 10 uM [gamma33P]ATP by radiometric method,False,7.36,7.36,7.36,c1coc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096a9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915ac0>
1087,CHEMBL4128410,,CN(C)C(=O)/C=C/c1ccc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)o1,7.11,IC50,=,78.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using KKSRGDYMTMQIG as substrate in presence of 10 uM [gamma33P]ATP by radiometric method,False,7.11,7.11,7.11,c1coc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096aa50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915b30>
1088,CHEMBL4159366,,CS(=O)(=O)Nc1ccc(-c2ccnc(Nc3ccc(N4CCC(C(=O)NCCCCCCCC(=O)NO)CC4)cc3)n2)cc1,7.13,IC50,=,74.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of ATP,False,7.13,7.13,7.13,c1ccc(-c2ccnc(Nc3ccc(N4CCCCC4)cc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096aac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915ba0>
1089,CHEMBL4160840,,O=C(NO)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,6.38,IC50,=,419.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of ATP,False,6.38,6.38,6.38,c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ab30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915c10>
1090,CHEMBL4175555,,CS(=O)(=O)Nc1ccc(-c2ccnc(Nc3ccc(N4CCC(C(=O)Nc5ccc(/C=C/C(=O)NO)cc5)CC4)cc3)n2)cc1,7.34,IC50,=,46.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of ATP,False,7.34,7.34,7.34,O=C(Nc1ccccc1)C1CCN(c2ccc(Nc3nccc(-c4ccccc4)n3)cc2)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096aba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915c80>
1091,CHEMBL4175808,,Cc1cnc(Nc2cc(N3C[C@@H]4C[C@H]3CN4C)cnc2F)nc1N[C@H](C)C(C)C,4.62,IC50,=,24000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human N-terminal GST-tagged TYK2 (871 to 1187 residues) expressed in baculovirus expression system using 5FAM-GEEPLYWSFPAKKK-NH2 as substrate after 10 mins by caliper assay,False,4.62,4.62,4.62,c1cnc(Nc2cncc(N3C[C@@H]4C[C@H]3CN4)c2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ac10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915cf0>
1092,CHEMBL4224807,,CN(c1ncnc2[nH]ccc12)[C@@H]1CCN(C(=O)CC#N)C1,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875-end residues) in presence of ATP,False,6.96,6.96,6.96,c1nc(N[C@@H]2CCNC2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ac80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915d60>
1093,CHEMBL4228766,,C1=C/COc2ccc(o2)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)COC/1,6.64,IC50,=,230.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,6.64,6.64,6.64,C1=C/COc2ccc(o2)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)COC/1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096acf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915dd0>
1094,CHEMBL4238190,,COCCn1cc(-c2nn(C3CCCN(C(=O)CC#N)C3)c3ncnc(N)c23)cn1,5.49,IC50,=,3219.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human GST-tagged TYK2 catalytic domain expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition measured after 30 mins by HTRF assay,False,5.49,5.49,5.49,c1ncc2c(-c3cn[nH]c3)nn(C3CCCNC3)c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ad60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915e40>
1095,CHEMBL4238357,,Cn1cc(-c2nn(CC3CCCN(C(=O)CC#N)C3)c3ncnc(N)c23)cn1,5.63,IC50,=,2352.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human GST-tagged TYK2 catalytic domain expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition measured after 30 mins by HTRF assay,False,5.63,5.63,5.63,c1ncc2c(-c3cn[nH]c3)nn(CC3CCCNC3)c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096add0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915eb0>
1096,CHEMBL4238926,,NC(=O)c1cnc2[nH]ccc2c1NC1C2CC3CC1CC(O)(C3)C2,8.30,IC50,=,5.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Tyk2 using Biotin-Lyn-Substrate-2 in presence of 1 mM ATP by phosphotyrosine-specific ELISA,False,8.31,8.32,8.3,c1cc(NC2C3CC4CC(C3)CC2C4)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ae40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915f20>
1097,CHEMBL4241272,,C=CC(=O)N1CCCC(Cn2nc(-c3cnn(C)c3)c3c(N)ncnc32)C1,5.40,IC50,=,3964.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human GST-tagged TYK2 catalytic domain expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition measured after 30 mins by HTRF assay,False,5.40,5.40,5.40,c1ncc2c(-c3cn[nH]c3)nn(CC3CCCNC3)c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096aeb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0915f90>
1098,CHEMBL4242999,,Br.NC(=O)c1cnc2[nH]ccc2c1NC1C2CC3CC1CC(O)(C3)C2,8.32,IC50,=,4.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human N-terminal GST-tagged TYK2 catalytic domain (871 to 1187 residues) expressed in baculovirus expression system using Biotin-Lyn-Substrate2 after 1 hr by ELISA,False,8.32,8.32,8.32,c1cc(NC2C3CC4CC(C3)CC2C4)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096af20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916040>
1099,CHEMBL4244148,,C=CC(=O)N1CCCC(n2nc(-c3cnn(C)c3)c3c(N)ncnc32)C1,5.93,IC50,=,1175.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human GST-tagged TYK2 catalytic domain expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition measured after 30 mins by HTRF assay,False,5.93,5.93,5.93,c1ncc2c(-c3cn[nH]c3)nn(C3CCCNC3)c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096af90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09160b0>
1100,CHEMBL4245422,,C=CC(=O)N1CCC(n2nc(-c3cnn(CCOC)c3)c3c(N)ncnc32)C1,5.76,IC50,=,1722.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human GST-tagged TYK2 catalytic domain expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition measured after 30 mins by HTRF assay,False,5.76,5.76,5.76,c1ncc2c(-c3cn[nH]c3)nn(C3CCNC3)c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916120>
1101,CHEMBL4248202,,Cn1cc(-c2nn(C3CCCN(C(=O)CC#N)C3)c3ncnc(N)c23)cn1,5.62,IC50,=,2427.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human GST-tagged TYK2 catalytic domain expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition measured after 30 mins by HTRF assay,False,5.62,5.62,5.62,c1ncc2c(-c3cn[nH]c3)nn(C3CCCNC3)c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916190>
1102,CHEMBL4249310,,C=CC(=O)N1CCC(n2nc(-c3cnn(C)c3)c3c(N)ncnc32)C1,5.85,IC50,=,1419.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human GST-tagged TYK2 catalytic domain expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition measured after 30 mins by HTRF assay,False,5.85,5.85,5.85,c1ncc2c(-c3cn[nH]c3)nn(C3CCNC3)c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916200>
1103,CHEMBL4249492,,C=CC(=O)N1CCCC(n2nc(-c3cnn(CCOC)c3)c3c(N)ncnc32)C1,5.67,IC50,=,2117.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human GST-tagged TYK2 catalytic domain expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition measured after 30 mins by HTRF assay,False,5.67,5.67,5.67,c1ncc2c(-c3cn[nH]c3)nn(C3CCCNC3)c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916270>
1104,CHEMBL4249872,,C=CC(=O)N1CCCC(Cn2nc(-c3cnn(CCOC)c3)c3c(N)ncnc32)C1,5.48,IC50,=,3296.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human GST-tagged TYK2 catalytic domain expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition measured after 30 mins by HTRF assay,False,5.48,5.48,5.48,c1ncc2c(-c3cn[nH]c3)nn(CC3CCCNC3)c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09162e0>
1105,CHEMBL4276860,,N#CN[C@@H]1CCc2ccc(-c3ncnc4[nH]ccc34)cc21,5.50,IC50,=,3144.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in SF21/baculovirus expression system using KAIETDKEYYTVKD-NH2 as substrate in presence of 1 mM ATP concentration by coupled PK/LDH assay,False,5.50,5.50,5.50,c1nc(-c2ccc3c(c2)CCC3)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916350>
1106,CHEMBL4277379,,CN(C)CCCn1c(=O)c2cc([N+](=O)[O-])ccc2c2cnc3[nH]ccc3c21,5.32,IC50,=,4766.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,5.32,5.32,5.32,O=c1[nH]c2c3cc[nH]c3ncc2c2ccccc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09163c0>
1107,CHEMBL4278647,,C[C@H]1Cc2ccc(-c3ncnc4[nH]ccc34)cc2[C@@H]1NC#N,5.70,IC50,=,2010.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in SF21/baculovirus expression system using KAIETDKEYYTVKD-NH2 as substrate in presence of 1 mM ATP concentration by coupled PK/LDH assay,False,5.70,5.70,5.70,c1nc(-c2ccc3c(c2)CCC3)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916430>
1108,CHEMBL4278757,,CNc1cc(Nc2cc(C)cc(C)c2)nn2c(C(=O)NCC(C)(CO)CO)cnc12,6.32,IC50,=,480.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,6.87,7.82,6.32,c1ccc(Nc2ccc3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09164a0>
1109,CHEMBL4278842,,COC(=O)Cn1c(=O)c2cc(OC)c(OC)cc2c2cnc3[nH]ccc3c21,7.74,IC50,=,18.42,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,7.74,7.74,7.74,O=c1[nH]c2c3cc[nH]c3ncc2c2ccccc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916510>
1110,CHEMBL4278853,,CC[C@H](C(=O)NCC(F)(F)F)n1c(=O)c2cc(OC)c(OC)cc2c2cnc3[nH]ccc3c21,6.47,IC50,=,336.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,6.47,6.47,6.47,O=c1[nH]c2c3cc[nH]c3ncc2c2ccccc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916580>
1111,CHEMBL4279157,,CNc1cc(Nc2cc(C)cc(C)c2)nn2c(C(N)=O)cnc12,7.00,IC50,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,7.48,8.15,7.0,c1ccc(Nc2ccc3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09165f0>
1112,CHEMBL4279720,,C[C@]1(NC#N)CCc2ccc(-c3ncnc4[nH]ccc34)cc21,6.75,IC50,=,179.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in SF21/baculovirus expression system using KAIETDKEYYTVKD-NH2 as substrate in presence of 1 mM ATP concentration by coupled PK/LDH assay,False,6.75,6.75,6.75,c1nc(-c2ccc3c(c2)CCC3)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916660>
1113,CHEMBL4279819,,CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC12CC2,6.60,IC50,=,250.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using GGMEDIYFEFMGGKKK as substrate after 40 mins in presence of [gamma-33P-ATP] by scintillation counting method,False,6.60,6.60,6.60,c1nc(N[C@H]2CNCC23CC3)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09166d0>
1114,CHEMBL4279883,,CNc1cc(Nc2cc(F)cc(F)c2OC)nn2c(C(=O)NC[C@](C)(O)CO)cnc12,6.43,IC50,=,370.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha-induced IP10 production,False,7.33,8.42,6.43,c1ccc(Nc2ccc3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916740>
1115,CHEMBL4279991,,COc1cc2c(=O)n([C@@H]3CCNC3)c3c4cc[nH]c4ncc3c2cc1OC,6.75,IC50,=,176.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,6.75,6.75,6.75,O=c1c2ccccc2c2cnc3[nH]ccc3c2n1[C@@H]1CCNC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09167b0>
1116,CHEMBL4280294,,CN(C#N)C1CCc2ccc(-c3ncnc4[nH]ccc34)cc21,5.02,IC50,=,9487.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in SF21/baculovirus expression system using KAIETDKEYYTVKD-NH2 as substrate in presence of 1 mM ATP concentration by coupled PK/LDH assay,False,5.02,5.02,5.02,c1nc(-c2ccc3c(c2)CCC3)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916820>
1117,CHEMBL4280783,,COc1cc2c(=O)n(CCCN(C)C)c3c4cc[nH]c4ncc3c2cc1OC,6.37,IC50,=,427.45,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,6.37,6.37,6.37,O=c1[nH]c2c3cc[nH]c3ncc2c2ccccc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916890>
1118,CHEMBL4281080,,COc1cc2c(=O)n(C3CCCCCCC3)c3c4cc[nH]c4ncc3c2cc1OC,8.08,IC50,=,8.38,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,8.08,8.08,8.08,O=c1c2ccccc2c2cnc3[nH]ccc3c2n1C1CCCCCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916900>
1119,CHEMBL4281304,,NC(=O)c1cnc2c(NC3CC3)cc(Nc3cccc(-c4ccc(C(F)(F)F)cc4F)c3)nn12,5.92,IC50,=,1200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,6.35,7.18,5.92,c1ccc(-c2cccc(Nc3cc(NC4CC4)c4nccn4n3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916970>
1120,CHEMBL4281393,,N#CN[C@H]1CCc2ccc(-c3ncnc4[nH]ccc34)cc21,5.74,IC50,=,1839.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in SF21/baculovirus expression system using KAIETDKEYYTVKD-NH2 as substrate in presence of 1 mM ATP concentration by coupled PK/LDH assay,False,5.74,5.74,5.74,c1nc(-c2ccc3c(c2)CCC3)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09169e0>
1121,CHEMBL4281492,,COC(=O)[C@@H](C(C)C)n1c(=O)c2cc(OC)c(OC)cc2c2cnc3[nH]ccc3c21,6.59,IC50,=,256.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,6.59,6.59,6.59,O=c1[nH]c2c3cc[nH]c3ncc2c2ccccc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916a50>
1122,CHEMBL4281693,,N#CN[C@@H]1c2cc(-c3ncnc4[nH]ccc34)ccc2C[C@H]1O,5.37,IC50,=,4285.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in SF21/baculovirus expression system using KAIETDKEYYTVKD-NH2 as substrate in presence of 1 mM ATP concentration by coupled PK/LDH assay,False,5.37,5.37,5.37,c1nc(-c2ccc3c(c2)CCC3)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096b9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916ac0>
1123,CHEMBL4282627,,Cc1cc(C)cc(Nc2cc(NC3CCC3)c3ncc(C(N)=O)n3n2)c1,5.21,IC50,=,6200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,5.85,6.96,5.21,c1ccc(Nc2cc(NC3CCC3)c3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ba50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916b30>
1124,CHEMBL4282720,,COc1cc2c(=O)n([C@@H](C(=O)N3CC(C#N)C3)C(C)C)c3c4cc[nH]c4ncc3c2cc1OC,5.24,IC50,=,5730.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,5.24,5.24,5.24,O=C(Cn1c(=O)c2ccccc2c2cnc3[nH]ccc3c21)N1CCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096bac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916ba0>
1125,CHEMBL4282878,,N#CN[C@@H]1CCOc2ccc(-c3ncnc4[nH]ccc34)cc21,5.74,IC50,=,1816.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in SF21/baculovirus expression system using KAIETDKEYYTVKD-NH2 as substrate in presence of 1 mM ATP concentration by coupled PK/LDH assay,False,5.74,5.74,5.74,c1nc(-c2ccc3c(c2)CCCO3)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096bb30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916c10>
1126,CHEMBL4283198,,C[C@@H]1Cc2ccc(-c3ncnc4[nH]ccc34)cc2[C@@H]1NC#N,5.33,IC50,=,4619.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in SF21/baculovirus expression system using KAIETDKEYYTVKD-NH2 as substrate in presence of 1 mM ATP concentration by coupled PK/LDH assay,False,5.33,5.33,5.33,c1nc(-c2ccc3c(c2)CCC3)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096bba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916c80>
1127,CHEMBL4283351,,CNc1cc(Nc2cccc(C(C)(C)C)c2)nn2c(C(N)=O)cnc12,6.29,IC50,=,510.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,6.86,7.89,6.29,c1ccc(Nc2ccc3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096bc10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916cf0>
1128,CHEMBL4283458,,COc1cc2c(=O)n(C3CCN(C)CC3)c3c4cc[nH]c4ncc3c2cc1OC,6.78,IC50,=,166.85,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,6.78,6.78,6.78,O=c1c2ccccc2c2cnc3[nH]ccc3c2n1C1CCNCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096bc80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916d60>
1129,CHEMBL4283724,,NC(=O)c1cnc2c(NC3CC3)cc(NC3CCCCC3)nn12,5.47,IC50,=,3400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,5.88,6.66,5.47,c1cn2nc(NC3CCCCC3)cc(NC3CC3)c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096bcf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916dd0>
1130,CHEMBL4284499,,COc1cc2c(=O)n(CC3CCCCC3)c3c4cc[nH]c4ncc3c2cc1OC,7.40,IC50,=,39.43,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,7.40,7.40,7.40,O=c1c2ccccc2c2cnc3[nH]ccc3c2n1CC1CCCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096bd60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916e40>
1131,CHEMBL4284952,,N#CN[C@H]1CCOc2ccc(-c3ncnc4[nH]ccc34)cc21,5.53,IC50,=,2971.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in SF21/baculovirus expression system using KAIETDKEYYTVKD-NH2 as substrate in presence of 1 mM ATP concentration by coupled PK/LDH assay,False,5.53,5.53,5.53,c1nc(-c2ccc3c(c2)CCCO3)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096bdd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916eb0>
1132,CHEMBL4285530,,Cc1cc(C)cc(Nc2cc(NC3CCCC3)c3ncc(C(N)=O)n3n2)c1,5.14,IC50,=,7300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,5.59,6.3,5.14,c1ccc(Nc2cc(NC3CCCC3)c3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096be40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916f20>
1133,CHEMBL4285755,,Cc1cc(C)cc(Nc2cc(NC3CC3)c3ncc(C(N)=O)n3n2)c1,5.85,IC50,=,1400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IFNalpha-stimulated human Kit225 T cells by luciferase reporter assay,False,6.56,7.66,5.85,c1ccc(Nc2cc(NC3CC3)c3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096beb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0916f90>
1134,CHEMBL4285841,,CNc1cc(Nc2cccc3c2OCCO3)nn2c(C(=O)NC3CC3)cnc12,7.70,IC50,=,20.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,7.97,8.22,7.7,O=C(NC1CC1)c1cnc2ccc(Nc3cccc4c3OCCO4)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096bf20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917040>
1135,CHEMBL4286006,,Cc1cc(C)cc(Nc2cc(Nc3ccccc3)c3ncc(C(N)=O)n3n2)c1,5.31,IC50,=,4900.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,6.01,7.3,5.31,c1ccc(Nc2cc(Nc3ccccc3)c3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096bf90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09170b0>
1136,CHEMBL4286103,,CC[C@H](C(=O)N1CC(C#N)C1)n1c(=O)c2cc(OC)c(OC)cc2c2cnc3[nH]ccc3c21,7.13,IC50,=,73.66,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,7.13,7.13,7.13,O=C(Cn1c(=O)c2ccccc2c2cnc3[nH]ccc3c21)N1CCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917120>
1137,CHEMBL4286762,,CCOC(=O)C(CC)n1c(=O)c2cc(OC)c(OC)cc2c2cnc3[nH]ccc3c21,7.76,IC50,=,17.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,7.76,7.76,7.76,O=c1[nH]c2c3cc[nH]c3ncc2c2ccccc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917190>
1138,CHEMBL4286867,,O=C(CCCCCCC(=O)Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)NO,7.10,IC50,=,79.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using KKSRGDYMTMQIG as substrate preincubated for 20 mins followed by [gamma33P]ATP addition measured after 120 mins by ion exchange filter paper method,False,7.10,7.10,7.10,c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917200>
1139,CHEMBL428690,ALVOCIDIB,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,5.46,Kd,=,3468.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",False,6.56,7.46,5.46,O=c1cc(-c2ccccc2)oc2c(C3CCNCC3)cccc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917270>
1140,CHEMBL4286963,,N#CN[C@H]1C[C@H](O)c2ccc(-c3ncnc4[nH]ccc34)cc21,5.47,IC50,=,3372.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in SF21/baculovirus expression system using KAIETDKEYYTVKD-NH2 as substrate in presence of 1 mM ATP concentration by coupled PK/LDH assay,False,5.47,5.47,5.47,c1nc(-c2ccc3c(c2)CCC3)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09172e0>
1141,CHEMBL4287081,,CCNc1cc(Nc2cc(C)cc(C)c2)nn2c(C(N)=O)cnc12,6.22,IC50,=,600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,6.74,7.77,6.22,c1ccc(Nc2ccc3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917350>
1142,CHEMBL4287153,,CNc1nc2sc(-c3cccc([C@@H](C)NC(=O)c4ccccc4S(C)(=O)=O)c3)nc2c2c1ncn2C,6.00,IC50,=,1000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,6.53,7.57,6.0,O=C(NCc1cccc(-c2nc3c(ncc4nc[nH]c43)s2)c1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09173c0>
1143,CHEMBL4287367,,Fc1cccc(F)c1-c1ccc2[nH]cc(-c3cncc(O[C@@H]4CCCNC4)n3)c2c1,6.60,Kd,=,250.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to TYK2 JH2 domain (unknown origin) after 90 mins by HTRF assay,False,6.60,6.60,6.60,c1ccc(-c2ccc3[nH]cc(-c4cncc(O[C@@H]5CCCNC5)n4)c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917430>
1144,CHEMBL4287761,,CNc1cc(Nc2cc(F)cc(F)c2OC)nn2c(C(=O)NCC(C)(C)CO)cnc12,7.16,IC50,=,70.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,7.63,8.22,7.16,c1ccc(Nc2ccc3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09174a0>
1145,CHEMBL4287893,,COc1cc2c(=O)n([C@@H]3CCCNC3)c3c4cc[nH]c4ncc3c2cc1OC,7.35,IC50,=,45.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,7.35,7.35,7.35,O=c1c2ccccc2c2cnc3[nH]ccc3c2n1[C@@H]1CCCNC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917510>
1146,CHEMBL4288201,,N#CNC1CCOc2ccc(-c3ncnc4[nH]ccc34)cc21,5.60,IC50,=,2517.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in SF21/baculovirus expression system using KAIETDKEYYTVKD-NH2 as substrate in presence of 1 mM ATP concentration by coupled PK/LDH assay,False,5.60,5.60,5.60,c1nc(-c2ccc3c(c2)CCCO3)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917580>
1147,CHEMBL4288673,,CN(C)CCCn1c(=O)c2ccccc2c2cnc3[nH]ccc3c21,6.15,IC50,=,708.65,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,6.15,6.15,6.15,O=c1[nH]c2c3cc[nH]c3ncc2c2ccccc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09175f0>
1148,CHEMBL4289149,,N#Cc1cc(Nc2cc(NC3CC3)c3ncc(C(N)=O)n3n2)cc(C(F)(F)F)c1,4.90,IC50,=,12600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IFNalpha-stimulated human Kit225 T cells by luciferase reporter assay,False,5.44,6.32,4.9,c1ccc(Nc2cc(NC3CC3)c3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917660>
1149,CHEMBL4289375,,COC(=O)[C@H](C(C)C)n1c(=O)c2cc(OC)c(OC)cc2c2cnc3[nH]ccc3c21,5.82,IC50,=,1502.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,5.82,5.82,5.82,O=c1[nH]c2c3cc[nH]c3ncc2c2ccccc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09176d0>
1150,CHEMBL4289426,,CNc1cc(Nc2cc(C)cc(C)c2)nn2c(C(=O)NCC(C)(C)CO)cnc12,6.52,IC50,=,300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,7.39,8.7,6.52,c1ccc(Nc2ccc3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917740>
1151,CHEMBL4289532,,CC[C@@H](C(=O)NCC(F)(F)F)n1c(=O)c2cc(OC)c(OC)cc2c2cnc3[nH]ccc3c21,6.56,IC50,=,273.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,6.56,6.56,6.56,O=c1[nH]c2c3cc[nH]c3ncc2c2ccccc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09177b0>
1152,CHEMBL4289875,,Cc1cc(F)cc(Nc2cc(NC3CC3)c3ncc(C(N)=O)n3n2)c1,5.77,IC50,=,1700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IFNalpha-stimulated human Kit225 T cells by luciferase reporter assay,False,6.41,7.62,5.77,c1ccc(Nc2cc(NC3CC3)c3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917820>
1153,CHEMBL4290130,,C[C@](O)(CO)CNc1cc(Nc2cccc(-c3ccc(C(F)(F)F)cc3F)c2)nn2c(C(N)=O)cnc12,5.38,IC50,=,4200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha-induced IP10 production,False,6.43,8.1,5.38,c1ccc(-c2cccc(Nc3ccc4nccn4n3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917890>
1154,CHEMBL4290597,,COc1cc2c(=O)n([C@@H]3CCCN(C(=O)CC#N)C3)c3c4cc[nH]c4ncc3c2cc1OC,8.36,IC50,=,4.35,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,8.36,8.36,8.36,O=c1c2ccccc2c2cnc3[nH]ccc3c2n1[C@@H]1CCCNC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917900>
1155,CHEMBL4291200,,CNc1cc(Nc2c(F)c(F)cc(F)c2F)nn2c(C(=O)NC[C@](C)(O)CO)cnc12,6.35,IC50,=,450.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IFNalpha-stimulated human Kit225 T cells by luciferase reporter assay,False,6.99,8.1,6.35,c1ccc(Nc2ccc3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917970>
1156,CHEMBL4291298,,COc1cc2c(=O)n(C3CCNCC3)c3c4cc[nH]c4ncc3c2cc1OC,7.49,IC50,=,32.39,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,7.49,7.49,7.49,O=c1c2ccccc2c2cnc3[nH]ccc3c2n1C1CCNCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09179e0>
1157,CHEMBL4291611,,CNc1cc(Nc2cccc(-c3ccccc3)c2)nn2c(C(N)=O)cnc12,6.48,IC50,=,330.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,7.19,8.4,6.48,c1ccc(-c2cccc(Nc3ccc4nccn4n3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917a50>
1158,CHEMBL4291720,,COc1cc2c(=O)n(C3CCCCCC3)c3c4cc[nH]c4ncc3c2cc1OC,8.65,IC50,=,2.24,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,8.65,8.65,8.65,O=c1c2ccccc2c2cnc3[nH]ccc3c2n1C1CCCCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096c9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917ac0>
1159,CHEMBL4292010,,N#CNC1CCc2ccc(-c3ncnc4[nH]ccc34)cc21,5.54,IC50,=,2890.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in SF21/baculovirus expression system using KAIETDKEYYTVKD-NH2 as substrate in presence of 1 mM ATP concentration by coupled PK/LDH assay,False,5.54,5.54,5.54,c1nc(-c2ccc3c(c2)CCC3)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ca50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917b30>
1160,CHEMBL4293510,,NC(=O)c1cnc2c(N[C@H]3C[C@H]3F)cc(Nc3cccc(-c4ccc(C(F)(F)F)cc4F)c3)nn12,6.39,IC50,=,410.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,6.83,7.6,6.39,c1ccc(-c2cccc(Nc3cc(NC4CC4)c4nccn4n3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096cac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917ba0>
1161,CHEMBL4293578,,CN(c1ncnc2[nH]ccc12)[C@H]1CN(S(=O)(=O)c2cccc(C#N)c2)CC12CC2,7.60,IC50,=,25.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using GGMEDIYFEFMGGKKK as substrate after 40 mins in presence of [gamma-33P-ATP] by scintillation counting method,False,7.60,7.60,7.60,O=S(=O)(c1ccccc1)N1C[C@H](Nc2ncnc3[nH]ccc23)C2(CC2)C1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096cb30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917c10>
1162,CHEMBL4293619,,NC(=O)c1cnc2c(NC3CC3)cc(Nc3ccccc3)nn12,5.82,IC50,=,1500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IFNalpha-stimulated human Kit225 T cells by luciferase reporter assay,False,6.43,7.5,5.82,c1ccc(Nc2cc(NC3CC3)c3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096cba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917c80>
1163,CHEMBL4293778,,CC1(NC#N)CCc2ccc(-c3ncnc4[nH]ccc34)cc21,6.62,IC50,=,239.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in SF21/baculovirus expression system using KAIETDKEYYTVKD-NH2 as substrate in presence of 1 mM ATP concentration by coupled PK/LDH assay,False,6.62,6.62,6.62,c1nc(-c2ccc3c(c2)CCC3)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096cc10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917cf0>
1164,CHEMBL4293907,,CNc1cc(Nc2cc(C)cc(C)c2)nn2c(C(=O)NC3CC3)cnc12,6.96,IC50,=,110.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,7.79,9.89,6.96,O=C(NC1CC1)c1cnc2ccc(Nc3ccccc3)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096cc80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917d60>
1165,CHEMBL4294002,,COc1cc2c(=O)n([C@@H](C(=O)NCC(F)(F)F)C(C)C)c3c4cc[nH]c4ncc3c2cc1OC,5.93,IC50,=,1163.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,5.93,5.93,5.93,O=c1[nH]c2c3cc[nH]c3ncc2c2ccccc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ccf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917dd0>
1166,CHEMBL4295039,,CNc1cc(Nc2ccccc2OC)nn2c(C(=O)NCC(C)(C)CO)cnc12,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IL23-stimulated human Kit225 T cells by luciferase reporter assay,False,7.35,8.3,6.82,c1ccc(Nc2ccc3nccn3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096cd60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917e40>
1167,CHEMBL4295151,,COc1cc2c(=O)n(C3CCCCC3)c3c4cc[nH]c4ncc3c2cc1OC,8.71,IC50,=,1.93,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) preincubated for 20 mins followed by [33P]-ATP addition measured after 2 hrs by filter-binding method,False,8.71,8.71,8.71,O=c1c2ccccc2c2cnc3[nH]ccc3c2n1C1CCCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096cdd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917eb0>
1168,CHEMBL4297507,DELGOCITINIB,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2,7.24,IC50,=,58.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-fused human TyK2 (871 to end residues) expressed in baculovirus expression system using TK-substrate-biotin as substrate incubated for 60 mins in presence of ATP by fluorescence method,False,7.24,7.24,7.24,c1nc(N2CC[C@@]3(CCN3)C2)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ce40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917f20>
1169,CHEMBL4434711,,CNc1cc(Nc2cccn(-c3ccc(C(C)(C)O)cc3)c2=O)nn2c(C(=O)NC3CC3)cnc12,10.15,Ki,=,0.07,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,7.73,10.15,6.09,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4ccccc4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ceb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0917f90>
1170,CHEMBL4435047,,CNc1cc(Nc2cccn(-c3ncccc3F)c2=O)nn2c(C(=O)NC3CC3)cnc12,6.50,Ki,=,313.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha/IL2-induced STAT phosphorylation preincubated for 1 hr followed by IFNalpha/IL2 stimulation and measured after 15 mins by fluorescence assay,False,7.88,9.92,6.5,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4ccccn4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096cf20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918040>
1171,CHEMBL4435079,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(-c2nncn2C)c1OC,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.82,6.82,6.82,c1ccc(Nc2cc(Nc3cccc(-c4nnc[nH]4)c3)ccn2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096cf90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09180b0>
1172,CHEMBL4435170,DEUCRAVACITINIB,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,10.70,Ki,=,0.02,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein labeled probe binding to His-tagged human TYK2 pseudokinase domain (575-869 residues) by Morrison titration based HTRF assay,False,8.62,10.7,7.75,O=C(Nc1cc(Nc2cccc(-c3nc[nH]n3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918120>
1173,CHEMBL4435302,,CCNC(=O)c1ccc(Nc2nccc(N3C[C@H]4C[C@@H]3CN4C(=O)CC#N)n2)cc1,5.57,IC50,=,2690.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using ATP at its Km level by microfluidic based mobility shift assay,False,5.57,5.57,5.57,c1ccc(Nc2nccc(N3C[C@H]4C[C@@H]3CN4)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918190>
1174,CHEMBL4436287,,CCNC(=O)c1ccc(Nc2nccc(N3CCN(C(=O)CC#N)CC3)n2)cc1,6.43,IC50,=,368.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using ATP at its Km level by microfluidic based mobility shift assay,False,6.43,6.43,6.43,c1ccc(Nc2nccc(N3CCNCC3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918200>
1175,CHEMBL4437714,,CNc1cc(Nc2cccn(-c3ncc(F)cn3)c2=O)nn2c(C(=O)NC3CC3)cnc12,6.33,Ki,=,464.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha/IL2-induced STAT phosphorylation preincubated for 1 hr followed by IFNalpha/IL2 stimulation and measured after 15 mins by fluorescence assay,False,7.46,9.42,6.33,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4ncccn4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918270>
1176,CHEMBL4438107,,CNc1cc(Nc2cccn(-c3ccccn3)c2=O)nn2c(C(=O)NC(C)C)cnc12,6.12,Ki,=,750.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha/IL2-induced STAT phosphorylation preincubated for 1 hr followed by IFNalpha/IL2 stimulation and measured after 15 mins by fluorescence assay,False,7.61,9.89,6.12,O=c1c(Nc2ccc3nccn3n2)cccn1-c1ccccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09182e0>
1177,CHEMBL4438202,,CNC(=O)c1cnc(NC(=O)C2CC2)cc1Nc1ccccc1S(C)(=O)=O,6.51,IC50,=,310.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,7.66,8.8,6.51,O=C(Nc1cc(Nc2ccccc2)ccn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918350>
1178,CHEMBL4438296,,CNc1cc(Nc2cccn(-c3ccccn3)c2=O)nn2c(C(=O)NC3CCC3)cnc12,6.42,Ki,=,384.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha/IL2-induced STAT phosphorylation preincubated for 1 hr followed by IFNalpha/IL2 stimulation and measured after 15 mins by fluorescence assay,False,7.74,9.59,6.42,O=C(NC1CCC1)c1cnc2ccc(Nc3cccn(-c4ccccn4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09183c0>
1179,CHEMBL4439617,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(C(=O)NCCO)c1OC,6.57,IC50,=,270.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.57,6.57,6.57,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918430>
1180,CHEMBL4439957,,CNc1cc(Nc2cccn(-c3ccc(F)cn3)c2=O)nn2c(C(=O)N[C@@H]3C[C@@H]3F)cnc12,10.46,Ki,=,0.035,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,8.37,10.46,7.07,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4ccccn4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09184a0>
1181,CHEMBL4440261,,CC(C)CNc1c(C(N)=O)cnn2cc(-c3ccccc3)cc12,7.20,IC50,=,63.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Hs-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate measured after 3 hrs by electrophoresis method,False,7.20,7.20,7.20,c1ccc(-c2cc3cccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918510>
1182,CHEMBL4440718,,[2H]C([2H])([2H])NC(=O)c1nnc(Nc2ccccn2)cc1Nc1ccccc1S(C)(=O)=O,10.15,Ki,=,0.07,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 (unknown origin) by morrison titration assay,False,8.77,10.15,6.89,c1ccc(Nc2cnnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918580>
1183,CHEMBL4440767,,COc1ccc(-c2cc3c(NC(CO)[C@H](O)C4CC4)c(C(N)=O)cnn3c2)cn1,5.70,IC50,=,2000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Hs-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate measured after 3 hrs by electrophoresis method,False,6.3,6.89,5.7,c1cncc(-c2cc3c(NCCC4CC4)ccnn3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09185f0>
1184,CHEMBL4441840,,CCNC(=O)c1cccc(Nc2cc(Nc3cc(C)c(F)cn3)ncc2C(=O)NC)c1OC,6.55,IC50,=,280.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.55,6.55,6.55,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918660>
1185,CHEMBL4442827,,CNc1cc(Nc2cccn(-c3ccc(C)nn3)c2=O)nn2c(C(=O)N[C@@H]3C[C@@H]3F)cnc12,10.74,Ki,=,0.018,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,8.44,10.74,7.2,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4cccnn4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09186d0>
1186,CHEMBL4443010,,CNc1cc(Nc2cccn(-c3ccc(C)nn3)c2=O)nn2c(C(=O)NC3CC3)cnc12,10.04,Ki,=,0.091,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,7.83,10.04,6.61,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4cccnn4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918740>
1187,CHEMBL4443834,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(-c2nnc(C)o2)c1OC,7.00,IC50,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,7.00,7.00,7.00,c1ccc(Nc2cc(Nc3cccc(-c4nnco4)c3)ccn2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09187b0>
1188,CHEMBL4444169,,[2H]C([2H])([2H])NC(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1ccccc1S(C)(=O)=O,6.80,IC50,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,8.06,9.31,6.8,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918820>
1189,CHEMBL4444178,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1ccccc1S(C)(=O)=O,4.30,IC50,=,50000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH1 domain (unknown origin),False,7.23,9.1,4.3,O=C(Nc1cc(Nc2ccccc2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918890>
1190,CHEMBL4444606,,CNC(=O)c1cnc(Nc2ccc(OC)cn2)cc1Nc1ccccc1S(C)(=O)=O,6.28,IC50,=,520.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,6.28,6.28,6.28,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918900>
1191,CHEMBL4445892,,CCNC(=O)c1ncc(Nc2ncc(F)c(N3C[C@H]4CC[C@H](C3)N4C(=O)C3CC3)n2)cc1C,7.32,IC50,=,48.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,7.32,7.32,7.32,O=C(C1CC1)N1[C@@H]2CC[C@@H]1CN(c1ccnc(Nc3cccnc3)n1)C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918970>
1192,CHEMBL4446102,,NC(=O)c1cnc2[nH]ccc2c1NC1C2CC3CC1CC(C2)C3O,8.30,IC50,=,5.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 kinase domain using biotin-IRS1-substrate as substrate incubated for 1 hr by ELISA,False,8.30,8.30,8.30,c1cc(NC2C3CC4CC(C3)CC2C4)c2cc[nH]c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09189e0>
1193,CHEMBL4447360,,C[C@@H](O)[C@@H](CO)Nc1c(C(N)=O)cnn2cc(-c3ccccc3)cc12,7.47,IC50,=,34.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Hs-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate measured after 3 hrs by electrophoresis method,False,7.47,7.47,7.47,c1ccc(-c2cc3cccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918a50>
1194,CHEMBL4447631,,Cc1cnc(Nc2ccc(N3CCC(N(C)CCO)CC3)c(F)c2)nc1-c1cnn(C(C)C)c1,8.70,IC50,=,2.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.70,8.70,8.70,c1cc(-c2cn[nH]c2)nc(Nc2ccc(N3CCCCC3)cc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096d9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918ac0>
1195,CHEMBL4448796,,CCNC(=O)c1ccc(Nc2ncc(F)c(N3C[C@H]4CC[C@H](C3)N4C(=O)C3CC3)n2)nc1,5.14,IC50,=,7202.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,5.14,5.14,5.14,O=C(C1CC1)N1[C@@H]2CC[C@@H]1CN(c1ccnc(Nc3ccccn3)n1)C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c096da50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918b30>
1196,CHEMBL4450347,,C[C@H](O)[C@@H](CO)Nc1c(C(N)=O)cnn2cc(-c3ccccc3)cc12,6.68,IC50,=,210.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Hs-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate measured after 3 hrs by electrophoresis method,False,6.68,6.68,6.68,c1ccc(-c2cc3cccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096dac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918ba0>
1197,CHEMBL4452772,,CC(Oc1cc(-c2cccc(N3CCNCC3)c2)cnc1N)c1cc(F)ccc1Cl,5.60,IC50,=,2530.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,False,5.60,5.60,5.60,c1ccc(COc2cncc(-c3cccc(N4CCNCC4)c3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096db30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918c10>
1198,CHEMBL4453441,,CNc1cc(Nc2cccn(-c3ccc(C#N)cc3)c2=O)nn2c(C(=O)NC3CC3)cnc12,6.57,Ki,=,268.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha/IL2-induced STAT phosphorylation preincubated for 1 hr followed by IFNalpha/IL2 stimulation and measured after 15 mins by fluorescence assay,False,7.77,9.7,6.57,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4ccccc4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096dba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918c80>
1199,CHEMBL4453545,,CNC(=O)c1cnc(Nc2ccc(C)nn2)cc1Nc1ccccc1S(C)(=O)=O,6.20,IC50,=,630.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,6.20,6.20,6.20,c1ccc(Nc2ccnc(Nc3cccnn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096dc10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918cf0>
1200,CHEMBL4453827,,CCS(=O)(=O)c1ccccc1Nc1cc(Nc2ccc(F)cn2)ncc1C(=O)NC,5.36,IC50,=,4400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,6.73,8.1,5.36,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096dc80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918d60>
1201,CHEMBL4454109,,CNc1cc(Nc2cccn(-c3cc(C)n(C)n3)c2=O)nn2c(C(=O)NC3CC3)cnc12,6.47,Ki,=,340.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha/IL2-induced STAT phosphorylation preincubated for 1 hr followed by IFNalpha/IL2 stimulation and measured after 15 mins by fluorescence assay,False,7.55,9.32,6.47,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4cc[nH]n4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096dcf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918dd0>
1202,CHEMBL4457060,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(-c2n[nH]c(C)n2)c1OC,7.40,IC50,=,40.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,7.40,7.40,7.40,c1ccc(Nc2cc(Nc3cccc(-c4nc[nH]n4)c3)ccn2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096dd60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918e40>
1203,CHEMBL4458435,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1,7.64,IC50,=,23.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,7.64,7.64,7.64,O=C(C1CC1)N1[C@@H]2CC[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ddd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918eb0>
1204,CHEMBL4459585,ROPSACITINIB,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1,7.77,IC50,=,17.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 JH1 kinase domain using 5FAM-KKSRGDYMTMQID as substrate incubated for 135 mins by caliper method,False,7.8,7.82,7.77,c1cc2c(-c3cnn(C4CCC4)c3)nc(-c3cn[nH]c3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096de40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918f20>
1205,CHEMBL4460194,,CNC(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1ccccc1OC,5.48,IC50,=,3300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,6.88,8.28,5.48,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096deb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0918f90>
1206,CHEMBL4460368,,CNc1cc(Nc2cccn(-c3cc(C)n(C)n3)c2=O)nn2c(C(=O)N[C@@H]3C[C@@H]3F)cnc12,10.82,Ki,=,0.015,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,8.51,10.82,7.05,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4cc[nH]n4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096df20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919040>
1207,CHEMBL4460904,,CCNC(=O)c1ccc(Nc2nccc(N3C[C@@H]4CC[C@H]3CN4C(=O)C3CC3)n2)cc1,6.83,IC50,=,148.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,6.83,6.83,6.83,O=C(C1CC1)N1C[C@@H]2CC[C@H]1CN2c1ccnc(Nc2ccccc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096df90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09190b0>
1208,CHEMBL4461011,,CC(C)(C)CNc1c(C(N)=O)cnn2cc(-c3ccccc3)cc12,7.16,IC50,=,70.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Hs-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate measured after 3 hrs by electrophoresis method,False,7.16,7.16,7.16,c1ccc(-c2cc3cccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919120>
1209,CHEMBL4461078,,COc1ccc(F)c(Cl)c1C(C)Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N,6.11,IC50,=,774.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,False,6.11,6.11,6.11,c1ccc(COc2cncc(-c3cnn(C4CCNCC4)c3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919190>
1210,CHEMBL4463007,,N#CC[C@H]1CC[C@H](n2c(=O)[nH]c3cnc(Nc4ccc[nH]c4=O)nc32)CC1,6.89,IC50,=,130.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human N-terminal GST-tagged TYK2 (871 to 1187 residues) expressed in baculovirus expression system using PolyGT-Biotin as substrate measured after 3 to 20 hrs by HTRF assay,False,6.89,6.89,6.89,O=c1[nH]cccc1Nc1ncc2[nH]c(=O)n(C3CCCCC3)c2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919200>
1211,CHEMBL4463195,,C[C@H](O)[C@H](CO)Nc1c(C(N)=O)cnn2cc(-c3ccccc3)cc12,5.89,IC50,=,1300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Hs-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate measured after 3 hrs by electrophoresis method,False,5.89,5.89,5.89,c1ccc(-c2cc3cccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919270>
1212,CHEMBL4465076,,COc1ccc(F)cc1C(C)Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N,6.10,IC50,=,794.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,False,6.10,6.10,6.10,c1ccc(COc2cncc(-c3cnn(C4CCNCC4)c3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09192e0>
1213,CHEMBL4465409,,CNC(=O)c1cnc(Nc2ccccn2)cc1Nc1ccccc1C(N)=O,8.80,IC50,=,1.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,8.80,8.80,8.80,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919350>
1214,CHEMBL4465866,,CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,8.10,Kd,=,8.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding affinity to recombinant N-terminal His-FLAG-GST-tagged TYK2 (unknown origin) (871 to 1187 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay,False,8.10,8.10,8.10,O=C(CCC1=[N+]2[BH2-]n3cccc3C=C2C=C1)NCCOCCOCCOCCN[C@H]1CC2O[C@H](C1)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09193c0>
1215,CHEMBL4466059,,O=C(CCCCCCn1cc(Nc2ncc(Cl)c(NC3CC3)n2)cn1)NO,7.92,IC50,=,12.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 using Ulight-CAGAGAIETDKEYYTVKD as substrate measured after 60 mins by LANCE assay,False,7.92,7.92,7.92,c1cc(NC2CC2)nc(Nc2cn[nH]c2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919430>
1216,CHEMBL4466139,,CNc1cc(Nc2cccn(-c3ccccn3)c2=O)nn2c(C(=O)NC3CC3)cnc12,6.42,Ki,=,382.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha/IL2-induced STAT phosphorylation preincubated for 1 hr followed by IFNalpha/IL2 stimulation and measured after 15 mins by fluorescence assay,False,7.64,9.47,6.42,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4ccccn4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09194a0>
1217,CHEMBL4466720,,NC(=O)c1ccccc1Nc1cc(Nc2ccc(F)cn2)ncc1C(=O)NC1CC1,7.48,IC50,=,33.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,7.48,7.48,7.48,O=C(NC1CC1)c1cnc(Nc2ccccn2)cc1Nc1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919510>
1218,CHEMBL4467881,,COc1ccc(-c2cc3c(N[C@H](CO)CC(C)C)c(C(N)=O)cnn3c2)cn1,6.75,IC50,=,180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Hs-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate measured after 3 hrs by electrophoresis method,False,6.75,6.75,6.75,c1cncc(-c2cc3cccnn3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919580>
1219,CHEMBL4468025,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(C(=O)NC)c1OC,6.85,IC50,=,140.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.85,6.85,6.85,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09195f0>
1220,CHEMBL4469583,,C[C@@H](O)[C@H](CO)Nc1c(C(N)=O)cnn2cc(-c3ccccc3)cc12,6.29,IC50,=,510.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Hs-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate measured after 3 hrs by electrophoresis method,False,6.29,6.29,6.29,c1ccc(-c2cc3cccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919660>
1221,CHEMBL4469750,,CNC(=O)c1cnc(Nc2ccc(C#N)cn2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,7.82,IC50,=,15.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,7.82,7.82,7.82,c1ccc(Nc2cc(Nc3cccc(-c4nc[nH]n4)c3)ccn2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09196d0>
1222,CHEMBL4469812,,CNC(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1ccccc1SC,5.51,IC50,=,3100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,7.12,8.74,5.51,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919740>
1223,CHEMBL4471290,,CC(C)CCNc1c(C(N)=O)cnn2cc(-c3ccccc3)cc12,6.80,IC50,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Hs-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate measured after 3 hrs by electrophoresis method,False,6.80,6.80,6.80,c1ccc(-c2cc3cccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09197b0>
1224,CHEMBL4471304,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@H](C3)N4C(=O)[C@H]3CC3(F)F)n2)cn1,6.15,IC50,=,702.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,6.15,6.15,6.15,O=C(C1CC1)N1[C@@H]2CC[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919820>
1225,CHEMBL4471710,,O=C(CCCCCCn1cc(Nc2ncc(Cl)c(Nc3cccc(Cl)c3)n2)cn1)NO,7.17,IC50,=,67.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 using Ulight-CAGAGAIETDKEYYTVKD as substrate measured after 60 mins by LANCE assay,False,7.17,7.17,7.17,c1ccc(Nc2ccnc(Nc3cn[nH]c3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919890>
1226,CHEMBL4472802,,CNC(=O)c1cnc(Nc2ccc(N3CCOCC3)cn2)cc1Nc1ccccc1S(C)(=O)=O,7.24,IC50,=,58.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,7.24,7.24,7.24,c1ccc(Nc2ccnc(Nc3ccc(N4CCOCC4)cn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919900>
1227,CHEMBL4472924,,NC(=O)c1cnn2cc(-c3ccccc3)cc2c1NC1CCCC1,7.70,IC50,=,20.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Hs-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate measured after 3 hrs by electrophoresis method,False,7.70,7.70,7.70,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919970>
1228,CHEMBL4474729,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(C(=O)NCc2ccccn2)c1OC,6.75,IC50,=,180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.75,6.75,6.75,O=C(NCc1ccccn1)c1cccc(Nc2ccnc(Nc3ccccn3)c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09199e0>
1229,CHEMBL4474801,,CNc1cc(Nc2cccn(-c3ccc(F)nc3)c2=O)nn2c(C(=O)NC3CC3)cnc12,6.42,Ki,=,380.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha/IL2-induced STAT phosphorylation preincubated for 1 hr followed by IFNalpha/IL2 stimulation and measured after 15 mins by fluorescence assay,False,7.71,9.85,6.42,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4cccnc4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919a50>
1230,CHEMBL4476261,,CNC(=O)c1cnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,7.80,IC50,=,16.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,7.80,7.80,7.80,O=C(Nc1cc(Nc2cccc(-c3nc[nH]n3)c2)ccn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096e9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919ac0>
1231,CHEMBL4476770,,NC(=O)c1nc(-c2c(F)cccc2Cl)oc1Nc1ccc(C(=O)N2CCOCC2)cc1,9.22,IC50,=,0.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells assessed as reduction in IFN-alpha stimulated TYK2 phosphorylation by caspase3/7 reagent-based Western blot analysis,False,9.22,9.22,9.22,O=C(c1ccc(Nc2cnc(-c3ccccc3)o2)cc1)N1CCOCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ea50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919b30>
1232,CHEMBL4476830,,CNC(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1ccc(F)c(F)c1OC,5.62,IC50,=,2400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,7.22,8.82,5.62,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096eac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919ba0>
1233,CHEMBL4483364,,CCc1cc(O)c(F)cc1-c1cc(NS(=O)(=O)CC)c2cn[nH]c2c1,6.80,IC50,=,158.49,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.80,6.80,6.80,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096eb30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919c10>
1234,CHEMBL4483484,,CCc1cc(O)c(F)cc1-c1cc(NP(=O)(CC)CC)c2cn[nH]c2c1,4.70,IC50,=,19952.62,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,4.70,4.70,4.70,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096eba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919c80>
1235,CHEMBL4483513,,CCc1cc(O)c(F)cc1-c1cc(NS(=O)(=O)CCC(=O)OC)c2cn[nH]c2c1,6.40,IC50,=,398.11,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.40,6.40,6.40,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ec10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919cf0>
1236,CHEMBL450786,PHA-665752,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1,5.18,Kd,=,6600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,5.18,5.18,5.18,O=C1Nc2ccc(S(=O)(=O)Cc3ccccc3)cc2/C1=C/c1cc(C(=O)N2CCC[C@@H]2CN2CCCC2)c[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ec80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919d60>
1237,CHEMBL4516272,,CN(C)C(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1ccccc1C(N)=O,7.06,IC50,=,87.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,7.06,7.06,7.06,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ecf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919dd0>
1238,CHEMBL4516561,,CCS(=O)(=O)Nc1cc(-c2ccc(O)c(F)c2)cc2[nH]ncc12,6.60,IC50,=,251.19,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.60,6.60,6.60,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ed60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919e40>
1239,CHEMBL4517542,,CNc1cc(Nc2cccn(C)c2=O)nn2c(C(=O)NC3CC3)cnc12,6.21,Ki,=,614.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in IFNalpha/IL23-stimulated human Kit225 cells by luciferase reporter assay,False,7.67,9.13,6.21,O=C(NC1CC1)c1cnc2ccc(Nc3ccc[nH]c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096edd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919eb0>
1240,CHEMBL4517702,,CCNC(=O)N1[C@@H]2CC[C@@H]1CN(c1ccnc(Nc3cnn(C)c3)n1)C2,7.15,IC50,=,71.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,7.15,7.15,7.15,c1cc(N2C[C@H]3CC[C@H](C2)N3)nc(Nc2cn[nH]c2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ee40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919f20>
1241,CHEMBL4518744,,CCS(=O)(=O)Nc1cc(-c2ccc(O)c(Cl)c2)cc2[nH]ncc12,6.60,IC50,=,251.19,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.60,6.60,6.60,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096eeb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0919f90>
1242,CHEMBL4518786,,N#CCC(=O)Nc1ccc(CNc2cc(Nc3ccc(N4CCOCC4)cc3)ncn2)cc1,5.81,IC50,=,1564.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using TK-substrate-biotin preincubated for 5 mins followed by substrate addition and further incubated for 30 mins and subsequently measured after 1 hr by HTRF assay,False,5.81,5.81,5.81,c1ccc(CNc2cc(Nc3ccc(N4CCOCC4)cc3)ncn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ef20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a040>
1243,CHEMBL4519857,,CCNC(=O)c1ccc(Nc2nccc(N3C[C@@H]4C[C@H]3CN4C(=O)CC#N)n2)cc1,6.11,IC50,=,774.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,6.88,7.64,6.11,c1ccc(Nc2nccc(N3C[C@@H]4C[C@H]3CN4)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ef90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a0b0>
1244,CHEMBL4520790,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@H](C3)N4C(=O)NCC#N)n2)cn1,7.80,IC50,=,16.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,7.80,7.80,7.80,c1cc(N2C[C@H]3CC[C@H](C2)N3)nc(Nc2cn[nH]c2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a120>
1245,CHEMBL4521312,,CCc1cc(O)c(F)cc1-c1cc(NS(=O)(=O)C2CCCC2)c2cn[nH]c2c1,6.40,IC50,=,398.11,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.40,6.40,6.40,O=S(=O)(Nc1cc(-c2ccccc2)cc2[nH]ncc12)C1CCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f0b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a190>
1246,CHEMBL4522317,,CCc1cc(O)c(F)cc1-c1cc(NS(=O)(=O)C(F)(F)F)c2cn[nH]c2c1,6.00,IC50,=,1000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.00,6.00,6.00,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a200>
1247,CHEMBL4524832,,CNC(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1cccc(C(=O)NC)c1OC,6.64,IC50,=,230.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.64,6.64,6.64,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a270>
1248,CHEMBL4525866,,CNC(=O)c1cnc(Nc2ncccn2)cc1Nc1ccccc1C(N)=O,7.22,IC50,=,60.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,7.22,7.22,7.22,c1ccc(Nc2ccnc(Nc3ncccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a2e0>
1249,CHEMBL4526032,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@H](C3)N4C(=O)NCC(F)(F)F)n2)cn1,7.55,IC50,=,28.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,7.55,7.55,7.55,c1cc(N2C[C@H]3CC[C@H](C2)N3)nc(Nc2cn[nH]c2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a350>
1250,CHEMBL4526274,,O=C(CCCCCn1cc(Nc2ncc(Cl)c(Nc3ccc(Cl)cc3)n2)cn1)NO,7.31,IC50,=,49.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 using Ulight-CAGAGAIETDKEYYTVKD as substrate measured after 60 mins by LANCE assay,False,7.31,7.31,7.31,c1ccc(Nc2ccnc(Nc3cn[nH]c3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f2e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a3c0>
1251,CHEMBL4526283,,CNC(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1ccccc1S(C)(=O)=O,6.75,IC50,=,180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,7.9,9.04,6.75,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a430>
1252,CHEMBL4527672,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(C(=O)NCC2CC2)c1OC,6.06,IC50,=,870.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.06,6.06,6.06,O=C(NCC1CC1)c1cccc(Nc2ccnc(Nc3ccccn3)c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f3c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a4a0>
1253,CHEMBL4528395,,CCc1cc(O)c(F)cc1-c1cc(NS(=O)(=O)c2ccccn2)c2cn[nH]c2c1,6.20,IC50,=,630.96,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.20,6.20,6.20,O=S(=O)(Nc1cc(-c2ccccc2)cc2[nH]ncc12)c1ccccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a510>
1254,CHEMBL4529314,,CCc1cc(O)c(F)cc1-c1cc(NS(=O)(=O)CCN2CCCCC2)c2cn[nH]c2c1,5.20,IC50,=,6309.57,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,5.20,5.20,5.20,O=S(=O)(CCN1CCCCC1)Nc1cc(-c2ccccc2)cc2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f4a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a580>
1255,CHEMBL4530719,,CS(=O)(=O)c1ccccc1Nc1cc(Nc2ccc(F)cn2)ncc1C(N)=O,7.38,IC50,=,42.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH1 domain (unknown origin),False,8.12,9.49,7.38,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a5f0>
1256,CHEMBL4531121,,CCS(=O)(=O)Nc1cc(-c2ccc(O)cc2)cc2[nH]ncc12,6.40,IC50,=,398.11,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.40,6.40,6.40,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a660>
1257,CHEMBL4531793,,CNC(=O)c1cnc(NC(=O)C(C)C)cc1Nc1ccccc1S(C)(=O)=O,5.28,IC50,=,5200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,5.28,5.28,5.28,c1ccc(Nc2ccncc2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f5f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a6d0>
1258,CHEMBL4532948,,CNc1cc(Nc2cccn(-c3ccccn3)c2=O)nn2c(C(=O)N[C@@H]3C[C@@H]3F)cnc12,10.07,Ki,=,0.086,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,8.25,10.07,7.09,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4ccccn4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a740>
1259,CHEMBL4534573,,CCc1cc(O)c(F)cc1-c1cc(NS(=O)(=O)N(C)C)c2cn[nH]c2c1,6.80,IC50,=,158.49,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.80,6.80,6.80,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f6d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a7b0>
1260,CHEMBL4534832,,CNC(=O)c1ccc(Nc2cc(Nc3ccc(F)cn3)ncc2C(=O)NC)c(OC)c1,6.28,IC50,=,520.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.28,6.28,6.28,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a820>
1261,CHEMBL4535276,,O=C(C1CC1)N1[C@@H]2CC[C@@H]1CN(c1nc(Nc3cnn(CCO)c3)ncc1F)C2,7.26,IC50,=,55.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,7.26,7.26,7.26,O=C(C1CC1)N1[C@@H]2CC[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f7b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a890>
1262,CHEMBL4535413,,CCc1cc(O)c(F)cc1-c1cc(NS(=O)(=O)CCN2CCN(C)CC2)c2cn[nH]c2c1,5.10,IC50,=,7943.28,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,5.10,5.10,5.10,O=S(=O)(CCN1CCNCC1)Nc1cc(-c2ccccc2)cc2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a900>
1263,CHEMBL4537259,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(C(N)=O)c1OC,7.21,IC50,=,62.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,7.21,7.21,7.21,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a970>
1264,CHEMBL4537678,,CNC(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1ccccc1C(N)=O,6.28,IC50,=,530.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,7.59,8.89,6.28,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091a9e0>
1265,CHEMBL4539805,,CC(C)Nc1c(C(N)=O)cnn2cc(-c3ccccc3)cc12,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Hs-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate measured after 3 hrs by electrophoresis method,False,6.82,6.82,6.82,c1ccc(-c2cc3cccnn3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091aa50>
1266,CHEMBL4541291,,CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1cc(F)ccc1Cl,5.89,IC50,=,1298.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,False,5.89,5.89,5.89,c1ccc(COc2cncc(-c3cnn(C4CCNCC4)c3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096f9e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091aac0>
1267,CHEMBL4541547,,C=CC(=O)Nc1ccc(CNc2cc(Nc3cnn(CCO)c3)ncn2)cc1,5.66,IC50,=,2175.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using TK-substrate-biotin preincubated for 5 mins followed by substrate addition and further incubated for 30 mins and subsequently measured after 1 hr by HTRF assay,False,5.66,5.66,5.66,c1ccc(CNc2cc(Nc3cn[nH]c3)ncn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096fa50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ab30>
1268,CHEMBL4542289,,CCCC(=O)Nc1cc(Nc2ccccc2S(C)(=O)=O)c(C(=O)NC)cn1,5.60,IC50,=,2500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,5.60,5.60,5.60,c1ccc(Nc2ccncc2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096fac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091aba0>
1269,CHEMBL4543066,,CNc1cc(Nc2cccn(-c3ccccn3)c2=O)nn2c(C(=O)NCC(C)(C)CO)cnc12,6.54,Ki,=,285.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha/IL2-induced STAT phosphorylation preincubated for 1 hr followed by IFNalpha/IL2 stimulation and measured after 15 mins by fluorescence assay,False,7.72,9.54,6.54,O=c1c(Nc2ccc3nccn3n2)cccn1-c1ccccn1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096fb30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ac10>
1270,CHEMBL4543715,,CCc1cc(O)c(F)cc1-c1cc(NS(=O)(=O)CCO)c2cn[nH]c2c1,6.20,IC50,=,630.96,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.20,6.20,6.20,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096fba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ac80>
1271,CHEMBL4543984,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(-c2nnco2)c1OC,6.77,IC50,=,170.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.77,6.77,6.77,c1ccc(Nc2cc(Nc3cccc(-c4nnco4)c3)ccn2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096fc10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091acf0>
1272,CHEMBL4544320,,CNC(=O)c1cnc(Nc2ccccn2)cc1Nc1ccccc1S(C)(=O)=O,6.60,IC50,=,250.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,7.81,9.02,6.6,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096fc80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ad60>
1273,CHEMBL4546009,,CN1CCN(c2ccc(Nc3cc(NCc4cccc(NC(=O)CC#N)c4)ncn3)cc2)CC1,5.82,IC50,=,1532.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using TK-substrate-biotin preincubated for 5 mins followed by substrate addition and further incubated for 30 mins and subsequently measured after 1 hr by HTRF assay,False,5.82,5.82,5.82,c1ccc(CNc2cc(Nc3ccc(N4CCNCC4)cc3)ncn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096fcf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091add0>
1274,CHEMBL4547009,,CNc1cc(Nc2cccn(C3CC3)c2=O)nn2c(C(=O)NC3CC3)cnc12,6.09,Ki,=,817.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha/IL2-induced STAT phosphorylation preincubated for 1 hr followed by IFNalpha/IL2 stimulation and measured after 15 mins by fluorescence assay,False,7.48,9.48,6.09,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(C4CC4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c096fd60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ae40>
1275,CHEMBL4547761,,COc1ccc(-c2cc3c(N[C@H](CO)[C@@H](C)O)c(C(N)=O)cnn3c2)cn1,7.57,IC50,=,27.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Hs-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate measured after 3 hrs by electrophoresis method,False,7.57,7.57,7.57,c1cncc(-c2cc3cccnn3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096fdd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091aeb0>
1276,CHEMBL4548200,,CNC(=O)c1cnc(Nc2cc(C)ccn2)cc1Nc1ccccc1S(C)(=O)=O,6.72,IC50,=,190.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,6.72,6.72,6.72,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096fe40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091af20>
1277,CHEMBL4549451,,COc1ccc(-c2cc3c(N[C@H](CO)CC4CC4)c(C(N)=O)cnn3c2)cn1,6.92,IC50,=,120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Hs-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate measured after 3 hrs by electrophoresis method,False,6.92,6.92,6.92,c1cncc(-c2cc3c(NCCC4CC4)ccnn3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096feb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091af90>
1278,CHEMBL4550335,,CC(Oc1cc(-c2cn[nH]c2)cnc1N)c1cc(F)ccc1Cl,5.84,IC50,=,1453.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) using peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,False,5.84,5.84,5.84,c1ccc(COc2cncc(-c3cn[nH]c3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ff20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b040>
1279,CHEMBL4550702,,Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1,7.04,IC50,=,92.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human N-terminal GST-tagged cytoplasmic TYK2 (833 to 1187 residues) catalytic domain expressed in baculovirus expression system by Z'-LYTE assay,False,7.04,7.04,7.04,c1cc(-c2cnn3cc(-c4cn[nH]c4)cnc23)cs1,<rdkit.Chem.rdchem.Mol object at 0x7f46c096ff90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b0b0>
1280,CHEMBL4551061,,CCc1cc(O)ccc1-c1cc(NS(=O)(=O)CC)c2cn[nH]c2c1,6.30,IC50,=,501.19,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.30,6.30,6.30,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b120>
1281,CHEMBL4551312,,CCS(=O)(=O)Nc1cc(-c2ccc(O)c(C)c2)cc2[nH]ncc12,6.10,IC50,=,794.33,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.10,6.10,6.10,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09700b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b190>
1282,CHEMBL4551587,,CCNC(=O)c1ccc(Nc2nccc(N3C[C@@H]4C[C@H](C3)N4C(=O)C3CC3)n2)cc1,6.70,IC50,=,201.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,6.70,6.70,6.70,O=C(C1CC1)N1[C@@H]2C[C@H]1CN(c1ccnc(Nc3ccccc3)n1)C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b200>
1283,CHEMBL4552370,,CCNC(=O)c1ccc(Nc2ncc(F)c(N3C[C@H]4CC[C@H](C3)N4C(=O)C3CC3)n2)cc1,7.72,IC50,=,19.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,7.72,7.72,7.72,O=C(C1CC1)N1[C@@H]2CC[C@@H]1CN(c1ccnc(Nc3ccccc3)n1)C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b270>
1284,CHEMBL4552628,,Cc1sc(C(=O)N[C@@H]2[C@H](N)CCCC2(F)F)cc1-c1cnn2cc(Cl)cnc12,5.00,IC50,=,10000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human N-terminal GST-tagged cytoplasmic TYK2 (833 to 1187 residues) catalytic domain expressed in baculovirus expression system by Z'-LYTE assay,False,5.00,5.00,5.00,O=C(NC1CCCCC1)c1cc(-c2cnn3cccnc23)cs1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b2e0>
1285,CHEMBL4554460,,CCc1cc(O)c(F)cc1-c1cc(NS(=O)(=O)C2CC2)c2cn[nH]c2c1,6.50,IC50,=,316.23,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.50,6.50,6.50,O=S(=O)(Nc1cc(-c2ccccc2)cc2[nH]ncc12)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b350>
1286,CHEMBL4554881,,CCNC(=O)c1ccc(Nc2nccc(N3C[C@@H]4C[C@H]3CN4C(=O)C3CC3)n2)cc1,5.76,IC50,=,1738.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,5.76,5.76,5.76,O=C(C1CC1)N1C[C@@H]2C[C@H]1CN2c1ccnc(Nc2ccccc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09702e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b3c0>
1287,CHEMBL4557190,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,7.92,IC50,=,12.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,7.92,7.92,7.92,c1ccc(Nc2cc(Nc3cccc(-c4nc[nH]n4)c3)ccn2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b430>
1288,CHEMBL4559521,,CCNC(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1ccccc1C(N)=O,7.89,IC50,=,13.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,7.89,7.89,7.89,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09703c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b4a0>
1289,CHEMBL4559585,,CNC(=O)c1cnc(Nc2ccc(C(F)(F)F)cn2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,7.16,IC50,=,69.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,7.16,7.16,7.16,c1ccc(Nc2cc(Nc3cccc(-c4nc[nH]n4)c3)ccn2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b510>
1290,CHEMBL4560212,,CCc1cc(O)c(F)cc1-c1cc(NS(=O)(=O)c2ccccc2Cl)c2cn[nH]c2c1,6.50,IC50,=,316.23,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.50,6.50,6.50,O=S(=O)(Nc1cc(-c2ccccc2)cc2[nH]ncc12)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09704a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b580>
1291,CHEMBL4561123,,CNc1cc(Nc2cccn(-c3ccc(F)cn3)c2=O)nn2c(C(=O)NC3CC3)cnc12,6.63,Ki,=,236.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha/IL2-induced STAT phosphorylation preincubated for 1 hr followed by IFNalpha/IL2 stimulation and measured after 15 mins by fluorescence assay,False,7.82,9.82,6.63,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4ccccn4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b5f0>
1292,CHEMBL4561663,,NC(=O)c1ccccc1Nc1cc(Nc2ccc(F)cn2)ncc1C(N)=O,10.22,Ki,=,0.06,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 (unknown origin) by morrison titration assay,False,8.89,10.22,7.82,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b660>
1293,CHEMBL4562491,,O=C(CCCCCCn1cc(Nc2ncc(Cl)c(N3CCCCC3)n2)cn1)NO,7.22,IC50,=,60.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 using Ulight-CAGAGAIETDKEYYTVKD as substrate measured after 60 mins by LANCE assay,False,7.22,7.22,7.22,c1cc(N2CCCCC2)nc(Nc2cn[nH]c2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09705f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b6d0>
1294,CHEMBL4562564,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@H](C3)N4C(=O)C3CC3)n2)cn1,7.12,IC50,=,76.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,7.12,7.12,7.12,O=C(C1CC1)N1[C@@H]2CC[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b740>
1295,CHEMBL4563039,,CCc1cc(O)c(F)cc1-c1cc(NS(=O)(=O)c2cccnc2)c2cn[nH]c2c1,5.60,IC50,=,2511.89,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,5.60,5.60,5.60,O=S(=O)(Nc1cc(-c2ccccc2)cc2[nH]ncc12)c1cccnc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09706d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b7b0>
1296,CHEMBL4563864,,COCCn1cc(Nc2cc(NCc3cccc(NC(=O)CC#N)c3)ncn2)cn1,5.76,IC50,=,1740.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using TK-substrate-biotin preincubated for 5 mins followed by substrate addition and further incubated for 30 mins and subsequently measured after 1 hr by HTRF assay,False,5.76,5.76,5.76,c1ccc(CNc2cc(Nc3cn[nH]c3)ncn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b820>
1297,CHEMBL4564318,,CCS(=O)(=O)Nc1cc(-c2ccc(O)c(OC)c2)cc2[nH]ncc12,5.60,IC50,=,2511.89,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,5.60,5.60,5.60,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09707b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b890>
1298,CHEMBL4564337,,COc1cc2c(-c3cnc(-c4ccc[nH]4)o3)c[nH]c2cc1Br,5.75,Kd,=,1800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding affinity to wild-type human partial length TYK2 JH2 domain-pseudokinase expressed in mammalian expression system by active-site directed competition binding assay based Kinomescan method,False,5.75,5.75,5.75,c1c[nH]c(-c2ncc(-c3c[nH]c4ccccc34)o2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b900>
1299,CHEMBL4565054,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(-c2ncnn2C)c1OC,7.06,IC50,=,87.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,7.06,7.06,7.06,c1ccc(Nc2cc(Nc3cccc(-c4ncn[nH]4)c3)ccn2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b970>
1300,CHEMBL4566158,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(-c2ccn(C)n2)c1OC,7.10,IC50,=,79.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,7.10,7.10,7.10,c1ccc(Nc2cc(Nc3cccc(-c4cc[nH]n4)c3)ccn2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091b9e0>
1301,CHEMBL4567992,,CCS(=O)(=O)Nc1cc(-c2ccc(O)cc2C)cc2[nH]ncc12,6.10,IC50,=,794.33,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.10,6.10,6.10,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ba50>
1302,CHEMBL4568087,,Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1,7.28,IC50,=,52.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human N-terminal GST-tagged cytoplasmic TYK2 (833 to 1187 residues) catalytic domain expressed in baculovirus expression system by Z'-LYTE assay,False,7.28,7.28,7.28,O=C(NC1CCCCC1)c1cc(-c2cnn3cc(-c4cn[nH]c4)cnc23)cs1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09709e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091bac0>
1303,CHEMBL4568896,,COc1ccc(-c2cc3c(NC(CO)CO)c(C(N)=O)cnn3c2)cn1,6.48,IC50,=,330.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Hs-tagged TYK2 (unknown origin) using fluoresceinated peptide as substrate measured after 3 hrs by electrophoresis method,False,6.48,6.48,6.48,c1cncc(-c2cc3cccnn3c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091bb30>
1304,CHEMBL4569337,,CNC(=O)c1cnc(Nc2ccccc2)cc1Nc1ccccc1C(N)=O,7.48,IC50,=,33.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,7.48,7.48,7.48,c1ccc(Nc2ccnc(Nc3ccccc3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091bba0>
1305,CHEMBL4569508,,O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1,7.12,IC50,=,75.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human N-terminal GST-tagged cytoplasmic TYK2 (833 to 1187 residues) catalytic domain expressed in baculovirus expression system by Z'-LYTE assay,False,7.12,7.12,7.12,c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091bc10>
1306,CHEMBL4569613,,CCc1cc(O)c(F)cc1-c1cc(NS(=O)(=O)CCOC)c2cn[nH]c2c1,6.30,IC50,=,501.19,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.30,6.30,6.30,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091bc80>
1307,CHEMBL4571117,,[2H]C([2H])([2H])NC(=O)c1cnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,7.89,IC50,=,13.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,7.89,7.89,7.89,O=C(Nc1cc(Nc2cccc(-c3nc[nH]n3)c2)ccn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091bcf0>
1308,CHEMBL4571920,,CNc1cc(Nc2cccn(-c3cccc(F)n3)c2=O)nn2c(C(=O)N[C@@H]3C[C@@H]3F)cnc12,10.62,Ki,=,0.024,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,8.47,10.62,6.87,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4ccccn4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091bd60>
1309,CHEMBL4572373,,C=CC(=O)Nc1cccc(CNc2cc(Nc3cnn(CCO)c3)ncn2)c1,5.59,IC50,=,2561.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using TK-substrate-biotin preincubated for 5 mins followed by substrate addition and further incubated for 30 mins and subsequently measured after 1 hr by HTRF assay,False,5.59,5.59,5.59,c1ccc(CNc2cc(Nc3cn[nH]c3)ncn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091bdd0>
1310,CHEMBL4572426,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(-c2ccnn2C)c1OC,6.52,IC50,=,300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.52,6.52,6.52,c1ccc(Nc2cc(Nc3cccc(-c4ccn[nH]4)c3)ccn2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091be40>
1311,CHEMBL4572855,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(-c2nc[nH]n2)c1OC,7.64,IC50,=,23.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,7.64,7.64,7.64,c1ccc(Nc2cc(Nc3cccc(-c4nc[nH]n4)c3)ccn2)nc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091beb0>
1312,CHEMBL4574614,,C=CC(=O)Nc1cccc(CNc2cc(Nc3cnn(CCOC)c3)ncn2)c1,5.64,IC50,=,2290.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using TK-substrate-biotin preincubated for 5 mins followed by substrate addition and further incubated for 30 mins and subsequently measured after 1 hr by HTRF assay,False,5.64,5.64,5.64,c1ccc(CNc2cc(Nc3cn[nH]c3)ncn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091bf20>
1313,CHEMBL4575813,,O=C(CCCCCCn1cc(Nc2ncc(Cl)c(Nc3ccc(Cl)cc3)n2)cn1)NO,7.03,IC50,=,94.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 using Ulight-CAGAGAIETDKEYYTVKD as substrate measured after 60 mins by LANCE assay,False,7.03,7.03,7.03,c1ccc(Nc2ccnc(Nc3cn[nH]c3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091bf90>
1314,CHEMBL4576489,,CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,7.31,Kd,=,49.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding affinity to recombinant N-terminal His-FLAG-GST-tagged TYK2 (unknown origin) (871 to 1187 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay,False,7.31,7.31,7.31,O=C(CCC1=[N+]2[BH2-]n3cccc3C=C2C=C1)NCCOCCOCCOCCN[C@H]1CC2O[C@H](C1)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c040>
1315,CHEMBL4577224,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(C(=O)N(C)C)c1OC,6.12,IC50,=,750.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.12,6.12,6.12,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0970f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c0b0>
1316,CHEMBL4577523,AZD4205,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1,5.55,IC50,=,2800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,5.55,5.55,5.55,O=C(CN1CCNCC1)Nc1cccc2c(-c3ccnc(Nc4cn[nH]c4)n3)c[nH]c12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c120>
1317,CHEMBL4577685,,CCS(=O)(=O)Nc1cc(-c2c(C)cc(O)cc2C)cc2[nH]ncc12,5.20,IC50,=,6309.57,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,5.20,5.20,5.20,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09710b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c190>
1318,CHEMBL4578980,,CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(C(=O)NCCN2CCOCC2)c1OC,6.80,IC50,=,160.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.80,6.80,6.80,O=C(NCCN1CCOCC1)c1cccc(Nc2ccnc(Nc3ccccn3)c2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c200>
1319,CHEMBL4579439,,CNc1cc(Nc2cccn(-c3cccc(F)n3)c2=O)nn2c(C(=O)NC3CC3)cnc12,6.43,Ki,=,371.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha/IL2-induced STAT phosphorylation preincubated for 1 hr followed by IFNalpha/IL2 stimulation and measured after 15 mins by fluorescence assay,False,7.75,9.66,6.43,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4ccccn4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c270>
1320,CHEMBL4580425,,CCc1cc(O)c(F)cc1-c1cc(NS(=O)(=O)CC2CCC2)c2cn[nH]c2c1,6.10,IC50,=,794.33,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.10,6.10,6.10,O=S(=O)(CC1CCC1)Nc1cc(-c2ccccc2)cc2[nH]ncc12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c2e0>
1321,CHEMBL4580625,,CNC(=O)c1cnc(Nc2cc(C)nc(C)n2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,7.72,IC50,=,19.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,7.72,7.72,7.72,c1cc(Nc2ccnc(Nc3ccncn3)c2)cc(-c2nc[nH]n2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c350>
1322,CHEMBL4580693,,CNC(=O)c1cnc(Nc2ncccc2F)cc1Nc1ccccc1C(N)=O,8.23,IC50,=,5.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,8.23,8.23,8.23,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09712e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c3c0>
1323,CHEMBL4580985,,Cn1cc(Nc2ncc(F)c(N3C[C@H]4CC[C@H](C3)N4C(=O)C3CC3)n2)cn1,7.28,IC50,=,53.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,7.28,7.28,7.28,O=C(C1CC1)N1[C@@H]2CC[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c430>
1324,CHEMBL4581296,,CNC(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1ccc(C(N)=O)cc1OC,6.41,IC50,=,390.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.41,6.41,6.41,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09713c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c4a0>
1325,CHEMBL4582205,,CNC(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1cccc(C(N)=O)c1OC,6.92,IC50,=,120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.92,6.92,6.92,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c510>
1326,CHEMBL4583185,,[2H]C([2H])([2H])NC(=O)c1nnc(Nc2ccc(F)cn2)cc1Nc1ccccc1S(C)(=O)=O,6.70,IC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as inhibition of IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by IFNalpha stimulation and measured after 15 mins by fluorescence assay,False,7.97,9.24,6.7,c1ccc(Nc2cnnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09714a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c580>
1327,CHEMBL4583948,,CNC(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1ccccc1,7.96,IC50,=,11.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of fluorescein-labeled kinase tracer binding to His-TVMV-fused TYK2 JH2 domain (575 to 869 residues) (unknown origin) measured after 90 mins by HTRF assay,False,7.96,7.96,7.96,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c5f0>
1328,CHEMBL4585272,,CNc1cc(Nc2cccn(-c3ccncc3)c2=O)nn2c(C(=O)NC3CC3)cnc12,6.46,Ki,=,346.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain in human whole blood assessed as decrease in IFNalpha/IL2-induced STAT phosphorylation preincubated for 1 hr followed by IFNalpha/IL2 stimulation and measured after 15 mins by fluorescence assay,False,7.61,9.54,6.46,O=C(NC1CC1)c1cnc2ccc(Nc3cccn(-c4ccncc4)c3=O)nn12,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c660>
1329,CHEMBL4587406,,CCNC(=O)c1ccc(Nc2nccc(N3C[C@H]4CC[C@H](C3)N4C(=O)C3CC3)n2)cc1,7.50,IC50,=,32.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using fluorescence labeled peptide as substrate and using 1 mM ATP level by microfluidic based mobility shift assay,False,7.50,7.50,7.50,O=C(C1CC1)N1[C@@H]2CC[C@@H]1CN(c1ccnc(Nc3ccccc3)n1)C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c09715f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c6d0>
1330,CHEMBL4587924,,CNC(=O)c1cnc(Nc2ccc(F)cn2)cc1Nc1cccc(C#N)c1OC,6.24,IC50,=,570.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation with IFN-alpha for 15 mins by fluorescence analysis,False,6.24,6.24,6.24,c1ccc(Nc2ccnc(Nc3ccccn3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c740>
1331,CHEMBL4589842,,CCS(=O)(=O)Nc1cc(-c2ccc(O)cc2Cl)cc2[nH]ncc12,6.50,IC50,=,316.23,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human Gst-tagged TYK2 ( 871 to 1187 residues) expressed in baculovirus using biotin-synthetic peptide as substrate after 20 mins by HTRF assay,False,6.50,6.50,6.50,c1ccc(-c2ccc3cn[nH]c3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09716d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c7b0>
1332,CHEMBL4590082,,Cc1cnc(Nc2ccc(N3CCOCC3)cc2)nc1-c1cc2c(o1)CCN(C(=O)CC#N)C2,8.52,IC50,=,3.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tyk2 (unknown origin),False,8.52,8.52,8.52,c1cc(-c2cc3c(o2)CCNC3)nc(Nc2ccc(N3CCOCC3)cc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c820>
1333,CHEMBL4593058,,C=CC(=O)Nc1ccc(CNc2cc(Nc3cnn(CCOC)c3)ncn2)cc1,5.64,IC50,=,2295.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human TYK2 using TK-substrate-biotin preincubated for 5 mins followed by substrate addition and further incubated for 30 mins and subsequently measured after 1 hr by HTRF assay,False,5.64,5.64,5.64,c1ccc(CNc2cc(Nc3cn[nH]c3)ncn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09717b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c890>
1334,CHEMBL4632897,,Cc1[nH]nc2[nH]c(=O)cc([C@H]3CC[C@H](NC(=O)C4CCCC4)CC3)c12,5.17,IC50,=,6800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,5.17,5.17,5.17,O=C(N[C@H]1CC[C@H](c2cc(=O)[nH]c3n[nH]cc32)CC1)C1CCCC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c900>
1335,CHEMBL4632980,,Cc1[nH]nc2[nH]c(=O)c(C#N)c(C3CCCCC3)c12,4.96,IC50,=,11000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,4.96,4.96,4.96,O=c1cc(C2CCCCC2)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c970>
1336,CHEMBL4633028,,Cc1[nH]nc2[nH]c(=O)cc([C@H]3CC[C@H](NC(=O)C4CC4)CC3)c12,5.55,IC50,=,2800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,5.55,5.55,5.55,O=C(N[C@H]1CC[C@H](c2cc(=O)[nH]c3n[nH]cc32)CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091c9e0>
1337,CHEMBL4634289,,Cc1[nH]nc2[nH]c(=O)cc([C@@H]3C[C@@H]4C[C@H]3C[C@@H]4CC#N)c12,6.66,IC50,=,220.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,6.66,6.66,6.66,O=c1cc([C@@H]2C[C@H]3CC[C@@H]2C3)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ca50>
1338,CHEMBL4634433,,C[C@@H]1[C@@H]2CN(c3nc(Nc4cnn(C)c4)ncc3F)C[C@]12NC(=O)[C@@H]1C[C@H]1C#N,7.50,IC50,=,32.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 assessed as level of phosphorylation in presence of peptide substrate 5FAM-KKSRGDYMTMQID and ATP by mobility shift assay,False,7.50,7.50,7.50,O=C(N[C@@]12C[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09719e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091cac0>
1339,CHEMBL4635104,,C[C@@H]1[C@@H]2CN(c3nc(Nc4cnn(C)c4)ncc3F)C[C@]12NC(=O)[C@H]1CC1(F)F,7.25,IC50,=,56.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 assessed as level of phosphorylation in presence of peptide substrate 5FAM-KKSRGDYMTMQID and ATP by mobility shift assay,False,7.25,7.25,7.25,O=C(N[C@@]12C[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091cb30>
1340,CHEMBL4635334,,O=C(N[C@]12C[C@H]1CN(c1nc(Nc3cnn(CCO)c3)ncc1F)C2)C1CC1,5.28,IC50,=,5303.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 assessed as level of phosphorylation in presence of peptide substrate 5FAM-KKSRGDYMTMQID and ATP by mobility shift assay,False,5.28,5.28,5.28,O=C(N[C@]12C[C@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091cba0>
1341,CHEMBL4635464,,Cc1[nH]nc2[nH]c(=O)cc(-c3ccccc3)c12,5.41,IC50,=,3900.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,5.41,5.41,5.41,O=c1cc(-c2ccccc2)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091cc10>
1342,CHEMBL4635625,,C[C@@H]1[C@@H]2CN(c3nc(Nc4cnn(C)c4)ncc3F)C[C@]12NC(=O)[C@@H]1CC1(F)F,7.54,IC50,=,29.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 assessed as level of phosphorylation in presence of peptide substrate 5FAM-KKSRGDYMTMQID and ATP by mobility shift assay,False,7.54,7.54,7.54,O=C(N[C@@]12C[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091cc80>
1343,CHEMBL4636220,,Cc1[nH]nc2[nH]c(=O)cc([C@H]3C[C@H]4CC[C@@H]3C4)c12,6.37,IC50,=,430.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,6.37,6.37,6.37,O=c1cc([C@H]2C[C@H]3CC[C@@H]2C3)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ccf0>
1344,CHEMBL4636368,,Cc1[nH]nc2[nH]c(=O)cc([C@H]3CC[C@H](N)CC3)c12,4.80,IC50,=,16000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,4.80,4.80,4.80,O=c1cc(C2CCCCC2)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091cd60>
1345,CHEMBL4636371,,Cc1[nH]nc2[nH]c(=O)cc(C3CCCCC3)c12,6.17,IC50,=,670.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,6.17,6.17,6.17,O=c1cc(C2CCCCC2)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091cdd0>
1346,CHEMBL4636795,,CN(C)C(=O)c1ccc(Nc2cc(N3CC[C@@](C#N)(C4CC4)C3=O)ccn2)nc1,8.96,IC50,=,1.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.96,8.96,8.96,O=C1C(C2CC2)CCN1c1ccnc(Nc2ccccn2)c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ce40>
1347,CHEMBL4637190,,C[C@@H]1[C@@H]2CN(c3nc(Nc4cnn(CCO)c4)ncc3F)C[C@]12NC(=O)[C@H]1C[C@@H]1C#N,7.50,IC50,=,32.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 assessed as level of phosphorylation in presence of peptide substrate 5FAM-KKSRGDYMTMQID and ATP by mobility shift assay,False,7.50,7.50,7.50,O=C(N[C@@]12C[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ceb0>
1348,CHEMBL4637587,,N#C[C@]1(C2CC2)C(=O)N2C[C@H]1COCC(=O)NCc1cccc(n1)Nc1cc2ccn1,5.89,IC50,=,1300.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells by luciferase reporter gene assay,False,6.39,6.89,5.89,O=C1COC[C@@H]2CN(C(=O)C2C2CC2)c2ccnc(c2)Nc2cccc(n2)CN1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091cf20>
1349,CHEMBL4638206,,CCNC(=O)c1ccc(Nc2nccc(N3CC4CCC(C3)N4C(=O)C3CC3)n2)cc1,7.50,IC50,=,32.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 assessed as level of phosphorylation in presence of peptide substrate 5FAM-KKSRGDYMTMQID and ATP by mobility shift assay,False,7.50,7.50,7.50,O=C(C1CC1)N1C2CCC1CN(c1ccnc(Nc3ccccc3)n1)C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091cf90>
1350,CHEMBL4638696,,Cc1[nH]nc2[nH]c(=O)c(CO)c(C3CCCCC3)c12,6.19,IC50,=,650.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,6.19,6.19,6.19,O=c1cc(C2CCCCC2)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d040>
1351,CHEMBL4638906,,N#C[C@H]1C[C@@H]1C(=O)N[C@@]12C[C@@H]1CN(c1nc(Nc3cnn(CCO)c3)ncc1F)C2,7.17,IC50,=,67.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 assessed as level of phosphorylation in presence of peptide substrate 5FAM-KKSRGDYMTMQID and ATP by mobility shift assay,False,7.17,7.17,7.17,O=C(N[C@@]12C[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0971f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d0b0>
1352,CHEMBL4638953,,Cc1[nH]nc2[nH]c(=O)cc([C@H]3CC[C@H](NC(=O)[C@H]4CC4(F)F)CC3)c12,5.57,IC50,=,2700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,5.57,5.57,5.57,O=C(N[C@H]1CC[C@H](c2cc(=O)[nH]c3n[nH]cc32)CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d120>
1353,CHEMBL4639973,,Cc1[nH]nc2[nH]c(=O)cc([C@H]3CC[C@H](NC(=O)[C@@H]4CC4(F)F)CC3)c12,6.66,IC50,=,220.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,6.66,6.66,6.66,O=C(N[C@H]1CC[C@H](c2cc(=O)[nH]c3n[nH]cc32)CC1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09720b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d190>
1354,CHEMBL4640314,,O=C(C1CC1)N1C2CCC1CN(c1nc(Nc3cnn(CCO)c3)ncc1F)C2,7.26,IC50,=,55.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 assessed as level of phosphorylation in presence of peptide substrate 5FAM-KKSRGDYMTMQID and ATP by mobility shift assay,False,7.26,7.26,7.26,O=C(C1CC1)N1C2CCC1CN(c1ccnc(Nc3cn[nH]c3)n1)C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d200>
1355,CHEMBL4640335,,Cc1[nH]nc2[nH]c(=O)cc(C3CCCC3)c12,6.08,IC50,=,830.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,6.08,6.08,6.08,O=c1cc(C2CCCC2)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d270>
1356,CHEMBL4640521,,Cc1[nH]nc2[nH]c(=O)cc([C@H]3CCCC[C@H]3C)c12,6.16,IC50,=,700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,6.16,6.16,6.16,O=c1cc(C2CCCCC2)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d2e0>
1357,CHEMBL4640981,,O=C(N[C@@]12C[C@@H]1CN(c1nc(Nc3cnn(CCO)c3)ncc1F)C2)C1CC1,6.86,IC50,=,139.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 assessed as level of phosphorylation in presence of peptide substrate 5FAM-KKSRGDYMTMQID and ATP by mobility shift assay,False,6.86,6.86,6.86,O=C(N[C@@]12C[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d350>
1358,CHEMBL4641006,,N#C[C@]1(C2CC2)C(=O)N2C[C@H]1COCC(=O)NCCCc1cccc(n1)Nc1cc2ccn1,6.75,IC50,=,180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells by luciferase reporter gene assay,False,7.5,8.26,6.75,O=C1COC[C@@H]2CN(C(=O)C2C2CC2)c2ccnc(c2)Nc2cccc(n2)CCCN1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09722e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d3c0>
1359,CHEMBL4641076,,Cc1[nH]nc2[nH]c(=O)cc(CC3CCC3)c12,5.96,IC50,=,1100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,5.96,5.96,5.96,O=c1cc(CC2CCC2)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d430>
1360,CHEMBL4642546,,Cc1[nH]nc2[nH]c(=O)c(CCO)c(C3CCCCC3)c12,5.47,IC50,=,3400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,5.47,5.47,5.47,O=c1cc(C2CCCCC2)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09723c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d4a0>
1361,CHEMBL4643061,,Cc1[nH]nc2[nH]c(=O)cc([C@H]3C[C@H]4C[C@@H]3C[C@@H]4CC#N)c12,7.70,IC50,=,20.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,7.70,7.70,7.70,O=c1cc([C@H]2C[C@@H]3CC[C@H]2C3)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d510>
1362,CHEMBL4643392,,N#C[C@]1(C2CC2)C(=O)N2C[C@H]1COCCCCOCc1cccc(n1)Nc1cc2ccn1,6.68,IC50,=,210.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells by luciferase reporter gene assay,False,7.5,8.31,6.68,O=C1C(C2CC2)[C@@H]2COCCCCOCc3cccc(n3)Nc3cc(ccn3)N1C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c09724a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d580>
1363,CHEMBL4643899,,N#C[C@]1(C2CC2)C(=O)N2C[C@H]1COC/C=C\COCc1cccc(n1)Nc1cc2ccn1,6.58,IC50,=,260.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells by luciferase reporter gene assay,False,7.43,8.28,6.58,O=C1C(C2CC2)[C@@H]2COC/C=C\COCc3cccc(n3)Nc3cc(ccn3)N1C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d5f0>
1364,CHEMBL4644138,,N#C[C@@H]1C[C@H]1C(=O)N[C@@]12C[C@@H]1CN(c1nc(Nc3cnn(CCO)c3)ncc1F)C2,7.54,IC50,=,29.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 assessed as level of phosphorylation in presence of peptide substrate 5FAM-KKSRGDYMTMQID and ATP by mobility shift assay,False,7.54,7.54,7.54,O=C(N[C@@]12C[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d660>
1365,CHEMBL4644578,,C[C@@H]1[C@@H]2CN(c3nc(Nc4cnn(CCO)c4)ncc3F)C[C@]12NC(=O)[C@@H]1C[C@H]1C#N,7.43,IC50,=,37.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 assessed as level of phosphorylation in presence of peptide substrate 5FAM-KKSRGDYMTMQID and ATP by mobility shift assay,False,7.43,7.43,7.43,O=C(N[C@@]12C[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09725f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d6d0>
1366,CHEMBL4645039,,CCNC(=O)c1ccc(Nc2nccc(N3CC4CC(C3)N4C(=O)C3CC3)n2)cc1,6.68,IC50,=,209.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 assessed as level of phosphorylation in presence of peptide substrate 5FAM-KKSRGDYMTMQID and ATP by mobility shift assay,False,6.68,6.68,6.68,O=C(C1CC1)N1C2CC1CN(c1ccnc(Nc3ccccc3)n1)C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d740>
1367,CHEMBL4645110,,N#C[C@]1(C2CC2)C(=O)N2C[C@H]1COC/C=C/COCc1cccc(n1)Nc1cc2ccn1,6.36,IC50,=,440.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells by luciferase reporter gene assay,False,7.14,7.92,6.36,O=C1C(C2CC2)[C@@H]2COC/C=C/COCc3cccc(n3)Nc3cc(ccn3)N1C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c09726d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d7b0>
1368,CHEMBL4645113,,O=c1cc(C2CCCCC2)c2c[nH]nc2[nH]1,4.62,IC50,=,24000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,4.62,4.62,4.62,O=c1cc(C2CCCCC2)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d820>
1369,CHEMBL4645258,,N#C[C@]1(C2CC2)C(=O)N2C[C@H]1COCC(=O)NCCc1cccc(n1)Nc1cc2ccn1,6.68,IC50,=,210.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human Jurkat cells by luciferase reporter gene assay,False,7.16,7.64,6.68,O=C1COC[C@@H]2CN(C(=O)C2C2CC2)c2ccnc(c2)Nc2cccc(n2)CCN1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09727b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d890>
1370,CHEMBL4645613,,Cc1[nH]nc2[nH]c(=O)cc([C@@H]3C[C@H]4CC[C@@H]3C4)c12,6.82,IC50,=,150.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,6.82,6.82,6.82,O=c1cc([C@@H]2C[C@H]3CC[C@@H]2C3)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d900>
1371,CHEMBL4645814,,Cc1[nH]nc2[nH]c(=O)cc([C@H]3CC[C@H](CC#N)CC3)c12,6.89,IC50,=,130.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,6.89,6.89,6.89,O=c1cc(C2CCCCC2)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d970>
1372,CHEMBL4647115,,Cc1[nH]nc2[nH]c(=O)cc([C@@H]3C[C@@H]4C[C@H]3C[C@H]4CC#N)c12,6.75,IC50,=,180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,6.75,6.75,6.75,O=c1cc([C@@H]2C[C@H]3CC[C@@H]2C3)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091d9e0>
1373,CHEMBL4647223,,C[C@@H]1[C@@H]2CN(c3nc(Nc4cnn(CCO)c4)ncc3F)C[C@]12NC(=O)C1CC1,7.24,IC50,=,57.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 assessed as level of phosphorylation in presence of peptide substrate 5FAM-KKSRGDYMTMQID and ATP by mobility shift assay,False,7.24,7.24,7.24,O=C(N[C@@]12C[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091da50>
1374,CHEMBL4647506,,Cc1[nH]nc2[nH]c(=O)cc([C@H]3CC[C@H](O)CC3)c12,5.38,IC50,=,4200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,5.38,5.38,5.38,O=c1cc(C2CCCCC2)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09729e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091dac0>
1375,CHEMBL4648246,,O=c1cc(C2CCCCC2)c2c(C3CC3)[nH]nc2[nH]1,5.80,IC50,=,1600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,5.80,5.80,5.80,O=c1cc(C2CCCCC2)c2c(C3CC3)[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091db30>
1376,CHEMBL4648612,,Cc1[nH]nc2[nH]c(=O)cc(C3CC4CCC3CC4)c12,6.66,IC50,=,220.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,6.66,6.66,6.66,O=c1cc(C2CC3CCC2CC3)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091dba0>
1377,CHEMBL4648631,,C[C@@H]1[C@@H]2CN(c3nc(Nc4cnn(C)c4)ncc3F)C[C@]12NC(=O)[C@H]1C[C@@H]1C#N,7.31,IC50,=,49.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 assessed as level of phosphorylation in presence of peptide substrate 5FAM-KKSRGDYMTMQID and ATP by mobility shift assay,False,7.31,7.31,7.31,O=C(N[C@@]12C[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091dc10>
1378,CHEMBL4648820,,Cc1[nH]nc2[nH]c(=O)cc([C@H]3C[C@H]4C[C@@H]3C[C@H]4CC#N)c12,6.48,IC50,=,330.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,6.48,6.48,6.48,O=c1cc([C@H]2C[C@@H]3CC[C@H]2C3)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091dc80>
1379,CHEMBL4649054,,Cc1[nH]nc2[nH]c(=O)cc([C@H]3CC[C@H](C(=O)NC4CC4)CC3)c12,4.85,IC50,=,14000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of N-terminal GST-tagged human TYK2 catalytic domain (871 to 1187 residues) incubated for 40 mins in presence of TK substrate-biotin by TR-FRET assay,False,4.85,4.85,4.85,O=c1cc([C@H]2CC[C@H](C(=O)NC3CC3)CC2)c2c[nH]nc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091dcf0>
1380,CHEMBL4740088,,CCN1CC(CC#N)(n2cc(-c3nc(-c4cnn(C)c4)cn4nccc34)cn2)C1,7.34,IC50,=,46.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,7.34,7.34,7.34,c1cc2c(-c3cnn(C4CNC4)c3)nc(-c3cn[nH]c3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091dd60>
1381,CHEMBL4740298,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@H](C#N)C4)c3)n2)cn1,8.22,IC50,=,6.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,8.22,8.22,8.22,c1cc2c(-c3cnn(C4CCC4)c3)nc(-c3cn[nH]c3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ddd0>
1382,CHEMBL4740831,,N#CC[C@]1(n2cc(-c3nc(-c4cn[nH]c4)cn4nccc34)cn2)C[C@H](C#N)C1,7.36,IC50,=,44.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,7.36,7.36,7.36,c1cc2c(-c3cnn(C4CCC4)c3)nc(-c3cn[nH]c3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091de40>
1383,CHEMBL4741075,,Cc1cnc(Nc2ccc3c(c2)CN(C(=O)/C=C/C(=O)c2ccccc2)CC3)nc1-c1cnn(C(C)C)c1,7.28,IC50,=,52.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGGKKK as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.28,7.28,7.28,O=C(/C=C/C(=O)N1CCc2ccc(Nc3nccc(-c4cn[nH]c4)n3)cc2C1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091deb0>
1384,CHEMBL4741376,,CNC(=O)c1cnc2[nH]ccc2c1NC1CCCN(Cc2ccc(OC)cc2)CC1,7.29,IC50,=,51.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,7.29,7.29,7.29,c1ccc(CN2CCCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091df20>
1385,CHEMBL4741588,,COCCn1cc(Nc2cc(-c3cccc(NC(=O)CC#N)c3)ncn2)cn1,5.64,IC50,=,2264.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,A,Inhibition of recombinant human N-terminal GST-tagged TYK2 cytoplasmic domain (833 to 1187 residues) expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition and measured after 30 mins by HTRF assay,False,5.64,5.64,5.64,c1ccc(-c2cc(Nc3cn[nH]c3)ncn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091df90>
1386,CHEMBL4741903,,Cn1cc(-c2cn3nccc3c(-c3cnn(C4(CC#N)CN(CC#N)C4)c3)n2)cn1,8.15,IC50,=,7.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,8.15,8.15,8.15,c1cc2c(-c3cnn(C4CNC4)c3)nc(-c3cn[nH]c3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e040>
1387,CHEMBL4742766,,CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2cccc(OC)c2)C[C@H]1F,6.16,IC50,=,696.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.16,6.16,6.16,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0972f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e0b0>
1388,CHEMBL4742822,,CNC(=O)c1cnc2[nH]ccc2c1NC1CCN(Cc2ccc(Cl)cc2)C1,6.18,IC50,=,657.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.18,6.18,6.18,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)C2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e120>
1389,CHEMBL4743357,,C/C=C/C(=O)Nc1cccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1,5.58,IC50,=,2653.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,A,Inhibition of recombinant human N-terminal GST-tagged TYK2 cytoplasmic domain (833 to 1187 residues) expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition and measured after 30 mins by HTRF assay,False,5.58,5.58,5.58,c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09730b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e190>
1390,CHEMBL4744048,,CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2ccccc2)[C@@H](C)C1,6.56,IC50,=,276.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.56,6.56,6.56,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e200>
1391,CHEMBL4744519,,COCCn1cc(Nc2nccc(-c3ccc(NC(=O)CC#N)cc3)n2)cn1,5.60,IC50,=,2496.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,A,Inhibition of recombinant human N-terminal GST-tagged TYK2 cytoplasmic domain (833 to 1187 residues) expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition and measured after 30 mins by HTRF assay,False,5.60,5.60,5.60,c1ccc(-c2ccnc(Nc3cn[nH]c3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e270>
1392,CHEMBL4744772,,CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2ccc(C#N)cc2)[C@H](C)C1,8.17,IC50,=,6.73,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,8.17,8.17,8.17,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e2e0>
1393,CHEMBL4746186,,CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2ccc(OC)cc2)[C@@H](C)C1,6.30,IC50,=,504.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.30,6.30,6.30,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e350>
1394,CHEMBL4746272,,C=CC(=O)Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,5.55,IC50,=,2783.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,A,Inhibition of recombinant human N-terminal GST-tagged TYK2 cytoplasmic domain (833 to 1187 residues) expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition and measured after 30 mins by HTRF assay,False,5.55,5.55,5.55,c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09732e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e3c0>
1395,CHEMBL4746952,,CNC(=O)c1cnc2[nH]ccc2c1NCC1CCN(Cc2ccc(Cl)cc2)CC1,7.31,IC50,=,48.9,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,7.31,7.31,7.31,c1ccc(CN2CCC(CNc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e430>
1396,CHEMBL4747270,,CNC(=O)c1cnc2[nH]ccc2c1NC1CCN(Cc2ccccc2)CC1,6.23,IC50,=,586.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.23,6.23,6.23,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09733c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e4a0>
1397,CHEMBL4747285,,CNC(=O)c1cnc2[nH]ccc2c1NC1CCCN(Cc2ccc(C#N)cc2)CC1,6.92,IC50,=,120.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.92,6.92,6.92,c1ccc(CN2CCCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e510>
1398,CHEMBL4747591,,Cn1cc(Nc2nccc(N3CC4CCC(C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1,7.64,IC50,=,23.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human Tyk2 expressed in sf21 baculovirus expression system assessed as phosphorylation level in presence of 1 mM ATP,False,7.64,7.64,7.64,O=C(C1CC1)N1C2CCC1CN(c1ccnc(Nc3cn[nH]c3)n1)C2,<rdkit.Chem.rdchem.Mol object at 0x7f46c09734a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e580>
1399,CHEMBL4747742,,CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2cccc(OC)c2)C[C@@H]1F,6.94,IC50,=,116.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.94,6.94,6.94,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e5f0>
1400,CHEMBL4748354,,Cc1cnc(Nc2ccc3c(c2)CCN(C(=O)/C=C/C(=O)c2ccccc2)C3)nc1-c1cnn(C(C)C)c1,7.10,IC50,=,79.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGGKKK as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.10,7.10,7.10,O=C(/C=C/C(=O)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc2C1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e660>
1401,CHEMBL4749677,,CNC(=O)c1cnc2[nH]ccc2c1NCC1CCN(Cc2ccc(OC)cc2)CC1,6.70,IC50,=,200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.70,6.70,6.70,c1ccc(CN2CCC(CNc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09735f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e6d0>
1402,CHEMBL4750448,,N#CC[C@]1(n2cc(-c3nc(-c4cc[nH]n4)cn4nccc34)cn2)C[C@H](C#N)C1,7.58,IC50,=,26.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,7.58,7.58,7.58,c1cc2c(-c3cnn(C4CCC4)c3)nc(-c3cc[nH]n3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e740>
1403,CHEMBL4750605,,CNC(=O)c1cnc2[nH]ccc2c1NC1CCN(Cc2cccc(Cl)c2)C1,6.22,IC50,=,597.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.22,6.22,6.22,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)C2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09736d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e7b0>
1404,CHEMBL4750665,,O=C(NC1CC1)c1cnc2[nH]ccc2c1NC1CCN(Cc2ccccc2)CC1,5.87,IC50,=,1346.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,5.87,5.87,5.87,O=C(NC1CC1)c1cnc2[nH]ccc2c1NC1CCN(Cc2ccccc2)CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e820>
1405,CHEMBL4750779,,CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2cccc(OC)c2)[C@@H](C)C1,6.81,IC50,=,155.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.81,6.81,6.81,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09737b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e890>
1406,CHEMBL475251,R-406,COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC,6.72,Kd,=,190.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH1domain-catalytic) kinase domain,False,7.26,7.8,6.72,O=C1COc2ccc(Nc3ccnc(Nc4ccccc4)n3)nc2N1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e900>
1407,CHEMBL4753549,,Cc1cnc(Nc2ccc3c(c2)CCN(C(=O)/C=C/CN(C)C)C3)nc1-c1cnn(C(C)C)c1,7.12,IC50,=,75.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGGKKK as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.12,7.12,7.12,c1cc(-c2cn[nH]c2)nc(Nc2ccc3c(c2)CCNC3)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e970>
1408,CHEMBL4754005,,Cn1ccc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)n1,7.17,IC50,=,67.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,7.17,7.17,7.17,c1cc2c(-c3cnn(C4CCC4)c3)nc(-c3cc[nH]n3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091e9e0>
1409,CHEMBL4754557,,C=CC(=O)Nc1cccc(-c2ccnc(Nc3cnn(CCOC)c3)n2)c1,5.54,IC50,=,2871.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,A,Inhibition of recombinant human N-terminal GST-tagged TYK2 cytoplasmic domain (833 to 1187 residues) expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition and measured after 30 mins by HTRF assay,False,5.54,5.54,5.54,c1ccc(-c2ccnc(Nc3cn[nH]c3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ea50>
1410,CHEMBL4754856,,COC(=O)/C=C/CN1CCc2cc(Nc3ncc(C)c(-c4cnn(C(C)C)c4)n3)ccc2C1,7.06,IC50,=,88.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGGKKK as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.06,7.06,7.06,c1cc(-c2cn[nH]c2)nc(Nc2ccc3c(c2)CCNC3)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09739e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091eac0>
1411,CHEMBL4755612,,CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2cccc(OC)c2)[C@H](C)C1,7.10,IC50,=,79.5,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,7.10,7.10,7.10,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091eb30>
1412,CHEMBL4755671,,COCCn1cc(Nc2cc(-c3ccc(NC(=O)CC#N)cc3)ncn2)cn1,5.73,IC50,=,1872.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,A,Inhibition of recombinant human N-terminal GST-tagged TYK2 cytoplasmic domain (833 to 1187 residues) expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition and measured after 30 mins by HTRF assay,False,5.73,5.73,5.73,c1ccc(-c2cc(Nc3cn[nH]c3)ncn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091eba0>
1413,CHEMBL4756422,,Cc1cnc(Nc2ccc3c(c2)CN(C(=O)/C=C/CN(C)C)CC3)nc1-c1cnn(C(C)C)c1,7.35,IC50,=,45.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGGKKK as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.35,7.35,7.35,c1cc(-c2cn[nH]c2)nc(Nc2ccc3c(c2)CNCC3)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ec10>
1414,CHEMBL4756788,,CNC(=O)c1cnc2[nH]ccc2c1NC1CCN(Cc2ccccc2OC)CC1,5.38,IC50,=,4180.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,5.38,5.38,5.38,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ec80>
1415,CHEMBL4758753,,CO[C@H]1C[C@](CC#N)(n2cc(-c3nc(-c4cnn(C)c4)cn4nccc34)cn2)C1,7.66,IC50,=,22.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,7.66,7.66,7.66,c1cc2c(-c3cnn(C4CCC4)c3)nc(-c3cn[nH]c3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ecf0>
1416,CHEMBL4758891,,C=CC(=O)Nc1cccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1,5.61,IC50,=,2439.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,A,Inhibition of recombinant human N-terminal GST-tagged TYK2 cytoplasmic domain (833 to 1187 residues) expressed in baculovirus expression system using TK-substrate-biotin preincubated for 5 mins followed by substrate addition and measured after 30 mins by HTRF assay,False,5.61,5.61,5.61,c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ed60>
1417,CHEMBL4759320,,CNC(=O)c1cnc2[nH]ccc2c1NC1CC2CCC(C1)N2Cc1cccc(Cl)c1,6.54,IC50,=,292.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.54,6.54,6.54,c1ccc(CN2C3CCC2CC(Nc2ccnc4[nH]ccc24)C3)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091edd0>
1418,CHEMBL4759666,,CNC(=O)c1cnc2[nH]ccc2c1NC1CCCN(Cc2cccc(Cl)c2)CC1,7.22,IC50,=,59.8,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,7.22,7.22,7.22,c1ccc(CN2CCCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ee40>
1419,CHEMBL4759953,,Cc1ccc(C(=O)/C=C/C(=O)N2CCc3cc(Nc4ncc(C)c(-c5cnn(C(C)C)c5)n4)ccc3C2)cc1,7.00,IC50,=,100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGGKKK as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.00,7.00,7.00,O=C(/C=C/C(=O)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc2C1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091eeb0>
1420,CHEMBL4761132,,CC(=O)N1CC(CC#N)(n2cc(-c3nc(-c4cnn(C)c4)cn4nccc34)cn2)C1,6.17,IC50,=,678.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,6.17,6.17,6.17,c1cc2c(-c3cnn(C4CNC4)c3)nc(-c3cn[nH]c3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ef20>
1421,CHEMBL4761365,,CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2ccc(Cl)cc2)[C@H](C)C1,6.03,IC50,=,940.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,7.05,8.07,6.03,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ef90>
1422,CHEMBL4761611,,Cn1cc(-c2cn3nccc3c(-c3cnn(C4(CC#N)CN(CC5CC5)C4)c3)n2)cn1,7.40,IC50,=,40.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,7.40,7.40,7.40,c1cc2c(-c3cnn(C4CN(CC5CC5)C4)c3)nc(-c3cn[nH]c3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f040>
1423,CHEMBL4761631,,CNC(=O)c1cnc2[nH]ccc2c1NC1CCCN(Cc2ccccc2)CC1,6.56,IC50,=,276.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.56,6.56,6.56,c1ccc(CN2CCCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0973f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f0b0>
1424,CHEMBL4763801,,CNC(=O)c1cnc2[nH]ccc2c1NC1CCN(Cc2cccc(OC)c2)CC1,5.92,IC50,=,1212.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,5.92,5.92,5.92,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f120>
1425,CHEMBL4764176,,CO[C@H]1C[C@@](CC#N)(n2cc(-c3nc(-c4cnn(C)c4)cn4nccc34)cn2)C1,7.80,IC50,=,16.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,7.80,7.80,7.80,c1cc2c(-c3cnn(C4CCC4)c3)nc(-c3cn[nH]c3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09740b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f190>
1426,CHEMBL4776752,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2nccc(OC)n2)c1OC,6.34,IC50,=,461.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.5,8.85,6.34,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f200>
1427,CHEMBL4777175,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncc(C(C)(O)C(F)(F)F)cn2)c1OC,7.28,IC50,=,53.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,8.24,9.36,7.28,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f270>
1428,CHEMBL4777200,,CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2cccc(Cl)c2)C[C@H]1F,6.51,IC50,=,308.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.51,6.51,6.51,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f2e0>
1429,CHEMBL4777528,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2cnc(C(=O)N(C)C)cn2)c1OC,7.62,IC50,=,24.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.92,8.21,7.62,O=C(Nc1cc(Nc2cccc(-c3cnccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f350>
1430,CHEMBL4777577,,CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2ccc(Cl)cc2)[C@@H](C)C1,6.82,IC50,=,153.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.82,6.82,6.82,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09742e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f3c0>
1431,CHEMBL4777648,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ccncn2)c1OC,6.95,IC50,=,113.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.85,8.89,6.95,O=C(Nc1cc(Nc2cccc(-c3ccncn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f430>
1432,CHEMBL477772,PAZOPANIB,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,5.47,Kd,=,3400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH1domain-catalytic) kinase domain,False,5.47,5.47,5.47,c1ccc(Nc2nccc(Nc3ccc4c[nH]nc4c3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09743c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f4a0>
1433,CHEMBL4777969,,Cn1ccc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@H](C#N)C4)c3)n2)n1,8.00,IC50,=,10.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,8.00,8.00,8.00,c1cc2c(-c3cnn(C4CCC4)c3)nc(-c3cc[nH]n3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f510>
1434,CHEMBL4778704,,Cn1cc(-c2cn3nccc3c(-c3cnn(C4(CC#N)CN(CC(F)(F)F)C4)c3)n2)cn1,8.00,IC50,=,10.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,8.00,8.00,8.00,c1cc2c(-c3cnn(C4CNC4)c3)nc(-c3cn[nH]c3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09744a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f580>
1435,CHEMBL4779060,,CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2cccc(Cl)c2)[C@H](C)C1,7.31,IC50,=,48.6,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,7.31,7.31,7.31,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f5f0>
1436,CHEMBL4779340,,CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2ccc(OC)cc2)[C@H](C)C1,6.79,IC50,=,161.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.79,6.79,6.79,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f660>
1437,CHEMBL4780057,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2nccc(C)n2)c1OC,6.65,IC50,=,226.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.39,8.35,6.65,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09745f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f6d0>
1438,CHEMBL4780233,,[2H]C([2H])([2H])NC(=O)c1cnc(NC(=O)C2CC2)cc1Nc1cccc(-c2cnc(C)cn2)c1OC,6.63,IC50,=,233.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.91,9.57,6.63,O=C(Nc1cc(Nc2cccc(-c3cnccn3)c2)ccn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f740>
1439,CHEMBL4780288,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@H](CC#N)C4)c3)n2)cn1,8.10,IC50,=,8.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,8.10,8.10,8.10,c1cc2c(-c3cnn(C4CCC4)c3)nc(-c3cn[nH]c3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09746d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f7b0>
1440,CHEMBL4780315,,[2H]C([2H])([2H])NC(=O)c1cnc(NC(=O)C2CC2)cc1Nc1cccc(-c2cnc(OC)cn2)c1OC,6.47,IC50,=,341.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.75,9.27,6.47,O=C(Nc1cc(Nc2cccc(-c3cnccn3)c2)ccn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f820>
1441,CHEMBL4781679,,CNC(=O)c1cnc2[nH]ccc2c1NC1CCN(Cc2cccc(C#N)c2)CC1,6.15,IC50,=,710.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.15,6.15,6.15,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09747b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f890>
1442,CHEMBL4781706,,CNC(=O)c1cnc2[nH]ccc2c1NC1CCCN(Cc2ccc(Cl)cc2)CC1,7.31,IC50,=,49.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,7.31,7.31,7.31,c1ccc(CN2CCCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f900>
1443,CHEMBL4781973,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](CC#N)C4)c3)n2)cn1,7.62,IC50,=,24.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,7.62,7.62,7.62,c1cc2c(-c3cnn(C4CCC4)c3)nc(-c3cn[nH]c3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f970>
1444,CHEMBL4781984,,N#CC[C@]1(n2cc(-c3nc(-c4cn[nH]c4)cn4nccc34)cn2)C[C@@H](C#N)C1,8.10,IC50,=,8.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,8.10,8.10,8.10,c1cc2c(-c3cnn(C4CCC4)c3)nc(-c3cn[nH]c3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091f9e0>
1445,CHEMBL4782355,,Cn1cc(-c2cn3nccc3c(-c3cnn(C4(CC#N)CN(CCO)C4)c3)n2)cn1,6.72,IC50,=,189.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,6.72,6.72,6.72,c1cc2c(-c3cnn(C4CNC4)c3)nc(-c3cn[nH]c3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091fa50>
1446,CHEMBL4782449,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2cnccn2)c1OC,7.06,IC50,=,87.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.97,9.3,7.06,O=C(Nc1cc(Nc2cccc(-c3cnccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09749e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091fac0>
1447,CHEMBL4782814,,Cc1cc(Nc2cc3ncccc3c(N[C@H]3CC[C@@H]4C[C@H](C3)N4CCC#N)n2)n[nH]1,7.50,IC50,=,32.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human Tyk2 expressed in sf21 baculovirus expression system assessed as phosphorylation level in presence of 1 mM ATP,False,7.50,7.50,7.50,c1cnc2cc(Nc3cc[nH]n3)nc(N[C@H]3CC[C@@H]4C[C@H](C3)N4)c2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091fb30>
1448,CHEMBL4783938,,CNC(=O)c1cnc2[nH]ccc2c1N[C@H]1CCN(Cc2ccc(Cl)cc2)[C@@H](C)C1,8.09,IC50,=,8.17,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,8.09,8.09,8.09,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091fba0>
1449,CHEMBL4784391,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncc(F)cn2)c1OC,6.79,IC50,=,163.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.67,8.72,6.79,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091fc10>
1450,CHEMBL4784838,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cc(F)cc(-c2ncc(C(C)(C)O)cn2)c1OC,7.14,IC50,=,73.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,8.06,9.29,7.14,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091fc80>
1451,CHEMBL4785512,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ccc(C(=O)N(C)C)cn2)c1OC,7.38,IC50,=,42.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.62,7.85,7.38,O=C(Nc1cc(Nc2cccc(-c3ccccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091fcf0>
1452,CHEMBL4785910,,CNC(=O)c1cnc2[nH]ccc2c1NC1CC2CCC(C1)N2Cc1ccc(C#N)cc1,7.02,IC50,=,96.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,7.02,7.02,7.02,c1ccc(CN2C3CCC2CC(Nc2ccnc4[nH]ccc24)C3)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091fd60>
1453,CHEMBL4785957,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncc(C)cn2)c1OC,6.89,IC50,=,130.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.9,8.92,6.89,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091fdd0>
1454,CHEMBL4785998,,C[C@@H]1C[C@H](Nc2c(C(N)=O)cnc3[nH]ccc23)CCN1Cc1cccc(Cl)c1,7.32,IC50,=,48.4,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,7.32,7.32,7.32,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091fe40>
1455,CHEMBL4786466,,CNC(=O)c1cnc2[nH]ccc2c1NC1CC2CCC(C1)N2Cc1ccc(OC)cc1,7.10,IC50,=,79.1,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,7.10,7.10,7.10,c1ccc(CN2C3CCC2CC(Nc2ccnc4[nH]ccc24)C3)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091feb0>
1456,CHEMBL4787133,,CNC(=O)c1cnc2[nH]ccc2c1NC1CCCN(Cc2cccc(OC)c2)CC1,7.37,IC50,=,42.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,7.37,7.37,7.37,c1ccc(CN2CCCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ff20>
1457,CHEMBL4787411,,Cn1cc(-c2cc(-c3cnn(C4(CC#N)CN(CC(F)(F)F)C4)c3)n3ccnc3c2)cn1,6.54,IC50,=,290.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,6.54,6.54,6.54,c1cn2c(-c3cnn(C4CNC4)c3)cc(-c3cn[nH]c3)cc2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c091ff90>
1458,CHEMBL4787731,,COc1cccc(CN2CC[C@@H](Nc3c(C(N)=O)cnc4[nH]ccc34)C[C@H]2C)c1,6.80,IC50,=,157.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.80,6.80,6.80,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920040>
1459,CHEMBL4787974,,CNC(=O)c1cnc2[nH]ccc2c1NC1CC2CCC(C1)N2Cc1ccc(Cl)cc1,6.87,IC50,=,134.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,6.87,6.87,6.87,c1ccc(CN2C3CCC2CC(Nc2ccnc4[nH]ccc24)C3)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0974f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09200b0>
1460,CHEMBL4788122,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2cccnn2)c1OC,6.74,IC50,=,183.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.58,8.85,6.74,O=C(Nc1cc(Nc2cccc(-c3cccnn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920120>
1461,CHEMBL4789015,,[2H]C([2H])([2H])NC(=O)c1cnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncccn2)c1OC,7.39,IC50,=,41.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.79,8.19,7.39,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)ccn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09750b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920190>
1462,CHEMBL4789273,,Cc1ccc(C(=O)/C=C/C(=O)N2CCc3ccc(Nc4ncc(C)c(-c5cnn(C(C)C)c5)n4)cc3C2)cc1,7.52,IC50,=,30.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGGKKK as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.52,7.52,7.52,O=C(/C=C/C(=O)N1CCc2ccc(Nc3nccc(-c4cn[nH]c4)n3)cc2C1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920200>
1463,CHEMBL4789639,,[2H]C([2H])([2H])NC(=O)c1cnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncc(F)cn2)c1OC,10.70,Ki,=,0.02,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 JH2 domain (unknown origin) by HTRF assay based Morrison titration analysis,False,8.72,10.7,7.24,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)ccn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920270>
1464,CHEMBL4789693,,CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2cccc(Cl)c2)[C@@H](C)C1,7.21,IC50,=,61.7,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,7.21,7.21,7.21,c1ccc(CN2CCC(Nc3ccnc4[nH]ccc34)CC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09202e0>
1465,CHEMBL4791733,,N#CC[C@]1(n2cc(-c3nc(-c4cc[nH]n4)cn4nccc34)cn2)C[C@@H](C#N)C1,8.05,IC50,=,9.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,8.05,8.05,8.05,c1cc2c(-c3cnn(C4CCC4)c3)nc(-c3cc[nH]n3)cn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920350>
1466,CHEMBL4792231,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncc(C(C)(C)O)cn2)c1OC,7.39,IC50,=,41.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.72,8.05,7.39,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09752e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09203c0>
1467,CHEMBL4792694,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ccc(C(=O)N(C)C)nn2)c1OC,7.36,IC50,=,44.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.66,7.96,7.36,O=C(Nc1cc(Nc2cccc(-c3cccnn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920430>
1468,CHEMBL4792780,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cc(F)cc(-c2ncc(C(=O)N(C)C)cn2)c1OC,7.33,IC50,=,47.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,8.2,9.28,7.33,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09753c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09204a0>
1469,CHEMBL4793760,,[2H]C([2H])([2H])NC(=O)c1cnc(NC(=O)C2CC2)cc1Nc1cc(F)cc(-c2ncccn2)c1OC,7.23,IC50,=,59.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,8.2,9.6,7.23,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)ccn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920510>
1470,CHEMBL4795231,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncc(C(=O)N(C)C)cn2)c1OC,7.27,IC50,=,54.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.69,8.12,7.27,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09754a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920580>
1471,CHEMBL4795299,,Cn1cc(-c2cc(-c3cnn(C4(CC#N)CN(CC(F)(F)F)C4)c3)n3ncnc3c2)cn1,6.32,IC50,=,476.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human His-tagged TYK2 expressed in baculovirus infected Sf21 cells using 5FAM-KKSRGDYMTMQID as substrate in presence of ATP at Km by microfluidic assay,False,6.32,6.32,6.32,c1nc2cc(-c3cn[nH]c3)cc(-c3cnn(C4CNC4)c3)n2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09205f0>
1472,CHEMBL4795901,,CNC(=O)c1cnc2[nH]ccc2c1NC1CC2CCC(C1)N2Cc1cccc(OC)c1,7.05,IC50,=,88.2,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant TYK2 (unknown origin) using GFP-STAT1 as substrate incubated for 1 hr followed by anti-pSTAT1 antibody addition and measured after 30 mins by Lanthascreen TR-FRET assay,False,7.05,7.05,7.05,c1ccc(CN2C3CCC2CC(Nc2ccnc4[nH]ccc24)C3)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920660>
1473,CHEMBL4796821,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ccc(C(C)(C)O)cn2)c1OC,6.97,IC50,=,107.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,8.07,9.32,6.97,O=C(Nc1cc(Nc2cccc(-c3ccccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09755f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09206d0>
1474,CHEMBL4796925,,C[C@H](CO)n1cnnc1-c1cccc(NC(=O)Nc2cc3ccccn3n2)n1,5.77,IC50,=,1689.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of human recombinant TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis,False,5.77,5.77,5.77,O=C(Nc1cccc(-c2nnc[nH]2)n1)Nc1cc2ccccn2n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920740>
1475,CHEMBL4797596,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ccc(C(C)(C)O)nn2)c1OC,7.20,IC50,=,63.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,8.05,9.15,7.2,O=C(Nc1cc(Nc2cccc(-c3cccnn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09756d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09207b0>
1476,CHEMBL4798378,,Cc1cnc(Nc2ccc3c(c2)CCN(CC#N)C3)nc1-c1cnn(C(C)C)c1,7.25,IC50,=,56.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGGKKK as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.25,7.25,7.25,c1cc(-c2cn[nH]c2)nc(Nc2ccc3c(c2)CCNC3)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920820>
1477,CHEMBL4799019,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncc(OC)cn2)c1OC,7.04,IC50,=,92.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,8.18,9.6,7.04,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09757b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920890>
1478,CHEMBL4799031,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncccn2)c1OC,7.28,IC50,=,53.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,8.12,9.32,7.28,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920900>
1479,CHEMBL4799559,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2cnc(C(C)(C)O)cn2)c1OC,7.16,IC50,=,70.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,8.18,9.52,7.16,O=C(Nc1cc(Nc2cccc(-c3cnccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920970>
1480,CHEMBL4799830,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ccccn2)c1OC,6.37,IC50,=,430.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.52,8.8,6.37,O=C(Nc1cc(Nc2cccc(-c3ccccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09209e0>
1481,CHEMBL4800399,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncc(C(=O)N(CC)CC)cn2)c1OC,7.38,IC50,=,42.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation,False,7.72,8.07,7.38,O=C(Nc1cc(Nc2cccc(-c3ncccn3)c2)cnn1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920a50>
1482,CHEMBL482967,CYC-116,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1,5.99,Kd,=,1021.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",False,6.54,7.1,5.99,c1cc(-c2cncs2)nc(Nc2ccc(N3CCOCC3)cc2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09759e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920ac0>
1483,CHEMBL482968,ENMD-2076,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1,5.92,Kd,=,1196.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",False,5.92,5.92,5.92,C(=C/c1nc(Nc2cc[nH]n2)cc(N2CCNCC2)n1)\c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920b30>
1484,CHEMBL4845662,,Cc1cnc(Nc2ccc3c(c2)CNC3=O)nc1-c1cnn(CCC#N)c1,9.17,IC50,=,0.67,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,9.17,9.17,9.17,O=C1NCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920ba0>
1485,CHEMBL4845758,,CCCS(=O)(=O)N1CCc2cc(Nc3ncc(C)c(-c4cnn(C(C)C)c4)n3)ccc21,8.42,IC50,=,3.84,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.42,8.42,8.42,c1cc(-c2cn[nH]c2)nc(Nc2ccc3c(c2)CCN3)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920c10>
1486,CHEMBL4846148,,Cc1cnc(Nc2ccc3c(c2)CCN3S(=O)(=O)c2ccc(C(F)(F)F)cc2)nc1-c1cnn(C2CCC2)c1,7.92,IC50,=,12.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.92,7.92,7.92,O=S(=O)(c1ccccc1)N1CCc2cc(Nc3nccc(-c4cnn(C5CCC5)c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920c80>
1487,CHEMBL4846163,,Cc1cnc(Nc2ccc3c(c2)CCN3S(=O)(=O)c2ccc3c(c2)CC(=O)N3C)nc1-c1cnn(C(C)C)c1,7.20,IC50,=,62.98,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.20,7.20,7.20,O=C1Cc2cc(S(=O)(=O)N3CCc4cc(Nc5nccc(-c6cn[nH]c6)n5)ccc43)ccc2N1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920cf0>
1488,CHEMBL4846921,,CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1,8.37,IC50,=,4.3,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin),False,8.37,8.37,8.37,c1ccc(-c2csc3cnc(Nc4ccc(N5CCNCC5)cc4)nc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920d60>
1489,CHEMBL4849458,,Cc1cnc(Nc2ccc3c(c2)CCN3S(=O)(=O)C2CC2)nc1-c1cnn(C(C)C)c1,8.57,IC50,=,2.69,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.57,8.57,8.57,O=S(=O)(C1CC1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920dd0>
1490,CHEMBL4849617,,CC(C)(C)c1ccc(C(=O)N2CCc3cc(Nc4ncc(F)c(-c5cnn(CCC#N)c5)n4)ccc32)cc1,7.40,IC50,=,40.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.40,7.40,7.40,O=C(c1ccccc1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920e40>
1491,CHEMBL4850588,,CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3ccccc3Cl)n2)cc1,7.41,IC50,=,39.07,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) measured after 40 mins by HTRF,False,7.41,7.41,7.41,c1ccc(CNc2ccnc(Nc3ccccc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920eb0>
1492,CHEMBL4851075,,N#CCCn1cc(-c2nc(Nc3ccc4c(c3)CCN4)ncc2F)cn1,8.70,IC50,=,2.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.70,8.70,8.70,c1cc(-c2cn[nH]c2)nc(Nc2ccc3c(c2)CCN3)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920f20>
1493,CHEMBL4851606,,Cc1cnc(Nc2ccc3c(c2)CCN3S(=O)(=O)c2ccc(C(F)(F)F)cc2)nc1-c1cnn(C)c1,6.83,IC50,=,148.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,6.83,6.83,6.83,O=S(=O)(c1ccccc1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0920f90>
1494,CHEMBL4852080,,Cc1cnc(Nc2ccc3c(c2)CCN3S(=O)(=O)c2ccc3c(c2)CC(=O)N3)nc1-c1cnn(C(C)C)c1,7.91,IC50,=,12.32,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.91,7.91,7.91,O=C1Cc2cc(S(=O)(=O)N3CCc4cc(Nc5nccc(-c6cn[nH]c6)n5)ccc43)ccc2N1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921040>
1495,CHEMBL4853438,,N#CCCn1cc(-c2nc(Nc3ccc4c(c3)CCN4S(=O)(=O)c3ccc(C(F)(F)F)cc3)ncc2F)cn1,8.05,IC50,=,9.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.05,8.05,8.05,O=S(=O)(c1ccccc1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0975f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09210b0>
1496,CHEMBL4854514,,Cc1cnc(Nc2ccc3c(c2)CCN3C(=O)Cc2ccc(OC(F)(F)F)cc2)nc1-c1cnn(C(C)C)c1,7.29,IC50,=,51.06,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.29,7.29,7.29,O=C(Cc1ccccc1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921120>
1497,CHEMBL4854704,,Cc1cnc(Nc2ccc3c(c2)CCN3C(=O)C2CC2)nc1-c1cnn(C(C)C)c1,8.43,IC50,=,3.76,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.43,8.43,8.43,O=C(C1CC1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c09760b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921190>
1498,CHEMBL4855542,,Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O,6.22,IC50,=,600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 domain 2 in human NCI-H929 cells by mass spectroscopic analysis,False,6.22,6.22,6.22,O=C1NCCc2cc(-c3cncc(-c4cccc5ncsc45)c3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921200>
1499,CHEMBL4856634,,N#CCCn1cc(-c2nc(Nc3ccc4c(c3)CCN4C(=O)C3(C#N)CC3)ncc2F)cn1,8.22,IC50,=,6.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.22,8.22,8.22,O=C(C1CC1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921270>
1500,CHEMBL4858303,,Cc1cnc(Nc2ccc3c(c2)CCN3C(=O)CCN2CCOCC2)nc1-c1cnn(C(C)C)c1,8.02,IC50,=,9.64,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.02,8.02,8.02,O=C(CCN1CCOCC1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09212e0>
1501,CHEMBL4859660,,Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O,4.52,IC50,=,29900.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 domain 2 in human NCI-H929 cells by mass spectroscopic analysis,False,4.52,4.52,4.52,O=C1NCCc2cc(-c3cncc(-c4ccccc4)c3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921350>
1502,CHEMBL4860979,,CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1,5.42,IC50,=,3800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 domain 2 in human NCI-H929 cells by mass spectroscopic analysis,False,5.42,5.42,5.42,O=C1NCCc2cc(-c3cncc(-c4ccc(S(=O)(=O)NC5CC5)cc4)c3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c09762e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09213c0>
1503,CHEMBL4861517,,Cc1cnc(Nc2ccc3c(c2)CCN3C(=O)c2cccc(C(F)(F)F)c2)nc1-c1cnn(C(C)C)c1,7.84,IC50,=,14.56,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.84,7.84,7.84,O=C(c1ccccc1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921430>
1504,CHEMBL4862108,,Cc1cnc(Nc2ccc3c(c2)CCN3C(=O)CN2CCS(=O)(=O)CC2)nc1-c1cnn(C(C)C)c1,8.70,IC50,=,1.99,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.70,8.70,8.70,O=C(CN1CCS(=O)(=O)CC1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c09763c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09214a0>
1505,CHEMBL4862231,,Cc1cnc(Nc2ccc3c(c2)CCN3S(=O)(=O)c2ccc(C(F)(F)F)cc2)nc1-c1cnn(C(C)C)c1,7.80,IC50,=,16.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.80,7.80,7.80,O=S(=O)(c1ccccc1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921510>
1506,CHEMBL4862564,,Cc1cnc(Nc2ccc(NS(=O)(=O)c3ccc(C(F)(F)F)cc3)c(F)c2)nc1-c1cnn(C(C)C)c1,7.89,IC50,=,13.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.89,7.89,7.89,O=S(=O)(Nc1ccc(Nc2nccc(-c3cn[nH]c3)n2)cc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09764a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921580>
1507,CHEMBL4862667,,Cc1cnc(Nc2ccc3c(c2)CCN3S(=O)(=O)c2ccc(C(F)(F)F)cc2)nc1-c1cnn(C2CC2)c1,7.22,IC50,=,60.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.22,7.22,7.22,O=S(=O)(c1ccccc1)N1CCc2cc(Nc3nccc(-c4cnn(C5CC5)c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09215f0>
1508,CHEMBL4864328,,Cc1cnc(Nc2ccc3c(c2)CCN3C(=O)[C@@H]2C[C@@H]2F)nc1-c1cnn(C(C)C)c1,8.20,IC50,=,6.28,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.20,8.20,8.20,O=C(C1CC1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921660>
1509,CHEMBL4864387,,N#CCCn1cc(-c2nc(Nc3ccc4c(ccn4S(=O)(=O)C(F)(F)F)c3)ncc2F)cn1,8.05,IC50,=,9.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.05,8.05,8.05,c1cc(-c2cn[nH]c2)nc(Nc2ccc3[nH]ccc3c2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09765f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09216d0>
1510,CHEMBL4864674,,Cc1cnc(Nc2ccc3c(c2)CCN3C(=O)C2CC2(F)F)nc1-c1cnn(C(C)C)c1,8.24,IC50,=,5.72,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.24,8.24,8.24,O=C(C1CC1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921740>
1511,CHEMBL4865102,,N#CCCn1cc(-c2nc(Nc3ccc4c(c3)CCN4C(=O)CN3CCS(=O)(=O)CC3)ncc2F)cn1,8.70,IC50,=,2.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.70,8.70,8.70,O=C(CN1CCS(=O)(=O)CC1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c09766d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09217b0>
1512,CHEMBL4865736,,Cc1cnc(Nc2ccc3c(c2)CCN3C(=O)c2ccc(C(F)(F)F)cc2F)nc1-c1cnn(C(C)C)c1,7.97,IC50,=,10.62,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.97,7.97,7.97,O=C(c1ccccc1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921820>
1513,CHEMBL4867814,,CCS(=O)(=O)N1CCc2cc(Nc3ncc(C)c(-c4cnn(C(C)C)c4)n3)ccc21,8.79,IC50,=,1.61,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.79,8.79,8.79,c1cc(-c2cn[nH]c2)nc(Nc2ccc3c(c2)CCN3)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09767b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921890>
1514,CHEMBL4867931,,COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1,4.54,IC50,=,28800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 domain 2 in human NCI-H929 cells by mass spectroscopic analysis,False,4.54,4.54,4.54,O=C1NCCc2cc(-c3cncc(-c4ccc(NS(=O)(=O)C5CC5)cc4)c3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976820>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921900>
1515,CHEMBL4868074,,Cc1cnc(Nc2ccc3c(c2)CCN3C(=O)[C@@H](O)CO)nc1-c1cnn(C(C)C)c1,7.96,IC50,=,10.84,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.96,7.96,7.96,c1cc(-c2cn[nH]c2)nc(Nc2ccc3c(c2)CCN3)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976890>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921970>
1516,CHEMBL4868858,,N#CCCn1cc(-c2nc(Nc3ccc4c(c3)CCN4C(=O)c3ccc(C(F)(F)F)cc3)ncc2F)cn1,8.30,IC50,=,5.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.30,8.30,8.30,O=C(c1ccccc1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976900>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09219e0>
1517,CHEMBL4869302,,CC(=O)N1CCc2cc(Nc3ncc(C)c(-c4cnn(C(C)C)c4)n3)ccc21,8.74,IC50,=,1.81,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.74,8.74,8.74,c1cc(-c2cn[nH]c2)nc(Nc2ccc3c(c2)CCN3)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976970>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921a50>
1518,CHEMBL4871133,,N#CCCn1cc(-c2nc(Nc3ccc4c(c3)CNC4=O)ncc2F)cn1,8.15,IC50,=,7.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.15,8.15,8.15,O=C1NCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c09769e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921ac0>
1519,CHEMBL4872338,,Cn1ccc2cc(Nc3ncc(F)c(-c4cnn(CCC#N)c4)n3)ccc21,7.75,IC50,=,18.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.75,7.75,7.75,c1cc(-c2cn[nH]c2)nc(Nc2ccc3[nH]ccc3c2)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976a50>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921b30>
1520,CHEMBL4872557,,N#CCCn1cc(-c2nc(Nc3ccc4c(ccn4C(=O)C4CC4)c3)ncc2F)cn1,6.82,IC50,=,151.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,6.82,6.82,6.82,O=C(C1CC1)n1ccc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976ac0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921ba0>
1521,CHEMBL4872684,,CCOC(C)n1cc(-c2nc(Nc3ccc4c(c3)CCN4S(=O)(=O)c3ccc(C(F)(F)F)cc3)ncc2C)cn1,7.42,IC50,=,38.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.42,7.42,7.42,O=S(=O)(c1ccccc1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976b30>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921c10>
1522,CHEMBL4873109,,N#CCCn1cc(-c2nc(Nc3ccc4c(c3)CCN4S(=O)(=O)C(F)(F)F)ncc2F)cn1,8.40,IC50,=,4.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.40,8.40,8.40,c1cc(-c2cn[nH]c2)nc(Nc2ccc3c(c2)CCN3)n1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976ba0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921c80>
1523,CHEMBL4873455,,Cc1cnc(Nc2ccc3c(c2)CCN3C(=O)[C@H]2CCCN2)nc1-c1cnn(C(C)C)c1,8.30,IC50,=,5.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.30,8.30,8.30,O=C([C@H]1CCCN1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976c10>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921cf0>
1524,CHEMBL4873733,,Cc1cnc(Nc2ccc3c(c2)CCN3C(=O)[C@H]2CCCN2C(=O)C2(C#N)CC2)nc1-c1cnn(C(C)C)c1,8.69,IC50,=,2.05,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.69,8.69,8.69,O=C([C@H]1CCCN1C(=O)C1CC1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976c80>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921d60>
1525,CHEMBL4873919,,Cc1cnc(Nc2ccc3c(c2)CCN3S(=O)(=O)c2ccc(C(F)(F)F)cc2)nc1-c1cnn(CCC#N)c1,8.70,IC50,=,2.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.70,8.70,8.70,O=S(=O)(c1ccccc1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976cf0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921dd0>
1526,CHEMBL4874046,,CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccccc3OC)n2)cc1,7.66,IC50,=,21.94,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2 (unknown origin) measured after 40 mins by HTRF,False,7.66,7.66,7.66,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976d60>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921e40>
1527,CHEMBL4876711,,CCCn1cc(-c2nc(Nc3ccc4c(c3)CCN4S(=O)(=O)c3ccc(C(F)(F)F)cc3)ncc2C)cn1,7.64,IC50,=,23.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,7.64,7.64,7.64,O=S(=O)(c1ccccc1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976dd0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921eb0>
1528,CHEMBL4876729,,COc1ccc(S(=O)(=O)N2CCc3cc(Nc4ncc(C)c(-c5cnn(C(C)C)c5)n4)ccc32)cc1,8.11,IC50,=,7.82,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay,False,8.11,8.11,8.11,O=S(=O)(c1ccccc1)N1CCc2cc(Nc3nccc(-c4cn[nH]c4)n3)ccc21,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976e40>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921f20>
1529,CHEMBL491758,,Fc1cnc(Nc2ccccc2)nc1Nc1ccccc1,6.20,Ki,=,630.96,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,F,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TYK2,False,6.20,6.20,6.20,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976eb0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0921f90>
1530,CHEMBL495727,AT-9283,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1,6.55,Kd,=,279.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",False,7.78,9.0,6.55,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976f20>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0922040>
1531,CHEMBL498859,,Nc1n[nH]c2ccc(-c3ccccc3Cl)cc12,6.55,IC50,=,280.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of recombinant human TYK2 kinase domain (885-1176 residues) using Ulight-JAK1 substrate peptide assessed as reduction in ATP-dependent substrate phosphorylation after 45 mins by TR-FRET assay,False,6.55,6.55,6.55,c1ccc(-c2ccc3[nH]ncc3c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0976f90>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09220b0>
1532,CHEMBL502835,NINTEDANIB,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,6.30,Kd,=,500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,6.86,7.43,6.3,O=C(CN1CCNCC1)Nc1ccc(N/C(=C2\C(=O)Nc3ccccc32)c2ccccc2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977040>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0922120>
1533,CHEMBL509032,TAE-684,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,5.64,IC50,=,2309.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of Tel-fused TYK2 kinase-mediated mouse BaF3 cell proliferation,False,6.29,7.11,5.64,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09770b0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0922190>
1534,CHEMBL514409,HESPERADIN,CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2,7.12,Kd,=,75.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding affinity to human TYK2,False,7.12,7.12,7.12,O=C1Nc2ccccc2/C1=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977120>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0922200>
1535,CHEMBL521851,PICTILISIB,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,5.75,Kd,=,1800.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,5.75,5.75,5.75,c1cc(-c2nc(N3CCOCC3)c3sc(CN4CCNCC4)cc3n2)c2cn[nH]c2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977190>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0922270>
1536,CHEMBL522892,DOVITINIB,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,5.66,Kd,=,2200.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,6.39,6.82,5.66,O=c1[nH]c2ccccc2cc1-c1nc2ccc(N3CCNCC3)cc2[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977200>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09222e0>
1537,CHEMBL535,SUNITINIB,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,5.80,Kd,=,1600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH1domain-catalytic) kinase domain,False,6.12,6.44,5.8,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977270>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0922350>
1538,CHEMBL553,ERLOTINIB,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,5.62,Kd,=,2400.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,5.62,5.62,5.62,c1ccc(Nc2ncnc3ccccc23)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09772e0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09223c0>
1539,CHEMBL558752,RAF-265,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,6.39,Kd,=,410.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH1domain-catalytic) kinase domain,False,6.39,6.39,6.39,c1ccc(Nc2nc3cc(Oc4ccnc(-c5ncc[nH]5)c4)ccc3[nH]2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977350>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0922430>
1540,CHEMBL572878,TOZASERTIB,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,5.18,Kd,=,6600.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,6.06,6.7,5.18,O=C(Nc1ccc(Sc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1)C1CC1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09773c0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09224a0>
1541,CHEMBL573339,PI-103,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,5.23,Kd,=,5900.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,5.23,5.23,5.23,c1ccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977430>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0922510>
1542,CHEMBL574738,AST-487,CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1,5.68,Kd,=,2100.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(Kin.Dom.2/JH1 - catalytic) kinase domain,False,5.72,5.75,5.68,O=C(Nc1ccc(CN2CCNCC2)cc1)Nc1ccc(Oc2ccncn2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09774a0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0922580>
1543,CHEMBL590109,,NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21,5.00,IC50,=,10000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Inhibition of TYK2,False,5.35,5.7,5.0,c1ccc2sc(-c3cc(-c4c[nH]c5cncnc45)cc4cn[nH]c34)cc2c1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977510>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09225f0>
1544,CHEMBL601719,CRIZOTINIB,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,5.70,Kd,=,2000.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,6.09,6.68,5.7,c1ccc(COc2cncc(-c3cnn(C4CCNCC4)c3)c2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977580>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0922660>
1545,CHEMBL603469,LESTAURTINIB,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,6.04,Kd,=,910.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,6.93,7.82,6.04,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CC[C@H]3O1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09775f0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09226d0>
1546,CHEMBL608154,,COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C,6.30,Kd,=,500.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,6.30,6.30,6.30,O=C(Nc1cccc2c1[nH]c1cnccc12)c1cccnc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977660>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0922740>
1547,CHEMBL608533,MIDOSTAURIN,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,6.60,Kd,=,250.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH1domain-catalytic) kinase domain,False,6.60,6.60,6.60,O=C(N[C@H]1CC2O[C@H](C1)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O)c1ccccc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c09776d0>,<rdkit.Chem.rdchem.Mol object at 0x7f46c09227b0>
1548,CHEMBL941,IMATINIB,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,5.06,Kd,=,8700.0,nM,0,Tyrosine-protein kinase TYK2,Homo sapiens,B,Binding constant for TYK2(JH2domain-pseudokinase) kinase domain,False,5.06,5.06,5.06,O=C(Nc1cccc(Nc2nccc(-c3cccnc3)n2)c1)c1ccc(CN2CCNCC2)cc1,<rdkit.Chem.rdchem.Mol object at 0x7f46c0977740>,<rdkit.Chem.rdchem.Mol object at 0x7f46c0922820>
